U.S. patent application number 10/811332 was filed with the patent office on 2005-05-19 for carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors.
This patent application is currently assigned to PROLIFIX LIMITED. Invention is credited to Andrianov, Victor, Dikovska, Klara, Duffy, James E.S., Finn, Paul W., Gailite, Vija, Harris, C. John, Kalvinsh, Ivars, Loza, Einars, Moore, Kathryn G., Piskunova, Irina, Ritchie, James, Romero-Martin, Maria Rosario, Starchenkov, Igor, Vorona, Maxim, Watkins, Clare J..
Application Number | 20050107445 10/811332 |
Document ID | / |
Family ID | 27255912 |
Filed Date | 2005-05-19 |
United States Patent
Application |
20050107445 |
Kind Code |
A1 |
Watkins, Clare J. ; et
al. |
May 19, 2005 |
Carbamic acid compounds comprising a sulfonamide linkage as HDAC
inhibitors
Abstract
This invention pertains to certain active carbamic acid
compounds which inhibit HDAC activity and which have the following
formula: (I) A is an aryl group; Q.sup.1 is a covalent bond or an
aryl leader group; J is a sulfonamide linkage selected from:
--S(.dbd.O).sub.2NR.sup.1-- and --NR.sup.1S(.dbd.O).sub.2--;
R.sup.1 is a sulfonamido substituent; and, Q.sup.2 is an acid
leader group; with the proviso that if J is
--S(.dbd.O).sub.2NR.sup.1--, then Q.sup.1 is an aryl leader group;
and pharmaceutically acceptable salts, solvates, amides, esters,
ethers, chemically protected forms, and prodrugs thereof. The
present invention also pertains to pharmaceutical compositions
comprising such compounds, and the use of such compounds and
compositions, both in vitro and in vivo, to inhibit HDAC, and,
e.g., to inhibit proliferative conditions, such as cancer and
psoriasis.
Inventors: |
Watkins, Clare J.;
(Abingdon, GB) ; Romero-Martin, Maria Rosario;
(Didcot, GB) ; Moore, Kathryn G.; (Abingdon,
GB) ; Ritchie, James; (Abingdon, GB) ; Finn,
Paul W.; (Abingdon, GB) ; Kalvinsh, Ivars;
(Riga, LV) ; Loza, Einars; (Riga, LV) ;
Dikovska, Klara; (Riga, LV) ; Gailite, Vija;
(Riga, LV) ; Vorona, Maxim; (Riga, LV) ;
Piskunova, Irina; (Riga, LV) ; Starchenkov, Igor;
(Riga, LV) ; Andrianov, Victor; (Riga, LV)
; Harris, C. John; (Eynsford, GB) ; Duffy, James
E.S.; (Sittingbourne, GB) |
Correspondence
Address: |
NIXON & VANDERHYE, PC
1100 N GLEBE ROAD
8TH FLOOR
ARLINGTON
VA
22201-4714
US
|
Assignee: |
PROLIFIX LIMITED
Oxfordshire
GB
|
Family ID: |
27255912 |
Appl. No.: |
10/811332 |
Filed: |
March 29, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10811332 |
Mar 29, 2004 |
|
|
|
10381790 |
Aug 20, 2003 |
|
|
|
10381790 |
Aug 20, 2003 |
|
|
|
PCT/GB01/04326 |
Sep 27, 2001 |
|
|
|
60297784 |
Jun 14, 2001 |
|
|
|
60308136 |
Jul 30, 2001 |
|
|
|
Current U.S.
Class: |
514/345 ;
514/424; 514/575; 546/293; 548/541; 562/621 |
Current CPC
Class: |
A61P 11/02 20180101;
C07D 209/88 20130101; C07D 213/42 20130101; A61P 33/00 20180101;
A61P 37/08 20180101; C07D 213/71 20130101; A61P 3/10 20180101; C07C
311/06 20130101; A61P 9/10 20180101; A61P 7/06 20180101; A61P 17/00
20180101; A61P 25/16 20180101; C07C 311/29 20130101; A61P 33/04
20180101; A61P 35/00 20180101; C07C 311/21 20130101; C07D 307/52
20130101; A61P 21/04 20180101; A61P 37/00 20180101; A61P 43/00
20180101; C07C 311/19 20130101; C07C 2602/08 20170501; A61P 1/16
20180101; A61P 31/10 20180101; C07D 213/40 20130101; C07C 311/16
20130101; C07D 317/58 20130101; A61P 17/06 20180101; A61P 37/02
20180101; A61P 19/02 20180101; A61P 25/28 20180101; A61P 25/00
20180101; C07D 213/65 20130101; A61P 33/06 20180101; A61P 31/12
20180101; C07C 311/20 20130101; A61P 11/06 20180101; C07C 311/13
20130101; A61P 1/04 20180101; A61P 29/00 20180101 |
Class at
Publication: |
514/345 ;
514/575; 562/621; 514/424; 546/293; 548/541 |
International
Class: |
A61K 031/44; A61K
031/4015; A61K 031/19; C07C 311/35 |
Foreign Application Data
Date |
Code |
Application Number |
Sep 29, 2000 |
GB |
0023986.3 |
Claims
1-219. (canceled)
220. An inhibitor of histone deacetylase represented by the formula
Cy-L.sup.1-Ar--Y.sup.1--C(O)--NH-Z wherein Cy is cycloalkyl, aryl,
heteroaryl, or heterocyclyl, any of which may be optionally
substituted; L.sup.1 is --(CH.sub.2).sub.m--W--, where m is 0, 1,
2, 3, or 4, and W is selected from the group consisting of
--C(O)NH--, --S(O).sub.2NH--, --NHS(O).sub.2--, and
--NH--C(O)--NH--; Ar is arylene, wherein said arylene optionally
may be additionally substituted and optionally may be fused to an
aryl or heteroaryl ring, or to a saturated or partially unsaturated
cycloalkyl or heterocyclic ring, any of which may be optionally
substituted; Y.sup.1 is a chemical bond or a straight- or
branched-chain saturated alkylene, wherein said alkylene may be
optionally substituted; and Z is selected from the group consisting
of anilinyl, pyridyl, thiadiazolyl, and --O-M, M being H or a
pharmaceutically acceptable cation; provided that when L.sup.1 is
--C(O)NH--, Y.sup.1 is an alklene of formula --(CH.sub.2).sub.n--,
n being 1, 2 or 3, and Z is --O-M, then Cy is not aminophenyl,
dimethylaminophenyl, or hydroxyphenyl; and further provided that
when L.sup.1 is --C(O)NH-- and Z is pyridyl, then Cy is not
substituted indolinyl.
221. The inhibitor of claim 220, wherein Z is selected from the
group consisting of 2-anilinyl, 2-pyridyl, 1,3,4-thiadiazol-2-yl,
and --O-M, M being H or a pharmaceutically acceptable cation.
222. The inhibitor of claim 221, wherein Z is 1,3,4-thiadiazol-2-yl
which is substituted at the 5-position with a substituent selected
from the group consisting of thiol, trifluoromethyl, amino, and
sulfonamido.
223. The inhibitor of claim 220, wherein Y.sup.1 is C.sub.1-C.sub.6
alkylene.
224. The inhibitor of claim 220, wherein Y.sup.1 is C.sub.1-C.sub.3
alkylene.
225. The inhibitor of claim 220, wherein Ar is substituted or
unsubstituted phenylene, which optionally may be fused to an aryl
or heteroaryl ring, or to a saturated or partially unsaturated
cycloalkyl or heterocyclic ring, any of which may be optionally
substituted.
226. The inhibitor of claim 225, wherein the phenylene is
4-phenylene.
227. The inhibitor of claim 220, wherein Cy is selected from the
group consisting of phenyl, naphthyl, thienyl, benzothienyl, and
quinolyl, any of which may be optionally substituted.
228. The inhibitor of claim 227, herein the phenyl, naphthyl,
thienyl, benzothienyl, or quinolyl is unsubstituted or is
substituted by one or two substituents independently selected from
the group consisting of C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4
haloalkyl, C.sub.6-C.sub.10 aryl,
(C.sub.6-C.sub.10)ar(C.sub.1-C.sub.6)alkyl, halo, nitro, hydroxy,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkoxycarbonyl, carboxy,
and amino.
229. The inhibitor of claim 220, wherein m is zero.
230. An inhibitor of histone deacetylase represented by the formula
Cy-L.sup.2-Ar--Y.sup.2--C(O)NH-Z wherein Cy is cycloalkyl, aryl,
heteroaryl, or heterocyclyl, any of which may be optionally
substituted, provided that Cy is not a
(spirocycloalkyl)heterocyclyl; L.sup.2 is C.sub.1-C.sub.6 saturated
alkylene or C.sub.2-C.sub.6 alkenylene, wherein the alkylene or
alkenylene optionally may be substituted, provided that L.sup.2 is
not --C(O)--, and wherein one of the carbon atoms of the alkylene
optionally may be replaced by a heteroatom moiety selected from the
group consisting of O; NR', R' being alkyl, acyl, or hydrogen; S;
S(O); or S(O).sub.2; Ar is arylene, wherein said arylene optionally
may be additionally substituted and optionally may be fused to an
aryl or heteroaryl ring, or to a saturated or partially unsaturated
cycloalkyl or heterocyclic ring, any of which may be optionally
substituted; and Y.sup.2 is a chemical bond or a straight- or
branched-chain saturated alkylene, which may be optionally
substituted, provided that the alkylene is not substituted with a
substituent of the formula --C(O)R wherein R comprises an
.alpha.-amino acyl moiety; and Z is selected from the group
consisting of anilinyl, pyridyl, thiadiazolyl, and --O-M, M being H
or a pharmaceutically acceptable cation; provided that when the
carbon atom to which Cy is attached is oxo substituted, then Cy and
Z are not both pyridyl.
231. The inhibitor of claim 230, wherein Z is selected from the
group consisting of 2-nilinyl, 2-pyridyl, 1,3,4-thiadiazol-2-yl,
and --O-M, M being H or a pharmaceutically acceptable cation.
232. The inhibitor of claim 231, wherein Z is 1,3,4-thiadiazol-2-yl
which is substituted at the 5-position with a substituent selected
from the group consisting of thiol, trifluoromethyl, amino, and
sulfonamido.
233. The inhibitor of claim 230, wherein Y.sup.2 is a chemical
bond.
234. The inhibitor of claim 230, wherein Y.sup.2 is C.sub.1-C.sub.3
alkylene.
235. The inhibitor of claim 230, wherein Y.sup.2 is C.sub.1-C.sub.2
alkylene.
236. The inhibitor of claim 230, wherein Ar is substituted or
unsubstituted phenylene, which optionally may be fused to an aryl
or heteroaryl ring, or to a saturated or partially unsaturated
cycloalkyl or heterocyclic ring, any of which may be optionally
substituted.
237. The inhibitor of claim 236, wherein the phenylene is
4-phenylene.
238. The inhibitor of claim 230, wherein Cy is selected from the
group consisting of phenyl, naphthyl, thienyl, benzothienyl, and
quinolyl, any of which may be optionally substituted.
239. The inhibitor of claim 238, wherein the phenyl, naphthyl,
thienyl, benzothienyl, or quinolyl is unsubstituted or is
substituted by one or two substituents independently selected from
the group consisting of C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4
haloalkyl, C.sub.6-C.sub.10 aryl,
(C.sub.6-C.sub.10)ar(C.sub.1-C.sub.6)alkyl, halo, nitro, hydroxy,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkoxycarbonyl, carboxy,
and amino.
240. The inhibitor of claim 230, wherein one or two saturated
carbons in L.sup.2 are substituted with a substituent independently
selected from the group consisting of C.sub.1-C.sub.6 alkyl,
C.sub.6-C.sub.10 aryl, amino, oxo, hydroxy, C.sub.1-C.sub.4 alkoxy,
and C.sub.6-C.sub.10 aryloxy.
241. The inhibitor of claim 240, wherein the substituent is oxo or
hydroxy.
242. The inhibitor of claim 230, wherein L.sup.2 is C.sub.1-C.sub.6
saturated alkylene, and no carbon atom of the alkylene is replaced
by a heteroatom moiety.
243. The inhibitor of claim 230, wherein one carbon atom of the
Y.sup.2 alkylene is replaced by a heteroatom moiety selected from
the group consisting of O; NR', R' being alkyl, acyl, or hydrogen;
S; S(O); or S(O).sub.2.
244. The inhibitor of claim 243, wherein L.sup.2 is selected from
the group consisting of --S--(CH.sub.2).sub.n,
--S(O)--(CH.sub.2).sub.n--, and --S(O).sub.2--(CH.sub.2).sub.n--,
wherein n is 0, 1, 2, 3, or 4.
245. An inhibitor of histone deacetylase represented by the formula
Cy-L.sup.3-Ar--Y.sup.3--C(O)NH-Z wherein Cy is cycloalkyl, aryl,
heteroaryl, or heterocyclyl, any of which may be optionally
substituted, provided that Cy is not a
(spirocycloalkyl)heterocyclyl; L.sup.3 is selected from the group
consisting of (a) --(CH.sub.2).sub.m--W--, where m is 0, 1, 2, 3,
or 4, and W is selected from the group consisting of --C(O)NH--,
--S(O).sub.2NH--, --NHC(O)--, --NHS(O).sub.2--, and
--NH--C(O)--NH--; and (b) C.sub.1-C.sub.6 alkylene or
C.sub.2-C.sub.6 alkenylene, wherein the alkylene or alkenylene
optionally may be substituted, provided that L.sup.3 is not
--C(O)--, and wherein one of the carbon atoms of the alkylene
optionally may be replaced by O; NR', R' being alkyl, acyl, or
hydrogen; S; S(O); or S(O).sub.2; Ar is arylene, wherein said
arylene optionally may be additionally substituted and optionally
may be fused to an aryl or heteroaryl ring, or to a saturated or
partially unsaturated cycloalkyl or heterocyclic ring, any of which
may be optionally substituted; and Y.sup.3 is C.sub.2 alkenylene or
C.sub.2 alkynylene, wherein one or both carbon atoms of the
alkenylene optionally may be substituted with alkyl, aryl, alkaryl,
or aralkyl; and Z is selected from the group consisting of
anilinyl, pyridyl, thiadiazolyl, and --O-M, M being H or a
pharmaceutically acceptable cation; provided that when Cy is
unsubstituted phenyl, Ar is not phenyl wherein L.sup.3 and Y.sup.3
are oriented ortho or meta to each other.
246. The inhibitor of claim 245, wherein Z is selected from the
group consisting of 2-anilinyl, 2-pyridyl, 1,3,4-thiadiazol-2-yl,
and --O-M, M being H or a pharmaceutically acceptable cation.
247. The inhibitor of claim 246, wherein Z is 1,3,4-thiadiazol-2-yl
which is substituted at the 5-position with a substituent selected
from the group consisting of thiol, trifluoromethyl, amino, and
sulfonamido.
248. The inhibitor of claim 245, wherein Y.sup.3 is selected from
the group consisting of --CH.dbd.CH--, --C(CH.sub.3).dbd.CH--, and
--CH.dbd.C(CH.sub.3)--.
249. The inhibitor of claim 245, wherein Ar is substituted or
unsubstituted phenylene, which optionally may be fused to an aryl
or heteroaryl ring, or to a saturated or partially unsaturated
cycloalkyl or heterocyclic ring, any of which may be optionally
substituted.
250. The inhibitor of claim 249, wherein the phenylene is
4-phenylene.
251. The inhibitor of claim 245, wherein Cy is selected from the
group consisting of phenyl, naphthyl, thienyl, benzothienyl, and
quinolyl, any of which may be optionally substituted.
252. The inhibitor of claim 251, wherein the phenyl, naphthyl,
thienyl, benzothienyl, or quinolyl is unsubstituted or is
substituted by one or two substituents independently selected from
the group consisting of C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4
haloalkyl, C.sub.6-C.sub.10 aryl,
(C.sub.6-C.sub.10)ar(C.sub.1-C.sub.6)alkyl, halo, nitro, hydroxy,
C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkoxycarbonyl, carboxy,
and amino.
253. An inhibitor of histone deacetylase selected from the group
consisting of 393
254. An inhibitor of histone deacetylase represented by the formula
Cy-L.sup.1-Ar--Y.sup.1--C(O)--N H-Z wherein Cy is aryl or
heteroaryl, any of which may be optionally substituted; L.sup.1 is
--(CH.sub.2).sub.m--W--, where m is 0, 1, 2, 3, or 4, and W is
selected from the group consisting of --S(O).sub.2NH-- and
--NHS(O).sub.2--Ar is arylene, wherein said arylene optionally may
be additionally substituted and optionally may be fused to an aryl
or heteroaryl ring, or to a saturated or partially unsaturated
cycloalkyl or heterocyclic ring, any of which may be optionally
substituted; Y.sup.1 is a chemical bond or a straight- or
branched-chain saturated alkylene, wherein said alkylene may be
optionally substituted; and Z is --O-M, M being H or a
pharmaceutically acceptable cation.
255. The inhibitor of claim 254, wherein Y.sup.1 is C.sub.1-C.sub.7
alkylene.
256. The inhibitor of claim 254, wherein Y.sup.1 is --CH.sub.2--,
--CH(CH.sub.3)--, --CH.sub.2CH.sub.2--, --CH.dbd.CH--,
--C.ident.C--, --CH(CH.sub.2CH.sub.3)--, --CH(CH.sub.3)CH.sub.2--,
--CH.sub.2CH(CH.sub.3)--, --CH.dbd.C(CH.sub.3)--,
--C(CH.sub.3).dbd.CH.su- b.2--, --CH.sub.2CH.sub.2CH.sub.2--,
--CH.dbd.CHCH.sub.2--, --CH.sub.2CH.dbd.CH--, --C.dbd.CCH.sub.2--,
or --CH.sub.2
257. The inhibitor of claim 254, wherein Ar is substituted or
unsubstituted phenylene, which optionally may be fused to an aryl
or heteroaryl ring, or to a saturated or partially unsaturated
cycloalkyl or heterocyclic ring, any of which may be optionally
substituted.
258. The inhibitor of claim 257, wherein the phenylene is
4-phenylene.
259. The inhibitor of claim 254, wherein Cy is selected from the
group consisting of phenyl, naphthyl, benzothienyl, and quinolyl,
any of which may be optionally substituted.
260. The inhibitor of claim 259, herein the phenyl, naphthyl,
thienyl, benzothienyl, or quinolyl is unsubstituted or is
substituted by one or two substituents independently selected from
the group consisting of C.sub.1-C.sub.7 alkyl, C.sub.1-C.sub.7
haloalkyl, C.sub.5-C.sub.20 aryl,
(C.sub.5-C.sub.20)ar(C.sub.1-C.sub.7)alkyl, halo, nitro, hydroxy,
C.sub.1-C.sub.7 alkoxy, C.sub.1-C.sub.7 alkoxycarbonyl, carboxy,
and amino.
261. The inhibitor of claim 254, wherein m is zero.
262. An inhibitor of histone deacetylase represented by the formula
Cy-L.sup.2-Ar--Y.sup.2--C(O)NH-Z wherein Cy is aryl orheteroaryl,
any of which may be optionally substituted, provided that Cy is not
a (spirocycloalkyl)heterocyclyl; L.sup.2 is C.sub.1-C.sub.7
saturated alkylene or C.sub.2-C.sub.7 alkenylene, wherein the
alkylene or alkenylene optionally may be substituted, provided that
L.sup.2 is not --C(O)--; Ar is arylene, wherein said arylene
optionally may be additionally substituted and optionally may be
fused to an aryl or heteroaryl ring, or to a saturated or partially
unsaturated cycloalkyl or heterocyclic ring, any of which may be
optionally substituted; and Y.sup.2 is a chemical bond or a
straight- or branched-chain saturated alkylene, which may be
optionally substituted, provided that the alkylene is not
substituted with a substituent of the formula --C(O)R wherein R
comprises an .alpha.-amino acyl moiety; and Z is --O-M, M being H
or a pharmaceutically acceptable cation; provided that when the
carbon atom to which Cy is attached is oxo substituted, then Cy and
Z are not both pyridyl.
263. The inhibitor of claim 262, wherein Y.sup.2 is a chemical
bond.
264. The inhibitor of claim 262, wherein Y.sup.2 is C.sub.1-C.sub.3
--CH.sub.2--, --CH(CH.sub.3)--, --CH.sub.2CH.sub.2--,
--CH.dbd.CH--, --C.ident.C--, --CH(CH.sub.2CH.sub.3)--,
--CH(CH.sub.3)CH.sub.2--, --CH.sub.2CH(CH.sub.3)--,
--CH.dbd.C(CH.sub.3)--, --C(CH.sub.3).dbd.CH.su- b.2--,
--CH.sub.2CH.sub.2CH.sub.2--, --CH.dbd.CHCH.sub.2--,
--CH.sub.2CH.dbd.CH--, --C.ident.CCH.sub.2--, or
--CH.sub.2C.ident.C--.
265. The inhibitor of claim 262, wherein Y.sup.2 is --CH.sub.2--,
--CH(CH.sub.3)--, --CH.sub.2CH.sub.2--, --CH.dbd.CH--, or
--C.ident.C--.
266. The inhibitor of claim 262, wherein Ar is substituted or
unsubstituted phenylene, which optionally may be fused to an aryl
or heteroaryl ring, or to a saturated or partially unsaturated
cycloalkyl or heterocyclic ring, any of which may be optionally
substituted.
267. The inhibitor of claim 266, wherein the phenylene is
4-phenylene.
268. The inhibitor of claim 262, wherein Cy is selected from the
group consisting of phenyl, naphthyl, benzothienyl, and quinolyl,
any of which may be optionally substituted.
269. The inhibitor of claim 268, wherein the phenyl, naphthyl,
benzothienyl, or quinolyl is unsubstituted or is substituted by one
or two substituents independently selected from the group
consisting of C.sub.1-C.sub.7 alkyl, C.sub.1-C.sub.7 haloalkyl,
C.sub.5-C.sub.20 aryl, (C.sub.5-C.sub.20)ar(C.sub.1-C.sub.7)alkyl,
halo, nitro, hydroxy, C.sub.1-C.sub.7 alkoxy, C.sub.1-C.sub.7
alkoxycarbonyl, carboxy, and amino.
270. The inhibitor of claim 262, wherein one or more carbons in
L.sup.2 are substituted with a substituent independently selected
from the group consisting of C.sub.1-C.sub.7 alkyl,
C.sub.5-C.sub.20 aryl, amino, oxo, hydroxy, C.sub.1-C.sub.7 alkoxy,
and C.sub.5-C.sub.20 aryloxy.
271. The inhibitor of claim 270, wherein the substituent is oxo or
hydroxy.
272. The inhibitor of claim 264, wherein L.sup.2 is C.sub.1-C.sub.7
saturated alkylene, and no carbon atom of the alkylene is replaced
by a heteroatom moiety.
273. An inhibitor of histone deacetylase represented by the formula
Cy-L.sup.3-Ar--Y.sup.3--C(O)NH-Z wherein Cy is arylor heteroaryl,
any of which may be optionally substituted, provided that Cy is not
a (spirocycloalkyl)heterocyclyl; L.sup.3 is selected from the group
consisting of (a) --(CH.sub.2).sub.m--W--, where m is 0, 1, 2, 3,
or 4, and W is selected from the group consisting of
--S(O).sub.2NH-- and --NHS(O).sub.2--; and (b) C.sub.1-C.sub.7
alkylene or C.sub.2-C.sub.7 alkenylene, wherein the alkylene or
alkenylene optionally may be substituted, provided that L.sup.3 is
not --C(O)--; Ar is arylene, wherein said arylene optionally may be
additionally substituted and optionally may be fused to an aryl or
heteroaryl ring, or to a saturated or partially unsaturated
cycloalkyl or heterocyclic ring, any of which may be optionally
substituted; and Y.sup.3 is --CH.dbd.CH-- or --C.ident.C--, wherein
one or both carbon atoms of --CH.dbd.CH-- optionally may be
substituted with C.sub.1-7alkyl, C.sub.5-20aryl,
C.sub.1-7alkyl-C.sub.5-20aryl, or C.sub.1-7alkyl; and Z is --O-M, M
being H or a pharmaceutically acceptable cation; provided that when
Cy is unsubstituted phenyl, Ar is not phenyl wherein L.sup.3 and
Y.sup.3 are oriented ortho or meta to each other.
274. The inhibitor of claim 273, wherein Y.sup.3 is selected from
the group consisting of --CH.dbd.CH--, --C(CH.sub.3).dbd.CH--, and
--CH.dbd.C(CH.sub.3)--.
275. The inhibitor of claim 273, wherein Ar is substituted or
unsubstituted phenylene, which optionally may be fused to an aryl
or heteroaryl ring, or to a saturated or partially unsaturated
cycloalkyl or heterocyclic ring, any of which may be optionally
substituted.
276. The inhibitor of claim 275, wherein the phenylene is
4-phenylene.
277. The inhibitor of claim 273, wherein Cy is selected from the
group consisting of phenyl, naphthyl, benzothienyl, and quinolyl,
any of which may be optionally substituted.
278. The inhibitor of claim 277, wherein the phenyl, naphthyl,
benzothienyl, or quinolyl is unsubstituted or is substituted by one
or two substituents independently selected from the group
consisting of C.sub.1-C.sub.7 alkyl, C.sub.1-C.sub.7 haloalkyl,
C.sub.5-C.sub.20 aryl, (C.sub.5-C.sub.20)ar(C.sub.1-C.sub.7)alkyl,
halo, nitro, hydroxy, C.sub.1-C.sub.7 alkoxy, C.sub.1-C.sub.7
alkoxycarbonyl, carboxy, and amino.
Description
RELATED APPLICATIONS
[0001] This application claims priority to United Kingdom Patent
Application Number GB 0023986.3 filed 29 Sep. 2000; U.S.
Provisional Patent Application No. 60/297,784 filed 14 Jun. 2001;
and, U.S. Provisional Patent Application No. 60/308,136 filed 30
Jul. 2001; the contents of each of which are incorporated herein by
reference in their entirety.
TECHNICAL FIELD
[0002] This invention pertains generally to the field of
biologically active compounds, and more specifically to certain
active carbamic acid compounds which inhibit HDAC (histone
deacetylase) activity. The present invention also pertains to
pharmaceutical compositions comprising such compounds, and the use
of such compounds and compositions, both in vitro and in vivo, to
inhibit HDAC, and, e.g., to inhibit proliferative conditions, such
as cancer and psoriasis.
BACKGROUND
[0003] DNA in eukaryotic cells is tightly complexed with proteins
(histones) to form chromatin. Histones are small, positively
charged proteins which are rich in basic amino acids (positively
charged at physiological pH), which contact the phosphate groups
(negatively charged at physiological pH) of DNA. There are five
main classes of histones, H1, H2A, H2B, H3, and H4. The amino acid
sequences of histones H2A, H2B, H3, and H4 show remarkable
conservation between species, whereas H1 varies somewhat, and in
some cases is replaced by another histone, e.g., H5. Four pairs of
each of H2A, H2B, H3, and H4 together form a disk-shaped octomeric
protein core, around which DNA (about 140 base pairs) is wound to
form a nucleosome. Individual nucleosomes are connected by short
stretches of linker DNA associated with another histone molecule
(e.g., H1, or in certain cases, H5) to form a structure resembling
a beaded string, which is itself arranged in a helical stack, known
as a solenoid.
[0004] The majority of histones are synthesised during the S phase
of the cell cycle, and newly synthesised histones quickly enter the
nucleus to become associated with DNA. Within minutes of its
synthesis, new DNA becomes associated with histones in nucleosomal
structures.
[0005] A small fraction of histones, more specifically, the amino
side chains thereof, are enzymatically modified by
post-translational addition of methyl, acetyl, or phosphate groups,
neutralising the positive charge of the side chain, or converting
it to a negative charge. For example, lysine and arginine groups
may be methylated, lysine groups may be acetylated, and serine
groups may be phosphorylated. For lysine, the
--(CH.sub.2).sub.4--NH.sub.2 sidechain may be acetylated, for
example by an acetyltransferase enzyme, to give the amide
--(CH.sub.2).sub.4--NHC(.d- bd.O)CH.sub.3. Methylation,
acetylation, and phosphorylation of amino termini of histones which
extend from the nucleosomal core affects chromatin structure and
gene expression. (See, for example, Spencer and Davie, 1999).
[0006] Acetylation and deacetylation of histones is associated with
transcriptional events leading to cell proliferation and/or
differentiation. Regulation of the function of transcription
factors is also mediated through acetylation. Recent reviews of
histone deacetylation include Kouzarides, 1999 and Pazin et al.,
1997.
[0007] The correlation between the acetylation status of histones
and the transcription of genes has been known for over 30 years
(see, for example, Howe et al., 1999). Certain enzymes,
specifically acetylases (e.g., histone acetyltransferase, HAT) and
deacetylases (e.g., histone deacetylase, HDAC), which regulate the
acetylation state of histones have been identified in many
organisms and have been implicated in the regulation of numerous
genes, confirming the link between acetylation and transcription.
See, for example, Davie, 1998. In general, histone acetylation
correlates with transcriptional activation, whereas histone
deacetylation is associated with gene repression.
[0008] A growing number of histone deacetylases (HDACs) have been
identified (see, for example, Ng and Bird, 2000). The first
deacetylase, HDAC1, was identified in 1996 (see, for example,
Tauton et al., 1996). Subsequently, two other nuclear mammalian
deacetylases has been found, HDAC2 and HDAC3 (see, for example,
Yang et al., 1996, 1997, and Emiliani et al., 1998). See also,
Grozinger et al., 1999; Kao et al., 2000; and Van den Wyngaert et
al., 2000.
[0009] Eight human HDACs have been cloned so far:
[0010] HDAC1 (Genbank Accession No. NP.sub.--004955)
[0011] HDAC2 (Genbank Accession No. NP.sub.--001518)
[0012] HDAC3 (Genbank Accession No. O15739)
[0013] HDAC4 (Genbank Accession No. AAD29046)
[0014] HDAC5 (Genbank Accession No. NP.sub.--005465)
[0015] HDAC6 (Genbank Accession No. NP.sub.--006035)
[0016] HDAC7 (Genbank Accession No. AAF63491)
[0017] HDAC8 (Genbank Accession No. AAF73428).
[0018] These eight human HDACs fall in two distinct classes: HDACs
1,2,3 and 8 are in class 1, and HDACs 4,5,6 and 7 are in class
11.
[0019] There are a number of histone deacetylases in yeast,
including the following:
[0020] RPD3 (Genbank Accession No. NP.sub.--014069)
[0021] HDA1 (Genbank Accession No. P53973)
[0022] HOS1 (Genbank Accession No. Q12214)
[0023] HOS2 (Genbank Accession No. P53096)
[0024] HOS3 (Genbank Accession No. Q02959).
[0025] There are also numerous plant deacetylases, for example,
HD2, in Zea mays (Genbank Accession No. AF254073.sub.--1).
[0026] HDACs function as part of large multiprotein complexes,
which are tethered to the promoter and repress transcription. Well
characterised transcriptional repressors such as Mad (Laherty et
al., 1997), pRb (Brehm et al., 1998), nuclear receptors (Wong et
al., 1998) and YY1 (Yang et al., 1997) associate with HDAC
complexes to exert their repressor function.
[0027] The study of inhibitors of histone deacetylases indicates
that these enzymes play an important role in cell proliferation and
differentiation. The inhibitor Trichostatin A (TSA) (Yoshida et
al., 1990a) causes cell cycle arrest at both G1 and G2 phases
(Yoshida and Beppu, 1988), reverts the transformed phenotype of
different cell lines, and induces differentiation of Friend
leukaemia cells and others (Yoshida et al., 1990b). TSA (and SAHA)
have been reported to inhibit cell growth, induce terminal
differentiation, and prevent the formation of tumours in mice
(Finnin et al., 1999). 1
[0028] Cell cycle arrest by TSA correlates with an increased
expression of gelsolin (Hoshikawa et al., 1994), an actin
regulatory protein that is down regulated in malignant breast
cancer (Mielnicki et al., 1999). Similar effects on cell cycle and
differentiation have been observed with a number of deacetylase
inhibitors (Kim et al., 1999).
[0029] Trichostatin A has also been reported to be useful in the
treatment of fibrosis, e.g., liver fibrosis and liver cirrhosis.
See, e.g., Geerts et al., 1998.
[0030] Recently, certain compounds that induce differentiation have
been reported to inhibit histone deacetylases. Several experimental
antitumour compounds, such as trichostatin A (TSA), trapoxin,
suberoylanilide hydroxamic acid (SAHA), and phenylbutyrate have
been reported to act, at least in part, by inhibiting histone
deacetylase (see, e.g., Yoshida et al., 1990; Richon et al., 1998;
Kijima et al., 1993). Additionally, diallyl sulfide and related
molecules (see, e.g., Lea et al., 1999), oxamflatin (see, e.g., Kim
et al., 1999), MS-27-275, a synthetic benzamide derivative (see,
e.g., Saito et al., 1999; Suzuki et al., 1999; note that MS27-275
was later re-named as MS-275), butyrate derivatives (see, e.g., Lea
and Tulsyan, 1995), FR901228 (see, e.g., Nokajima et al., 1998),
depudecin (see, e.g., Kwon et al., 1998), and m-carboxycinnamic
acid bishydroxamide (see, e.g., Richon et al., 1998) have been
reported to inhibit histone deacetylases. In vitro, some of these
compounds are reported to inhibit the growth of fibroblast cells by
causing cell cycle arrest in the G1 and G2 phases, and can lead to
the terminal differentiation and loss of transforming potential of
a variety of transformed cell lines (see, e.g., Richon et al, 1996;
Kim et al., 1999; Yoshida et al., 1995; Yoshida & Beppu, 1988).
In vivo, phenybutyrate is reported to be effective in the treatment
of acute promyelocytic leukemia in conjunction with retinoic acid
(see, e.g., Warrell et al., 1998). SAHA is reported to be effective
in preventing the formation of mammary tumours in rats, and lung
tumours in mice (see, e.g., Desai et al., 1999).
[0031] The clear involvement of HDACs in the control of cell
proliferation and differentiation suggest that aberrant HDAC
activity may play a role in cancer. The most direct demonstration
that deacetylases contribute to cancer development comes from the
analysis of different acute promyelocytic leukaemias (APL). In most
APL patients, a translocation of chromosomes 15 and 17 (t(15;17))
results in the expression of a fusion protein containing the
N-terminal portion of PML gene product linked to most of RAR.alpha.
(retinoic acid receptor). In some cases, a different translocation
(t(11;17)) causes the fusion between the zinc finger protein PLZF
and RAR.alpha.. In the absence of ligand, the wild type RAR.alpha.
represses target genes by tethering HDAC repressor complexes to the
promoter DNA. During normal hematopoiesis, retinoic acid (RA) binds
RAR.alpha. and displaces the repressor complex, allowing expression
of genes implicated in myeloid differentiation. The RAR.alpha.
fusion proteins occurring in APL patients are no longer responsive
to physiological levels of RA and they interfere with the
expression of the RA-inducible genes that promote myeloid
differentiation. This results in a clonal expansion of
promyelocytic cells and development of leukaemia. In vitro
experiments have shown that TSA is capable of restoring
RA-responsiveness to the fusion RAR.alpha. proteins and of allowing
myeloid differentiation. These results establish a link between
HDACs and oncogenesis and suggest that HDACs are potential targets
for pharmaceutical intervention in APL patients. (See, for example,
Kitamura et al., 2000; David et al., 1998; Lin et al., 1998).
[0032] Furthermore, different lines of evidence suggest that HDACs
may be important therapeutic targets in other types of cancer. Cell
lines derived from many different cancers (prostate, colorectal,
breast, neuronal, hepatic) are induced to differentiate by HDAC
inhibitors (Yoshida and Horinouchi, 1999). A number of HDAC
inhibitors have been studied in animal models of cancer. They
reduce tumour growth and prolong the lifespan of mice bearing
different types of transplanted tumours, including melanoma,
leukaemia, colon, lung and gastric carcinomas, etc. (Ueda et al.,
1994; Kim et al., 1999).
[0033] Psoriasis is a common chronic disfiguring skin disease which
is characterised by well-demarcated, red, hardened scaly plaques:
these may be limited or widespread. The prevalence rate of
psoriasis is approximately 2%, i.e., 12.5 million sufferers in the
triad countries (US/Europe/Japan). While the disease is rarely
fatal, it clearly has serious detrimental effects upon the quality
of life of the patient: this is further compounded by the lack of
effective therapies. Present treatments are either ineffective,
cosmetically unacceptable, or possess undesired side effects. There
is therefore a large unmet clinical need for effective and safe
drugs for this condition.
[0034] Psoriasis is a disease of complex etiology. Whilst there is
clearly a genetic component, with a number of gene loci being
involved, there are also undefined environmental triggers. Whatever
the ultimate cause of psoriasis, at the cellular level, it is
characterised by local T-cell mediated inflammation, by
keratinocyte hyperproliferation, and by localised angiogenesis.
These are all processes in which histone deacetylases have been
implicated (see, e.g., Saunders et al., 1999; Bernhard et al, 1999;
Takahashi et al, 1996; Kim et al, 2001). Therefore HDAC inhibitors
may be of use in therapy for psoriasis. Candidate drugs may be
screened, for example, using proliferation assays with T-cells
and/or keratinocytes.
[0035] Thus, one aim of the present invention is the provision of
compounds which are potent inhibitors of histone deacetylases
(HDACs). There is a pressing need for such compounds, particularly
for use as antiproliferatives, for example, anti-cancer agents,
agents for the treatment of psoriasis, etc.
[0036] Such molecules desirably have one or more of the following
properties and/or effects:
[0037] (a) easily gain access to and act upon tumour cells;
[0038] (b) down-regulate HDAC activity;
[0039] (c) inhibit the formation of HDAC complexes;
[0040] (d) inhibit the interactions of HDAC complexes;
[0041] (e) inhibit tumour cell proliferation;
[0042] (e) promote tumour cell apoptosis;
[0043] (f) inhibit tumour growth; and,
[0044] (g) complement the activity of traditional chemotherapeutic
agents.
[0045] A number of carbamic acid compounds have been described.
[0046] Amides
[0047] Hashimoto et al., 1989 describe hydroxamic acid compounds
which are claimed to inhibit cell proliferation. Some of the
compounds are carbamic acid compounds having a substituted
phenyl-dione group linked to a carbamic acid group (--CONHOH) via
an aryl-substituted alkylene group.
[0048] Ohtani et al., 1993 describe a number of hydroxamic acid
compounds which are claimed to be inhibitors of ras transformation.
A few of the compounds are carbamic acid compounds having a
phenylacylamido group (--NHCOPh) linked to a carbamic acid group
(--CONHOH) via a phenylene-meta-alkylene group having a
carbon-carbon triple bond. See, for example, compounds 1-29 (page
69), I-39 (page 87), and 1-41 (page 90). Compound 1-41, shown
below, employs an aryl leader. 2
[0049] Onishi et al., 1996, describe several hydroxamic acid
compounds which have a phenyl (or substituted phenyl) group linked
via an oxazole group to a carbamic acid group. These compounds were
reported to inhibit a deacetylase enzyme critical in the
biosynthesis of lipid A (a component of the outer membrance of
Gram-negative bacteria).
[0050] Parsons et al., 1998 describe a number of hydroxamic acid
compounds which are claimed to selectively prevent the growth of a
variety of human tumour cell lines.
[0051] Some of the compounds are carbamic acid compounds having an
arylamide group linked to a carbamic acid group via a methylene or
substituted methylene group (see, for example, pages 16 and
17).
[0052] Some of the compounds are carbamic acid compounds having a
phenylamido group (--CONHPh) linked to a carbamic acid group
(--CONHOH) via a long alkylene chain, --(CH.sub.2).sub.n--, wherein
n is from 4 to 7 (see, for example, pages 47, 48, and 58
therein).
[0053] Some of the compounds are carbamic acid compounds having an
aryl group linked via a short chain to an amide group (--CONH--),
which in turn is linked via a short chain (e.g., 3 atoms or less)
to a carbamic acid group (--CONHOH). See, for example, page 16, 2nd
formula; page 46, 4th formula; page 51, compound 7; and page 61,
2nd formula. 3
[0054] Richon et al., 1998 describe several hydroxamic acid
compounds, including SAHA, which apparently inhibit HDAC activity,
and induce terminal differentiation and/or apoptosis in various
transformed cells (see, for example, Table 1 therein).
[0055] Suzuki et al., 1998 describe a number of hydroxamic acid
compounds which are claimed to have antitumour activity. Some of
the compounds are carbamic acid compounds having a substituted
phenylamido group (--CONHPh) linked to a carbamic acid (--CONHOH)
group via a phenylene-meta-ethenylen- e or phenylene-para-ethylene
group (see, for example, pages 8 and 9, compounds 31-50).
[0056] Breslow et al., 1994, 1995, 1997 describe a number of
hydroxamic acid compounds which are claimed to selectively induce
terminal differentiation of neoplastic cells.
[0057] Some of the compounds are carbamic acid compounds having a
substituted phenylacylamido group (--NHCOPh) linked to a carbamic
acid (--CONHOH) group via a long alkylene chain,
--(CH.sub.2).sub.n--, wherein n is from 4 to 8.
[0058] Some of the compounds are carbamic acid compounds having a
substituted phenylamido group (--CONHPh) or phenylacylamido group
(--NHCOPh) linked to a carbamic acid (--CONHOH) group via a long
alkylene chain, --(CH.sub.2).sub.n--, wherein n is from 4 to 8
(see, for example, columns 7 and 13 of Breslow et al., 1997), or
via a phenylene group (see, for example, columns 24, 30-31 and
compounds 20-55 in Table 1 of Breslow et al., 1997).
[0059] One of the compounds is a carbamic acid compound having
benzylamido group (--CONHCH.sub.2Ph) linked to a carbamic acid
group (--CONHOH) via a --(CH.sub.2).sub.6-- group (see, for
example, compound 19 in Table 1, at column 37 of Breslow et al.,
1997).
[0060] Jung et al., 1997, 1999, describe several aromatic
hydroxamic acid compounds which apparently inhibit HDAC. Some of
the compounds have a phenylamido group (PhCONH--). One compound, a
peptide analog, is shown below (see, e.g., compound 6 in Jung et
al., 1997; compound 4 in Jung et al., 1999). 4
[0061] Kato et al., 1998, describe a number of aromatic hydroxamic
acid compounds, comprising an aryl group linked via an alkylene
group to a carbamic acid group, which are apparently active in the
treatment of neurodegenerative conditions. One compound, 4-1 at
columns 63-64, has a phenylamido group (PhCONH--) linked via a
--(CH.sub.2).sub.5-- group to a carbamic acid group.
[0062] Glick et al., 1999, describe the apparent apoptotic and
differentiating effects of m-carboxy-cinnamic acid bishydroxamide
(CBHA) on various tumour cell lines.
[0063] Massa et al., 2001, describe various hydroxamic acid
compounds which have a benzoyl (or substituted benzoyl) group
linked via a pyrrolyl group and an C.sub.2alkylene group
(--CH.dbd.CH-- or --CH.sub.2CH.sub.2--) to a carbamic acid group.
The compounds apparently showed HDAC inhibitory activity in the
micromolar range.
[0064] Sulfonamides
[0065] Oxamflatin, also known as
(2E)-5-[3-[(phenylsulfonyl)amino]phenyl]--
pent-2-en-4-ynohydroxamic acid, shown below, has been reported to
have in vitro antiproliferative activity against various mouse and
human tumour cell lines, and in vivo antitumour activity against
B16 melanoma (see, e.g., Sonoda et al., 1996; Kim et al., 1999).
5
[0066] Ohtani et al., 1993, describe a number of hydroxamic acid
compounds which are claimed to be inhibitors of ras transformation.
Many of the compounds are hydroxmic acid compounds which have a
sulfonamide group, and which employ an acid leader which is: a
phenylene-ortho-alkylene (e.g., I-10); phenylene-meta-alkylene
(e.g., I-24); phenylene-para-alkylene (e.g., I-12); or
napthylen-1,2-diyl (e.g., I-20). However, in every case, the
sulfonamide group is --SO.sub.2NR--, as opposed to --NRSO.sub.2--.
Also, in every case, the terminal aryl group is linked directly to
the --SO.sub.2NR-- sulfonamide group, without an intervening aryl
leader. Ohtani et al., 1996, describe similar compounds.
[0067] Richon et al., 2001, describe various branched compounds
which apparently inhibit histone deacetylase. See the table at
pages 96-101 therein. Some of the compounds are carbamic acid
compounds having a carbamic acid group (--CONHOH) linked to a
branch point, from which two aryl groups are appended. A few linear
carbamic acid compounds are also described, including a single
--SO.sub.2NH-- sulfonamide carbamic acid with a
--(CH.sub.2).sub.5-- acid leader (compound 671).
[0068] Delorme et al., 2001, describe various carbamic acid
compounds, including compounds having, inter alia, a sulfonamide
group. Of the 108 compounds in the table at pages 114-123 therein,
88 are carbamic acids (--CONHOH), and the remainder are terminal
amides, --CONHR. Of the 88 carbamic acid compounds, 54 have a
sulfonamide linkage.
[0069] Of the 54 sulfonamide carbamic acids, 51 are indicated to
have a --SO.sub.2NR-sulfonamide group, and 3 (compounds 98, 161,
and 162) are indicated to have a --NRSO.sub.2-- sulfonamide
group.
[0070] All of the 54 sulfonamide carbamic acids employ a
phenylene-alkylene acid leader group (analogous to Q.sup.2 herein).
Of the 54 compounds, 52 employ a phenylene-para-alkylene group, and
only 2 (compounds 41 and 26) employ a phenylene-meta-alkylene group
(--Ph-CH.sub.2-- and --Ph-(CH.sub.2).sub.4--, respectively).
Compounds 41 and 26 both have a --SO.sub.2NR-- sulfonamide group,
as opposed to a --NRSO.sub.2-- sulfonamide group; the former has a
benzothiophenyl group, and the latter has a phenyl group.
[0071] All but one of the 54 sulfonamide carbamic acids have an
aryl group linked directly to the sulfonamide; compound 100 has a
benzyl group (Ph-CH.sub.2--) linked a --SO.sub.2NR-- sulfonamide
group linked to phenylene-para-ethylene.
SUMMARY OF THE INVENTION
[0072] One aspect of the invention pertains to active carbamic acid
compounds, as described herein, which inhibit HDAC activity.
[0073] Another aspect of the invention pertains to active
compounds, as described herein, which treat a proliferative
condition, such as cancer or psoriasis.
[0074] Another aspect of the invention pertains to active
compounds, as described herein, which treat conditions which are
known to be mediated by HDAC, or which are known to be treated by
HDAC inhibitors (such as, e.g., trichostatin A).
[0075] Another aspect of the present invention pertains to a
composition comprising a compound as described herein and a
pharmaceutically acceptable carrier.
[0076] Another aspect of the present invention pertains to methods
of inhibiting HDAC in a cell, comprising contacting said cell with
an effective amount of an active compound, as described herein.
[0077] Another aspect of the present invention pertains to methods
of inhibiting cell proliferation, comprising contacting a cell with
an effective amount of an active compound, as described herein,
whether in vitro or in vivo.
[0078] Another aspect of the present invention pertains to methods
of treating a proliferative condition in a patient comprising
administering to said patient a therapeutically-effective amount of
an active compound, as described herein. In one preferred
embodiment, the proliferative condition is cancer. In one preferred
embodiment, the proliferative condition is psoriasis.
[0079] Another aspect of the present invention pertains to methods
of treating a condition in a patient which is known to be mediated
by HDAC, or which is known to be treated by HDAC inhibitors (such
as, e.g., trichostatin A), comprising administering to said patient
a therapeutically-effective amount of an active compound, as
described herein.
[0080] Another aspect of the present invention pertains to an
active compound, as described herein, for use in a method of
treatment of the human or animal body.
[0081] Another aspect of the present invention pertains to use of
an active compound, as described herein, for the manufacture of a
medicament for use in the treatment of a proliferative condition.
In one preferred embodiment the proliferative condition is cancer.
In one preferred embodiment, the proliferative condition is
psoriasis.
[0082] Another aspect of the present invention pertains to use of
an active compound for the manufacture of a medicament, for
example, for the treatment of conditions which are known to be
mediated by HDAC, or which are known to be treated by HDAC
inhibitors (such as, e.g., trichostatin A), as discussed
herein.
[0083] Another aspect of the present invention pertains to a kit
comprising (a) the active compound, preferably provided as a
pharmaceutical composition and in a suitable container and/or with
suitable packaging; and (b) instructions for use, for example,
written instructions on how to administer the active compound.
[0084] Another aspect of the present invention pertains to
compounds obtainable by a method of synthesis-as described herein,
or a method comprising a method of synthesis as described
herein.
[0085] Another aspect of the present invention pertains to
compounds obtained by a method of synthesis as described herein, or
a method comprising a method of synthesis as described herein.
[0086] Another aspect of the present invention pertains to novel
intermediates, as described herein, which are suitable for use in
the methods of synthesis described herein.
[0087] Another aspect of the present invention pertains to the use
of such novel intermediates, as described herein, in the methods of
synthesis described herein.
[0088] As will be appreciated by one of skill in the art, features
and preferred embodiments of one aspect of the invention will also
pertain to other aspects of the invention.
DETAILED DESCRIPTION OF THE INVENTION
[0089] Compounds
[0090] In one embodiment, the present invention pertains to
carbamic acid compounds of the formula: 6
[0091] wherein:
[0092] A is an aryl group;
[0093] Q.sup.1 is a covalent bond or an aryl leader group;
[0094] J is a sulfonamide linkage selected from: 7
[0095] R.sup.1 is a sulfonamido substituent; and,
[0096] Q.sup.2 is an acid leader group;
[0097] with the proviso that if J is: 8
[0098] then Q.sup.1 is an aryl leader group;
[0099] and pharmaceutically acceptable salts, solvates, amides,
esters, ethers, chemically protected forms, and prodrugs
thereof.
[0100] In preferred embodiments, the carbamic acid group,
--C(.dbd.O)NHOH, is unmodified (e.g., is not an ester).
[0101] In one preferred embodiment, the present invention pertains
to carbamic acid compounds of the formula: 9
[0102] wherein:
[0103] A is an aryl group;
[0104] Q.sup.1 is an aryl leader group;
[0105] J is a sulfonamide linkage selected from: 10
[0106] R.sup.1 is an sulfonamido substituent; and,
[0107] Q.sup.2 is an acid leader group.
[0108] In one preferred embodiment, the present invention pertains
to carbamic acid compounds of the formula: 11
[0109] wherein:
[0110] A is an aryl group;
[0111] Q.sup.1 is a covalent bond or an aryl leader group;
[0112] J is a sulfonamide linkage selected from: 12
[0113] R.sup.1 is an sulfonamido substituent; and,
[0114] Q.sup.2 is an acid leader group.
[0115] In one preferred embodiment, Q.sup.1 is an aryl leader
group, J is --SO.sub.2NR.sup.1--, and the compounds have the
following formula: 13
[0116] In one preferred embodiment, Q.sup.1 is a covalent bond or
an aryl leader group, J is --NR.sup.1SO.sub.2--, and the compounds
have the following formula: 14
[0117] In one preferred embodiment, Q.sup.1 is an aryl leader
group, J is --NR.sup.1SO.sub.2--, and the compounds have the
following formula: 15
[0118] In one preferred embodiment, Q.sup.1 is a covalent bond, J
is --NR.sup.1SO.sub.2--, and the compounds have the following
formula: 16
[0119] In one embodiment, where Q.sup.1 is an aryl leader, the aryl
group, A, is linked to Q.sup.1 via a covalent single bond.
[0120] In one embodiment, where Q.sup.1 is a cyclic aryl leader,
the aryl group, A, may be fused to Q.sup.1 and so the moiety
A-Q.sup.1- forms a fused polycyclic structure. For example, the
moiety 2,3-dihydro-1H-indene-2-yl, derived from indan
(2,3-dihydro-1H-indene), is considered to be a phenyl group (A)
fused to a C.sub.5cycloalkyl group (Q.sup.1): 17
[0121] In such cases, the tridentate aryl leader, Q.sup.1, may be
denoted as: 18
[0122] In a similar example, the moiety 9H-fluorene-9-yl, derived
from fluorene, is considered to be two phenyl groups (either of
which is A), fused to a C.sub.5cycloalkyl group, which forms part
of Q.sup.1: 19
[0123] In such cases, the pentadentate aryl leader, Q.sup.1, may be
denoted as: 20
[0124] The Aryl Group, A
[0125] The aryl group, A, is a C.sub.5-20aryl group, and is
optionally substituted.
[0126] In one preferred embodiment, A is a C.sub.5-20heteroaryl
group, and is optionally substituted. In one preferred embodiment,
A is a monocyclic C.sub.5-20heteroaryl group, and is optionally
substituted. In one preferred embodiment, A is a monocyclic C
heteroaryl group, and is optionally substituted. In one preferred
embodiment, A is a C.sub.5-20carboaryl group, and is optionally
substituted. In one preferred embodiment, A is a monocyclic
C.sub.5-20carboaryl group, and is optionally substituted. In one
preferred embodiment, A is a monocyclic C.sub.5-6carboaryl group,
and is optionally substituted. In one preferred embodiment, A is a
phenyl group, and is optionally substituted.
[0127] In one preferred embodiment, A is a C.sub.5-20aryl group
derived from one of the following: benzene, pyridine, furan,
indole, pyrrole, imidazole, naphthalene, quinoline, benzimidazole,
benzothiofuran, fluorene, acridine, and carbazole.
[0128] In one preferred embodiment, A is an optionally substituted
phenyl group of the formula: 21
[0129] wherein n is an integer from 0 to 5, and each R.sup.A is
independently a substituent as defined herein.
[0130] Thus, in one preferred embodiment, A is an optionally
substituted phenyl group, Q.sup.1 is an aryl leader group, J is
--SO.sub.2NR.sup.1--, and the compounds have the following formula:
22
[0131] In one preferred embodiment, A is an optionally substituted
phenyl group, Q.sup.1 is a covalent bond or an aryl leader group, J
is --NR.sup.1SO.sub.2--, and the compounds have the following
formula: 23
[0132] In one preferred embodiment, A is an optionally substituted
phenyl group, Q.sup.1 is an aryl leader group, J is
--NR.sup.1SO.sub.2--, and the compounds have the following formula:
24
[0133] In one preferred embodiment, A is an optionally substituted
phenyl group, Q.sup.1 is a covalent bond, J is --NR.sup.1SO.sub.2,
and the compounds have the following formula: 25
[0134] In one preferred embodiment, n is an integer from 0 to 5. In
one preferred embodiment, n is an integer from 0 to 4. In one
preferred embodiment, n is an integer from 0 to 3. In one preferred
embodiment, n is an integer from 0 to 2. In one preferred
embodiment, n is 0 or 1.
[0135] In one preferred embodiment, n is an integer from 1 to
5.
[0136] In one preferred embodiment, n is an integer from 1 to
4.
[0137] In one preferred embodiment, n is an integer from 1 to
3.
[0138] In one preferred embodiment, n is 1 or 2.
[0139] In one preferred embodiment, n is 5.
[0140] In one preferred embodiment, n is 4.
[0141] In one preferred embodiment, n is 3.
[0142] In one preferred embodiment, n is 2.
[0143] In one preferred embodiment, n is 1.
[0144] In one preferred embodiment, n is 0.
[0145] If the phenyl group has less than the full complement of
ring substituents, R.sup.A, they may be arranged in any
combination. For example, if n is 1, R.sup.A may be in the 2'-,
3'-, 4'-, 5'-, or 6'-position; Similarly, if n is 2, the two
R.sup.A groups may be in, for example, the 2',3'-, 2',4'-, 2',5'-,
2',6'-, 3',4'-, or 3',5'-positions. If n is 3, the three R.sup.A
groups may be in, for example, the 2',3',4'-, 2',3',5'-, 2',3',6'-,
or 3',4',5'-positions.
[0146] In one preferred embodiment, n is 1, and the R.sup.A group
is in the 4'-position.
[0147] In one preferred embodiment, n is 2, and one R.sup.A group
is in the 4'-position, and the other R.sup.A group is in the
2'-position.
[0148] In one preferred embodiment, n is 2, and one R.sup.A group
is in the 4'-position, and the other R.sup.A group is in the
3'-position.
[0149] Each aryl substituent, R.sup.A, is a substituent as defined
herein.
[0150] Examples of preferred aryl substituents, R.sup.A, include,
but are not limited to, the following: fluoro, chloro, bromo, iodo,
methyl, ethyl, isopropyl, t-butyl, cyano, trifluoromethyl, hydroxy,
methoxy, ethoxy, isopropoxy, trifluoromethoxy, phenoxy, methylthio,
trifluoromethylthio, hydroxymethyl, amino, dimethylamino,
diethylamino, morpholino, amido (unsubstituted, i.e.,
--CONH.sub.2), acetamido, acetyl, nitro, sulfonamido
(unsubstituted, i.e., --SO.sub.2NH.sub.2), and phenyl.
[0151] In one preferred embodiment, A is a substituted phenyl group
selected from:
[0152] para-(fluoro)phenyl; ortho-(fluoro)phenyl;
meta-(fluoro)phenyl;
[0153] para-(chloro)phenyl; ortho-(chloro)phenyl;
meta-(chloro)phenyl;
[0154] para-(bromo)phenyl; ortho-(bromo)phenyl;
meta-(bromo)phenyl;
[0155] para-(iodo)phenyl; ortho-(iodo)phenyl;
meta-(iodo)phenyl;
[0156] para-(methyl)phenyl; ortho-(methyl)phenyl;
meta-(methyl)phenyl;
[0157] para-(ethyl)phenyl; ortho-(ethyl)phenyl;
meta-(ethyl)phenyl;
[0158] para-(isopropyl)phenyl; ortho-(isopropyl)phenyl;
meta-(isopropyl)phenyl;
[0159] para-(t-butyl)phenyl; ortho-(t-butyl)phenyl;
meta-(t-butyl)phenyl;
[0160] para-(cyano)phenyl; ortho-(cyano)phenyl;
meta-(cyano)phenyl;
[0161] para-(trifluoromethyl)phenyl; ortho-(trifluoromethyl)phenyl;
meta-(trifluoromethyl)phenyl;
[0162] para-(hydroxy)phenyl; ortho-(hydroxy)phenyl;
meta-(hydroxy)phenyl;
[0163] para-(methoxy)phenyl; ortho-(methoxy)phenyl;
meta-(methoxy)phenyl;
[0164] para-(ethoxy)phenyl; ortho-(ethoxy)phenyl;
meta-(ethoxy)phenyl;
[0165] para-(isopropoxy)phenyl; ortho-(isopropoxy)phenyl;
meta-(isopropoxy)phenyl;
[0166] para-(trifluoromethoxy)phenyl;
ortho-(trifluoromethoxy)phenyl; meta-(trifluoromethoxy)phenyl;
[0167] para-(phenoxy)phenyl; ortho-(phenoxy)phenyl;
meta-(phenoxy)phenyl;
[0168] para-(methylthio)phenyl; ortho-(methylthio)phenyl;
meta-(methylthio)phenyl;
[0169] para-(trifluoromethylthio)phenyl;
ortho-(trifluoromethylthio)phenyl- ;
meta-(trifluoromethylthio)phenyl;
[0170] para-(hydroxymethyl)phenyl; ortho-(hydroxymethyl)phenyl;
meta-(hydroxymethyl)phenyl;
[0171] para-(amino)phenyl; ortho-(amino)phenyl;
meta-(amino)phenyl;
[0172] para-(dimethylamino)phenyl; ortho-(dimethylamino)phenyl;
meta-(dimethylamino)phenyl;
[0173] para-(diethylamino)phenyl; ortho-(diethylamino)phenyl;
meta-(diethylamino)phenyl;
[0174] para-(morpholino)phenyl; ortho-(morpholino)phenyl;
meta-(morpholino)phenyl;
[0175] para-(amido)phenyl; ortho-(amido)phenyl;
meta-(amido)phenyl;
[0176] para-(acetamido)phenyl; ortho-(acetamido)phenyl;
meta-(acetamido)phenyl;
[0177] para-(acetyl)phenyl; ortho-(acetyl)phenyl;
meta-(acetyl)phenyl;
[0178] para-(nitro)phenyl; ortho-(nitro)phenyl;
meta-(nitro)phenyl;
[0179] para-(sulfonamido)phenyl; ortho-(sulfonamido)phenyl;
meta-(sulfonamido)phenyl; and,
[0180] para-(phenyl)phenyl; ortho-(phenyl)phenyl;
meta-(phenyl)phenyl.
[0181] In one preferred embodiment, A is a substituted phenyl group
selected from:
[0182] para-(fluoro)phenyl;
[0183] para-(chloro)phenyl;
[0184] para-(bromo)phenyl;
[0185] para-(iodo)phenyl;
[0186] para-(methyl)phenyl;
[0187] para-(ethyl)phenyl;
[0188] para-(isopropyl)phenyl;
[0189] para-(t-butyl)phenyl;
[0190] para-(cyano)phenyl;
[0191] para-(trifluoromethyl)phenyl;
[0192] para-(hydroxy)phenyl;
[0193] para-(methoxy)phenyl;
[0194] para-(ethoxy)phenyl;
[0195] para-(isopropoxy)phenyl; para-(trifluoromethoxy)phenyl;
[0196] para-(phenoxy)phenyl;
[0197] para-(methylthio)phenyl;
[0198] para-(trifluoromethylthio)phenyl;
[0199] para-(hydroxymethyl)phenyl;
[0200] para-(amino)phenyl;
[0201] para-(dimethylamino)phenyl;
[0202] para-(diethylamino)phenyl;
[0203] para-(morpholino)phenyl;
[0204] para-(amido)phenyl;
[0205] para-(acetamido)phenyl;
[0206] para-(acetyl)phenyl;
[0207] para-(nitro)phenyl;
[0208] para-(sulfonamido)phenyl; and,
[0209] para-(phenyl)phenyl.
[0210] In one preferred embodiment, A is a substituted phenyl group
selected from:
[0211] ortho,para-di(methoxy)phenyl;
[0212] ortho,para-di(halo)phenyl;
[0213] ortho,para-di(fluoro)phenyl;
[0214] ortho-(methoxy),para-(methyl)phenyl;
[0215] ortho-(methoxy), para-(trifluoromethyl)phenyl;
[0216] ortho-(trifluoromethyl),para-(halo)phenyl;
[0217] ortho,meta-di(trifluoromethyl)phenyl;
[0218] ortho-(halo),meta-(trifluoromethyl)phenyl;
[0219] meta,para-di(halo)phenyl;
[0220] meta,para-di(hydroxy)phenyl;
[0221] meta,para-di(methyl)phenyl;
[0222] meta,para-di(methoxy)phenyl;
[0223] meta-(halo),para-(nitro)phenyl;
[0224] 3',5'-di(trifluoromethyl)phenyl;
[0225] 3'-(trifluoromethyl),5'-(methoxy)phenyl;
[0226] 3'-(trifluoromethyl),5'-(halo)phenyl;
[0227] 2'-(halo),5'-(methyl)phenyl;
[0228] 2',6'-di(methyl)phenyl;
[0229] 2',6'-di(halo)phenyl;
[0230] 2',6'-di(isopropyl)phenyl;
[0231] 2',4',6'-tri(halo)phenyl;
[0232] 3',4',5'-tri(halo)phenyl;
[0233] 3',4' 5'-tri(methoxy)phenyl;
[0234] 2',5'-di(halo).sub.4'-(hydroxy)phenyl; and
[0235] 3'-(trifuoromethyl),5',6'-di(halo)phenyl.
[0236] The Aryl Leader Group, Q.sup.1
[0237] As mentioned above, in some embodiments, Q.sup.1 is a
covalent bond or an aryl leader group; in some embodiments, Q.sup.1
is a covalent bond; in some embodiments, Q.sup.1 is an aryl leader
group.
[0238] In one preferred embodiment, Q.sup.1 is a covalent bond.
[0239] In one preferred embodiment, Q.sup.1 is a C.sub.1-7alkylene
group and is optionally substituted.
[0240] In one preferred embodiment, Q.sup.1 is a covalent bond or a
C.sub.1-7alkylene group and is optionally substituted.
[0241] In one preferred embodiment, Q.sup.1 is a covalent bond or a
saturated C.sub.1-7alkylene group. In one preferred embodiment,
Q.sup.1 is a saturated C.sub.1-7alkylene group.
[0242] In one preferred embodiment, Q.sup.1 is a covalent bond or a
partially unsaturated C.sub.1-7alkylene group. In one preferred
embodiment, Q.sup.1 is a partially unsaturated C.sub.1-7alkylene
group.
[0243] In one preferred embodiment, Q.sup.1 is a covalent bond or
an aliphatic C.sub.1-7alkylene group. In one preferred embodiment,
Q.sup.1 is an aliphatic C.sub.1-7alkylene group.
[0244] In one preferred embodiment, Q.sup.1 is a covalent bond or a
linear C.sub.1-7alkylene group.
[0245] In one preferred embodiment, Q.sup.1 is a linear
C.sub.1-7alkylene group.
[0246] In one preferred embodiment, Q.sup.1 is a covalent bond or a
branched C.sub.1-7alkylene group. In one preferred embodiment,
Q.sup.1 is a branched C.sub.1-7alkylene group.
[0247] In one preferred embodiment, Q.sup.1 is a covalent bond or
an alicyclic C.sub.1-7alkylene group. In one preferred embodiment,
Q.sup.1 is an alicyclic C.sub.1-7alkylene group.
[0248] In one preferred embodiment, Q.sup.1 is a covalent bond or a
saturated aliphatic C.sub.1-7alkylene group. In one preferred
embodiment, Q.sup.1 is a saturated aliphatic C.sub.1-7alkylene
group.
[0249] In one preferred embodiment, Q.sup.1 is a covalent bond or a
saturated linear C.sub.1-7alkylene group. In one preferred
embodiment, Q.sup.1 is a saturated linear C.sub.1-7alkylene
group.
[0250] In one preferred embodiment, Q.sup.1 is a covalent bond or a
saturated branched C.sub.1-7alkylene group. In one preferred
embodiment, Q.sup.1 is a saturated branched C.sub.1-7alkylene
group.
[0251] In one preferred embodiment, Q.sup.1 is a covalent bond or a
saturated alicyclic C.sub.1-7alkylene group. In one preferred
embodiment, Q.sup.1 is a saturated alicyclic C.sub.1-7alkylene
group.
[0252] In one preferred embodiment, Q.sup.1 is a covalent bond or a
partially unsaturated aliphatic C.sub.1-7alkylene group. In one
preferred embodiment, Q.sup.1 is a partially unsaturated aliphatic
C.sub.1-7alkylene group.
[0253] In one preferred embodiment, Q.sup.1 is a covalent bond or a
partially unsaturated linear C.sub.1-7alkylene group. In one
preferred embodiment, Q.sup.1 is a partially unsaturated linear
C.sub.1-7alkylene group.
[0254] In one preferred embodiment, Q.sup.1 is a covalent bond or a
partially unsaturated branched C.sub.1-7alkylene group. In one
preferred embodiment, Q.sup.1 is a partially unsaturated branched
C.sub.1-7alkylene group.
[0255] In one preferred embodiment, Q.sup.1 is a covalent bond or a
partially unsaturated alicyclic C.sub.1-7alkylene group. In one
preferred embodiment, Q.sup.1 is a partially unsaturated alicyclic
C.sub.1-7alkylene group.
[0256] The Aryl Leader Group, Q.sup.1: Backbone Length
[0257] In one embodiment, the aryl leader group, Q.sup.1, has a
backbone of at least 2 carbon atoms; that is, the shortest chain of
atoms linking the aryl group, A, and the sulfonamide group, J, has
2 or more atoms, more specifically, 2 or more carbon atoms. In this
way, groups such as methylene (--CH.sub.2--) and substituted
methylene (--CR.sub.2-- and --CHR--) are excluded.
[0258] If there are two or more paths linking the aryl group, A,
and the sulfonamide group, J, then the shortest path is relevant.
For example, in the embodiments shown below, where the moiety
A-Q.sup.1- is derived from indan (2,3-dihydro-1H-indene), A is
considered to be a phenyl group fused to Q.sup.1, a
C.sub.5cycloalkyl group: 26
[0259] In each case, there are two paths to the aryl group. In the
first case, one path has 1 carbon atom, and the other path has 3
carbon atoms, and so the relevant backbone length is 1. In the
second case, both paths have 2 carbon atoms, and so the relevant
backbone length is 2.
[0260] If the group A-Q.sup.1- has two or more aryl groups, the
aryl group furthest from the sulfonamide group, J, as measured by
counting chain atoms, is identified as A; the relevant backbone is
then the shortest chain of atoms linking that aryl group and the
sulfonamide group, J. For example, where the group A-Q.sup.1- is as
shown below, the phenyl group marked "1" is identified as the A,
Q.sup.1 is --CH.sub.2CH(Ph)-- (i.e., substituted ethylene), and the
backbone length is 2. 27
[0261] If the sulfonamide group is --NR.sup.1SO.sub.2-- (as opposed
to --SO.sub.2NR.sup.1--), and substituent, R.sup.1, discussed
below, is or comprises an aryl group (or two or more aryl groups),
then the aryl group furthest from the sulfonamide group nitrogen
atom, as measured by counting chain atoms, is identified as A. For
example, where the group A-Q.sup.1-NR.sup.1SO.sub.2-- is as shown
below, the phenyl group marked "1" is identified as the A, Q.sup.1
is --CH.sub.2--, and the backbone length is 1. 28
[0262] In one preferred embodiment, the aryl leader group, Q.sup.1,
has a backbone of at least 3 carbon atoms.
[0263] In one preferred embodiment, the aryl leader group, Q.sup.1,
has a backbone of at least 4 carbon atoms.
[0264] In one preferred embodiment, the aryl leader group, Q.sup.1,
has a backbone of at least 5 carbon atoms.
[0265] In one embodiment, the aryl leader group, Q.sup.1, has a
backbone of:
[0266] from 2 to 7 carbon atoms;
[0267] from 2 to 6 carbon atoms; or,
[0268] from 2 to 5 carbon atoms.
[0269] In one embodiment, the aryl leader group, Q.sup.1, has a
backbone of:
[0270] from 3 to 7 carbon atoms;
[0271] from 3 to 6 carbon atoms; or,
[0272] from 3 to 5 carbon atoms.
[0273] In one embodiment, the aryl leader group, Q.sup.1, has a
backbone of:
[0274] from 4 to 7 carbon atoms;
[0275] from 4 to 6 carbon atoms; or,
[0276] from 4 to 5 carbon atoms.
[0277] In one embodiment, the aryl leader group, Q.sup.1, has a
backbone of 2 carbon atoms.
[0278] In one embodiment, the aryl leader group, Q.sup.1, has a
backbone of 3 carbon atoms.
[0279] In one embodiment, the aryl leader group, Q.sup.1, has a
backbone of 4 carbon atoms.
[0280] In one embodiment, the aryl leader group, Q.sup.1, has a
backbone of 5 carbon atoms.
[0281] The Aryl Leader Group, Q.sup.1: Alkylene
[0282] In one embodiment, the aryl leader group, Q.sup.1, is an
alkylene group, and has a backbone of at least 2 carbon atoms.
[0283] In one preferred embodiment, the aryl leader group, Q.sup.1,
has a backbone of at least 2 carbon atoms, and is a
C.sub.2-7alkylene group.
[0284] In one preferred embodiment, the aryl leader group, Q.sup.1,
has a backbone of at least 3 carbon atoms, and is a
C.sub.3-7alkylene group.
[0285] In one preferred embodiment, Q.sup.1 has a backbone of at
least 2 carbon atoms, and is a saturated C.sub.2-7alkylene
group.
[0286] In one preferred embodiment, Q.sup.1 has a backbone of at
least 3 carbon atoms, and is a saturated C.sub.3-7alkylene
group.
[0287] In one preferred embodiment, Q.sup.1 has a backbone of at
least 2 carbon atoms, and is a partially unsaturated
C.sub.2-7alkylene group.
[0288] In one preferred embodiment, Q.sup.1 has a backbone of at
least 3 carbon atoms, and is a partially unsaturated
C.sub.3-7alkylene group.
[0289] In one preferred embodiment, Q.sup.1 has a backbone of at
least 2 carbon atoms, and is an aliphatic C.sub.2-7alkylene
group.
[0290] In one preferred embodiment, Q.sup.1 has a backbone of at
least 3 carbon atoms, and is an aliphatic C.sub.3-7alkylene
group.
[0291] In one preferred embodiment, Q.sup.1 has a backbone of at
least 2 carbon atoms, and is a linear C.sub.2-7alkylene group.
[0292] In one preferred embodiment, Q.sup.1 has a backbone of at
least 3 carbon atoms, and is a linear C.sub.3-7alkylene group.
[0293] In one preferred embodiment, Q.sup.1 has a backbone of at
least 2 carbon atoms, and is a branched C.sub.2-7alkylene
group.
[0294] In one preferred embodiment, Q.sup.1 has a backbone of at
least 3 carbon atoms, and is a branched C.sub.3-7alkylene
group.
[0295] In one preferred embodiment, Q.sup.1 has a backbone of at
least 2 carbon atoms, and is an alicyclic C.sub.2-7alkylene
group.
[0296] In one preferred embodiment, Q.sup.1 has a backbone of at
least 3 carbon atoms, and is an alicyclic C.sub.3-7alkylene
group.
[0297] In one preferred embodiment, Q.sup.1 has a backbone of at
least 2 carbon atoms, and is a saturated aliphatic
C.sub.2-7alkylene group.
[0298] In one preferred embodiment, Q.sup.1 has a backbone of at
least 3 carbon atoms, and is a saturated aliphatic
C.sub.3-7alkylene group.
[0299] In one preferred embodiment, Q.sup.1 has a backbone of at
least 2 carbon atoms, and is a saturated linear C.sub.2-7alkylene
group.
[0300] In one preferred embodiment, Q.sup.1 has a backbone of at
least 3 carbon atoms, and is a saturated linear C.sub.3-7alkylene
group.
[0301] In one preferred embodiment, Q.sup.1 has a backbone of at
least 2 carbon atoms, and is a saturated branched C.sub.2-7alkylene
group.
[0302] In one preferred embodiment, Q.sup.1 has a backbone of at
least 3 carbon atoms, and is a saturated branched C.sub.3-7alkylene
group.
[0303] In one preferred embodiment, Q.sup.1 has a backbone of at
least 2 carbon atoms, and is a saturated alicyclic
C.sub.2-7alkylene group.
[0304] In one preferred embodiment, Q.sup.1 has a backbone of at
least 3 carbon atoms, and is a saturated alicyclic
C.sub.3-7alkylene group.
[0305] In one preferred embodiment, Q.sup.1 has a backbone of at
least 2 carbon atoms, and is a partially unsaturated aliphatic
C.sub.2-7alkylene group.
[0306] In one preferred embodiment, Q.sup.1 has a backbone of at
least 3 carbon atoms, and is a partially unsaturated aliphatic
C.sub.3-7alkylene group.
[0307] In one preferred embodiment, Q.sup.1 has a backbone of at
least 2 carbon atoms, and is a partially unsaturated linear
C.sub.2-7alkylene group.
[0308] In one preferred embodiment, Q.sup.1 has a backbone of at
least 3 carbon atoms, and is a partially unsaturated linear
C.sub.3-7alkylene group.
[0309] In one preferred embodiment, Q.sup.1 has a backbone of at
least 2 carbon atoms, and is a partially unsaturated branched
C.sub.2-7alkylene group.
[0310] In one preferred embodiment, Q.sup.1 has a backbone of at
least 3 carbon atoms, and is a partially unsaturated branched
C.sub.3-7alkylene group.
[0311] In one preferred embodiment, Q.sup.1 has a backbone of at
least 2 carbon atoms, and is a partially unsaturated alicyclic
C.sub.2-7alkylene group.
[0312] In one preferred embodiment, Q.sup.1 has a backbone of at
least 3 carbon atoms, and is a partially unsaturated alicyclic
C.sub.3-7alkylene group.
[0313] The Aryl Leader Group, Q.sup.1: Backbone Length of 0 or 2 or
More
[0314] In one preferred embodiment, the aryl leader group, Q.sup.1
is either: a covalent bond, or: has a backbone of at least 2 carbon
atoms.
[0315] In one preferred embodiment, Q.sup.1 is either: a covalent
bond, or: has a backbone of at least 2 carbon atoms and is a
C.sub.2-7alkylene group.
[0316] In one preferred embodiment, Q.sup.1 is either: a covalent
bond, or: has a backbone of at least 2 carbon atoms and is a
saturated C.sub.2-7alkylene group.
[0317] In one preferred embodiment, Q.sup.1 is either: a covalent
bond, or: has a backbone of at least 2 carbon atoms and is a
partially unsaturated C.sub.2-7alkylene group.
[0318] In one preferred embodiment, Q.sup.1 is either: a covalent
bond, or: has a backbone of at least 2 carbon atoms and is an
aliphatic C.sub.2-7alkylene group.
[0319] In one preferred embodiment, Q.sup.1 is either: a covalent
bond, or: has a backbone of at least 2 carbon atoms and is a linear
C.sub.2-7alkylene group.
[0320] In one preferred embodiment, Q.sup.1 is either: a covalent
bond, or: has a backbone of at least 2 carbon atoms and is a
branched C.sub.2-7alkylene group.
[0321] In one preferred embodiment, Q.sup.1 is either: a covalent
bond, or: has a backbone of at least 2 carbon atoms and is an
alicyclic C.sub.2-7alkylene group.
[0322] In one preferred embodiment, Q.sup.1 is either: a covalent
bond, or: has a backbone of at least 2 carbon atoms and is a
saturated aliphatic C.sub.2-7alkylene group.
[0323] In one preferred embodiment, Q.sup.1 is either: a covalent
bond, or: has a backbone of at least 2 carbon atoms and is a
saturated linear C.sub.2-7alkylene group.
[0324] In one preferred embodiment, Q.sup.1 is either: a covalent
bond, or: has a backbone of at least 2 carbon atoms and is a
saturated branched C.sub.2-7alkylene group.
[0325] In one preferred embodiment, Q.sup.1 is either: a covalent
bond, or: has a backbone of at least 2 carbon atoms and is a
saturated alicyclic C.sub.2-7alkylene group.
[0326] In one preferred embodiment, Q.sup.1 is either: a covalent
bond, or: has a backbone of at least 2 carbon atoms and is a
partially unsaturated aliphatic C.sub.2-7alkylene group.
[0327] In one preferred embodiment, Q.sup.1 is either: a covalent
bond, or: has a backbone of at least 2 carbon atoms and is a
partially unsaturated linear C.sub.2-7alkylene group.
[0328] In one preferred embodiment, Q.sup.1 is either: a covalent
bond, or: has a backbone of at least 2 carbon atoms and is a
partially unsaturated branched C.sub.2-7alkylene group.
[0329] In one preferred embodiment, Q.sup.1 is either: a covalent
bond, or: has a backbone of at least 2 carbon atoms and is a
partially unsaturated alicyclic C.sub.2-7alkylene group.
[0330] Note that, as discussed below in the context of isomers,
where unsaturation permits isomers, e.g., cis- and trans, E- and
Z-, etc., and combinations thereof, a reference to one isomer is to
be considered a reference to all such isomers, unless otherwise
specified.
[0331] The Aryl Leader Group, Q.sup.1: Substituents
[0332] In one embodiment, Q.sup.1 is unsubstituted.
[0333] In one embodiment, Q.sup.1 is optionally substituted.
[0334] In one embodiment, Q.sup.1 is substituted.
[0335] Examples of substituents on Q.sup.1 include, but are not
limited to, those described under the heading "Substituents"
below.
[0336] In one preferred embodiment, substituents on Q.sup.1, if
present, are independently selected from: halo, hydroxy, ether
(e.g., C.sub.1-7alkoxy), C.sub.5-20aryl, acyl, amido, and oxo.
[0337] In one preferred embodiment, substituents on Q.sup.1, if
present, are independently selected from --F, --Cl, --Br, --I,
--OH, --OMe, --OEt, --OPr, -Ph, and .dbd.O.
[0338] In one preferred embodiment, substituents on Q.sup.1, if
present, are --OH or -Ph.
[0339] In one preferred embodiment, substituents on Q.sup.1, if
present, are -Ph.
[0340] For example, in one embodiment, Q.sup.1 is unsubsituted
ethylene, and is --CH.sub.2--CH.sub.2--; in one embodiment, Q.sup.1
is oxo (.dbd.O) subsituted ethylene, and is
--C(.dbd.O)--CH.sub.2--; in one embodiment, Q.sup.1 is hydroxy
(--OH) subsituted ethylene, and is --CH(OH)--CH.sub.2--; in one
embodiment, Q.sup.1 is phenyl (--Ph) substituted ethylene, and is
--CH.sub.2CH(Ph)--.
[0341] The Aryl Leader Group, Q.sup.1: Certain Embodiments
[0342] Note that, for embodiments excluding, e.g., a covalent bond,
certain backbone lengths, etc., it is to be understood that the
corresponding species listed below are similarly excluded from the
respective embodiments discussed below.
[0343] In one preferred embodiment, Q.sup.1 is selected from the
following:
[0344] a covalent bond;
[0345] --(CH.sub.2).sub.r-- where n is an integer from 1 to 7;
[0346] --CH(CH.sub.3)--;
[0347] CH(CH.sub.3)CH.sub.2-- and --CH.sub.2CH(CH.sub.3)--;
[0348] --CH(CH.sub.3)CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.3)CH.sub.2--, and
--CH.sub.2CH.sub.2CH(CH.sub.3)--;
[0349] --CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.3)CH.- sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH(CH.sub.3)CH.sub.2--, and
--CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.3)--;
[0350] --CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2--,
[0351] --CH.sub.2CH.sub.2CH(CH.sub.3)CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.3)CH.sub.2--, and
[0352] --CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.3);
[0353] --CH(CH.sub.2CH.sub.3Y;
[0354] --CH(CH.sub.2CH.sub.3)CH.sub.2-- and
--CH.sub.2CH(CH.sub.2CH.sub.3)- --;
[0355] --CH(CH.sub.2CH.sub.3)CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.2CH.s- ub.3)CH.sub.2--, and
--CH.sub.2CH.sub.2CH(CH.sub.2CH.sub.3)--;
[0356] --CH(CH.sub.2CH.sub.3)CH.sub.2CH.sub.2CH.sub.2,
--CH.sub.2CH(CH.sub.2CH.sub.3)CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH(CH- .sub.2CH.sub.3)CH.sub.2--, and
--CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.2CH.sub- .3)--;
[0357] --CH(CH.sub.2CH.sub.3)CH.sub.2CH.sub.2CH.sub.2CH.sub.r--,
--CH.sub.2CH(CH.sub.2CH.sub.3)CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH(CH.sub.2CH.sub.3)CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.2CH.sub.3)CH.sub.2--, and
[0358]
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.2CH.sub.3)--;
[0359] --CH.dbd.CH--;
[0360] --CH.dbd.CHCH.sub.2-- and --CH.sub.2CH.dbd.CH--;
[0361] --CH.dbd.CHCH.sub.2CH.sub.2--,
--CH.sub.2CH.dbd.CHCH.sub.2--, and
--CH.sub.2CH.sub.2CH.dbd.CH--;
[0362] --CH.dbd.CHCH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.dbd.CHCH.sub.2C- H.sub.2--,
--CH.sub.2CH.sub.2CH.dbd.CHCH.sub.2--, and
--CH.sub.2CH.sub.2CH.sub.2CH.dbd.CH--;
[0363] --CH.dbd.CHCH.sub.2CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.dbd.CHCH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.dbd.C- HCH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2CH.dbd.CHCH.sub.2--, and
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.dbd.CH--;
[0364] --C(CH.sub.3).dbd.CH-- and --CH.dbd.C(CH.sub.3)--;
[0365] --C(CH.sub.3).dbd.CHCH.sub.2--,
--CH.dbd.C(CH.sub.3)CH.sub.2--, and --CH.dbd.CHCH(CH.sub.3)--;
[0366] --CH(CH.sub.3)CH.dbd.CH--, --CH.sub.2C(CH.sub.3).dbd.CH--,
and --CH.sub.2CH.dbd.C(CH.sub.3)--;
[0367] --CH.dbd.CHCH.dbd.CH--;
[0368] --CH.dbd.CHCH.dbd.CHCH.sub.2--,
--CH.sub.2CH.dbd.CHCH.dbd.CH--, and
--CH.dbd.CHCH.sub.2CH.dbd.CH--;
[0369] --CH.dbd.CHCH.dbd.CHCH.sub.2CH.sub.2--,
--CH.dbd.CHCH.sub.2CH.dbd.C- HCH.sub.2--,
--CH.dbd.CHCH.sub.2CH.sub.2CH.dbd.CH--,
--CH.sub.2CH.dbd.CHCH.dbd.CHCH.sub.2--,
--CH.sub.2CH.dbd.CHCH.sub.2CH.dbd- .CH--, and
--CH.sub.2CH.sub.2CH.dbd.CHCH.dbd.CH--;
[0370] --C(CH.sub.3).dbd.CHCH.dbd.CH--,
--CH.dbd.C(CH.sub.3)CH.dbd.CH--, --CH.dbd.CHC(CH.sub.3).dbd.CH--,
and --CH.dbd.CHCH.dbd.C(CH.sub.3)--;
[0371] --C.ident.C--;
[0372] --C.ident.CCH.sub.2--, --CH.sub.2C.ident.C--;
--C.ident.CCH(CH.sub.3)--, and --CH(CH.sub.3)C.ident.C--;
[0373] --C.ident.CCH.sub.2CH.sub.2--,
--CH.sub.2C.ident.CCH.sub.2--, and
--CH.sub.2CH.sub.2C.ident.C--;
[0374] --C.ident.CCH(CH.sub.3)CH.sub.2-- and
--C.ident.CCH.sub.2CH(CH.sub.- 3)--;
[0375] --CH(CH.sub.3)C.ident.CCH.sub.2-- and
--CH.sub.2C.ident.CCH(CH.sub.- 3)--;
[0376] --CH(CH.sub.3)CH.sub.2C.ident.C-- and
--CH.sub.2CH(CH.sub.3)C.ident- .C--;
[0377] --C.ident.CCH.dbd.CH--, --CH.dbd.CHC.ident.C--, and
--C.ident.CC.ident.C--;
[0378] --C.ident.CCH.sub.2CH.sub.2CH.sub.2-- and
--CH.sub.2CH.sub.2CH.sub.- 2C.ident.C--;
[0379] --C.ident.CCH.sub.2CH.sub.2CH.sub.2CH.sub.2-- and
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2C.ident.C--;
[0380] --C.ident.CCH.dbd.CHCH.dbd.CH--,
--CH.dbd.CHC.ident.C--CH.dbd.CH--, and
--CH.dbd.CHCH.dbd.CHC.ident.C--;
[0381] --C(CH.sub.3).dbd.CHC.ident.C--,
--CH.dbd.C(CH.sub.3)C.ident.C--, --C.ident.CC(CH.sub.3).dbd.CH--,
and --C.ident.CCH.dbd.C(CH.sub.3)--;
[0382] cyclopentylene and cyclopentenylene; and,
[0383] cyclohexylene, cyclohexenylene, and cyclohexadienylene.
[0384] In one preferred embodiment, Q.sup.1 is selected from:
[0385] a covalent bond;
[0386] --CH.sub.2--, --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, and
--(CH.sub.2).sub.6--;
[0387] --CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.su- b.2CH(CH.sub.3)CH.sub.2--, and
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH(CH.sub- .3)--;
[0388] --CH.dbd.CH--;
[0389] --CH.dbd.CH--CH.dbd.CH--;
[0390] --CH.dbd.CHCH.sub.2CH.sub.2CH.sub.2-- and
--CH.sub.2CH.sub.2CH.sub.- 2CH.dbd.CH--;
[0391] --CH.dbd.CHCH.sub.2CH.sub.2CH.sub.2CH.sub.2-- and
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.dbd.CH--;
[0392] --C(CH.sub.3).dbd.CHCH.dbd.CH--,
--CH.dbd.C(CH.sub.3)CH.dbd.CH--, --CH.dbd.CHC(CH.sub.3).dbd.CH--,
and --CH.dbd.CHCH.dbd.C(CH.sub.3)--; 29
[0393] In one preferred embodiment, Q.sup.1 is selected from:
[0394] a covalent bond;
[0395] --CH.sub.2--, --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, --CH.dbd.CH--;
[0396] --CH.dbd.CH--CH.dbd.CH--;
[0397] --C(CH.sub.3).dbd.CHCH.dbd.CH--,
--CH.dbd.C(CH.sub.3)CH.dbd.CH--, --CH.dbd.CHC(CH.sub.3).dbd.CH--,
and CH.dbd.CHCH.dbd.C(CH.sub.3)--;
[0398] --CH.dbd.CHCH.sub.2CH.sub.2CH.sub.2-- and
--CH.sub.2CH.sub.2CH.sub.- 2CH.dbd.CH--; and, 30
[0399] In one preferred embodiment, Q.sup.1 is selected from: a
covalent bond, --CH.sub.2--, --CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2--, --CH.dbd.CH--, and
--CH.dbd.CH--CH.dbd.CH--.
[0400] In one preferred embodiment, Q.sup.1 is selected from: a
covalent bond, --CH.sub.2--, --CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2--, --CH.dbd.CH--,
--CH.dbd.CH--CH.dbd.CH--, and C.sub.5cycloalkyl (e.g.,
cyclopentylene and cyclopentenylene, e.g., as in indan, fluorene,
etc.).
[0401] The Sulfonamido Substituent, R.sup.1
[0402] The sulfonamido substituent, R.sup.1, is hydrogen,
C.sub.1-7alkyl (including, e.g., C.sub.5-20aryl-C.sub.1-7alkyl),
C.sub.3-20heterocyclyl, or C.sub.5-20aryl.
[0403] Note that R.sup.1 is a monodentate species. It is not
intended that R.sup.1 be additionally linked to A, Q.sup.1, and/or
Q.sup.2, thereby forming a cyclic group.
[0404] In one preferred embodiment, R.sup.1 is hydrogen,
C.sub.1-7alkyl, or C.sub.5-20aryl.
[0405] In one preferred embodiment, R.sup.1 is hydrogen or
C.sub.1-7alkyl.
[0406] In one preferred embodiment, R.sup.1 is hydrogen, saturated
C.sub.1-7alkyl, or C.sub.5-20aryl.
[0407] In one preferred embodiment, R.sup.1 is hydrogen or
saturated C.sub.1-7alkyl.
[0408] In one preferred embodiment, R.sup.1 is hydrogen, saturated
aliphatic C.sub.1-7alkyl, or C.sub.5-20aryl.
[0409] In one preferred embodiment, R.sup.1 is hydrogen or
saturated aliphatic C.sub.1-7alkyl.
[0410] In one preferred embodiment, R.sup.1 is --H, -Me, -Et, -nPr,
-iPr, -nBu, -sBu, -tBu, -Ph, or -Bn.
[0411] In one preferred embodiment, R.sup.1 is --H, -Me, -Et, -nPr,
-iPr, -nBu, -sBu, or -tBu.
[0412] In one preferred embodiment, R.sup.1 is --H, -Me, -Et, -Ph,
or -Bn.
[0413] In one preferred embodiment, R.sup.1 is --H, -Me, or
-Et.
[0414] In one preferred embodiment, R.sup.1 is --H.
[0415] The Acid Leader Group, Q.sup.2
[0416] The acid leader group, Q.sup.2, is C.sub.1-7alkylene;
C.sub.5-20arylene; C.sub.5-20arylene-C.sub.1-7alkylene;
C.sub.1-7alkylene-C.sub.5-20arylene; or an ether linkage (i.e.
--R.sup.2--X--R.sup.3--); and is optionally substituted.
[0417] In one preferred embodiment, Q.sup.2 is C.sub.1-7alkylene;
C.sub.5-20arylene;
[0418] C.sub.5-20arylene-C.sub.1-7alkylene; or
C.sub.1-7alkylene-C.sub.5-2- 0arylene; and is optionally
substituted.
[0419] In one embodiment, Q.sup.2 is unsubstituted.
[0420] In one embodiment, Q.sup.2 is optionally substituted.
[0421] In one embodiment, Q.sup.2 is substituted.
[0422] The Acid Leader Group, Q.sub.2: Alkylene
[0423] In one preferred embodiment, the acid leader group, Q.sup.2,
is C.sub.1-7alkylene and is optionally substituted.
[0424] In one preferred embodiment, Q.sup.2 is a C.sub.1-7alkylene
group.
[0425] In one preferred embodiment, Q.sup.2 is a saturated
C.sub.1-7alkylene group.
[0426] In one preferred embodiment, Q.sup.2 is a partially
unsaturated C.sub.1-7alkylene group.
[0427] In one preferred embodiment, Q.sup.2 is an aliphatic
C.sub.1-7alkylene group.
[0428] In one preferred embodiment, Q.sup.2 is a linear
C.sub.1-7alkylene group.
[0429] In one preferred embodiment, Q.sup.2 is a branched
C.sub.1-7alkylene group.
[0430] In one preferred embodiment, Q.sup.2 is an alicyclic
C.sub.1-7alkylene group.
[0431] In one preferred embodiment, Q.sup.2 is a saturated
aliphatic C.sub.1-7alkylene group.
[0432] In one preferred embodiment, Q.sup.2 is a saturated linear
C.sub.1-7alkylene group.
[0433] In one preferred embodiment, Q.sup.2 is a saturated branched
C.sub.1-7alkylene group.
[0434] In one preferred embodiment, Q.sup.2 is a saturated
alicyclic C.sub.1-7alkylene group.
[0435] In one preferred embodiment, Q.sup.2 is a partially
unsaturated aliphatic C.sub.1-7alkylene group.
[0436] In one preferred embodiment, Q.sup.2 is a partially
unsaturated linear C.sub.1-7alkylene group.
[0437] In one preferred embodiment, Q.sup.2 is a partially
unsaturated branched C.sub.1-7alkylene group.
[0438] In one preferred embodiment, Q.sup.2 is a partially
unsaturated alicyclic C.sub.1-7alkylene group.
[0439] Note that, for embodiments excluding, e.g., unsaturation,
etc., it is to be understood that the corresponding species listed
below are similarly excluded from the respective embodiments
discussed below.
[0440] In one preferred embodiment, Q.sup.2 is selected from:
[0441] --(CH.sub.2).sub.n-- where n is an integer from 1 to 7;
[0442] --CH(CH.sub.3)--;
[0443] --CH(CH.sub.3)CH.sub.2-- and --CH.sub.2CH(CH.sub.3)--;
[0444] --CH(CH.sub.3)CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.3)CH.sub.2--, and
--CH.sub.2CH.sub.2CH(CH.sub.3)--;
[0445] --CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.3)CH.- sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH(CH.sub.3)CH.sub.2--, and
--CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.3)--;
[0446] --CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH(CH- .sub.3)CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.3)CH.sub.2-- -, and
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.3)--;
[0447] --CH(CH.sub.2CH.sub.3)--;
[0448] --CH(CH.sub.2CH.sub.3)CH.sub.2-- and
--CH.sub.2CH(CH.sub.2CH.sub.3)- --;
[0449] --CH(CH.sub.2CH.sub.3)CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.2CH.s- ub.3)CH.sub.2--, and
--CH.sub.2CH.sub.2CH(CH.sub.2CH.sub.3)--;
[0450] --CH(CH.sub.2CH.sub.3)CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.2CH.sub.3)CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH(CH- .sub.2CH.sub.3)CH.sub.2--, and
--CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.2CH.sub- .3)--;
[0451] --CH(CH.sub.2CH.sub.3)CH.sub.2CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.2CH.sub.3)CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH(CH.sub.2CH.sub.3)CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.2CH.sub.3)CH.sub.2--, and
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.2CH.sub.3)--;
[0452] --CH.dbd.CH--;
[0453] --CH.dbd.CHCH.sub.2-- and --CH.sub.2CH.dbd.CH--;
[0454] --CH.dbd.CHCH.sub.2CH.sub.2--,
--CH.sub.2CH.dbd.CHCH.sub.2--, and
--CH.sub.2CH.sub.2CH.dbd.CH--;
[0455] --CH.dbd.CHCH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.dbd.CHCH.sub.2C- H.sub.2--,
--CH.sub.2CH.sub.2CH.dbd.CHCH.sub.2--, and
--CH.sub.2CH.sub.2CH.sub.2CH.dbd.CH--;
[0456] --CH.dbd.CHCH.sub.2CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.dbd.CHCH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.dbd.C- HCH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2CH.dbd.CHCH.sub.2--, and
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.dbd.CH--;
[0457] --C(CH.sub.3).dbd.CH-- and --CH.dbd.C(CH.sub.3)--;
[0458] --C(CH.sub.3).dbd.CHCH.sub.2--,
--CH.dbd.C(CH.sub.3)CH.sub.2--, and --CH.dbd.CHCH(CH.sub.3)--;
[0459] --CH(CH.sub.3)CH.dbd.CH--, --CH.sub.2C(CH.sub.3).dbd.CH--,
and --CH.sub.2CH.dbd.C(CH.sub.3)--;
[0460] --CH.dbd.CHCH.dbd.CH--;
[0461] --CH.dbd.CHCH.dbd.CHCH.sub.2--,
--CH.sub.2CH.dbd.CHCH.dbd.CH--, and
--CH.dbd.CHCH.sub.2CH.dbd.CH--;
[0462] --CH.dbd.CHCH.dbd.CHCH.sub.2CH.sub.2--,
--CH.dbd.CHCH.sub.2CH.dbd.C- HCH.sub.2--, and
--CH.dbd.CHCH.sub.2CH.sub.2CH.dbd.CH--,
--CH.sub.2CH.dbd.CHCH.dbd.CHCH.sub.2--,
--CH.sub.2CH.dbd.CHCH.sub.2CH.dbd- .CH--, and
--CH.sub.2CH.sub.2CH.dbd.CHCH.dbd.CH--;
[0463] --C(CH.sub.3).dbd.CHCH.dbd.CH--,
--CH.dbd.C(CH.sub.3)CH.dbd.CH--, --CH.dbd.CHC(CH.sub.3).dbd.CH--,
and --CH.dbd.CHCH.dbd.C(CH.sub.3)--;
[0464] --C.ident.C--;
[0465] --C.ident.CCH.sub.2--, --CH.sub.2C.ident.C--;
--C.ident.CCH(CH.sub.3)--, and --CH(CH.sub.3)C.ident.C--;
[0466] --C.ident.CCH.sub.2CH.sub.2--,
--CH.sub.2C.ident.CCH.sub.2--, and
--CH.sub.2CH.sub.2C.ident.C--;
[0467] --C.ident.CCH(CH.sub.3)CH.sub.2-- and
--C.dbd.CCH.sub.2CH(CH.sub.3)- --;
[0468] --CH(CH.sub.3)C.ident.CCH.sub.2-- and
--CH.sub.2C.ident.CCH(CH.sub.- 3)--;
[0469] --CH(CH.sub.3)CH.sub.2C.ident.C-- and
--CH.sub.2CH(CH.sub.3)C.ident- .C--;
[0470] --C.ident.CCH.dbd.CH--, --CH.dbd.CHC.ident.C--, and
--C.ident.CC.ident.C--;
[0471] --C.ident.CCH.sub.2CH.sub.2CH.sub.2-- and
--CH.sub.2CH.sub.2CH.sub.- 2C.ident.C--;
[0472] --C.ident.CCH.sub.2CH.sub.2CH.sub.2CH.sub.2-- and
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2C.ident.C--;
[0473] --C.ident.CCH.dbd.CHCH.dbd.CH--,
--CH.dbd.CHC.ident.C--CH.dbd.CH--, and
--CH.dbd.CHCH.dbd.CHC.ident.C--;
[0474] --C(CH.sub.3).dbd.CHC.ident.C--,
--CH.dbd.C(CH.sub.3)C.ident.C--, --C.ident.CC(CH.sub.3).dbd.CH--,
and --C.ident.CCH.dbd.C(CH.sub.3)--; cyclopentylene and
cyclopentenylene; and, cyclohexylene, cyclohexenylene, and
cyclohexadienylene.
[0475] In one preferred embodiment, Q.sup.2 is selected from:
[0476] --CH.sub.2--, --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, and
--(CH.sub.2).sub.6--;
[0477] --CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.su- b.2CH(CH.sub.3)CH.sub.2--, and
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH(CH.sub- .3)--;
[0478] --CH.dbd.CHCH.sub.2CH.sub.2CH.sub.2-- and
--CH.sub.2CH.sub.2CH.sub.- 2CH.dbd.CH--;
[0479] --CH.dbd.CHCH.sub.2CH.sub.2CH.sub.2CH.sub.2-- and
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.dbd.CH--; 31
[0480] In one preferred embodiment, Q.sup.2 is selected from:
[0481] --CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2CH.sub.2-- and
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.3)--;
[0482] --CH.sub.2CH.sub.2CH.sub.2CH.dbd.CH--; and,
[0483] --CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.dbd.CH--.
[0484] The Acid Leader Group, Q.sup.2: Arylene
[0485] In one preferred embodiment, the acid leader group, Q.sup.2,
is C.sub.5-20arylene, and is optionally substituted.
[0486] In one preferred embodiment, Q.sup.2 is C.sub.5-20arylene.
In one preferred embodiment, Q.sup.2 is C.sub.5-6arylene. In one
preferred embodiment, Q.sup.2 is phenylene.
[0487] The Acid Leader Group, Q.sup.2:
[0488] Alkylene-Arylene and Arylene-Alkylene
[0489] In one preferred embodiment, the acid leader group, Q.sup.2,
is C.sub.5-20arylene-C.sub.1-7alkylene or
C.sub.1-7alkylene-C.sub.5-20arylen- e, and is optionally
substituted.
[0490] In one preferred embodiment, Q.sup.2 is
C.sub.5-6arylene-C.sub.1-7a- lkylene or C.sub.1-7alkylene-C.sub.5
arylene, and is optionally substituted.
[0491] In one preferred embodiment, Q.sup.2 is
C.sub.1-7alkylene-C.sub.5-2- 0arylene. In one preferred embodiment,
Q.sup.2 is C.sub.1-7alkylene-C.sub.- 5-20arylene.
[0492] In one preferred embodiment, Q.sup.2 is
C.sub.5-20arylene-C.sub.1-7- alkylene. In one preferred embodiment,
Q.sup.2 is C.sub.5-6arylene-C.sub.1- -7alkylene.
[0493] In one preferred embodiment, Q.sup.2 is
C.sub.1-7alkylene-phenylene- . In one preferred embodiment, Q.sup.2
is methylene-phenylene, ethylene-phenylene, propylene-phenylene,
and ethenylene-phenylene (also known as vinylene-phenylene).
[0494] In one preferred embodiment, Q.sup.2 is
phenylene-C.sub.1-7alkylene- . In one preferred embodiment, Q.sup.2
is phenylene-methylene, phenylene-ethylene, phenylene-propylene, or
phenylene-ethenylene (also known as phenylene-vinylene).
[0495] In the above alkylene-phenylene and phenylene-alkylene
groups, the phenylene linkage may be ortho, meta, or para, and the
phenylene group is optionally substituted with from 1 to 4 aryl
substituents, R.sup.B: 32
[0496] In one preferred embodiment; the phenylene linkage is meta
or para. In one preferred embodiment, the phenylene linkage is
para. In one preferred embodiment, the phenylene linkage is
meta.
[0497] In one preferred embodiment, m is an integer from 0 to
4.
[0498] In one preferred embodiment, m is an integer from 0 to
3.
[0499] In one preferred embodiment, m is an integer from 0 to
2.
[0500] In one preferred embodiment, m is 0 or 1.
[0501] In one preferred embodiment, m is an integer from 1 to
4.
[0502] In one preferred embodiment, m is an integer from 1 to
3.
[0503] In one preferred embodiment, m is 1 or 2.
[0504] In one preferred embodiment, m is 4.
[0505] In one preferred embodiment, m is 3.
[0506] In one preferred embodiment, m is 2.
[0507] In one preferred embodiment, m is 1.
[0508] In one preferred embodiment, m is 0.
[0509] Each aryl substituent, R.sup.B, is a substituent as defined
herein.
[0510] Examples of preferred aryl substituents, R.sup.B, include,
but are not limited to, the following: fluoro, chloro, methyl,
ethyl, isopropyl, t-butyl, trifluoromethyl, hydroxy, methoxy,
ethoxy, isopropoxy, methylthio, amino, dimethylamino, diethylamino,
morpholino, acetamido, nitro, and phenyl.
[0511] In one preferred embodiment, the phenylene linkage is meta,
and Q.sup.2 has the following formula, wherein R.sup.Q2 is
C.sub.1-7alkylene and is optionally substitued (referred to herein
as "phenylene-meta-C.sub.1-7alkylene"): 33
[0512] In one preferred embodiment, R.sup.Q2 is a saturated
C.sub.1-7alkylene group.
[0513] In one preferred embodiment, R.sup.Q2 is a partially
unsaturated C.sub.1-7alkylene group.
[0514] In one preferred embodiment, R.sup.Q2 is an aliphatic
C.sub.1-7alkylene-group.
[0515] In one preferred embodiment, R.sup.Q2 is a linear
C.sub.1-7alkylene group.
[0516] In one preferred embodiment, R.sup.Q2 is a branched
C.sub.1-7alkylene group.
[0517] In one preferred embodiment, R.sup.Q2 is an alicyclic
C.sub.1-7alkylene group.
[0518] In one preferred embodiment, R.sup.Q2 is a saturated
aliphatic C.sub.1-7alkylene group.
[0519] In one preferred embodiment, R.sup.Q2 is a saturated linear
C.sub.1-7alkylene group.
[0520] In one preferred embodiment, R.sup.Q2 is a saturated
branched C.sub.1-7alkylene group.
[0521] In one preferred embodiment, R.sup.Q2 is a saturated
alicyclic C.sub.1-7alkylene group.
[0522] In one preferred embodiment, R.sup.Q2 is a partially
unsaturated aliphatic C.sub.1-7alkylene group.
[0523] In one preferred embodiment, R.sup.Q2 is a partially
unsaturated linear C.sub.1-7alkylene group.
[0524] In one preferred embodiment, R.sup.Q2 is a partially
unsaturated branched C.sub.1-7alkylene group.
[0525] In one preferred embodiment, R.sup.Q2 is a partially
unsaturated alicyclic C.sub.1-7alkylene group.
[0526] In one preferred embodiment, R.sup.Q2 is selected from:
[0527] --(CH.sub.2).sub.n-- where n is an integer from 1 to 7;
[0528] --CH(CH.sub.3)--;
[0529] --CH(CH.sub.3)CH.sub.2-- and --CH.sub.2CH(CH.sub.3)--;
[0530] --CH(CH.sub.3)CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.3)CH.sub.2--, and
--CH.sub.2CH.sub.2CH(CH.sub.3)--;
[0531] --CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.3)CH.- sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH(CH.sub.3)CH.sub.2--, and
--CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.3)--;
[0532] --CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH(CH- .sub.3)CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.3)CH.sub.2-- -, and
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.3)--;
[0533] --CH(CH.sub.2CH.sub.3)--;
[0534] --CH(CH.sub.2CH.sub.3)CH.sub.2-- and
--CH.sub.2CH(CH.sub.2CH.sub.3)- --;
[0535] --CH(CH.sub.2CH.sub.3)CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.2CH.s- ub.3)CH.sub.2--, and
--CH.sub.2CH.sub.2CH(CH.sub.2CH.sub.3)--;
[0536] --CH(CH.sub.2CH.sub.3)CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.2CH.sub.3)CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH(CH- .sub.2CH.sub.3)CH.sub.2--, and
--CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.2CH.sub- .3)--;
[0537] --CH(CH.sub.2CH.sub.3)CH.sub.2CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.2CH.sub.3)CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH(CH.sub.2CH.sub.3)CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.2CH.sub.3)CH.sub.2--, and
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.2CH.sub.3)--;
[0538] --CH.dbd.CH--;
[0539] --CH.dbd.CHCH.sub.2-- and --CH.sub.2CH.dbd.CH--;
[0540] --CH.dbd.CHCH.sub.2CH.sub.2--,
--CH.sub.2CH.dbd.CHCH.sub.2--, and
--CH.sub.2CH.sub.2CH.dbd.CH--;
[0541] --CH.dbd.CHCH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.dbd.CHCH.sub.2C- H.sub.2--,
--CH.sub.2CH.sub.2CH.dbd.CHCH.sub.2--, and
CH.sub.2CH.sub.2CH.sub.2CH.dbd.CH--;
[0542] --CH.dbd.CHCH.sub.2CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.dbd.CHCH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.dbd.C- HCH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2CH.dbd.CHCH.sub.2--, and
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.dbd.CH--;
[0543] --C(CH.sub.3).dbd.CH-- and --CH.dbd.C(CH.sub.3)--;
[0544] --C(CH.sub.3).dbd.CHCH.sub.2--,
--CH.dbd.C(CH.sub.3)CH.sub.2--, and --CH.dbd.CHCH(CH.sub.3)--;
[0545] --CH(CH.sub.3)CH.dbd.CH--, --CH.sub.2C(CH.sub.3).dbd.CH--,
and --CH.sub.2CH.dbd.C(CH.sub.3)--;
[0546] --CH.dbd.CHCH.dbd.CH--;
[0547] --CH.dbd.CHCH.dbd.CHCH.sub.2--,
--CH.sub.2CH.dbd.CHCH.dbd.CH--, and
--CH.dbd.CHCH.sub.2CH.dbd.CH--;
[0548] --CH.dbd.CHCH.dbd.CHCH.sub.2CH.sub.2--,
--CH.dbd.CHCH.sub.2CH.dbd.C- HCH.sub.2--, and
--CH.dbd.CHCH.sub.2CH.sub.2CH.dbd.CH--,
--CH.sub.2CH.dbd.CHCH.dbd.CHCH.sub.2--,
--CH.sub.2CH.dbd.CHCH.sub.2CH.dbd- .CH--, and
--CH.sub.2CH.sub.2CH.dbd.CHCH.dbd.CH--;
[0549] --C(CH.sub.3).dbd.CHCH.dbd.CH--,
--CH.dbd.C(CH.sub.3)CH.dbd.CH--, --CH.dbd.CHC(CH.sub.3).dbd.CH--,
and --CH.dbd.CHCH.dbd.C(CH.sub.3)--;
[0550] --C.ident.C--;
[0551] --C.ident.CCH.sub.2--, --CH.sub.2C.ident.C--;
--C.ident.CCH(CH.sub.3)--, and --CH(CH.sub.3)C.ident.C--;
[0552] --C.ident.CCH.sub.2CH.sub.2--,
--CH.sub.2C.ident.CCH.sub.2--, and
--CH.sub.2CH.sub.2C.ident.C--;
[0553] --C.ident.CCH(CH.sub.3)CH.sub.2-- and
--C.ident.CCH.sub.2CH(CH.sub.- 3);
[0554] --CH(CH.sub.3)C.ident.CCH.sub.2-- and
--CH.sub.2C.ident.CCH(CH.sub.- 3)--;
[0555] --CH(CH.sub.3)CH.sub.2C.ident.C-- and
--CH.sub.2CH(CH.sub.3)C.ident- .C--;
[0556] --C.ident.CCH.dbd.CH--, --CH.dbd.CHC.ident.C--, and
--C.ident.CC.ident.C--;
[0557] --C.ident.CCH.sub.2CH.sub.2CH.sub.2-- and
--CH.sub.2CH.sub.2CH.sub.- 2C.ident.C--;
[0558] --C.ident.CCH.sub.2CH.sub.2CH.sub.2CH.sub.2-- and
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2C.ident.C--;
[0559] --C.ident.CCH.dbd.CHCH.dbd.CH--,
--CH.dbd.CHC.ident.C--CH.dbd.CH--, and
--CH.dbd.CHCH.dbd.CHC.ident.C--;
[0560] --C(CH.sub.3).dbd.CHC.ident.C--,
--CH.dbd.C(CH.sub.3)C.ident.C--, --C.ident.CC(CH.sub.3).dbd.CH--,
and --C.ident.CCH.dbd.C(CH.sub.3)--;
[0561] cyclopentylene and cyclopentenylene; and,
[0562] cyclohexylene, cyclohexenylene, and cyclohexadienylene.
[0563] In one preferred embodiment, R.sup.Q2 is selected from:
[0564] --CH.sub.2--, --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, and
--(CH.sub.2).sub.6--;
[0565] --CH.dbd.CH--, --CH.dbd.CH--CH.dbd.CH--;
[0566] In one preferred embodiment, R.sup.Q2 is cis or trans
--CH.dbd.CH--.
[0567] In one preferred embodiment, R.sup.Q2 is cis
--CH.dbd.CH--.
[0568] In one preferred embodiment, R.sup.Q2 is trans
--CH.dbd.CH--.
[0569] In one preferred embodiment, R.sup.Q2 is --CH.dbd.CH--, and
Q.sup.2 is (referred to herein as "phenylene-meta-trans-ethylene"):
34
[0570] In one preferred embodiment, m is 0, and Q.sup.2 is
(referred to herein as "unsubstituted
phenylene-meta-trans-ethylene"): 35
[0571] The Acid Leader Group, Q.sup.2: Ether
[0572] In one embodiment, Q.sup.2 is an ether linkage,
--R.sup.2--X--R.sup.3--, wherein X is an ether heteroatom, and is
--O-- or --S-- and each of R.sup.2 and R.sup.3 is independently an
ether group.
[0573] Each of the ether groups, R.sup.2 and R.sup.3, is
independently a C.sub.1-7alkylene group, and is optionally
substituted.
[0574] In one embodiment, each of R.sup.2 and R.sup.3 is
unsubstituted. In one embodiment, each of R.sup.2 and R.sup.3 is
optionally substituted. In one embodiment, each of R.sup.2 and
R.sup.3 is substituted.
[0575] In one preferred embodiment, R.sup.2 and/or R.sup.3 is a
saturated C.sub.1-7alkylene group.
[0576] In one preferred embodiment, R.sup.2 and/or R.sup.3 is a
partially unsaturated C.sub.1-7alkylene group.
[0577] In one preferred embodiment, R.sup.2 and/or R.sup.3 is an
aliphatic C.sub.1-7alkylene group.
[0578] In one preferred embodiment, R.sup.2 and/or R.sup.3 is a
linear C.sub.1-7alkylene group.
[0579] In one preferred embodiment, R.sup.2 and/or R.sup.3 is a
branched C.sub.1-7alkylene group.
[0580] In one preferred embodiment, R.sup.2 and/or R.sup.3 is an
alicyclic C.sub.1-7alkylene group.
[0581] In one preferred embodiment, R.sup.2 and/or R.sup.3 is a
saturated aliphatic C.sub.1-7alkylene group.
[0582] In one preferred embodiment, R.sup.2 and/or R.sup.3 is a
saturated linear C.sub.1-7alkylene group.
[0583] In one preferred embodiment, R.sup.2 and/or R.sup.3 is a
saturated branched C.sub.1-7alkylene group.
[0584] In one preferred embodiment, R.sup.2 and/or R.sup.3 is a
saturated alicyclic C.sub.1-7alkylene group.
[0585] In one preferred embodiment, R.sup.2 and/or R.sup.3 is a
partially unsaturated aliphatic C.sub.1-7alkylene group.
[0586] In one preferred embodiment, R.sup.2 and/or R.sup.3 is a
partially unsaturated linear C.sub.1-7alkylene group.
[0587] In one preferred embodiment, R.sup.2 and/or R.sup.3 is a
partially unsaturated branched C.sub.1-7alkylene group.
[0588] In one preferred embodiment, R.sup.2 and/or R.sup.3 is a
partially unsaturated alicyclic C.sub.1-7alkylene group.
[0589] In one preferred embodiment, R.sup.2 and/or R.sup.3 is
selected from:
[0590] --(CH.sub.2).sub.n-- where n is an integer from 1 to 7;
[0591] --CH(CH.sub.3)--;
[0592] --CH(CH.sub.3)CH.sub.2-- and --CH.sub.2CH(CH.sub.3)--;
[0593] --CH(CH.sub.3)CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.3)CH.sub.2--, and
--CH.sub.2CH.sub.2CH(CH.sub.3)--;
[0594] --CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.3)CH.- sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH(CH.sub.3)CH.sub.2--, and
--CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.3)--;
[0595] --CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH(CH- .sub.3)CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.3)CH.sub.2-- -, and
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.3)--;
[0596] --CH(CH.sub.2CH.sub.3);
[0597] --CH(CH.sub.2CH.sub.3)CH.sub.2-- and
--CH.sub.2CH(CH.sub.2CH.sub.3)- --;
[0598] --CH(CH.sub.2CH.sub.3)CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.2CH.s- ub.3)CH.sub.2--, and
--CH.sub.2CH.sub.2CH(CH.sub.2CH.sub.3)--;
[0599] --CH(CH.sub.2CH.sub.3)CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.2CH.sub.3)CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH(CH- .sub.2CH.sub.3)CH.sub.2--, and
--CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.2CH.sub- .3)--;
[0600] --CH(CH.sub.2CH.sub.3)CH.sub.2CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.2CH.sub.3)CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH(CH.sub.2CH.sub.3)CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.2CH.sub.3)CH.sub.2--, and
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH(CH.sub.2CH.sub.3)--;
[0601] --CH.dbd.CH--;
[0602] --CH.dbd.CHCH.sub.2-- and --CH.sub.2CH.dbd.CH--;
[0603] --CH.dbd.CHCH.sub.2CH.sub.2--,
--CH.sub.2CH.dbd.CHCH.sub.2--, and
--CH.sub.2CH.sub.2CH.dbd.CH--;
[0604] --CH.dbd.CHCH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.dbd.CHCH.sub.2C- H.sub.2--,
--CH.sub.2CH.sub.2CH.dbd.CHCH.sub.2--, and
--CH.sub.2CH.sub.2CH.sub.2CH.dbd.CH--;
[0605] --CH.dbd.CHCH.sub.2CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.dbd.CHCH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.dbd.C- HCH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2CH.dbd.CHCH.sub.2--, and
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.dbd.CH--;
[0606] --C(CH.sub.3).dbd.CH-- and --CH.dbd.C(CH.sub.3)--;
[0607] --C(CH.sub.3).dbd.CHCH.sub.2--,
--CH.dbd.C(CH.sub.3)CH.sub.2--, and --CH.dbd.CHCH(CH.sub.3)--;
[0608] --CH(CH.sub.3)CH.dbd.CH--, --CH.sub.2C(CH.sub.3).dbd.CH--,
and --CH.sub.2CH.dbd.C(CH.sub.3)--;
[0609] --CH.dbd.CHCH.dbd.CH--;
[0610] --CH.dbd.CHCH.dbd.CHCH.sub.2--,
--CH.sub.2CH.dbd.CHCH.dbd.CH--, and
--CH.dbd.CHCH.sub.2CH.dbd.CH--;
[0611] --CH.dbd.CHCH.dbd.CHCH.sub.2CH.sub.2--,
--CH.dbd.CHCH.sub.2CH.dbd.C- HCH.sub.2--, and
--CH.dbd.CHCH.sub.2CH.sub.2CH.dbd.CH--,
--CH.sub.2CH.dbd.CHCH.dbd.CHCH.sub.2--,
--CH.sub.2CH.dbd.CHCH.sub.2CH.dbd- .CH--, and
--CH.sub.2CH.sub.2CH.dbd.CHCH.dbd.CH--;
[0612] --C(CH.sub.3).dbd.CHCH.dbd.CH--,
--CH.dbd.C(CH.sub.3)CH.dbd.CH--, --CH.dbd.CHC(CH.sub.3).dbd.CH--,
and --CH.dbd.CHCH.dbd.C(CH.sub.3)--;
[0613] --C.ident.C--;
[0614] --C.ident.CCH.sub.2--, --CH.sub.2C.ident.C--;
--C.dbd.CCH(CH.sub.3)--, and --CH(CH.sub.3)C.ident.C--;
[0615] --C.ident.CCH.sub.2CH.sub.2--, --CH.sub.2C.dbd.CCH.sub.2--,
and --CH.sub.2CH.sub.2C.dbd.C--;
[0616] --C.ident.CCH(CH.sub.3)CH.sub.2-- and
--C.ident.CCH.sub.2CH(CH.sub.- 3)--;
[0617] --CH(CH.sub.3)C.ident.CCH.sub.2-- and
--CH.sub.2C--CCH(CH.sub.3)--;
[0618] --CH(CH.sub.3)CH.sub.2C.ident.C-- and
--CH.sub.2CH(CH.sub.3)C.ident- .C--;
[0619] --C.ident.CCH.dbd.CH--, --CH.dbd.CHC.ident.C--, and
--C.ident.CC.ident.C--;
[0620] --C.ident.CCH.sub.2CH.sub.2CH.sub.2-- and
--CH.sub.2CH.sub.2CH.sub.- 2C.ident.C--;
[0621] --C.ident.CCH.sub.2CH.sub.2CH.sub.2CH.sub.2-- and
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2C.ident.C--;
[0622] --C.ident.CCH.dbd.CHCH.dbd.CH--,
--CH.dbd.CHC.ident.C--CH.dbd.CH--, and
--CH.dbd.CHCH.dbd.CHC.ident.C--;
[0623] --C(CH.sub.3).dbd.CHC.ident.C--,
--CH.dbd.C(CH.sub.3)C.ident.C--, --C.dbd.CC(CH.sub.3).dbd.CH--, and
--C.dbd.CCH.dbd.C(CH.sub.3)--;
[0624] cyclopentylene and cyclopentenylene; and,
[0625] cyclohexylene, cyclohexenylene, and cyclohexadienylene.
[0626] In one preferred embodiment, R.sup.2 and/or R.sup.3 is
selected from:
[0627] --CH.sub.2--, --(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--,
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, and
--(CH.sub.2).sub.6--;
[0628] --CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.su- b.2CH(CH.sub.3)CH.sub.2--, and
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH(CH.sub- .3)--;
[0629] --CH.dbd.CHCH.sub.2CH.sub.2CH.sub.2-- and
--CH.sub.2CH.sub.2CH.sub.- 2CH.dbd.CH--;
[0630] --CH.dbd.CHCH.sub.2CH.sub.2CH.sub.2CH.sub.2-- and
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.dbd.CH--; 36
[0631] In one preferred embodiment, each of R.sup.2 and R.sup.3 is
a saturated C.sub.1-7alkylene group.
[0632] In one preferred embodiment, each of R.sup.2 and R.sup.3 is
selected from --(CH.sub.2).sub.n--, wherein n is an integer from 1
to 5.
[0633] In one preferred embodiment, the group R.sup.2--X--R.sup.3
is selected from the following:
[0634] --CH.sub.2--O--CH.sub.2-- and --CH.sub.2--S--CH.sub.2--;
[0635] --CH.sub.2--O--CH.sub.2CH.sub.2-- and
--CH.sub.2--S--CH.sub.2CH.sub- .2--;
[0636] --CH.sub.2CH.sub.2--O-0H.sub.2-- and
--CH.sub.2CH.sub.2--S--CH.sub.- 2--;
[0637] --CH.sub.2--O--CH.sub.2CH.sub.2CH.sub.2-- and
--CH.sub.2--S--CH.sub.2CH.sub.2CH.sub.2--;
[0638] --CH.sub.2CH.sub.2--O--CH.sub.2CH.sub.2-- and
--CH.sub.2CH.sub.2--S--CH.sub.2CH.sub.2--;
[0639] --CH.sub.2CH.sub.2CH.sub.2--O--CH.sub.2-- and
--CH.sub.2CH.sub.2CH.sub.2--S--CH.sub.2--;
[0640] --CH.sub.2--O--CH.sub.2CH.sub.2CH.sub.2CH.sub.2-- and
--CH.sub.2--S--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--;
[0641] --CH.sub.2CH.sub.2--O--CH.sub.2CH.sub.2CH.sub.2-- and
--CH.sub.2CH.sub.2--S--CH.sub.2CH.sub.2CH.sub.2--;
[0642] --CH.sub.2CH.sub.2CH.sub.2--O--CH.sub.2CH.sub.2-- and
--CH.sub.2CH.sub.2CH.sub.2--S--CH.sub.2CH.sub.2--;
[0643] --CH.sub.2CH.sub.2CH.sub.2CH.sub.2--O--CH.sub.2-- and
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2S--CH.sub.2--;
[0644] --CH.sub.2--O--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2--
and --CH.sub.2--S--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2--;
[0645] --CH.sub.2CH.sub.2--O--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--
and --CH.sub.2CH.sub.2--S--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--;
[0646] --CH.sub.2CH.sub.2CH.sub.2--O--CH.sub.2CH.sub.2CH.sub.2--
and --CH.sub.2CH.sub.2CH.sub.2--S--CH.sub.2CH.sub.2CH.sub.2--;
[0647] --CH.sub.2CH.sub.2CH.sub.2CH.sub.2--O--CH.sub.2CH.sub.2--
and --CH.sub.2CH.sub.2CH.sub.2CH.sub.2--S--CH.sub.2CH.sub.2--;
[0648] --CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2--O--CH.sub.2--
and --CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2--S--CH.sub.2--;
[0649] In one preferred embodiment, the group R.sup.2--X--R.sup.3
is selected from the following:
[0650] --CH.sub.2--O--CH.sub.2-- and --CH.sub.2--S--CH.sub.2--.
[0651] In one preferred embodiment, the group R.sup.2--X--R.sup.3
is selected from the following:
[0652] --CH.sub.2--O--CH.sub.2CH.sub.2-- and
--CH.sub.2--S--CH.sub.2CH.sub- .2--;
[0653] --CH.sub.2CH.sub.2--O--CH.sub.2-- and
--CH.sub.2CH.sub.2--S--CH.sub- .2--.
[0654] In one preferred embodiment, the group R.sup.2--X--R.sup.3
is selected from the following:
[0655] --CH.sub.2--O--CH.sub.2CH.sub.2CH.sub.2-- and
--CH.sub.2--S--CH.sub.2CH.sub.2CH.sub.2--;
[0656] --CH.sub.2CH.sub.2--O--CH.sub.2CH.sub.2-- and
--CH.sub.2CH.sub.2--S--CH.sub.2CH.sub.2--;
[0657] --CH.sub.2CH.sub.2CH.sub.2--O--CH.sub.2-- and
--CH.sub.2CH.sub.2CH.sub.2--S--CH.sub.2--.
[0658] In one preferred embodiment, the group R.sup.2--X--R.sup.3
is selected from the following:
[0659] --CH.sub.2--O--CH.sub.2CH.sub.2CH.sub.2CH.sub.2-- and
--CH.sub.2--S--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--;
[0660] --CH.sub.2CH.sub.2--O--CH.sub.2CH.sub.2CH.sub.2-- and
--CH.sub.2CH.sub.2--S--CH.sub.2CH.sub.2CH.sub.2--;
[0661] --CH.sub.2CH.sub.2CH.sub.2--O--CH.sub.2CH.sub.2-- and
--CH.sub.2CH.sub.2CH.sub.2--S--CH.sub.2CH.sub.2--;
[0662] --CH.sub.2CH.sub.2CH.sub.2CH.sub.2--O--CH.sub.2-- and
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--S--CH.sub.2--.
[0663] In one preferred embodiment, the group R.sup.2--X--R.sup.3
is selected from the following:
[0664] --CH.sub.2--O--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2--
and --CH.sub.2--S--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2--;
[0665] --CH.sub.2CH.sub.2--O--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--
and --CH.sub.2CH.sub.2--S--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--;
[0666] --CH.sub.2CH.sub.2CH.sub.2--O--CH.sub.2CH.sub.2CH.sub.2--
and --CH.sub.2CH.sub.2CH.sub.2--S--CH.sub.2CH.sub.2CH.sub.2--;
[0667] --CH.sub.2CH.sub.2CH.sub.2CH.sub.2--O--CH.sub.2CH.sub.2--
and --CH.sub.2CH.sub.2CH.sub.2CH.sub.2--S--CH.sub.2CH.sub.2--;
[0668] --CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2--O--CH.sub.2--
and --CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2--S--CH.sub.2--.
[0669] Certain Embodiments
[0670] In one preferred embodiment, Q.sup.1 is a covalent bond or
an aryl leader group, J is --NR.sup.1SO.sub.2--, Q.sup.2 is
meta-phenylene-C.sub.1-7alkylene, and the compounds have the
following formula: 37
[0671] In one preferred embodiment, Q.sup.1 is a covalent bond, J
is --NR.sup.1SO.sub.2--, Q.sup.2 is
meta-phenylene-C.sub.1-7alkylene, and the compounds have the
following formula: 38
[0672] In one preferred embodiment, Q.sup.1 is an aryl leader
group, J is --NR.sup.1SO.sub.2--, Q.sup.2 is
meta-phenylene-C.sub.1-7alkylene, and the compounds have the
following formula: 39
[0673] In one preferred embodiment, the aryl leader group, Q.sup.1,
has a backbone of at least 2 carbon atoms.
[0674] In one preferred embodiment, the aryl leader group, Q.sup.1,
has a backbone of at least 3 carbon atoms.
[0675] In one preferred embodiment, the aryl leader group, Q.sup.1,
has a backbone of at least 4 carbon atoms.
[0676] In one preferred embodiment, the aryl leader group, Q.sup.1,
has a backbone of at least 5 carbon atoms.
[0677] In one preferred embodiment, Q.sup.1 is
--CH.sub.2CH.sub.2--, J is --NR.sup.1SO.sub.2--, Q.sup.2 is
meta-phenylene-C.sub.1-7alkylene, and the compounds have the
following formula: 40
[0678] In one preferred embodiment, Q.sup.1 is a covalent bond or
an aryl leader group, J is --NR.sup.1SO.sub.2--, Q.sup.2 is
phenylene-meta-trans-ethylene, and the compounds have the following
formula: 41
[0679] In one preferred embodiment, Q.sup.1 is a covalent bond, J
is --NR.sup.1SO.sub.2--, Q.sup.2 is phenylene-meta-trans-ethylene,
and the compounds have the following formula: 42
[0680] In one preferred embodiment, Q.sup.1 is an aryl leader
group, J is --NR.sup.1SO.sub.2--, Q.sup.2 is
phenylene-meta-trans-ethylene, and the compounds have the following
formula: 43
[0681] In one preferred embodiment, the aryl leader group, Q.sup.1,
has a backbone of at least 2 carbon atoms.
[0682] In one preferred embodiment, the aryl leader group, Q.sup.1,
has a backbone of at least 3 carbon atoms.
[0683] In one preferred embodiment, the aryl leader group, Q.sup.1,
has a backbone of at least 4 carbon atoms.
[0684] In one preferred embodiment, the aryl leader group, Q.sup.1,
has a backbone of at least 5 carbon atoms.
[0685] In one preferred embodiment, Q.sup.1 is
--CH.sub.2CH.sub.2--, J is --NR.sup.1SO.sub.2--, Q.sup.2 is
phenylene-meta-trans-ethylene, and the compounds have the following
formula: 44
[0686] In one preferred embodiment, A is an optionally substituted
phenyl group, Q.sup.1 is a covalent bond or an aryl leader group, J
is --NR.sup.1SO.sub.2--, Q.sup.2 is phenylene-meta-trans-ethylene,
and the compounds have the following formula: 45
[0687] In one preferred embodiment, A is an optionally substituted
phenyl group, Q.sup.1 is a covalent bond, J is
--NR.sup.1SO.sub.2--, Q.sup.2 is phenylene-meta-trans-ethylene, and
the compounds have the following formula: 46
[0688] In one preferred embodiment, A is an optionally substituted
phenyl group, Q.sup.1 is an aryl leader group, J is
--NR.sup.1SO.sub.2--, Q.sup.2 is phenylene-meta-trans-ethylene, and
the compounds have the following formula: 47
[0689] In one preferred embodiment, the aryl leader group, Q.sup.1,
has a backbone of at least 2 carbon atoms.
[0690] In one preferred embodiment, the aryl leader group, Q.sup.1,
has a backbone of at least 3 carbon atoms.
[0691] In one preferred embodiment, the aryl leader group, Q.sup.1,
has a backbone of at least 4 carbon atoms.
[0692] In one preferred embodiment, the aryl leader group, Q.sup.1,
has a backbone of at least 5 carbon atoms.
[0693] In one preferred embodiment, A is an optionally substituted
phenyl group, Q.sup.1 is --CH.sub.2CH.sub.2--, J is
--NR.sup.1SO.sub.2--, Q.sup.2 is phenylene-meta-trans-ethylene, and
the compounds have the following formula: 48
EXAMPLES OF SPECIFIC EMBODIMENTS
[0694] Examples of compounds with J as --SO.sub.2NR.sup.1-- and no
Q.sup.1 group (i.e., where Q.sup.1 is a covalent bond) are shown
below, for comparison purposes.
1 1 49 PX089342 2 50 PX089344 3 51 PX106499 4 52 PX106522 5 53
PX117432 6 54 PX117780 7 55 PX117781 8 56 PX117793 9 57
PX117794
[0695] Some individual embodiments of the present invention include
the following compounds.
2 10 58 PX089343 11 59 PX105684 12 60 PX105685 13 61 PX105844 14 62
PX106508 15 63 PX106509 16 64 PX106510 17 65 PX106511 18 66
PX106512 19 67 PX116238 20 68 PX116242 21 69 PX117225 22 70
PX117226 23 71 PX117227 24 72 PX117228 25 73 PX117233 26 74
PX117234 27 75 PX117235 28 76 PX117236 29 77 PX117245 30 78
PX117250 31 79 PX117260 32 80 PX117410 33 81 PX117411 34 82
PX117412 35 83 PX117414 36 84 PX117429 37 85 PX117445 38 86
PX117446 39 87 PX117447 40 88 PX117448 41 89 PX117450 42 90
PX117453 43 91 PX117710 44 92 PX117712 45 93 PX117713 46 94
PX117715 47 95 PX117734 48 96 PX117735 49 97 PX117736 50 98
PX117773 51 99 PX117774 52 100 PX117775 53 101 PX117778 54 102
PX117779 55 103 PX117782 56 104 PX117787 57 105 PX117788 58 106
PX117789 59 107 PX117790 60 108 PX117791 61 109 PX117792 62 110
PX117795 63 111 PX117796 64 112 PX117798 65 113 66 114 67 115 68
116 69 117 70 118 71 119 72 120 73 121 74 122 75 123 76 124 77 125
78 126 79 127 80 128 81 129 82 130 83 131 84 132 85 133 86 134 87
135 88 136 89 137 90 138 91 139 92 140 93 141 94 142 95 143 96 144
97 145 98 146 99 147 100 148 101 149 102 150 103 151 104 152 105
153 106 154 107 155 108 156 109 157 110 158 111 159 112 160 113 161
114 162 115 163 116 164 117 165 118 166 119 167 120 168 121 169 123
170 122 171 124 172 125 173
[0696] Chemical Terms
[0697] The term "carbo," "carbyl," "hydrocarbon" and "hydrocarbyl,"
as used herein, pertain to compounds and/or groups which have only
carbon and hydrogen atom.
[0698] The term "hetero," as used herein, pertains to compounds
and/or groups which have at least one heteroatom, for example,
multivalent heteroatoms (which are also suitable as ring
heteroatoms) such as boron, silicon, nitrogen, phosphorus, oxygen,
and sulfur, and monovalent heteroatoms, such as fluorine, chlorine,
bromine, and iodine.
[0699] The term "saturated," as used herein, pertains to compounds
and/or groups which do not have any carbon-carbon double bonds or
carbon-carbon triple bonds.
[0700] The term "unsaturated," as used herein, pertains to
compounds and/or groups which have at least one carbon-carbon
double bond or carbon-carbon triple bond.
[0701] The term "aliphatic," as used herein, pertains to compounds
and/or groups which are linear or branched, but not cyclic (also
known as "acyclic" or "open-chain" groups).
[0702] The term "cyclic," as used herein, pertains to compounds
and/or groups which have one ring, or two or more rings (e.g.,
spiro, fused, bridged).
[0703] The term "ring," as used herein, pertains to a closed ring
of from 3 to 10 covalently linked atoms, more preferably 3 to 8
covalently linked atoms.
[0704] The term "aromatic ring," as used herein, pertains to a
closed ring of from 3 to 10 covalently linked atoms, more
preferably 5 to 8 covalently linked atoms, which ring is
aromatic.
[0705] The term "heterocyclic ring," as used herein, pertains to a
closed ring of from 3 to 10 covatently linked atoms, more
preferably 3 to 8 covalently linked atoms, wherein at least one of
the ring atoms is a multivalent ring heteroatom, for example,
nitrogen, phosphorus, silicon, oxygen, and sulfur, though more
commonly nitrogen, oxygen, and sulfur.
[0706] The term "alicyclic," as used herein, pertains to compounds
and/or groups which have one ring, or two or more rings (e.g.,
spiro, fused, bridged), wherein said ring(s) are not aromatic.
[0707] The term "aromatic," as used herein, pertains to compounds
and/or groups which have one ring, or two or more rings (e.g.,
fused), wherein at least one of said ring(s) is aromatic.
[0708] The term "heterocyclic," as used herein, pertains to cyclic
compounds and/or groups which have one heterocyclic ring, or two or
more heterocyclic rings (e.g., spiro, fused, bridged), wherein said
ring(s) may be alicyclic or aromatic.
[0709] The term "heteroaromatic," as used herein, pertains to
cyclic compounds and/or groups which have one heterocyclic ring, or
two or more heterocyclic rings (e.g., fused), wherein said ring(s)
is aromatic.
[0710] Substituents
[0711] The phrase "optionally substituted," as used herein,
pertains to a parent group which may be unsubstituted or which may
be substituted.
[0712] Unless otherwise specified, the term "substituted," as used
herein, pertains to a parent group which bears one or more
substituents. The term "substituent" is used herein in the
conventional sense and refers to a chemical moiety which is
covalently attached to, appended to, or if appropriate, fused to, a
parent group. A wide variety of substituents are well known, and
methods for their formation and introduction into a variety of
parent groups are also well known.
[0713] In one preferred embodiment, the substituent(s), often
referred to herein as R, are independently selected from: halo;
hydroxy; ether (e.g., C.sub.1-7alkoxy); formyl; acyl (e.g.,
C.sub.1-7alkylacyl, C.sub.5-20arylacyl); acylhalide; carboxy;
ester; acyloxy; amido; acylamido; thioamido; tetrazolyl; amino;
nitro; nitroso; azido; cyano; isocyano; cyanato; isocyanato;
thiocyano; isothiocyano; sulfhydryl; thioether (e.g.,
C.sub.1-7alkylthio); sulfonic acid; sulfonate; sulfone;
sulfonyloxy; sulfinyloxy; sulfamino; sulfonamino; sulfinamino;
sulfamyl; sulfonamido; C.sub.1-7alkyl (including, e.g.,
C.sub.1-7haloalkyl, C.sub.1-7hydroxyalkyl, C.sub.1-7carboxyalkyl,
C.sub.1-7aminoalkyl, C.sub.5-20aryl-C.sub.1-7alkyl);
C.sub.3-20heterocyclyl; or C.sub.5-20aryl (including, e.g.,
C.sub.5-20carboaryl, C.sub.5-20heteroaryl,
C.sub.1-7alkyl-C.sub.5-20aryl and C.sub.5-20haloaryl)).
[0714] In one preferred embodiment, the substituent(s), often
referred to herein as R, are independently selected from:
[0715] --F, --Cl, --Br, and --I;
[0716] --OH;
[0717] --OMe, --OEt, --O(tBu), and --OCH.sub.2Ph;
[0718] --SH;
[0719] --SMe, --SEt, --S(tBu), and --SCH.sub.2Ph;
[0720] --C(.dbd.O)H;
[0721] --C(.dbd.O)Me, --C(.dbd.O)Et, --C(.dbd.O)(tBu), and
--C(.dbd.O)Ph;
[0722] --C(.dbd.O)OH;
[0723] --C(.dbd.O)OMe, --C(.dbd.O)OEt, and --C(.dbd.O)O(tBu);
[0724] --C(.dbd.O)NH.sub.2, --C(.dbd.O)NHMe, --C(.dbd.O)NMe.sub.2,
and --C(.dbd.O)NHEt;
[0725] --NHC(.dbd.O)Me, --NHC(.dbd.O)Et, --NHC(.dbd.O)Ph,
succinimidyl, and maleimidyl;
[0726] --NH.sub.2, --NHMe, --NHEt, --NH(iPr), --NH(nPr),
--NMe.sub.2, --NEt.sub.2, --N(iPr).sub.2, --N(nPr).sub.2,
--N(nBu).sub.2, and --N(tBu).sub.2;
[0727] --CN;
[0728] --NO.sub.2;
[0729] -Me, -Et, -nPr, -iPr, -nBu, -tBu;
[0730] --CF.sub.3, --CHF.sub.2, --CH.sub.2F, --CCl.sub.3,
--CBr.sub.3, --CH.sub.2CH.sub.2F, --CH.sub.2CHF.sub.2, and
--CH.sub.2CF.sub.3;
[0731] --OCF.sub.3, --OCHF.sub.2, --OCH.sub.2F, --OCCl.sub.3,
--OCBr.sub.3, --OCH.sub.2CH.sub.2F, --OCH.sub.2CHF.sub.2, and
--OCH.sub.2CF.sub.3;
[0732] --CH.sub.2OH, --CH.sub.2CH.sub.2OH, and
--CH(OH)CH.sub.2OH;
[0733] --CH.sub.2NH.sub.2, --CH.sub.2CH.sub.2NH.sub.2, and
--CH.sub.2CH.sub.2NMe.sub.2; and,
[0734] optionally substituted phenyl.
[0735] In one preferred embodiment, the substituent(s), often
referred to herein as R, are independently selected from: --F,
--Cl, --Br, --I, --OH, --OMe, --OEt, --SH, --SMe, --SEt,
--C(.dbd.O)Me, --C(.dbd.O)OH, --C(.dbd.O)OMe, --CONH.sub.2,
--CONHMe, --NH.sub.2, --NMe.sub.2, --NEt.sub.2, --N(nPr).sub.2,
--N(iPr).sub.2, --CN, --NO.sub.2, -Me, -Et, --CF.sub.3,
--OCF.sub.3, --CH.sub.2OH, --CH.sub.2CH.sub.2OH,
--CH.sub.2NH.sub.2, --CH.sub.2CH.sub.2NH.sub.2, and -Ph.
[0736] In one preferred embodiment, the substituent(s), often
referred to herein as R, are independently selected from: hydroxy;
ether (e.g., C.sub.1-7alkoxy); ester; amido; amino; and,
C.sub.1-7alkyl (including, e.g., C.sub.1-7haloalkyl,
C.sub.1-7hydroxyalkyl, C.sub.1-7carboxyalkyl, C.sub.1-7aminoalkyl,
C.sub.5-20aryl-C.sub.1-7alkyl).
[0737] In one preferred embodiment, the substituent(s), often
referred to herein as R, are independently selected from:
[0738] --OH;
[0739] --OMe, --OEt, --O(tBu), and --OCH.sub.2Ph;
[0740] --C(.dbd.O)OMe, --C(.dbd.O)OEt, and --C(.dbd.O)O(tBu);
[0741] --C(.dbd.O)NH.sub.2, --C(.dbd.O)NHMe, --C(.dbd.O)NMe.sub.2,
and --C(.dbd.O)NHEt;
[0742] --NH.sub.2, --NHMe, --NHEt, --NH(iPr), --NH(nPr),
--NMe.sub.2, --NEt.sub.2, --N(iPr).sub.2, --N(nPr).sub.2,
--N(nBu).sub.2, and --N(tBu).sub.2; -Me, -Et, -nPr, -iPr, -nBu,
-tBu;
[0743] --CF.sub.3, --CHF.sub.2, --CH.sub.2F, --CCl.sub.3,
--CBr.sub.3, --CH.sub.2CH.sub.2F, --CH.sub.2CHF.sub.2, and
--CH.sub.2CF.sub.3--CH.sub.- 2OH, --CH.sub.2CH.sub.2OH, and
--CH(OH)CH.sub.2OH; and,
[0744] --CH.sub.2NH.sub.2, --CH.sub.2CH.sub.2NH.sub.2, and
--CH.sub.2CH.sub.2NMe.sub.2.
[0745] The substituents are described in more detail below.
[0746] C.sub.1-7alkyl: The term "C.sub.1-7alkyl," as used herein,
pertains to a monovalent moiety obtained by removing a hydrogen
atom from a C.sub.1-7hydrocarbon compound having from 1 to 7 carbon
atoms, which may be aliphatic or alicyclic, or a combination
thereof, and which may be saturated, partially unsaturated, or
fully unsaturated.
[0747] Examples of (unsubstituted) saturated linear C.sub.1-7alkyl
groups include, but are not limited to, methyl, ethyl, n-propyl,
n-butyl, and n-pentyl (amyl).
[0748] Examples of (unsubstituted) saturated branched
C.sub.1-7alkyl groups include, but are not limited to, iso-propyl,
iso-butyl, sec-butyl, tert-butyl, and neo-pentyl.
[0749] Examples of saturated alicyclic (also carbocyclic)
C.sub.1-7alkyl groups (also referred to as "C.sub.3-7cycloalkyl"
groups) include, but are not limited to, unsubstituted groups such
as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and
norbornane, as well as substituted groups (e.g., groups which
comprise such groups), such as methylcyclopropyl,
dimethylcyclopropyl, methylcyclobutyl, dimethylcyclobutyl,
methylcyclopentyl, dimethylcyclopentyl, methylcyclohexyl,
dimethylcyclohexyl, cyclopropylmethyl and cyclohexylmethyl.
[0750] Examples of (unsubstituted) unsaturated C.sub.1-7alkyl
groups which have one or more carbon-carbon double bonds (also
referred to as "C.sub.2-7alkenyl" groups) include, but are not
limited to, ethenyl (vinyl, --CH.dbd.CH.sub.2), 2-propenyl (allyl,
--CH--CH.dbd.CH.sub.2), isopropenyl (--C(CH.sub.3).dbd.CH.sub.2),
butenyl, pentenyl, and hexenyl.
[0751] Examples of (unsubstituted) unsaturated C.sub.1-7alkyl
groups which have one or more carbon-carbon triple bonds (also
referred to as "C.sub.2-7alkynyl" groups) include, but are not
limited to, ethynyl (ethinyl) and 2-propynyl (propargyl).
[0752] Examples of unsaturated alicyclic (also carbocyclic)
C.sub.1-7alkyl groups which have one or more carbon-carbon double
bonds (also referred to as "C.sub.3-7cycloalkenyl" groups) include,
but are not limited to, unsubstituted groups such as cyclopropenyl,
cyclobutenyl, cyclopentenyl, and cyclohexenyl, as well as
substituted groups (e.g., groups which comprise such groups) such
as cyclopropenylmethyl and cyclohexenylmethyl.
[0753] Additional examples of substituted C.sub.3-7cycloalkyl
groups include, but are not limited to, those with one or more
other rings fused thereto, for example, those derived from: indene
(C.sub.9), indan (2,3-dihydro-1H-indene) (C.sub.9), tetraline
(1,2,3,4-tetrahydronaphthale- ne (C.sub.10), adamantane (C.sub.10),
decalin (decahydronaphthalene) (C.sub.12), fluorene (C.sub.13),
phenalene (C.sub.13). For example, 2H-inden-2-yl is a
C.sub.5cycloalkyl group with a substituent (phenyl) fused
thereto.
[0754] C.sub.3-20heterocyclyl: The term "C.sub.3-20heterocyclyl,"
as used herein, pertains to a monovalent moiety obtained by
removing a hydrogen atom from a ring atom of a
C.sub.3-20heterocyclic compound, said compound having one ring, or
two or more rings (e.g., spiro, fused, bridged), and having from 3
to 20 ring atoms, of which from 1 to 10 are ring heteroatoms, and
wherein at least one of said ring(s) is a heterocyclic ring.
Preferably, each ring has from 3 to 7 ring atoms, of which from 1
to 4 are ring heteroatoms.
[0755] In this context, the prefixes (e.g., C.sub.3-20, C.sub.3-7,
C.sub.5-6, etc.) denote the number of ring atoms, or range of
number of ring atoms, whether carbon atoms or heteroatoms. For
example, the term "C.sub.5-6heterocyclyl," as used herein, pertains
to a heterocyclyl group having 5 or 6 ring atoms. Examples of
groups of heterocyclyl groups include C.sub.3-20heterocyclyl,
C.sub.3-7heterocyclyl, C.sub.5-7heterocyclyl.
[0756] Examples of (non-aromatic) monocyclic heterocyclyl groups
include, but are not limited to, those derived from:
[0757] N.sub.1: aziridine (C.sub.3), azetidine (C.sub.4),
pyrrolidine (tetrahydropyrrole) (C.sub.5), pyrroline (e.g.,
3-pyrroline, 2,5-dihydropyrrole) (C.sub.5), 2H-pyrrole or
3H-pyrrole (isopyrrole, isoazole) (C.sub.5), piperidine (C.sub.6),
dihydropyridine (C.sub.6), tetrahydropyridine (C.sub.6), azepine
(C.sub.7);
[0758] O.sub.1: oxirane (C.sub.3), oxetane (C.sub.4), oxolane
(tetrahydrofuran) (C.sub.5), oxole (dihydrofuran) (C.sub.5), oxane
(tetrahydropyran) (C.sub.6), dihydropyran (C.sub.6), pyran
(C.sub.6), oxepin (C.sub.7);
[0759] S.sub.1: thiirane (C.sub.3), thietane (C.sub.4), thiolane
(tetrahydrothiophene) (C.sub.5), thiane (tetrahydrothiopyran)
(C.sub.6), thiepane (C.sub.7);
[0760] O.sub.2: dioxolane (C.sub.5), dioxane (C.sub.6), and
dioxepane (C.sub.7); 03: trioxane (C.sub.6);
[0761] N.sub.2: imidazolidine (C.sub.5), pyrazolidine (diazolidine)
(C.sub.5), imidazoline (C.sub.5), pyrazoline (dihydropyrazole)
(C.sub.5), piperazine (C.sub.6);
[0762] N.sub.1O.sub.1: tetrahydrooxazole (C.sub.5), dihydrooxazole
(C.sub.5), tetrahydroisoxazole (C.sub.5), dihydroisoxazole
(C.sub.5), morpholine (C.sub.6), tetrahydrooxazine (C.sub.6),
dihydrooxazine (C.sub.6), oxazine (C.sub.6);
[0763] N.sub.1S.sub.1: thiazoline (C.sub.5), thiazolidine
(C.sub.5), thiomorpholine (C.sub.6);
[0764] N.sub.2O.sub.1: oxadiazine (C.sub.6);
[0765] O.sub.1S.sub.1: oxathiole (C.sub.5) and oxathiane (thioxane)
(C.sub.6); and,
[0766] N.sub.1O.sub.1S.sub.1: oxathiazine (C.sub.6).
[0767] Examples of substituted (non-aromatic) monocyclic
heterocyclyl groups include saccharides, in cyclic form, for
example, furanoses (C.sub.5), such as arabinofuranose,
lyxofuranose, ribofuranose, and xylofuranse, and pyranoses
(C.sub.6), such as allopyranose, altropyranose, glucopyranose,
mannopyranose, gulopyranose, idopyranose, galactopyranose, and
talopyranose.
[0768] Examples of heterocyclyl groups which are also heteroaryl
groups are described below with aryl groups.
[0769] C.sub.5-20aryl: The term "C.sub.5-20aryl," as used herein,
pertains to a monovalent moiety obtained by removing a hydrogen
atom from an aromatic ring atom of a C.sub.5-20aromatic compound,
said compound having one ring, or two or more rings (e.g., fused),
and having from 5 to 20 ring atoms, and wherein at least one of
said ring(s) is an aromatic ring. Preferably, each ring has from 5
to 7 ring atoms. In this context, the prefixes (e.g., C.sub.3-20,
C.sub.5-7, Cr.sub.5-6, etc.) denote the number of ring atoms, or
range of number of ring atoms, whether carbon atoms or heteroatoms.
For example, the term "C.sub.5-6aryl," as used herein, pertains to
an aryl group having 5 or 6 ring atoms. Examples of groups of aryl
groups include C.sub.3-20aryl, C.sub.5-7aryl, C.sub.5-6aryl.
[0770] The ring atoms may be all carbon atoms, as in "carboaryl
groups" (e.g., C.sub.5-20carboaryl).
[0771] Examples of carboaryl groups include, but are not limited
to, those derived from benzene (i.e., phenyl) (C.sub.6),
naphthalene (C.sub.10), azulene (C.sub.10), anthracene (C.sub.14),
phenanthrene (C.sub.14), naphthacene (C.sub.18), and pyrene
(C.sub.16).
[0772] Examples of aryl groups which comprise fused rings, at least
one of which is an aromatic ring, include, but are not limited to,
groups derived from indene (C.sub.9), isoindene (C.sub.9), and
fluorene (C.sub.13).
[0773] Alternatively, the ring atoms may include one or more
heteroatoms, including but not limited to oxygen, nitrogen, and
sulfur, as in "heteroaryl groups." In this case, the group may
conveniently be referred to as a "C.sub.5-20heteroaryl" group,
wherein "C.sub.5-20" denotes ring atoms, whether carbon atoms or
heteroatoms. Preferably, each ring has from 5 to 7 ring atoms, of
which from 0 to 4 are ring heteroatoms.
[0774] Examples of monocyclic heteroaryl groups include, but are
not limited to, those derived from:
[0775] N.sub.1: pyrrole (azole) (C.sub.5), pyridine (azine)
(C.sub.6);
[0776] O.sub.1: furan (oxole) (C.sub.5);
[0777] S.sub.1: thiophene (thiole) (C.sub.5);
[0778] N.sub.1O.sub.1: oxazole (C.sub.5), isoxazole (C.sub.5),
isoxazine (C.sub.6); N.sub.2O.sub.1: oxadiazole (furazan)
(C.sub.5);
[0779] N.sub.3O.sub.1: oxatriazole (C.sub.5);
[0780] N.sub.1S.sub.1: thiazole (C.sub.5), isothiazole
(C.sub.5);
[0781] N.sub.2: imidazole (1,3-diazole) (C.sub.5), pyrazole
(1,2-diazole) (C.sub.5), pyridazine (1,2-diazine) (C.sub.6),
pyrimidine (1,3-diazine) (C.sub.6) (e.g., cytosine, thymine,
uracil), pyrazine (1,4-diazine) (C.sub.6);
[0782] N.sub.3: triazole (C.sub.5), triazine (C.sub.6); and,
[0783] N.sub.4: tetrazole (C.sub.5).
[0784] Examples of heterocyclic groups (some of which are also
heteroaryl groups) which comprise fused rings, include, but are not
limited to:
[0785] C.sub.9heterocyclic groups (with 2 fused rings) derived from
benzofuran (O.sub.1), isobenzofuran (O.sub.1), indole (N.sub.1),
isoindole (N.sub.1), purine (N.sub.4) (e.g., adenine, guanine),
benzimidazole (N.sub.2), benzoxazole (N.sub.1O.sub.1),
benzisoxazole (N.sub.1O.sub.1), benzodioxole (O.sub.2),
benzofurazan (N.sub.2O.sub.1), benzotriazole (N.sub.3),
benzothiofuran (S.sub.1), benzothiazole (N.sub.1S.sub.1),
benzothiadiazole (N.sub.2S);
[0786] C.sub.10heterocyclic groups (with 2 fused rings) derived
from benzodioxan (O.sub.2), quinoline (N.sub.1), isoquinoline
(N.sub.1), benzoxazine (N.sub.1O.sub.1), benzodiazine (N.sub.2),
pyridopyridine (N.sub.2), quinoxaline (N.sub.2), quinazoline
(N.sub.2);
[0787] C.sub.13heterocyclic groups (with 3 fused rings) derived
from carbazole (N.sub.1), dibenzofuran (O.sub.1), dibenzothiophene
(S.sub.1); and,
[0788] C.sub.14heterocyclic groups (with 3 fused rings) derived
from acridine (N.sub.1), xanthene (O.sub.1), phenoxathiin
(O.sub.1S.sub.1), phenazine (N.sub.2), phenoxazine
(N.sub.1O.sub.1), phenothiazine (N.sub.1S.sub.1), thianthrene
(S.sub.2), phenanthridine (N.sub.1), phenanthroline (N.sub.2),
phenazine (N.sub.2).
[0789] Heterocyclic groups (including heteroaryl groups) which have
a nitrogen ring atom in the form of an --NH-- group may be
N-substituted, that is, as --NR--. For example, pyrrole may be
N-methyl substituted, to give N-methypyrrole. Examples of
N-substitutents include, but are not limited to C.sub.1-7alkyl,
C.sub.3-20heterocyclyl, C.sub.5-20aryl, and acyl groups.
[0790] Heterocyclic groups (including heteroaryl groups) which have
a nitrogen ring atom in the form of an --N.dbd. group may be
substituted in the form of an N-oxide, that is, as
--N(.fwdarw.O).dbd. (also denoted --N.sup.+(.fwdarw.O.sup.-).dbd.).
For example, quinoline may be substituted to give quinoline
N-oxide; pyridine to give pyridine N-oxide; benzofurazan to give
benzofurazan N-oxide (also known as benzofuroxan).
[0791] Cyclic groups may additionally bear one or more oxo (.dbd.O)
groups on ring carbon atoms. Monocyclic examples of such groups
include, but are not limited to, those derived from:
[0792] C.sub.5: cyclopentanone, cyclopentenone,
cyclopentadienone;
[0793] C.sub.6: cyclohexanone, cyclohexenone, cyclohexadienone;
[0794] O.sub.1: furanone (C.sub.5), pyrone (C.sub.6);
[0795] N.sub.1: pyrrolidone (pyrrolidinone) (C.sub.5), piperidinone
(piperidone) (C.sub.6), piperidinedione (C.sub.6);
[0796] N.sub.2: imidazolidone (imidazolidinone) (C.sub.5),
pyrazolone (pyrazolinone) (C.sub.5), piperazinone (C.sub.6),
piperazinedione (C.sub.6), pyridazinone (C.sub.6), pyrimidinone
(C.sub.6) (e.g., cytosine), pyrimidinedione (C.sub.6) (e.g.,
thymine, uracil), barbituric acid (C.sub.6);
[0797] N.sub.1S.sub.1: thiazolone (C.sub.5), isothiazolone
(C.sub.5);
[0798] N.sub.1O.sub.1: oxazolinone (C.sub.5).
[0799] Polycyclic examples of such groups include, but are not
limited to, those derived from:
[0800] C.sub.9: indenedione;
[0801] N.sub.1: oxindole (C.sub.9);
[0802] O.sub.1: benzopyrone (e.g., coumarin, isocoumarin, chromone)
(C.sub.10);
[0803] N.sub.1O.sub.1: benzoxazolinone (C.sub.9), benzoxazolinone
(C.sub.10);
[0804] N.sub.2: quinazolinedione (C.sub.10);
[0805] N.sub.4: purinone (C.sub.9) (e.g., guanine).
[0806] Still more examples of cyclic groups which bear one or more
oxo (.dbd.O) groups on ring carbon atoms include, but are not
limited to, those derived from:
[0807] cyclic anhydrides (--C(.dbd.O)--O--C(.dbd.O in a ring),
including but not limited to maleic anhydride (C.sub.5), succinic
anhydride (C.sub.5), and glutaric anhydride (C.sub.6);
[0808] cyclic carbonates (--O--C(.dbd.O)--O-- in a ring), such as
ethylene carbonate (C.sub.5) and 1,2-propylene carbonate
(C.sub.5);
[0809] imides (--C(.dbd.O)--NR--C(.dbd.O)-- in a ring), including
but not limited to, succinimide (C.sub.5), maleimide (C.sub.5),
phthalimide, and glutarimide (C.sub.6);
[0810] lactones (cyclic esters, --O--C(.dbd.O)-- in a ring),
including, but not limited to, .beta.-propiolactone,
.gamma.-butyrolactone, .delta.-valerolactone (2-piperidone), and
.epsilon.-caprolactone;
[0811] lactams (cyclic amides, --NR--C(.dbd.O)-- in a ring),
including, but not limited to, .beta.-propiolactam (C.sub.4),
.gamma.-butyrolactam (2-pyrrolidone) (C.sub.5),
.delta.-valerolactam (C.sub.6), and .epsilon.-caprolactam
(C.sub.7);
[0812] cyclic carbamates (--O--C(--O)--NR-- in a ring), such as
2-oxazolidone (C.sub.5);
[0813] cyclic ureas (--NR--C(.dbd.O)--NR-- in a ring), such as
2-imidazolidone (C.sub.5) and pyrimidine-2,4-dione (e.g., thymine,
uracil) (C.sub.6).
[0814] The above C.sub.1-7alkyl, C.sub.3-20heterocyclyl, and
C.sub.5-20aryl groups, whether alone or part of another
substituent, may themselves optionally be substituted with one or
more groups selected from themselves and the additional
substituents listed below.
[0815] Hydrogen: --H. Note that if the substituent at a particular
position is hydrogen, it may be convenient to refer to the compound
as being "unsubstituted" at that position.
[0816] Halo: --F, --Cl, --Br, and --I.
[0817] Hydroxy:--OH.
[0818] Ether: --OR, wherein R is an ether substituent, for example,
a C.sub.1-7alkyl group (also referred to as a C.sub.1-7alkoxy
group, discussed below), a C.sub.3-20heterocyclyl group (also
referred to as a C.sub.3-20hetercyclyloxy group), or a
C.sub.5-20aryl group (also referred to as a C.sub.5-20aryloxy
group), preferably a C.sub.1-7alkyl group.
[0819] C.sub.1-7alkoxy: --OR, wherein R is a C.sub.1-7alkyl group.
Examples of C.sub.1-7alkoxy groups include, but are not limited to,
--OCH.sub.3 (methoxy), --OCH.sub.2CH.sub.3 (ethoxy) and
--OC(CH.sub.3).sub.3 (tert-butoxy).
[0820] Oxo (keto, -one): .dbd.O. Examples of cyclic compounds
and/or groups having, as a substituent, an oxo group (.dbd.O)
include, but are not limited to, carbocyclics such as
cyclopentanone and cyclohexanone; heterocyclics, such as pyrone,
pyrrolidone, pyrazolone, pyrazolinone, piperidone, piperidinedione,
piperazinedione, and imidazolidone; cyclic anhydrides, including
but not limited to maleic anhydride and succinic anhydride; cyclic
carbonates, such as propylene carbonate; imides, including but not
limited to, succinimide and maleimide; lactones (cyclic esters,
--O--C(.dbd.O)-- in a ring), including, but not limited to,
.beta.-propiolactone, .gamma.-butyrolactone, .delta.-valerolactone,
and .epsilon.-caprolactone; and lactams (cyclic amides,
--NH--C(.dbd.O)-- in a ring), including, but not limited to,
.beta.-propiolactam, .gamma.-butyrolactam, .delta.-valerolactam,
and .epsilon.-caprolactam.
[0821] Imino (imine): .dbd.NR, wherein R is an imino substituent,
for example, hydrogen, C.sub.1-7alkyl group, a
C.sub.3-20heterocyclyl group, or a C.sub.5-20aryl group, preferably
hydrogen or a C.sub.1-7alkyl group. Examples of imino groups
include, but are not limited to, .dbd.NH, .dbd.NMe, .dbd.NEt, and
.dbd.NPh.
[0822] Formyl (carbaldehyde, carboxaldehyde): --C(.dbd.O)H.
[0823] Acyl (keto): --C(.dbd.O)R, wherein R is an acyl substituent,
for example, a C.sub.1-7alkyl group (also referred to as
C.sub.1-7alkylacyl or C.sub.1-7alkanoyl), a C.sub.3-20heterocyclyl
group (also referred to as C.sub.3-20heterocyclylacyl), or a
C.sub.5-20aryl group (also referred to as C.sub.5-20arylacyl),
preferably a C.sub.1-7alkyl group. Examples of acyl groups include,
but are not limited to, --C(.dbd.O)CH.sub.3 (acetyl),
--C(.dbd.O)CH.sub.2CH.sub.3 (propionyl),
--C(.dbd.O)C(CH.sub.3).sub.3 (butyryl), and --C(.dbd.O)Ph (benzoyl,
phenone).
[0824] Acylhalide (haloformyl, halocarbonyl): --C(.dbd.O)X, wherein
X is --F, --Cl, --Br, or --I, preferably --Cl, --Br, or --I.
[0825] Carboxy (carboxylic acid): --COOH.
[0826] Ester (carboxylate, carboxylic acid ester, oxycarbonyl):
--C(.dbd.O)OR, wherein R is an ester substituent, for example, a
C.sub.1-7alkyl group, a C.sub.3-20heterocyclyl group, or a
C.sub.5-20aryl group, preferably a C.sub.1-7alkyl group. Examples
of ester groups include, but are not limited to,
--C(.dbd.O)OCH.sub.3, --C(.dbd.O)OCH.sub.2CH.sub.3,
--C(--O)OC(CH.sub.3).sub.3, and --C(.dbd.O)OPh.
[0827] Acyloxy (reverse ester): --OC(.dbd.O)R, wherein R is an
acyloxy substituent, for example, a C.sub.1-7alkyl group, a
C.sub.3-20heterocyclyl group, or a C.sub.5-20aryl group, preferably
a C.sub.1-7alkyl group. Examples of acyloxy groups include, but are
not limited to, --OC(.dbd.O)CH.sub.3 (acetoxy),
--OC(--O)CH.sub.2CH.sub.3, --OC(.dbd.O)C(CH.sub.3).sub.3,
--OC(.dbd.O)Ph, and --OC(.dbd.O)CH.sub.2Ph.
[0828] Amido (carbamoyl, carbamyl, aminocarbonyl, carboxamide):
--C(.dbd.O)NR.sup.1R.sup.2, wherein R.sup.1 and R.sup.2 are
independently amino substituents, as defined for amino groups.
Examples of amido groups include, but are not limited to,
--C(.dbd.O)NH.sub.2, --C(.dbd.O)NHCH.sub.3,
--C(.dbd.O)NH(CH.sub.3).sub.2, --C(.dbd.O)NHCH.sub.2CH.sub.3, and
--C(.dbd.O)N(CH.sub.2CH.sub.3).sub.2, as well as amido groups in
which R.sup.1 and R.sup.2, together with the nitrogen atom to which
they are attached, form a heterocyclic structure as in, for
example, piperidinocarbonyl, morpholinocarbonyl,
thiomorpholinocarbonyl, and piperazinocarbonyl.
[0829] Acylamido (acylamino): --NR.sup.1C(.dbd.O)R.sup.2, wherein
R.sup.1 is an amide substituent, for example, a C.sub.1-7alkyl
group, a C.sub.3-20heterocyclyl group, or a C.sub.5-20aryl group,
preferably a C.sub.1-7alkyl group, and R.sup.2 is an acyl
substituent, for example, a C.sub.1-7alkyl group, a
C.sub.3-20heterocyclyl group, or a C.sub.5-20aryl group, preferably
a C.sub.1-7alkyl group. Examples of acylamido groups include, but
are not limited to, --NHC(.dbd.O)CH.sub.3,
--NHC(.dbd.O)CH.sub.2CH.sub.3, and --NHC(.dbd.O)Ph. R.sup.1 and
R.sup.2 may together form a cyclic structure, as in, for example,
for example, succinimidyl, maleimidyl, and phthalimidyl: 174
[0830] Thioamido (thiocarbamyl): --C(.dbd.S)NR.sup.1R.sup.2,
wherein R.sup.1 and R.sup.2 are independently amino substituents,
as defined for amino groups. Examples of amido groups include, but
are not limited to, --C(.dbd.S)NH.sub.2, --C(.dbd.S)NHCH.sub.3,
--C(.dbd.S)NH(CH.sub.3).sub.2- , and
--C(.dbd.S)NHCH.sub.2CH.sub.3.
[0831] Tetrazolyl: a five membered aromatic ring having four
nitrogen atoms and one carbon atom, 175
[0832] Amino: --NR.sup.1R.sup.2, wherein R.sup.1 and R.sup.2 are
independently amino substituents, for example, hydrogen, a
C.sub.1-7alkyl group (also referred to as C.sub.1-7alkylamino or
di-C.sub.1-7alkylamino)- , a C.sub.3-20heterocyclyl group, or a
C.sub.5-20aryl group, preferably H or a C.sub.1-7alkyl group, or,
in the case of a "cyclic" amino group, R.sup.1 and R.sup.2, taken
together with the nitrogen atom to which they are attached, form a
heterocyclic ring having from 4 to 8 ring atoms. Examples of amino
groups include, but are not limited to, --NH.sub.2, --NHCH.sub.3,
--NHCH(CH.sub.3).sub.2, --N(CH.sub.3).sub.2,
--N(CH.sub.2CH.sub.3).sub.2, and --NHPh. Examples of cyclic amino
groups include, but are not limited to, aziridino, azetidino,
piperidino, piperazino, morpholino, and thiomorpholino.
[0833] Nitro: --NO.sub.2.
[0834] Nitroso: --NO.
[0835] Azido: --N.sub.3.
[0836] Cyano (nitrile, carbonitrile): --CN.
[0837] Isocyano: --NC.
[0838] Cyanato: --OCN.
[0839] Isocyanato: --NCO.
[0840] Thiocyano (thiocyanato): --SCN.
[0841] Isothiocyano (isothiocyanato): --NCS.
[0842] Sulfhydryl (thiol, mercapto): --SH.
[0843] Thioether (sulfide): --SR, wherein R is a thioether
substituent, for example, a C.sub.1-7alkyl group (also referred to
as a C.sub.1-7alkylthio group), a C.sub.3-20heterocyclyl group, or
a C.sub.5-20aryl group, preferably a C.sub.1-7alkyl group. Examples
of C.sub.1-7alkylthio groups include, but are not limited to,
--SCH.sub.3 and --SCH.sub.2CH.sub.3.
[0844] Sulfonic acid (sulfo): --S(.dbd.O).sub.2OH.
[0845] Sulfonate (sulfonic acid ester): --S(.dbd.O).sub.2OR,
wherein R is a sulfonate substituent, for example, a C.sub.1-7alkyl
group, a C.sub.3-20heterocyclyl group, or a C.sub.5-20aryl group,
preferably a C.sub.1-7alkyl group. Examples of sulfonate groups
include, but are not limited to, --S(.dbd.O).sub.2OCH.sub.3 and
--S(.dbd.O).sub.2OCH.sub.2CH.s- ub.3.
[0846] Sulfone (sulfonyl): --S(.dbd.O).sub.2R, wherein R is a
sulfone substituent, for example, a C.sub.1-7alkyl group, a
C.sub.3-20heterocyclyl group, or a C.sub.5-20aryl group, preferably
a C.sub.1-7alkyl group. Examples of sulfone groups include, but are
not limited to, --S(.dbd.O).sub.2CH.sub.3 (methanesulfonyl, mesyl),
--S(.dbd.O).sub.2CF.sub.3, --S(.dbd.O).sub.2CH.sub.2CH.sub.3, and
4-methylphenylsulfonyl (tosyl).
[0847] Sulfonyloxy: --OS(.dbd.O).sub.2R, wherein R is a sulfonyloxy
substituent, for example, a C.sub.1-7alkyl group, a
C.sub.3-20heterocyclyl group, or a C.sub.5-20aryl group, preferably
a C.sub.1-7alkyl group. Examples of sulfonyloxy groups include, but
are not limited to, --OS(.dbd.O).sub.2CH.sub.3 and
--OS(.dbd.O).sub.2CH.sub.2CH.s- ub.3.
[0848] Sulfinyloxy: --OS(.dbd.O)R, wherein R is a sulfinyloxy
substituent, for example, a C.sub.1-7alkyl group, a
C.sub.3-20heterocyclyl group, or a C.sub.5-20aryl group, preferably
a C.sub.1-7alkyl group. Examples of sulfinyloxy groups include, but
are not limited to, --OS(.dbd.O)CH.sub.3 and
--OS(.dbd.O)CH.sub.2CH.sub.3.
[0849] Sulfamino: --NR.sup.1S(.dbd.O).sub.2OH, wherein R.sup.1 is
an amino substituent, as defined for amino groups. Examples of
sulfamino groups include, but are not-limited to,
--NHS(.dbd.O).sub.2OH and --N(CH.sub.3)S(.dbd.O).sub.2OH.
[0850] Sulfonamino: --NR.sup.1S(.dbd.O).sub.2R, wherein R.sup.1 is
an amino substituent, as defined for amino groups, and R is a
sulfonamino substituent, for example, a C.sub.1-7alkyl group, a
C.sub.3-20heterocyclyl group, or a C.sub.5-20aryl group, preferably
a C.sub.1-7alkyl group. Examples of sulfonamino groups include, but
are not limited to, --NHS(.dbd.O).sub.2CH.sub.3 and
--N(CH.sub.3)S(.dbd.O).sub.2C- .sub.6H.sub.5.
[0851] Sulfinamino: --NR.sup.1S(.dbd.O)R, wherein R.sup.1 is an
amino substituent, as defined for amino groups, and R is a
sulfinamino substituent, for example, a C.sub.1-7alkyl group, a
C.sub.3-20heterocyclyl group, or a C.sub.5-20aryl group, preferably
a C.sub.1-7alkyl group. Examples of sulfinamino groups include, but
are not limited to, --NHS(.dbd.O)CH.sub.3 and
--N(CH.sub.3)S(.dbd.O)C.sub.6H.sub.- 5.
[0852] Sulfamyl: --S(.dbd.O)NR.sup.1R.sup.2, wherein R.sup.1 and
R.sup.2 are independently amino substituents, as defined for amino
groups. Examples of sulfamyl groups include, but are not limited
to, --S(.dbd.O)NH.sub.2, --S(.dbd.O)NH(CH.sub.3),
--S(.dbd.O)N(CH.sub.3).sub.- 2, --S(.dbd.O)NH(CH.sub.2CH.sub.3),
--S(.dbd.O)N(CH.sub.2CH.sub.3).sub.2, and --S(.dbd.O)NHPh.
[0853] Sulfonamido: --S(.dbd.O).sub.2NR.sup.1R.sup.2, wherein
R.sup.1 and R.sup.2 are independently amino substituents, as
defined for amino groups. Examples of sulfonamido groups include,
but are not limited to, --S(.dbd.O).sub.2NH.sub.2,
--S(.dbd.O).sub.2NH(CH.sub.3), --S(.dbd.O).sub.2N(CH.sub.3).sub.2,
--S(.dbd.O).sub.2N H(CH.sub.2CH.sub.3),
--S(.dbd.O).sub.2N(CH.sub.2CH.sub.3).sub.2, and
--S(.dbd.O).sub.2NHPh.
[0854] As mentioned above, a C.sub.1-7alkyl group may be
substituted with, for example, hydroxy (also referred to as a
C.sub.1-7hydroxyalkyl group), C.sub.1-7alkoxy (also referred to as
a C.sub.1-7alkoxyalkyl group), amino (also referred to as a
C.sub.1-7aminoalkyl group), halo (also referred to as a
C.sub.1-7haloalkyl group), carboxy (also referred to as a
C.sub.1-7carboxyalkyl group), and C.sub.5-20aryl (also referred to
as a C.sub.5-20aryl-C.sub.1-7alkyl group).
[0855] Similarly, a C.sub.5-20aryl group may be substituted with,
for example, hydroxy (also referred to as a C.sub.5-20hydroxyaryl
group), halo (also referred to as a C.sub.5-20haloaryl group),
amino (also referred to as a C.sub.5-20aminoaryl group, e.g., as in
aniline), C.sub.1-7alkyl (also referred to as a
C.sub.1-7alkyl-C.sub.5-20aryl group, e.g., as in toluene), and
C.sub.1-7alkoxy (also referred to as a
C.sub.1-7alkoxy-C.sub.5-20aryl group, e.g., as in anisole).
[0856] These and other specific examples of such substituted groups
are also discussed below.
[0857] C.sub.1-7haloalkyl group: The term "C.sub.1-7haloalkyl
group," as used herein, pertains to a C.sub.1-7alkyl group in which
at least one hydrogen atom (e.g., 1, 2, 3) has been replaced with a
halogen atom (e.g., F, Cl, Br, I). If more than one hydrogen atom
has been replaced with a halogen atom, the halogen atoms may
independently be the same or different. Every hydrogen atom may be
replaced with a halogen atom, in which case the group may
conveniently be referred to as a C.sub.1-7perhaloalkyl group."
Examples of C.sub.1-7haloalkyl groups include, but are not limited
to, --CF.sub.3, --CHF.sub.2, --CH.sub.2F, --CCl.sub.3, --CBr.sub.3,
--CH.sub.2CH.sub.2F, --CH.sub.2CHF.sub.2, and
--CH.sub.2CF.sub.3.
[0858] C.sub.1-7hydroxyalkyl: The term "C.sub.1-7hydroxyalkyl
group," as used herein, pertains to a C.sub.1-7alkyl group in which
at least one hydrogen atom has been replaced with a hydroxy group.
Examples of C.sub.1-7hydroxyalkyl groups include, but are not
limited to, --CH.sub.2OH, --CH.sub.2CH.sub.2OH, and
--CH(OH)CH.sub.2OH.
[0859] C.sub.1-7carboxyalkyl: The term "C.sub.1-7carboxyalkyl
group," as used herein, pertains to a C.sub.1-7alkyl group in which
at least one hydrogen atom has been replaced with a carboxy group.
Examples of C.sub.1-7carboxyalkyl groups include, but are not
limited to, --CH.sub.2COOH and --CH.sub.2CH.sub.2COOH.
[0860] C.sub.1-7aminoalkyl: The term "C.sub.1-7aminoalkyl group,"
as used herein, pertains to a C.sub.1-7alkyl group in which at
least one hydrogen atom has been replaced with an amino group.
Examples of C.sub.1-7aminoalkyl groups include, but are not limited
to, --CH.sub.2NH.sub.2, --CH.sub.2CH.sub.2NH.sub.2, and
--CH.sub.2CH.sub.2N(CH.sub.3).sub.2.
[0861] C.sub.1-7alkyl-C.sub.5-20aryl: The term
"C.sub.1-7alkyl-C.sub.5-20a- ryl," as used herein, describes
certain C.sub.5-20aryl groups which have been substituted with a
C.sub.1-7alkyl group. Examples of such groups include, but are not
limited to, tolyl (as in toluene), xylyl (as in xylene), mesityl
(as in mesitylene), styryl (as in styrene), and cumenyl (as in
cumene).
[0862] C.sub.5-20aryl-C.sub.1-7alkyl: The term
"C.sub.5-20aryl-C.sub.1-7al- kyl," as used herein, describers
certain C.sub.1-7alkyl groups which have been substituted with a
C.sub.5-20aryl group. Examples of such groups include, but are not
limited to, benzyl (phenylmethyl), tolylmethyl, phenylethyl, and
triphenylmethyl (trityl).
[0863] C.sub.5-20haloaryl: The term "C.sub.5-20haloaryl," as used
herein, describes certain C.sub.5-20aryl groups which have been
substituted with one or more halo groups. Examples of such groups
include, but are not limited to, halophenyl (e.g., fluorophenyl,
chlorophenyl, bromophenyl, or iodophenyl, whether ortho-, meta-, or
para-substituted), dihalophenyl, trihalophenyl, tetrahalophenyl,
and pentahalophenyl.
[0864] Bidentate Substituents
[0865] Some substituents are bidentate, that is, have two points
for covalent attachment. For example, a bidentate group may be
covalently bound to two different atoms on two different groups,
thereby acting as a linker therebetween. Alternatively, a bidentate
group may be covalently bound to two different atoms on the same
group, thereby forming, together with the two atoms to which it is
attached (and any intervening atoms, if present) a cyclic or ring
structure. In this way, the bidentate substituent may give rise to
a heterocyclic group/compound and/or an aromatic group/compound.
Typically, the ring has from 3 to 8 ring atoms, which ring atoms
are carbon or divalent heteroatoms (e.g., boron, silicon, nitrogen,
phosphorus, oxygen, and sulfur, typically nitrogen, oxygen, and
sulfur), and wherein the bonds between said ring atoms are single
or double bonds, as permitted by the valencies of the ring atoms.
Typically, the bidentate group is covalently bound to vicinal
atoms, that is, adjacent atoms, in the parent group.
[0866] C.sub.1-7alkylene: The term "C.sub.1-7alkylene," as used
herein, pertains to a bidentate moiety obtained by removing two
hydrogen atoms, either both from the same carbon atom, or one from
each of two different carbon atoms, of a C.sub.1-7hydrocarbon
compound having from 1 to 7 carbon atoms, which may be aliphatic or
alicyclic, or a combination thereof, and which may be saturated,
partially unsaturated, or fully unsaturated.
[0867] Examples of linear saturated C.sub.1-7alkylene groups
include, but are not limited to, --(CH.sub.2).sub.n-- where n is an
integer from 1 to 7, for example, --CH.sub.2-- (methylene),
--CH.sub.2CH.sub.2-- (ethylene), --CH.sub.2CH.sub.2CH.sub.2--
(propylene), and --CH.sub.2CH.sub.2CH.sub.2CH.sub.2-(butylene).
[0868] Examples of branched saturated C.sub.1-7alkylene groups
include, but are not limited to, --CH(CH.sub.3)--,
--CH(CH.sub.3)CH.sub.2--, --CH(CH.sub.3)CH.sub.2CH.sub.2--,
--CH(CH.sub.3)CH.sub.2CH.sub.2CH.sub.2-- -,
--CH.sub.2CH(CH.sub.3)CH.sub.2--,
--CH.sub.2CH(CH.sub.3)CH.sub.2CH.sub.- 2--,
--CH(CH.sub.2CH.sub.3)--, --CH(CH.sub.2CH.sub.3)CH.sub.2--, and
--CH.sub.2CH(CH.sub.2CH.sub.3)CH.sub.2--.
[0869] Examples of linear partially unsaturated C.sub.1-7alkylene
groups include, but are not limited to, --CH.dbd.CH-- (vinylene),
--CH.dbd.CH--CH.sub.2--, --CH.dbd.CH--CH.sub.2--CH.sub.2--,
--CH.dbd.CH--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.dbd.CH--CH.dbd.CH--, --CH.dbd.CH--CH.dbd.CH--CH.sub.2--,
--CH.dbd.CH--CH.dbd.CH--CH.sub.2--CH.- sub.2--,
--CH.dbd.CH--CH.sub.2--CH.dbd.CH--, and --CH.dbd.CH--CH.sub.2--CH-
.sub.2--CH.dbd.CH--.
[0870] Examples of branched partially unsaturated C.sub.1-7alkylene
groups include, but are not limited to, --C(CH.sub.3).dbd.CH--,
--C(CH.sub.3).dbd.CH--CH.sub.2--, and
--CH.dbd.CH--CH(CH.sub.3)--.
[0871] Examples of alicyclic saturated C.sub.1-7alkylene groups
include, but are not limited to, cyclopentylene (e.g.,
cyclopent-1,3-ylene), and cyclohexylene (e.g.,
cyclohex-1,4-ylene).
[0872] Examples of alicyclic partially unsaturated
C.sub.1-7alkylene groups include, but are not limited to,
cyclopentenylene (e.g., 4-cyclopenten-1,3-ylene), cyclohexenylene
(e.g., 2-cyclohexen-1,4-ylene, 3-cyclohexen-1,2-ylene,
2,5-cyclohexadien-1,4-ylene).
[0873] C.sub.5-20arylene: The term "C.sub.5-20arylene," as used
herein, pertains to a bidentate moiety obtained by removing two
hydrogen atoms, one from each of two different ring atoms of a
C.sub.5-20aromatic compound, said compound having one ring, or two
or more rings (e.g., fused), and having from 5 to 20 ring atoms,
and wherein at least one of said ring(s) is an aromatic ring.
Preferably, each ring has from 5 to 7 ring atoms.
[0874] The ring atoms may be all carbon atoms, as in "carboarylene
groups," in which case the group may conveniently be referred to as
a "C.sub.5-20carboarylene" group. Alternatively, the ring atoms may
include one or more heteroatoms, including but not limited to
oxygen, nitrogen, and sulfur, as in "heteroarylene groups." In this
case, the group may conveniently be referred to as a
"C.sub.5-20heteroarylene" group, wherein "C.sub.5-20" denotes ring
atoms, whether carbon atoms or heteroatoms. Preferably, each ring
has from 5 to 7 ring atoms, of which from 0 to 4 are ring
heteroatoms.
[0875] Examples of C.sub.5-20arylene groups which do not have ring
heteroatoms (i.e., C.sub.5-20carboarylene groups) include, but are
not limited to, those derived from benzene (i.e., phenyl)
(C.sub.6), naphthalene (C.sub.10), anthracene (C.sub.1 4),
phenanthrene (C.sub.14), and pyrene (C.sub.16).
[0876] Examples of C.sub.5-20heteroarylene groups include, but are
not limited to, C.sub.5heteroarylene groups derived from furan
(oxole), thiophene (thiole), pyrrole (azole), imidazole
(1,3-diazole), pyrazole (1,2-diazole), triazole, oxazole,
isoxazole, thiazole, isothiazole, oxadiazole, and oxatriazole; and
C.sub.6heteroarylene groups derived from isoxazine, pyridine
(azine), pyridazine (1,2-diazine), pyrimidine (1,3-diazine; e.g.,
cytosine, thymine, uracil), pyrazine (1,4-diazine), triazine,
tetrazole, and oxadiazole (furazan).
[0877] C.sub.5-20Arylene-C.sub.1-7alkylene: The term
"C.sub.5-20arylene-C.sub.1-7alkylene," as used herein, pertains to
a bidentate moiety comprising a C.sub.5-20arylene moiety,
-Arylene-, linked to a C.sub.1-7alkylene moiety, -Alkylene-, that
is, -Arylene-Alkylene-.
[0878] Examples of C.sub.5-20arylene-C.sub.1-7alkylene groups
include, but are not limited to, phenylene-methylene,
phenylene-ethylene, phenylene-propylene, and phenylene-ethenylene
(also known as phenylene-vinylene).
[0879] C.sub.5-20Alkylene-C.sub.1-7arylene: The term
"C.sub.5-20alkylene-C.sub.1-7arylene," as used herein, pertains to
a bidentate moiety comprising a C.sub.5-20alkylene moiety,
-Alkylene-, linked to a C.sub.1-7arylene moiety, -Arylene-, that
is, -Alkylene-Arylene-.
[0880] Examples of C.sub.5-20alkylene-C.sub.1-7arylene groups
include, but are not limited to, methylene-phenylene,
ethylene-phenylene, propylene-phenylene, and ethenylene-phenylene
(also known as vinylene-phenylene).
[0881] Included in the above are the well known ionic, salt,
solvate (e.g., hydrate), and protected forms of these substituents.
For example, a reference to carboxylic acid (--COOH) also includes
carboxylate (--COO.sup.-). Similarly, a reference to an amino group
includes a salt, for example, a hydrochloride salt, of the amino
group. A reference to a hydroxyl group also includes conventional
protected forms of a hydroxyl group. Similarly, a reference to an
amino group also includes conventional protected forms of an amino
group.
[0882] Acronyms
[0883] For convenience, many chemical moieties are represented
herein using well known abbreviations, including but not limited
to, methyl (Me), ethyl (Et), n-propyl (nPr), iso-propyl (iPr),
n-butyl (nBu), tert-butyl (tBu), n-hexyl (nHex), cyclohexyl (cHex),
phenyl (Ph), biphenyl (biPh), benzyl (Bn), naphthyl (naph), methoxy
(MeO), ethoxy (EtO), benzoyl (Bz), and acetyl (Ac).
[0884] For convenience, many chemical compounds are represented
herein using well known abbreviations, including but not limited
to, methanol (MeOH), ethanol (EtOH), iso-propanol (i-PrOH), methyl
ethyl ketone (MEK), acetic acid (AcOH), dichloromethane (methylene
chloride, DCM), trifluoroacetic acid (TFA), dimethylformamide
(DMF), and tetrahydrofuran (THF).
[0885] Isomers, Salts, Solvates, Protected Forms, and Prodrugs
[0886] A certain compound may exist in one or more particular
geometric, optical, enantiomeric, diasteriomeric, epimeric,
stereoisomeric, tautomeric, conformational, or anomeric forms,
including but not limited to, cis- and trans-forms; E- and Z-forms;
c-, t-, and r-forms; endo- and exo-forms; R-, S-, and meso-forms;
D- and L-forms; (+) and (-) forms; keto-, enol-, and enolate-forms;
syn- and anti-forms; synclinal- and anticlinal-forms; .alpha.- and
.beta.-forms; axial and equatorial forms; boat-, chair-, twist-,
envelope-, and halfchair-forms; and combinations thereof,
hereinafter collectively referred to as "isomers" (or "isomeric
forms").
[0887] Note that, except as discussed below for tautomeric forms,
specifically excluded from the term "isomers," as used herein, are
structural (or constitutional) isomers (i.e., isomers which differ
in the connections between atoms rather than merely by the position
of atoms in space). For example, a reference to a methoxy group,
--OCH.sub.3, is not to be construed as a reference to its
structural isomer, a hydroxymethyl group, --CH.sub.2OH. Similarly,
a reference to ortho-chlorophenyl is not to be construed as a
reference to its structural isomer, meta-chlorophenyl. However, a
reference to a class of structures may well include structurally
isomeric forms falling within that class (e.g., C.sub.1-7alkyl
includes n-propyl and iso-propyl; butyl includes n-, iso-, sec-,
and tert-butyl; methoxyphenyl includes ortho-, meta-, and
para-methoxyphenyl).
[0888] The above exclusion does not pertain to tautomeric forms,
for example, keto-, enol-, and enolate-forms, as in, for example,
the following tautomeric pairs: keto/enol (illustrated below),
imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime,
thioketone/enethiol, N-nitroso/hydroxyazo, and nitro/aci-nitro.
176
[0889] Note that specifically included in the term "isomer" are
compounds with one or more isotopic substitutions. For example, H
may be in any isotopic form, including .sup.1H, .sup.2H (D), and
.sup.3H (T); C may be in any isotopic form, including .sup.12C,
.sup.13C, and .sup.14C; O may be in any isotopic form, including
.sup.16O and .sup.18O; and the like.
[0890] Unless otherwise specified, a reference to a particular
compound includes all such isomeric forms, including racemic and
other mixtures thereof. Methods for the preparation (e.g.,
asymmetric synthesis) and separation (e.g., fractional
crystallisation and chromatographic means) of such isomeric forms
are either known in the art or are readily obtained by adapting the
methods taught herein in a known manner.
[0891] Unless otherwise specified, a reference to a particular
compound also includes ionic, salt, solvate (e.g., hydrate),
protected forms, and prodrugs thereof, for example, as discussed
below.
[0892] It may be convenient or desirable to prepare, purify, and/or
handle a corresponding salt of the active compound, for example, a
pharmaceutically-acceptable salt. Examples of pharmaceutically
acceptable salts are discussed in Berge et al., 1977,
"Pharmaceutically Acceptable Salts," J. Pharm. Sci., Vol. 66, pp.
1-19.
[0893] For example, if the compound is anionic, or has a functional
group which may be anionic (e.g., --COOH may be --COO.sup.-), then
a salt may be formed with a suitable cation. Examples of suitable
inorganic cations include, but are not limited to, alkali metal
ions such as Na+ and K.sup.+, alkaline earth cations such as
Ca.sup.2+ and Mg.sup.2+, and other cations such as Al.sup.+3.
Examples of suitable organic cations include, but are not limited
to, ammonium ion (i.e., NH.sub.4.sup.+) and substituted ammonium
ions (e.g., NH.sub.3R.sup.+, NH.sub.2R.sub.2.sup.+,
NHR.sub.3.sup.+, NR.sub.4.sup.+). Examples of some suitable
substituted ammonium ions are those derived from: ethylamine,
diethylamine, ethylenediamine, ethanolamine, diethanolamine,
piperazine. An example of a common quaternary ammonium ion is
N(CH.sub.3).sub.4.sup.+.
[0894] If the compound is cationic, or has a functional group which
may be cationic (e.g., --NH.sub.2 may be --NH.sub.3.sup.+), then a
salt may be formed with a suitable anion. Examples of suitable
inorganic anions include, but are not limited to, those derived
from the following inorganic acids: hydrochloric, hydrobromic,
hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric, and
phosphorous. Examples of suitable organic anions include, but are
not limited to, anions from the following organic acids: acetic,
propionic, succinic, gycolic, stearic, lactic, malic, tartaric,
citric, ascorbic, maleic, hydroxymaleic, phenylacetic, glutamic,
benzoic, salicylic, sulfanilic, 2-acetyoxybenzoic, fumaric,
toluenesulfonic, methanesulfonic, ethanesulfonic, ethane
disulfonic, oxalic, isethionic, and valeric.
[0895] It may be convenient or desirable to prepare, purify, and/or
handle a corresponding solvate of the active compound. The term
"solvate" is used herein in the conventional sense to refer to a
complex of solute (e.g., active compound, salt of active compound)
and solvent. If the solvent is water, the solvate may be
conveniently referred to as a hydrate, for example, a mono-hydrate,
a di-hydrate, a tri-hydrate, etc.
[0896] It may be convenient or desirable to prepare, purify, and/or
handle the active compound in a chemically protected form. The term
"chemically protected form," as used herein, pertains to a compound
in which one or more reactive functional groups are protected from
undesirable chemical reactions, that is, are in the form of a
protected or protecting group (also known as a masked or masking
group). By protecting a reactive functional group, reactions
involving other unprotected reactive functional groups can be
performed, without affecting the protected group; the protecting
group may be removed, usually in a subsequent step, without
substantially affecting the remainder of the molecule. See, for
example, Protective Groups in Organic Synthesis (T. Green and P.
Wuts, Wiley, 1991), and Protective Groups in Organic Synthesis (T.
Green and P. Wuts; 3rd Edition; John Wiley and Sons, 1999).
[0897] For example, a hydroxy group may be protected as an ether
(--OR) or an ester (--OC(.dbd.O)R), for example, as: a t-butyl
ether; a benzyl, benzhydryl (diphenylmethyl), or trityl
(triphenylmethyl) ether; a trimethylsilyl or t-butyidimethylsilyl
ether; or an acetyl ester (--OC(.dbd.O)CH.sub.3, --OAc).
[0898] For example, an aldehyde or ketone group may be protected as
an acetal or ketal, respectively, in which the carbonyl group
(>C.dbd.O) is converted to a diether (>C(OR).sub.2), by
reaction with, for example, a primary alcohol. The aldehyde or
ketone group is readily regenerated by hydrolysis using a large
excess of water in the presence of acid.
[0899] For example, an amine group may be protected, for example,
as an amide (--NRCO--R) or a urethane (--NRCO--OR), for example,
as: a methyl amide (--NHCO--CH.sub.3); a benzyloxy amide
(--NHCO--OCH.sub.2C.sub.6H.su- b.5, --NH-Cbz); as a t-butoxy amide
(--NHCO--OC(CH.sub.3).sub.3, --NH-Boc); a 2-biphenyl-2-propoxy
amide (--NHCO--OC(CH.sub.3).sub.2C.sub.- 6H.sub.4C.sub.6H.sub.5,
--NH-Bpoc), as a 9-fluorenylmethoxy amide (--NH-Fmoc), as a
6-nitroveratryloxy amide (--NH-Nvoc), as a 2-trimethylsilylethyloxy
amide (--NH-Teoc), as a 2,2,2-trichloroethyloxy amide (--NH-Troc),
as an allyloxy amide (--NH-Alloc), as a 2(-phenylsulfonyl)ethyloxy
amide (--NH-Psec); or, in suitable cases (e.g., cyclic amines), as
a nitroxide radical (>N--O.).
[0900] For example, a carboxylic acid group may be protected as an
ester or an amide, for example, as: a benzyl ester; a t-butyl
ester; a methyl ester; or a methyl amide.
[0901] For example, a thiol group may be protected as a thioether
(--SR), for example, as: a benzyl thioether; an acetamidomethyl
ether (--S--CH.sub.2NHC(.dbd.O)CH.sub.3).
[0902] It may be convenient or desirable to prepare, purify, and/or
handle the active compound in the form of a prodrug. The term
"prodrug," as used herein, pertains to a compound which, when
metabolised, yields the desired active compound. Typically, the
prodrug is inactive, or less active than the active compound, but
may provide advantageous handling, administration, or metabolic
properties. For example, some prodrugs are esters of the active
compound; during metabolysis, the ester group is cleaved to yield
the active drug. Also, some prodrugs are activated enzymatically to
yield the active compound, or a compound which, upon further
chemical reaction, yields the active compound. For example, the
prodrug may be a sugar derivative or other glycoside conjugate, or
may be an amino acid ester derivative.
[0903] Synthesis
[0904] Several methods for the chemical synthesis of compounds of
the present invention are described herein. These methods may be
modified and/or adapted in known ways in order to facilitate the
synthesis of additional compounds within the scope of the present
invention.
[0905] The compounds of the present invention may be prepared, for
example, by the methods described herein, or by adapting these or
other well known methods in well known ways.
[0906] In one method, an arylaldehyde is reacted with oleum to form
a sulfonyl-arylaldehyde product. The aldehyde group is then reacted
with a phosphono ester, to form a pendant carboxylic acid ester.
The sulfonyl group is then reacted with SOCl.sub.2 to form a
sulfonyl halide group. The product is then reacted with an amine
(e.g., an aryl amine) to form the corresponding sulfonamide. The
carboxylic acid ester is then deprotected by reaction with base,
and subsequently converted to an acyl halide. The acyl halide is
reacted with hydroxylamine to form the corresponding carbamic
acid.
[0907] One example of this approach is illustrated below, in Scheme
1, wherein the reaction conditions are as follows: (i)
H.sub.2SO.sub.4+SO.sub.3, 30.degree. C. at mixing, mixing
40.degree. C. for 10 hours, mixing at room temperature overnight,
add cold H.sub.2O, add CaCO.sub.3; (ii) K.sub.2CO.sub.3,
(MeO).sub.2P(.dbd.O)CH.sub.2COOMe, H.sub.2O, room temperature, 30
min.; (iii) thionyl chloride, benzene, DMF, reflux, one hour; (iv)
aniline, pyridine, DCM, 50.degree. C., 1 hour; (v) NaOH, MeOH; (vi)
oxalyl chloride, DMF, DCM, 40.degree. C., 1 hour, (vii)
hydroxylamine hydrochloride and NaHCO.sub.3 in THF, room
temperature, 1 hour. 177
[0908] By using amines instead of aniline, the corresponding
products may be obtained. The use of aniline, 4-methoxyaniline,
4-methylaniline, 4-bromoaniline, 4-chloroaniline, 4-benzylamine,
and 4-phenethyamine, among others, is described in the Examples
below.
[0909] In another method, a suitable amino acid (e.g., w-amino
acid) having a protected carboxylic acid (e.g., as an ester) and an
unprotected amino group is reacted with a sulfonyl chloride
compound (e.g., RSO.sub.2Cl) to give the corresponding sulfonamide
having a protected carboxylic acid. The protected carboxylic acid
is then deprotected using base to give the free carboxylic acid,
which is then reacted with, for example, hydroxylamine
2-chlorotrityl resin followed by acid (e.g., trifluoroacetic acid),
to give the desired carbamic acid.
[0910] One example of this approach is illustrated below, in Scheme
2, wherein the reaction conditions are as follows: (i) RSO.sub.2Cl,
pyridine, DCM, room temperature, 12 hours; (ii) 1 M LiOH or 1 M
NaOH, dioxane, room temperature, 3-48 hours; (iii) hydroxylamine
2-chlorotrityl resin, HOAt, HATU, DIPEA, DCM, room temperature, 16
hours; and (iv) TFA/DCM (5:95, v/v), room temperature, 1.5 hours.
178
[0911] Additional methods for the synthesis of compounds of the
present invention are illustrated below and are exemplified in the
examples below. 179 180 181 182 183 184 185 186 187 188 189 190
[0912] Uses
[0913] The present invention provides active compounds which are
capable of inhibiting HDAC (for example, inhibiting HDAC activity,
inhibiting formation of HDAC complexes, inhibiting activity of HDAC
complexes), as well as methods of inhibiting HDAC activity,
comprising contacting a cell with an effective amount of an active
compound, whether in vitro or in vivo.
[0914] The term "active," as used herein, pertains to compounds
which are capable of inhibiting HDAC activity, and specifically
includes both compounds with intrinsic activity (drugs) as well as
prodrugs of such compounds, which prodrugs may themselves exhibit
little or no intrinsic activity.
[0915] One of ordinary skill in the art is readily able to
determine whether or not a candidate compound is active, that is,
capable of inhibiting HDAC activity. For example, assays which may
conveniently be used to assess the inhibition offered by a
particular compound are described in the examples below.
[0916] For example, a sample of cells (e.g., from a tumour) may be
grown in vitro and a candidate compound brought into contact with
the cells, and the effect of the compound on those cells observed.
As examples of "effect," the morphological status of the cells may
be determined (e.g., alive or dead), or the expression levels of
genes regulated by HDAC. Where the candidate compound is found to
exert an influence on the cells, this may be used as a prognostic
or diagnostic marker of the efficacy of the compound in methods of
treating a patient carrying cells of the same type (e.g., the
tumour or a tumour of the same cellular type).
[0917] In one aspect, the present invention provides
antiproliferative agents. The term "antiproliferative agent" as
used herein, pertains to a compound which treats a proliferative
condition (i.e., a compound which is useful in the treatment of a
proliferative condition).
[0918] The terms "cell proliferation," "proliferative condition,"
"proliferative disorder," and "proliferative disease," are used
interchangeably herein and pertain to an unwanted or uncontrolled
cellular proliferation of excessive or abnormal cells which is
undesired, such as, neoplastic or hyperplastic growth, whether in
vitro or in vivo. Examples of proliferative conditions include, but
are not limited to, pre-malignant and malignant cellular
proliferation, including but not limited to, malignant neoplasms
and tumours, cancers, leukemias, psoriasis, bone diseases,
fibroproliferative disorders (e.g., of connective tissues), and
atherosclerosis. Any type of cell may be treated, including but not
limited to, lung, colon, breast, ovarian, prostate, liver,
pancreas, brain, and skin.
[0919] Antiproliferative compounds of the present invention have
application in the treatment of cancer, and so the present
invention further provides anticancer agents. The term "anticancer
agent" as used herein, pertains to a compound which treats a cancer
(i.e., a compound which is useful in the treatment of a cancer).
The anti-cancer effect may arise through one or more mechanisms,
including but not limited to, the regulation of cell proliferation,
the inhibition of angiogenesis (the formation of new blood
vessels), the inhibition of metastasis (the spread of a tumour from
its origin), the inhibition of invasion (the spread of tumour cells
into neighbouring normal structures), or the promotion of apoptosis
(programmed cell death).
[0920] The compounds of the present invention may also be used in
the treatment of conditions which are known to be mediated by HDAC,
or which are known to be treated by HDAC inhibitors (such as, e.g.
trichostatin A). Examples of such conditions include, but are not
limited to, the following:
[0921] Cancer (see, e.g., Vigushin et al., 2001).
[0922] Psoriasis (see, e.g., lavarone et al., 1999).
[0923] Fibroproliferative disorders (e.g., liver fibrosis) (see,
e.g., Niki et al., 1999; Corneil et al., 1998).
[0924] Smooth muscle proliferative disorder (e.g., atherosclerosis,
restenosis) (see, e.g., Kimura et al., 1994).
[0925] Neurodegenative diseases (e.g., Alzheimer's, Parkinson's,
Huntington's chorea, amyotropic lateral sclerosis, spino-cerebellar
degeneration) (see, e.g., Kuusisto et al., 2001).
[0926] Inflammatory disease (e.g., osteoarthritis, rheumatoid
arthritis) (see, e.g., Dangond et al., 1998; Takahashi et al.,
1996).
[0927] Diseases involving angiogenesis (e.g., cancer, rheumatoid
arthritis, psoriasis, diabetic retinopathy) (see, e.g., Kim et al.,
2001).
[0928] Haematopoietic disorders (e.g., anaemia, sickle cell
anaemia, thalassaeimia) (see, e.g., McCaffrey et al., 1997).
[0929] Fungal infection (see, e.g., Bernstein et al., 2000; Tsuji
et al., 1976). Parasitic infection (e.g., malaria, trypanosomiasis,
helminthiasis, protozoal infections (see, e.g., Andrews et al.,
2000).
[0930] Bacterial infection (see, e.g., Onishi et al., 1996).
[0931] Viral infection (see, e.g., Chang et al., 2000).
[0932] Conditions treatable by immune modulation (e.g., multiple
sclerosis, autoimmune diabetes, lupus, atopic dermatitis,
allergies, asthma, allergic rhinitis, inflammatory bowel disease;
and for improving grafting of transplants) (see, e.g., Dangond et
al., 1998; Takahashi et al., 1996).
[0933] The invention further provides active compounds for use in a
method of treatment of the human or animal body. Such a method may
comprise administering to such a subject a
therapeutically-effective amount of an active compound, preferably
in the form of a pharmaceutical composition.
[0934] The term "treatment," as used herein in the context of
treating a condition, pertains generally to treatment and therapy,
whether of a human or an animal (e.g., in veterinary applications),
in which some desired therapeutic effect is achieved, for example,
the inhibition of the progress of the condition, and includes a
reduction in the rate of progress, a halt in the rate of progress,
amelioration of the condition, and cure of the condition. Treatment
as a prophylactic measure is also included.
[0935] The term "therapeutically-effective amount," as used herein,
pertains to that amount of an active compound, or a material,
composition or dosage from comprising an active compound, which is
effective for producing some desired therapeutic effect,
commensurate with a reasonable benefit/risk ratio.
[0936] The term "treatment" includes combination treatments and
therapies, in which two or more treatments or therapies are
combined, for example, sequentially or simultaneously. Examples of
treatments and therapies include, but are not limited to,
chemotherapy (the administration of active agents, including, e.g.,
drugs, antibodies (e.g., as in immunotherapy), prodrugs (e.g., as
in photodynamic therapy, GDEPT, ADEPT, etc.); surgery; radiation
therapy; and gene therapy.
[0937] The invention further provides the use of an active compound
for the manufacture of a medicament, for example, for the treatment
of a proliferative condition, as discussed above.
[0938] The invention further provides the use of an active compound
for the manufacture of a medicament, for example, for the treatment
of conditions which are known to be mediated by HDAC, or which are
known to be treated by HDAC inhibitors (such as, e.g., trichostatin
A), as discussed above.
[0939] The invention further provides a method for inhibiting HDAC
in a cell comprising said cell with an effective amount of an
active compound.
[0940] The invention further provides a method of treatment of the
human or animal body, the method comprising administering to a
subject in need of treatment a therapeutically-effective amount of
an active compound, preferably in the form of a pharmaceutical
composition.
[0941] Active compounds may also be used, as described above, in
combination therapies, that is, in conjunction with other agents,
for example, cytotoxic agents.
[0942] Active compounds may also be used as part of an in vitro
assay, for example, in order to determine whether a candidate host
is likely to benefit from treatment with the compound in
question.
[0943] Active compounds may also be used as a standard, for
example, in an assay, in order to identify other active compounds,
other antiproliferative agents, etc.
[0944] The compounds of the present invention may also be used in
methods of improving protein production by cultured cells (see,
e.g., Furukawa et al., 1998).
[0945] Routes of Administration
[0946] The active compound or pharmaceutical composition comprising
the active compound may be administered to a subject by any
convenient route of administration, whether
systemically/peripherally or topically (i.e., at the site of
desired action).
[0947] Routes of administration include, but are not limited to,
oral (e.g., by ingestion); buccal; sublingual; transdermal
(including, e.g., by a patch, plaster, etc.); transmucosal
(including, e.g., by a patch, plaster, etc.); intranasal (e.g., by
nasal spray); ocular (e.g., by eyedrops); pulmonary (e.g., by
inhalation or insulation therapy using, e.g., via an aerosol, e.g.,
through the mouth or nose); rectal (e.g., by suppository or enema);
vaginal (e.g., by pessary); parenteral, for example, by injection,
including subcutaneous, intradermal, intramuscular, intravenous,
intraarterial, intracardiac, intrathecal, intraspinal,
intracapsular, subcapsular, intraorbital, intraperitoneal,
intratracheal, subcuticular, intraarticular, subarachnoid, and
intrasternal; by implant of a depot or reservoir, for example,
subcutaneously or intramuscularly.
[0948] The Subject
[0949] The subject may be a prokaryote (e.g., bacteria) or a
eukaryote (e.g., protoctista, fungi, plants, animals).
[0950] The subject may be a protoctista, an alga, or a
protozoan.
[0951] The subject may be a plant, an angiosperm, a dicotyledon, a
monocotyledon, a gymnosperm, a conifer, a ginkgo, a cycad, a fem, a
horsetail, a clubmoss, a liverwort, or a moss.
[0952] The subject may be an animal.
[0953] The subject may be a chordate, an invertebrate, an
echinoderm (e.g., starfish, sea urchins, brittlestars), an
arthropod, an annelid (segmented worms) (e.g., earthworms,
lugworms, leeches), a mollusk (cephalopods (e.g., squids, octopi),
pelecypods (e.g., oysters, mussels, clams), gastropods (e.g.,
snails, slugs)), a nematode (round worms), a platyhelminthes
(flatworms) (e.g., planarians, flukes, tapeworms), a cnidaria
(e.g., jelly fish, sea anemones, corals), or a porifera (e.g.,
sponges).
[0954] The subject may be an arthropod, an insect (e.g., beetles,
butterflies, moths), a chilopoda (centipedes), a diplopoda
(millipedes), a crustacean (e.g., shrimps, crabs, lobsters), or an
arachnid (e.g., spiders, scorpions, mites).
[0955] The subject may be a chordate, a vertebrate, a mammal, a
bird, a reptile (e.g., snakes, lizards, crocodiles), an amphibian
(e.g., frogs, toads), a bony fish (e.g., salmon, plaice, eel,
lungfish), a cartilaginous fish (e.g., sharks, rays), or a jawless
fish (e.g., lampreys, hagfish).
[0956] The subject may be a mammal, a placental mammal, a marsupial
(e.g., kangaroo, wombat), a monotreme (e.g., duckbilled platypus),
a rodent (e.g., a guinea pig, a hamster, a rat, a mouse), murine
(e.g., a mouse), a lagomorph (e.g., a rabbit), avian (e.g., a
bird), canine (e.g., a dog), feline (e.g., a cat), equine (e.g., a
horse), porcine (e.g., a pig), ovine (e.g., a sheep), bovine (e.g.,
a cow), a primate, simian (e.g., a monkey or ape), a monkey (e.g.,
marmoset, baboon), an ape (e.g., gorilla, chimpanzee, orangutang,
gibbon), or a human.
[0957] Furthermore, the subject may be any of its forms of
development, for example, a spore, a seed, an egg, a larva, a pupa,
or a foetus.
[0958] In one preferred embodiment, the subject is a human.
[0959] Formulations
[0960] While it is possible for the active ingredient to be
administered alone, it is preferable to present it as a
pharmaceutical composition (e.g., formulation) comprising at least
one active ingredient, as defined above, together with one or more
pharmaceutically acceptable carriers, excipients, buffers,
adjuvants, stabilisers, or other materials well known to those
skilled in the art and optionally other therapeutic agents.
[0961] Thus, the present invention further provides pharmaceutical
compositions, as defined above, and methods of making a
pharmaceutical composition comprising admixing at least one active
ingredient, as defined above, together with one or more
pharmaceutically acceptable carriers, excipients, buffers,
adjuvants, stabilisers, or other materials, as described
herein.
[0962] The term "pharmaceutically acceptable as used herein
pertains to compounds, materials, compositions, and/or dosage forms
which are, within the scope of sound medical judgement, suitable
for use in contact with the tissues of a subject (e.g., human)
without excessive toxicity, irritation, allergic response, or other
problem or complication, commensurate with a reasonable
benefit/risk ratio. Each carrier, excipient, etc. must also be
"acceptable" in the sense of being compatible with the other
ingredients of the formulation.
[0963] The formulations may conveniently be presented in unit
dosage form and may be prepared by any methods well known in the
art of pharmacy. Such methods include the step of bringing into
association the active ingredient with the carrier which
constitutes one or more accessory ingredients. In general, the
formulations are prepared by uniformly and intimately bringing into
association the active ingredient with liquid carriers or finely
divided solid carriers or both, and then if necessary shaping the
product.
[0964] Formulations may be in the form of liquids, solutions,
suspensions, emulsions, tablets, losenges, granules, powders,
capsules, cachets, pills, ampoules, suppositories, pessaries,
ointments, gels, pastes, creams, sprays, foams, lotions, oils,
boluses, electuaries, or aerosols.
[0965] Formulations suitable for oral administration (e.g., by
ingestion) may be presented as discrete units such as capsules,
cachets or tablets, each containing a predetermined amount of the
active ingredient; as a powder or granules; as a solution or
suspension in an aqueous or non-aqueous liquid; or as an
oil-in-water liquid emulsion or a water-in-oil liquid emulsion; as
a bolus; as an electuary; or as a paste.
[0966] A tablet may be made by compression or moulding, optionally
with one or more accessory ingredients. Compressed tablets may be
prepared by compressing in a suitable machine the active ingredient
in a free-flowing form such as a powder or granules, optionally
mixed with a binder (e.g., povidone, gelatin, hydroxypropylmethyl
cellulose), lubricant, inert diluent, preservative, disintegrant
(e.g., sodium starch glycolate, cross-linked povidone, cross-linked
sodium carboxymethyl cellulose), surface-active or dispersing
agent. Moulded tablets may be made by moulding in a suitable
machine a mixture of the powdered compound moistened with an inert
liquid diluent. The tablets may optionally be coated or scored and
may be formulated so as to provide slow or controlled release of
the active ingredient therein using, for example,
hydroxypropylmethyl cellulose in varying proportions to provide the
desired release profile. Tablets may optionally be provided with an
enteric coating, to provide release in parts of the gut other than
the stomach.
[0967] Formulations suitable for topical administration (e.g.,
transdermal, intranasal, ocular, buccal, and sublingual) may be
formulated as an ointment, cream, suspension, lotion, powder,
solution, paste, gel, spray, aerosol, or oil. Alternatively, a
formulation may comprise a patch or a dressing such as a bandage or
adhesive plaster impregnated with active ingredients and optionally
one or more excipients or diluents.
[0968] Formulations suitable for topical administration in the
mouth include losenges comprising the active ingredient in a
flavored basis usually sucrose and acacia or tragacanth; pastilles
comprising the active ingredient in an inert basis such as gelatin
and glycerin, or sucrose and acacia; and mouthwashes comprising the
active ingredient in a suitable liquid carrier.
[0969] Formulations suitable for topical administration to the eye
also include eye drops wherein the active ingredient is dissolved
or suspended in a suitable carrier, especially an aqueous solvent
for the active ingredient.
[0970] Formulations suitable for nasal administration, wherein the
carrier is a solid, include a coarse powder having a particle size,
for example, in the range of about 20 to about 500 microns which is
administered in the manner in which snuff is taken, i.e., by rapid
inhalation through the nasal passage from a container of the powder
held close up to the nose. Suitable formulations wherein the
carrier is a liquid for administration as, for example, nasal
spray, nasal drops, or by aerosol administration by nebuliser,
include aqueous or oily solutions of the active ingredient.
[0971] Formulations suitable for topical administration via the
skin include ointments, creams, and emulsions. When formulated in
an ointment, the active ingredient may optionally be employed with
either a paraffinic or a water-miscible ointment base.
Alternatively, the active ingredients may be formulated in a cream
with an oil-in-water cream base. If desired, the aqueous phase of
the cream base may include, for example, at least about 30% w/w of
a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl
groups such as propylene glycol, butane-1,3-diol, mannitol,
sorbitol, glycerol and polyethylene glycol and mixtures thereof.
The topical formulations may desirably include a compound which
enhances absorption or penetration of the active ingredient through
the skin or other affected areas. Examples of such dermal
penetration enhancers include dimethylsulfoxide and related
analogues.
[0972] When formulated as a topical emulsion, the oily phase may
optionally comprise merely an emulsifier (otherwise known as an
emulgent), or it may comprises a mixture of at least one emulsifier
with a fat or an oil or with both a fat and an oil. Preferably, a
hydrophilic emulsifier is included together with a lipophilic
emulsifier which acts as a stabiliser. It is also preferred to
include both an oil and a fat. Together, the emulsifier(s) with or
without stabiliser(s) make up the so-called emulsifying wax, and
the wax together with the oil and/or fat make up the so-called
emulsifying ointment base which forms the oily dispersed phase of
the cream formulations.
[0973] Suitable emulgents and emulsion stabilisers include Tween
60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl
monostearate and sodium lauryl sulfate. The choice of suitable oils
or fats for the formulation is based on achieving the desired
cosmetic properties, since the solubility of the active compound in
most oils likely to be used in pharmaceutical emulsion formulations
may be very low. Thus the cream should preferably be a non-greasy,
non-staining and washable product with suitable consistency to
avoid leakage from tubes or other containers. Straight or branched
chain, mono- or dibasic alkyl esters such as di-isoadipate,
isocetyl stearate, propylene glycol diester of coconut fatty acids,
isopropyl myristate, decyl oleate, isopropyl palmitate, butyl
stearate, 2-ethylhexyl palmitate or a blend of branched chain
esters known as Crodamol CAP may be used, the last three being
preferred esters. These may be used alone or in combination
depending on the properties required. Alternatively, high melting
point lipids such as white soft paraffin and/or liquid paraffin or
other mineral oils can be used.
[0974] Formulations suitable for rectal administration may be
presented as a suppository with a suitable base comprising, for
example, cocoa butter or a salicylate.
[0975] Formulations suitable for vaginal administration may be
presented as pessaries, tampons, creams, gels, pastes, foams or
spray formulations containing in addition to the active ingredient,
such carriers as are known in the art to be appropriate.
Formulations suitable for parenteral administration (e.g., by
injection, including cutaneous, subcutaneous, intramuscular,
intravenous and intradermal), include aqueous and non-aqueous
isotonic, pyrogen-free, sterile injection solutions which may
contain anti-oxidants, buffers, preservatives, stabilisers,
bacteriostats and solutes which render the formulation isotonic
with the blood of the intended recipient; and aqueous and
non-aqueous sterile suspensions which may include suspending agents
and thickening agents, and liposomes or other microparticulate
systems which are designed to target the compound to blood
components or one or more organs. Examples of suitable isotonic
vehicles for use in such formulations include Sodium Chloride
Injection, Ringer's Solution, or Lactated Ringer's Injection.
Typically, the concentration of the active ingredient in the
solution is from about 1 ng/ml to about 10 .mu.g/ml, for example
from about 10 ng/ml to about 1 .mu.g/ml. The formulations may be
presented in unit-dose or multi-dose sealed containers, for
example, ampoules and vials, and may be stored in a freese-dried
(lyophilised) condition requiring only the addition of the sterile
liquid carrier, for example water for injections, immediately prior
to use. Extemporaneous injection solutions and suspensions may be
prepared from sterile powders, granules, and tablets. Formulations
may be in the form of liposomes or other microparticulate systems
which are designed to target the active compound to blood
components or one or more organs.
[0976] Dosage
[0977] It will be appreciated that appropriate dosages of the
active compounds, and compositions comprising the active compounds,
can vary from patient to patient. Determining the optimal dosage
will generally involve the balancing of the level of therapeutic
benefit against any risk or deleterious side effects of the
treatments of the present invention. The selected dosage level will
depend on a variety of factors including, but not limited to, the
activity of the particular compound, the route of administration,
the time of administration, the rate of excretion of the compound,
the duration of the treatment, other drugs, compounds, and/or
materials used in combination, and the age, sex, weight, condition,
general health, and prior medical history of the patient. The
amount of compound and route of administration will ultimately be
at the discretion of the physician, although generally the dosage
will be to achieve local concentrations at the site of action which
achieve the desired effect.
[0978] Administration in vivo can be effected in one dose,
continuously or intermittently throughout the course of treatment.
Methods of determining the most effective means and dosage of
administration are well known to those of skill in the art and will
vary with the formulation used for therapy, the purpose of the
therapy, the target cell being treated, and the subject being
treated. Single or multiple administrations can be carried out with
the dose level and pattern being selected by the treating
physician.
[0979] In general, a suitable dose of the active compound is in the
range of about 0.1 to about 250 mg per kilogram body weight of the
subject per day. Where the active ingredient is a salt, an ester,
prodrug, or the like, the amount administered is calculated on the
basis the parent compound and so the actual weight to be used is
increased proportionately.
[0980] Kits
[0981] One aspect of the invention pertains to a kit comprising (a)
the active ingredient, preferably provided in a suitable container
and/or with suitable packaging; and (b) instructions for use, for
example, written instructions on how to administer the active
compound.
[0982] The written instructions may also include a list of
indications for which the active ingredient is a suitable
treatment.
EXAMPLES
[0983] The following are examples are provided solely to illustrate
the present invention and are not intended to limit the scope of
the invention, as described herein.
[0984] General
[0985] .sup.1H NMR spectra were recorded at ambient temperature
with WH-90/DS or Mercury 200 (Varian) spectrometers. The HPLC
measurements were performed on a Gilson Model 302 system equipped
with a spectrophotometer. Elemental analyses were obtained with a
Carlo Erba EA 1108 instrument. Melting points were measured on a
"Botius" or "Fisher" micro melting point apparatus and are
uncorrected. Silicagel, 0.035-0.070 mm, (Acros) was employed for
column chromatography. All the solvents were purified before use by
routine techniques. To isolate reaction products, the solvents were
removed by evaporation using a vacuum rotary evaporator, the water
bath temperature not exceeding 40.degree. C.
[0986] Various reagents were purchased from Sigma-Aldrich (The Old
Brickyard, New Road, Gillingham, Dorset, UK), Acros Organics
(Janssens Pharmaceuticalaan 3A, 2440 Geel, Belgium), Lancaster
Synthesis Ltd. (Eastgate, White Lund, Morecambe, Lancashire, LA3
3DY, UK), and Maybridge plc (Trevillett, Tingagel, Cornwall, PL34
0HW, UK).
Example 1
3-Formylbenzenesulfonic Acid, Sodium Salt (1)
[0987] 191
[0988] Oleum (5 ml) was placed in a reaction vessel and
benzaldehyde (2.00 g, 18.84 mmol) was slowly added not exceeding
the temperature of the reaction mixture more than 30.degree. C. The
obtained solution was stirred at 40.degree. C. for ten hours and at
ambient temperature overnight. The reaction mixture was poured into
ice and extracted with ethyl acetate. The aqueous phase was treated
with CaCO.sub.3 until the evolution of CO.sub.2 ceased
(pH.about.6-7), then the precipitated CaSO.sub.4 was filtered off
and washed with water. The filtrate was treated with
Na.sub.2CO.sub.3 until the pH of the reaction medium increased to
pH 8, obtained CaCO.sub.3 was filtered off and water solution was
evaporated in vacuum. The residue was washed with methanol, the
washings were evaporated and the residue was dried in desiccator
over P.sub.2O.sub.5 affording the title compound (2.00 g, 51%).
.sup.1H NMR (D.sub.2O), .delta.: 7.56-8.40 (4H, m); 10.04 ppm (1H,
s).
Example 2
3-(3-Sulfophenyl)acrylic Acid Methyl Ester, Sodium Salt (2)
[0989] 192
[0990] Sodium salt of 3-formylbenzenesulfonic acid (1) (1.00 g,
4.80 mmol), potassium carbonate (1.32 g, 9.56 mmol), trim ethyl
phosphonoacetate (1.05 g, 5.77 mmol) and water (2 ml) were stirred
at ambient temperature for 30 min., precipitated solid was filtered
and washed with methanol. The filtrate was evaporated and the title
compound (2) was obtained as a white solid (0.70 g, 55%). .sup.1H
NMR (DMSO-d.sub.6, HMDSO), .delta.: 3.68 (3H, s); 6.51 (1H, d,
J=16.0 Hz); 7.30-7.88 (5H, m).
Example 3
3-(3-Chlorosulfonylphenyl)acrylic Acid Methyl Ester (3)
[0991] 193
[0992] To the sodium salt of 3-(3-sulfophenyl)acrylic acid methyl
ester (2) (0.670 g, 2.53 mmol) benzene (2 ml), thionyl chloride
(1.508 g, 0.9 ml, 12.67 mmol) and 3 drops of dimethylformamide were
added and the resultant suspension was stirred at reflux for one
hour. The reaction mixture was evaporated, the residue was
dissolved in benzene (3 ml), filtered and the filtrate was
evaporated to give the title compound (0.640 g, 97%).
Example 4
3-(3-Phenylsulfamoylphenyl)acrylic Acid Methyl Ester (4a)
[0993] 194
[0994] A solution of 3-(3-chlorosulfonylphenyl)acrylic acid methyl
ester (3) (0.640 g, 2.45 mmol) in dichloromethane (2 ml) was added
to a mixture of aniline (0.465 g, 4.99 mmol) and pyridine (1 ml),
and the resultant solution was stirred at 50.degree. C. for one
hour. The reaction mixture was evaporated and the residue was
partitioned between ethyl acetate and 10% HCl. The organic layer
was washed successively with water, saturated NaCl, and dried
(Na.sub.2SO.sub.4). The solvent was removed and the residue was
chromatographed on silica gel with chloroform-ethyl acetate (7:1,
v/v) as eluent. The obtained product was washed with diethyl ether
to give the title compound (0.226 g, 29%). .sup.1H NMR (CDCl.sub.3,
HMDSO), .delta.: 3.72 (3H, s); 6.34 (1H, d, J=16.0 Hz); 6.68 (1H,
br s); 6.92-7.89 (10H, m).
Example 5
3-(3-Phenylsulfamoylphenyl)acrylic Acid (5a)
[0995] 195
[0996] 3-(3-Phenylsulfamoylphenyl)acrylic acid methyl ester (4a)
(0.220 g, 0.69 mmol) was dissolved in methanol (3 ml), 1N NaOH
(2.08 ml, 2.08 mmol) was added and the resultant solution was
stirred at ambient temperature overnight. The reaction mixture was
partitioned between ethyl acetate and water. The aqueous layer was
acidified with 10% HCl and stirred for 30 min. The precipitated
solid was filtered, washed with water and dried in desiccator over
P.sub.2O.sub.5 to give the title compound as a white solid (0.173
g, 82%).
Example 6
3-(3-Phenylsulfamoylphenyl)acryloyl Chloride (6a)
[0997] 196
[0998] To a suspension of 3-(3-phenylsulfamoylphenyl)acrylic acid
(5a) (0.173 g, 0.57 mmol) in dichloromethane (2.3 ml) oxalyl
chloride (0.17 ml, 1.95 mmol) and one drop of dimethylformamide
were added. The reaction mixture was stirred at 40.degree. C. for
one hour and concentrated under reduced pressure to give crude
title compound (0.185 g).
Example 7
N-Hydroxy-3-(3-phenylsulfamoylphenyl)acrylamide (7a) (PX105684)
[0999] 197
[1000] To a suspension of hydroxylamine hydrochloride (0.200 g,
2.87 mmol) in tetrahydrofuran (3.5 ml) a saturated NaHCO.sub.3
solution (2.5 ml) was added and the resultant mixture was stirred
at ambient temperature for 10 min. To the reaction mixture a
3-(3-phenylsulfamoylphenyl)acryloyl chloride (6a) (0.185 g)
solution in tetrahydrofuran (2.3 ml) was added and stirred at
ambient temperature for one hour. The reaction mixture was
partitioned between ethyl acetate and 2N HCl. The organic layer was
washed successively with water and saturated NaCl, the solvent was
removed and the residue was washed with acetonitrile and diethyl
ether.
[1001] The title compound was obtained as a white solid (0.066 g,
36%), m.p. 172.degree. C. .sup.1H NMR (DMSO-d.sub.6, HMDSO),
.delta.: 6.49 (1H, d, J=16.0 Hz); 7.18-8.05 (10H, m); 9.16 (1H, br
s); 10.34 (1H, s); 10.85 ppm (1H, br s). HPLC analysis on Symmetry
C.sub.8 column: impurities 4% (column size 3.9.times.150 mm; mobile
phase acetonitrile--0.1M phosphate buffer (pH 2.5), 40:60; sample
concentration 1 mg/ml; flow rate 0.8 ml/min; detector UV 220 nm).
Anal. Calcd for C.sub.15H.sub.14N.sub.2O.sub- .4S, %: C, 56.59, H,
4.43, N, 8.80. Found, %: C, 56.28; H, 4.44; N, 8.56.
Example 8
3-[3-(Methylphenylsulfamoyl)phenyl]acrylic Acid Methyl Ester
(4b)
[1002] 198
[1003] A solution of 3-(3-chlorosulfonylphenyl)acrylic acid methyl
ester (3) (0.440 g, 1.68 mmol) in dichloromethane (2 ml) was added
to a mixture of N-methylaniline (0.364 g, 3.40 mmol) and pyridine
(0.5 ml), and the resultant solution was stirred at 50.degree. C.
for one hour. The reaction mixture was evaporated and the residue
was partitioned between ethyl acetate and 10% HCl. The organic
layer was washed successively with water, saturated NaCl, and dried
(Na.sub.2SO.sub.4). The solvent was removed and the residue was
chromatographed on silica gel with chloroform-ethyl acetate (15:1,
v/v) as eluent. The obtained product was washed with diethyl ether
to give the title compound (0.155 g, 28%). .sup.1H NMR (CDCl.sub.3,
HMDSO), .delta.: 3.12 (3H, s); 3.74 (3H, s); 6.34 (1H, d, J=16.0
Hz); 6.97-7.74 (10H, m).
Example 9
3-[3-(Methylphenylsulfamoyl)phenyl]acrylic Acid (5b)
[1004] 199
[1005] 3-[3-(Methylphenylsulfamoyl)phenyl]acrylic acid methyl ester
(4b) (0.150 g, 0.45 mmol) was suspended in methanol (2 ml), 1 N
NaOH solution (1.35 ml, 1.35 mmol) was added and the resultant
solution was stirred at ambient temperature overnight. The reaction
mixture was partitioned between ethyl acetate and water. The
aqueous layer was acidified with 10% HCl and extracted with ethyl
acetate. The organic layer was washed successively with water,
saturated NaCl, and dried (Na.sub.2SO.sub.4). The solvent was
removed to give the title compound (0.135 g, 94%).
Example 10
3-[3-Methylphenylsulfamoyl)phenyl]acryloyl Chloride (6b)
[1006] 200
[1007] To a suspension of
3-[3-(methylphenylsulfamoyl)phenyl]acrylic acid (5b) (0.135 g, 0.42
mmol) in dichloromethane (2.3 ml) oxalyl chloride (0.17 ml, 1.95
mmol) and one drop of dimethylformamide were added. The reaction
mixture was stirred at 40.degree. C. for one hour and concentrated
under reduced pressure to give crude title compound (0.142 g).
Example 11
N-Hydroxy-[3-(3-methylphenylsulfamoyl)phenyl]acrylamide (7b)
(PX1.05685).
[1008] 201
[1009] To a suspension of hydroxylamine hydrochloride (0.200 g,
2.87 mmol) in tetrahydrofuran (3.5 ml) a saturated NaHCO.sub.3
solution (2.5 ml) was added and the resultant mixture was stirred
at ambient temperature for 10 min. To the reaction mixture a
3-[3-(methylphenylsulfamoyl)phenyl]acryloy- l chloride (6b) (0.142
g) solution in tetrahydrofuran (2.3 ml) was added and stirred at
ambient temperature for one hour. The reaction mixture was
partitioned between ethyl acetate and 2N HCl. The organic layer was
washed successively with water and saturated NaCl, the solvent was
removed and the residue was washed with diethyl ether.
[1010] The title compound was obtained as a white solid (0.062 mg,
42%), m.p. 152.degree. C. .sup.1H NMR (DMSO-d.sub.6, HMDSO),
.delta.: 3.16 (3H, s); 6.47 (1H, d, J=16.0 Hz); 7.03-7.96 (10H, m);
9.09 (1H, br s); 10.78 ppm (1H, br s). HPLC analysis on Symmetry
C.sub.18 column: impurities 1.7% (column size 3.9.times.150 mm;
mobile phase acetonitrile--0.1M phosphate buffer (pH 2.5), 40:60;
sample concentration 1 mg/ml; flow rate 0.0 ml/min; detector UV 220
nm). Anal. Calcd for C.sub.16H.sub.16n.sub.2O- .sub.4S, %: C,
57.82, H, 0.85, N, 8.43. Found, %: C, 57.82; H, 4.83; N, 8.35.
Example 12
3-[3-(4-Methoxyphenylsulfamoyl)-phenyl)]acrylic Acid Methyl Ester
(4c)
[1011] 202
[1012] A solution of 3-(3-chlorosulfonylphenyl)acrylic acid methyl
ester (3) (2.0 g, 7.23 mmol) in dioxane (10 ml) was added to a
mixture of 4-methoxyaniline (0.89 g, 7.23 mmol) in dioxane (15 ml)
and NaHCO.sub.3 (1.2 g, 14.5 mmol) in water (20 ml), and the
resultant solution was stirred at room temperature for one hour.
The reaction mixture was evaporated and the residue was partitioned
between ethyl acetate and 2N HCl. The organic layer was washed
successively with water, saturated NaCl, and dried
(Na.sub.2SO.sub.4). The solvent was removed and the residue was
chromatographed on silica gel with dichloromethane-ethyl acetate
(20:1, v/v) as-eluent. The obtained product was washed-with-diethyl
ether to the title compound (2.0 g, 80%). .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 3.65 (3H, s); 3.74 (3H, s); 6.65
(1H, d, J=16.0 Hz); 6.72-7.20 (4H, m); 7.56-8.18 (5H, m); 9.96 (1H,
br s).
Example 13
3-[3-(4-Methoxyphenylsulfamoyl)-phenyl)]-acrylic Acid (5c)
[1013] 203
[1014] To a suspension of
3-[3-(4-methoxyphenylsulfamoylyphenyl)]-acrylic acid methyl ester
(4c) (1.0 g, 2.88 mmol) in methanol (15 ml) 1N NaOH solution (8.63
ml, 8.63 mmol) was added and the resultant mixture was stirred at
ambient temperature overnight. The reaction mixture was partitioned
between ethyl acetate and water. The aqueous layer was acidified
with 2N HCl solution and stirred for 30 min. The precipitated solid
was filtered, washed with water and dried in desiccator over
P.sub.2O.sub.5 to give the title compound as a white solid (0.95 g,
99%).
Example 14
3-[3-(4-Methoxyphenylsulfamoyl)-phenyl)]-acryloyl Chloride (6c)
[1015] 204
[1016] To a suspension of
3-[3-(4-methoxyphenylsulfamoyl)-phenyl)]-acrylic Acid (5c) (0.95 g,
2.85 mmol) in dichloromethane (12.0 ml) oxalyl chloride (0.88 ml,
10.07 mmol) and one drop of dimethylformamide were added. The
reaction mixture was stirred at 40.degree. C. for one hour and
concentrated under reduced pressure to give crude title compound
(1.01 g).
Example 15
N-Hydroxy-3-[3-(4-methoxyphenylsulfamoyl)-phenyl)]-acrylamide (7c)
(PX105844)
[1017] 205
[1018] To a suspension of hydroxylamine hydrochloride (0.99 g,
14.38 mmol) in tetrahydrofuran (17.0 ml) a saturated NaHCO.sub.3
solution (12.0 ml) was added and the resultant mixture was stirred
at ambient temperature for 10 min. To the reaction mixture a
solution of 3-[3-(4-methoxyphenylsu- lfamoyl)-phenyl)-acryloyl
chloride (6c) (1.01 g) in tetrahydrofuran (12.0 ml) was added and
the mixture was stirred at ambient temperature for one hour. The
reaction mixture was partitioned between ethyl acetate and 2N HCl.
The organic layer was washed successively with water and saturated
NaCl, then the solvent was removed.
[1019] The residue was crystallised from ethyl acetate-methanol
affording the title compound (0.77 g, 77%), m.p. 186.degree. C.
.sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 3.67 (s, 3H); 6.49 (d,
J=16.0 Hz, 1H); 6.72-8.03 (m, 9H); 9.14 (br s, 1H); 9.91 (s, 1H);
10.85 (br s, 1H). HPLC analysis on Symmetry C.sub.18 column:
impurities 2.5% (column size 3.9.times.150 mm; mobile phase
acetonitrile --0.1M phosphate buffer (pH 2.5), 30:70; sample
concentration 0.25 mg/ml; flow rate 1.0 ml/min; detector UV 220
nm). Anal. Calcd for C.sub.16H.sub.16n.sub.2O.sub.5S, %: C, 55.16;
H, 4.63; N, 8.04, S 9.20. Found, %: C, 55.07; H, 4.60; N, 7.94, S,
9.01.
Example 16
3-(3-p-Tolylsulfamoyl-phenyl)-acrylic Acid Methyl Ester (4d)
[1020] 206
[1021] A solution of 3-(3-chlorosulfonylphenyl)-acrylic acid methyl
ester (3) (2.0 g, 7.23 mmol) in dioxane (10 ml) was added to a
mixture of 4-methylaniline (0.77 g, 7.23 mmol) in dioxane (20 ml)
and NaHCO.sub.3 (1.2 g, 14.5 mmol) in water (20 ml), and the
resultant solution was stirred at room temperature for one hour.
The reaction mixture was evaporated and the residue was partitioned
between ethyl acetate and 2N HCl. The organic layer was washed
successively with water, saturated NaCl, and dried
(Na.sub.2SO.sub.4). The solvent was removed and the residue was
chromatographed on silica gel with dichloromethane-ethyl acetate
(20:1, v/v) as eluent. The obtained product was washed with diethyl
ether to give the title compound (1.9 g, 79%). .sup.1H NMR
(DMSO-d.sub.6, HMDSO), 6:2.16 (3H, s); 3.69 (3H, s); 6.65 (1H, d,
J=16.0 Hz); 7.00 (4H, s); 7.49-8.11 (5H, m); 10.14 (1H, br s).
Example 17
3-(3-p-Tolylsulfamoyl-phenyl)-acrylic Acid (5d)
[1022] 207
[1023] To a suspension of 3-(3-p-tolylsulfamoyl-phenyl)-acrylic
acid methyl ester (4d) (0.89 g, 2.70 mmol) in methanol (12 ml) 1N
NaOH solution (8.10 ml, 8.10 mmol) was added and the resultant
mixture was stirred at ambient temperature overnight. The reaction
mixture was partitioned between ethyl acetate and water. The
aqueous layer was acidified with 2N HCl solution and stirred for 30
min. The precipitated solid was filtered, washed with water and
dried in desiccator over P.sub.2O.sub.5 to give the title compound
as a white solid (0.75 g, 87%).
Example 18
3-(3-p-Tolylsulfamoyl-phenyl)-acryloyl Chloride (6d)
[1024] 208
[1025] To a suspension of 3-(3-p-tolylsulfamoyl-phenyl)-acrylic
acid (5d) (0.75 g, 2.36 mmol) in dichloromethane (10.0 ml) oxalyl
chloride (0.62 ml, 7.08 mmol) and one drop of dimethylformamide
were added. The reaction mixture was stirred at 40.degree. C. for
one hour and concentrated under reduced pressure to give crude
title compound (0.79 g).
Example 19
N-Hydroxy-3-(3-p-tolylsulfamoyl)-phenyl)-acrylamide (7d)
(PX106508)
[1026] 209
[1027] To a suspension of hydroxylamine hydrochloride (0.82 g,
11.80 mmol) in tetrahydrofuran (10.0 ml) a saturated NaHCO.sub.3
solution (12.0 ml) was added and the resultant mixture was stirred
at ambient temperature for 10 min. To the reaction mixture a
solution of 3-(3-p-tolylsulfamoyl)-- phenyl)-acryloyl chloride (6d)
(0.79 g) in tetrahydrofuran (12.0 ml) was added and the mixture was
stirred at ambient temperature for one hour. The reaction mixture
was partitioned between ethyl acetate and 2N HCl. The organic layer
was washed successively with water and saturated NaCl, and the
solvent was removed.
[1028] The residue was crystallised from ethyl acetate giving the
title compound (0.67 g, 85%), m.p. 200.degree. C. .sup.1H NMR
(DMSO-d.sub.6, HMDSO) .delta.: 2.16 (s, 3H); 6.47 (d, 1H, J=16.0
Hz); 6.98 (s, 4H); 7.29-7.98 (m, 5H); 9.09 (br s, 1H); 10.09 (s,
1H); 10.76 (br s, 1H). HPLC analysis on Zorbax SB-C.sub.18 column:
impurities 4% (column size 4.6.times.150 mm; mobile phase
acetonitrile--0.1% H.sub.3PO.sub.4, gradient from 40 to 100%;
sample concentration 0.6 mg/ml; flow rate 1.5 ml/min; detector UV
270 nm). Anal. Calcd for C.sub.16H.sub.16n.sub.2O.sub- .4S, %: C,
57.82; H, 4.85; N, 8.43. Found, %: C, 57.61, H, 4.93, N, 0.16.
Example 20
3-[3-(4-Bromo-phenylsulfamoyl-phenyl)]-acrylic Acid Methyl Ester
(4e)
[1029] 210
[1030] A solution of 3-(3-chlorosulfonylphenyl)-acrylic acid methyl
ester (3) (1.85 g, 6.50 mmol) in dioxane (10 ml) was added to a
mixture of 4-bromoaniline (1.12 g, 6.50 mmol) in dioxane (20 ml)
and NaHCO.sub.3 (1.109, 13.09 mmol) in water (15 ml), and the
resultant solution was stirred at room temperature for one hour.
The reaction mixture was evaporated and the residue was partitioned
between ethyl acetate and 2N HCl. The organic layer was washed
successively with water, saturated NaCl, and dried
(Na.sub.2SO.sub.4). The solvent was removed and the residue was
chromatographed on silica gel with dichloromethane-ethyl acetate
(20:1, v/v) as eluent. The obtained product was washed with die
thyl ether to give the title compound (1.62 g, 63%). .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 3.76 (3H, s); 6.69 (1H, d, J=16.0
Hz); 6.98-7.23 (2H, m); 7.32-8.07 (7H, m); 10.47 (1H, br s).
Example 21
3-[(3-(4-Bromo-phenylsulfamoyl-phenyl)]-acrylic Acid (5e)
[1031] 211
[1032] To a suspension of
3-[3-(4-bromo-phenylsulfamoyl-phenyl)]-acrylic acid methyl ester
(4e) (0.80 g, 2.02 mmol) in methanol (10 ml) 1N NaOH solution (6.00
ml, 6.00 mmol) was added and the resultant mixture was stirred at
ambient temperature overnight. The reaction mixture was partitioned
between ethyl acetate and water. The aqueous layer was acidified
with 2N HCl and stirred for 30 min. The precipitated solid was
filtered, washed with water and dried in desiccator over
P.sub.2O.sub.5 to give the title compound as a white solid (0.64 g,
84%).
Example 22
3-[3-(4-Bromo-phenylsulfamoyl-phenyl)]-acryloyl Chloride (6e)
[1033] 212
[1034] To a suspension of
3-[3-(4-bromo-phenylsulfamoyl-phenyl)]-acrylic acid (5e) (0.64 g,
1.67 mmol) in dichloromethane (8.0 ml) oxalyl chloride (0.44 ml,
5.02 mmol) and one drop of dimethylformamide were added. The
reaction mixture was stirred at 40.degree. C. for one hour and
concentrated under reduced pressure to give crude title compound
(0.67 g).
Example 23
N-Hydroxy-3-[3-(4-bromo-phenylsulfamoyl)-phenyl)]-acrylamide (7e)
(PX106509)
[1035] 213
[1036] To a suspension of hydroxylamine hydrochloride (0.58 g, 8.35
mmol) in tetrahydrofuran (8.0 ml) a saturated NaHCO.sub.3 solution
(8.0 ml) was added and the resultant mixture was stirred at ambient
temperature for 10 min. To the reaction mixture a
3-[3-(4-bromo-phenylsulfamoyl)-phenyl)]-ac- ryloyl chloride (6e)
(0.67 g) solution in tetrahydrofuran (8.0 ml) was added and stirred
at ambient temperature for one hour. The reaction mixture was
partitioned between ethyl acetate and 2N HCl. The organic layer was
washed successively with water and saturated NaCl, and the solvent
was removed.
[1037] The residue was crystallised from ethyl acetate giving the
title compound (0.52 g, 78%), m.p. 204.degree. C. .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 6.49 (d, 1H, J=16.0 Hz); 7.05 (d,
2H, J=9.0 Hz); 7.34-7.98 (m, 7H); 9.09 (br s, 1H); 10.47 (s, 1H);
10.80 (br s, 1H). HPLC analysis on Zorbax SB-C.sub.18 column:
impurities 5% (column size 4.6.times.150 mm; mobile phase
acetonitrile --0.1% H.sub.3PO.sub.4, gradient from 40 to 100%;
sample concentration 0.9 mg/ml; flow rate 1.5 ml/min; detector UV
270 nm). Anal. Calcd for C.sub.15H.sub.13BrN.sub.2O.s- ub.4S, %: C,
45.35; H, 3.30; N, 7.05. Found, %: C, 45.73, H, 3.33, 6.81.
Example 24
3-[3-(4-Chloro-phenylsulfamoyl-phenyl)]-acrylic Acid Methyl Ester
(4f)
[1038] 214
[1039] A solution of 3-(3-chlorosulfonylphenyl) acrylic acid methyl
ester (3) (1.10 g, 4.22 mmol) in dioxane (10 ml) was added to a
mixture of 4-chloroaniline (0.53 g, 4.22 mmol) in dioxane (10 ml)
and NaHCO.sub.3 (0.50 g, 5.95 mmol) in water (10 ml), and the
resultant solution was stirred at room temperature for one hour.
The reaction mixture was evaporated and the residue was partitioned
between ethyl acetate and 2N HCl. The organic layer was washed
successively with water, saturated NaCl, and dried
(Na.sub.2SO.sub.4). The solvent was removed and the residue was
chromatographed on silica gel with dichloromethane-ethyl acetate
(20:1, v/v) as eluent. The obtained product was washed with diethyl
ether to give the title compound (1.01 g, 71%).
Example 25
3-[(3-(4-Chloro-phenylsulfamoyl-phenyl)]-acrylic Acid (5f)
[1040] 215
[1041] To a suspension of
3-[3-(4-chloro-phenylsulfamoyl-phenyl)]-acrylic acid methyl ester
(4f) (0.77 g, 2.12 mmol) in methanol (10 ml) 1N NaOH solution (6.57
ml, 6.57 mmol) was added and the resultant solution was stirred at
ambient temperature overnight. The reaction mixture was partitioned
between ethyl acetate and water. The aqueous layer was acidified
with 2N HCl and stirred for 30 min. The precipitated solid was
filtered, washed with water and dried in desiccator over
P.sub.2O.sub.5 to give the title compound as a white solid (0.64 g,
86%).
Example 26
3-[3-(4-Chloro-phenylsulfamoyl-phenyl)]-acryloyl Chloride (6f)
[1042] 216
[1043] To a suspension of
3-[3-(4-chloro-phenylsulfamoyl-phenyl)]-acrylic acid (5f) (0.64 g,
1.89 mmol) in dichloromethane (8.0 ml) oxalyl chloride (0.50 ml,
5.68 mmol) and one drop of dimethylformamide were added. The
reaction mixture was stirred at 40.degree. C. for one hour and
concentrated under reduced pressure to give crude title compound
(0.65 g).
Example 27
N-Hydroxy-3-[3-(4-chloro-phenylsulfamoyl)-phenyl)]-acrylamide (7f)
(PX106510)
[1044] 217
[1045] To a suspension of hydroxylamine hydrochloride (0.66 g, 9.45
mmol) in tetrahydrofuran (12.0 ml) a saturated NaHCO.sub.3 solution
(8.0 ml) was added and the resultant mixture was stirred at ambient
temperature for 10 min. To the reaction mixture a
3-[3-(4-chloro-phenylsulfamoyl)-phe- nyl)]-acryloyl chloride (6f)
(0.65 g) solution in tetrahydrofuran (8.0 ml) was added and the
mixture was stirred at ambient temperature for one hour. The
reaction mixture was partitioned between ethyl acetate and 2N HCl.
The organic layer was washed successively with water and saturated
NaCl, and the solvent was removed.
[1046] The residue was crystallised from acetonitrile giving the
title compound (0.47 g, 75%), m.p. 198.degree. C. .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 6.49 (d, 1H, J=16.0 Hz); 6.98-8.05
(m, 9H); 9.16 (br s, 1H); 10.49 (s, 1H); 10.85 (s, 1H). HPLC
analysis on Zorbax SB-C.sub.18 column: impurities 5% (column size
4.6.times.150 mm; mobile phase acetonitrile--0.1% H.sub.3PO.sub.4,
gradient from 30 to 100%; sample concentration 0.2 mg/ml; flow rate
1.5 ml/min; detector UV 270 nm). Anal. Calcd for
C.sub.15H.sub.13ClN.sub.2O.sub.4S, %: C, 51.07; H, 3.71; N, 7.94,
S, 9.09. Found, %: C, 50.96; H, 3.62; N, 7.76, S, 9.00.
Example 28
3-(3-Benzylsulfamoyl-phenyl)-acrylic Acid Methyl Ester (4g)
[1047] 218
[1048] A solution of 3-(3-chlorosulfonylphenyl) acrylic acid methyl
ester (3) (0.40 g, 1.53 mmol) in dioxane (5.0 ml) was added to a
mixture of 4-benzylamine (0.17 ml, 1.53 mmol) in dioxane (1.0 ml)
and NaHCO.sub.3 (0.26 g, 3.06 mmol) in water (3.0 ml), and the
resultant solution was stirred at room temperature for one hour.
The reaction mixture was evaporated and the residue was partitioned
between ethyl acetate and 2N HCl. The organic layer was washed
successively with water, saturated NaCl, and dried
(Na.sub.2SO.sub.4). The solvent was removed and the residue was
chromatographed on silica gel with petroleum ether-ethyl acetate
(2:1, v/v) as eluent. The obtained product was washed with diethyl
ether to give the title compound (0.29 g, 57%).
Example 29
3-(3-Benzylsulfamoyl-phenyl)-acrylic Acid (59)
[1049] 219
[1050] To a suspension of 3-(3-benzylsulfamoyl-phenyl)-acrylic acid
methyl ester (4 g) (0.29 g, 0.87 mmol) in methanol (4.5 ml) 1N NaOH
solution (2.60 ml, 2.60 mmol) was added and the resultant mixture
was stirred at ambient temperature overnight. The reaction mixture
was partitioned between ethyl acetate and water. The aqueous layer
was acidified with 2N HCl solution and stirred for 30 min. The
precipitated solid was filtered, washed with water and dried in
desiccator over P.sub.2O.sub.5 to give the title compound as a
white solid (0.22 g, 81%). .sup.1H NMR (DMSO-d.sub.6, HMDSO),
.delta.: 4.05 (2H, d, J=6.4 Hz); 6.60 (1H, d, J=16.0 Hz); 7.27 (4H,
s), 7.52-8.09 (6H, m); 8.20 (1H, t, J=6.4 Hz); 12.58 (1H, br
s).
Example 30
3-(3-Benzylsulfamoyl-phenyl)-acryloyl chloride (6g)
[1051] 220
[1052] To a suspension of 3-(3-(benzylsulfamoyl-phenyl)-acrylic
acid (5 g) (0.16 g, 0.52 mmol) in dichloromethane (2.0 ml) oxalyl
chloride (0.16 ml, 1.79 mmol) and one drop of dimethylformamide
were added. The reaction mixture was stirred at 40.degree. C. for
one hour and concentrated under reduced pressure to give crude
title compound (0.17 g).
Example 31
N-Hydroxy-3-(3-benzylsulfamoyl)-phenyl)-acrylamide (7 g)
(PX106511)
[1053] 221
[1054] To a suspension of hydroxylamine hydrochloride (0.18 g, 2.60
mmol) in tetrahydrofuran (3.0 ml) a saturated NaHCO.sub.3 solution
(2.5 ml) was added and the resultant mixture was stirred at ambient
temperature for 10 min. To the reaction mixture a
3-(3-benzylsulfamoyl)-phenyl)-acryloyl chloride (6 g) (0.17 g)
solution in tetrahydrofuran (2.0 ml) was added and stirred at
ambient temperature for one hour. The reaction mixture was
partitioned between ethyl acetate and 2N HCl. The organic layer was
washed successively with water and saturated NaCl, and the solvent
was removed.
[1055] The residue was crystallised from ethyl acetate giving the
title compound (0.12 g, 68%), m.p. 179.degree. C. .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 4.02 (d, 2H, J=6.4 Hz); 6.53 (d,
1H, J=16.0 Hz); 7.25 (s, 5H); 7.39-8.03 (m, 5H); 8.20 (t, 1H, J=6.4
Hz); 9.12 (br s, 1H); 10.80 (br s, 1H). HPLC analysis on Zorbax
SB-C.sub.18 column: impurities 5% (column size 4.6.times.150 mm;
mobile phase acetonitrile --0;1% H.sub.3PO.sub.4, gradient from 30
to 100%; sample concentration 0.5 mg/ml; flow rate 1.5 ml/min;
detector UV 230 nm). Anal. Calcd for
C.sub.16H.sub.16n.sub.2O.sub.4S, %: C, 57.82; H, 4.85; N, 8.43, S,
9.6. Found, %: C, 57.59; H, 4.82; N, 8.14, S, 9.6.
Example 32
3-(3-Phenethylsulfamoyl-phenyl)-acrylic Acid Methyl Ester (4h)
[1056] 222
[1057] A solution of 3-(3-chlorosulfonylphenyl)-acrylic acid methyl
ester (3) (0.40 g, 1.53 mmol) in dioxane (5.0 ml) was added to a
mixture of 4-phenethylamine (0.19 ml, 1.53 mmol) in dioxane (1.0
ml) and NaHCO.sub.3 (0.26 g, 3.06 mmol) in water (3.0 ml) and the
resultant solution was stirred at room temperature for one hour.
The reaction mixture was evaporated and the residue was partitioned
between ethyl acetate and 2N HCl. The organic layer was washed
successively with water, saturated NaCl, and dried
(Na.sub.2SO.sub.4). The solvent was removed and the residue was
chromatographed on silica gel with petroleum ether-ethyl acetate
(2:1, v/v) as eluent. The obtained product was washed with diethyl
ether to give the title compound (0.43 g, 82%). .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 2.69 (2H, m); 2.98 (2H, m); 3.72
(3H, s); 6.72 (1H, d, J=116.0 Hz); 7.05-7.43 (5H, m); 7.54-8.14
(6H, m).
Example 33
3-(3-Phenethylsulfamoyl-phenyl)-acrylic Acid (5h)
[1058] 223
[1059] To a suspension of 3-(3-phenethylsulfamoyl-phenyl)-acrylic
acid methyl ester (4h) (0.20 g, 0.58 mmol) in methanol (3.0 ml) 1N
NaOH solution (1.75 ml, 1.75 mmol) was added and the resultant
solution was stirred at ambient temperature overnight. The reaction
mixture was partitioned between ethyl acetate and water. The
aqueous layer was acidified with 2N HCl solution and extracted with
ethyl acetate. The organic layer was washed successively with
water, saturated NaCl, and dried (Na.sub.2SO.sub.4). The solvent
was removed and the residue was washed with ether to give the title
compound as a white solid (0.15 g, 77%).
Example 34
3-(3-Phenethylsulfamoyl-phenyl)-acryloyl Chloride (6h)
[1060] 224
[1061] To a suspension of 3-(3-phenethylsulfamoyl-phenyl)-acrylic
acid (5h) (0.15 g, 0.45 mmol) in dichloromethane (2.0 ml) oxalyl
chloride (0.14 ml, 1.57 mmol) and one drop of dimethylformamide
were added. The reaction mixture was stirred at 40.degree. C. for
one hour and concentrated under reduced pressure to give crude
title compound (0.16 g).
Example 35
N-Hydroxy-3-(3-phenethylsulfamoyl)-phenyl)-acrylamide (7h)
(PX106512)
[1062] 225
[1063] To a suspension of hydroxylamine hydrochloride (0.16 g, 2.25
mmol) in tetrahydrofuran (3.0 ml) a saturated NaHCO.sub.3 solution
(2.0 ml) was added and the resultant mixture was stirred at ambient
temperature for 10 min. To the reaction mixture a
3-(3-phenethylsulfamoyl)-phenyl)-acryloyl chloride (6h) (0.16 g)
solution in tetrahydrofuran (2.0 ml) was added and stirred at
ambient temperature for one hour. The reaction mixture was
partitioned between ethyl acetate and 2N HCl. The organic layer was
washed successively with water and saturated NaCl, and the solvent
was removed.
[1064] The residue was crystallised from dichloromethane-ether
giving the title compound (0.10 g, 66%), m.p. 114.degree. C.
.sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 2.67 (m, 2H); 3.00 (m,
2H); 6.55 (d, 1H, J=16.0 Hz); 7.00-8.05 (m, 11H); 9.12 (br s, 1H);
10.78 (br s, 1H). HPLC analysis on Zorbax SB-C.sub.18 column:
impurities 5% (column size 4.6.times.150 mm; mobile phase
acetonitrile--0.1% H.sub.3PO.sub.4, gradient from 30 to 100%;
sample concentration 1.0 mg/ml; flow rate 1.5 ml/min; detector: UV
230 nm). Anal. Calcd for C.sub.17H.sub.18N.sub.2O.su- b.4S, %: C,
58.94; H, 5.24; N, 8.09, S, 9.26. Found, %: C, 58.81; H, 5.16; N,
8.00, S, 9.05.
Example 36
3-[3-(3-Methoxy-phenylsulfamoyl)-phenyl]-acrylic acid methyl ester
(4i)
[1065] A solution of 3-(3-chlorosulfonylphenyl)-acrylic acid methyl
ester (3) (0.4 g, 1.53 mmol) in dioxane (5 ml) was added to a
mixture of 3-methoxyphenylamine (0.189 g, 1.53 mmol) in dioxane (1
ml) and NaHCO.sub.3 (0.25 g, 3.06 mmol) in water (3 ml), and the
resultant solution was stirred at room temperature until the
completion of the reaction (control by TLC). The reaction mixture
was evaporated and the residue was partitioned between ethyl
acetate and 2N HCl. The organic layer was washed successively with
water, saturated NaCl, and dried (Na.sub.2SO.sub.4). The solvent
was-removed and the residue-was-chromatographed on-silica gel with
petroleum ether-ethyl acetate (2:1, v/v) as eluent. The obtained
product was washed with diethyl ether to give the title compound
(0.44 g, 82%) as a white solid. .sup.1H NMR (DMSO-d.sub.6, HMDSO),
.delta.: 3.60 (3H, s), 3.71 (3H, s); 6.52-6.74 (3H, m); 6.63 (1
J=16.0 Hz); 7.07 (1H, m); 7.43-8.05 (5H, m); 10.27 ppm (1H, br
s).
Example 37
3-[3-(3-Methoxy-phenylsulfamoyl)-phenyl]-acrylic acid (5i)
[1066] To a suspension of
3-[3-(3-methoxyphenyl-sulfamoyl)-phenyl]-acrylic acid methyl ester
(4i) (0.42 g, 1.2 mmol) in methanol (5.5 ml) 1N NaOH solution (3.6
ml, 3.6 mmol) was added and the resultant mixture was stirred at
ambient temperature overnight. The reaction mixture was partitioned
between ethyl acetate and water. The aqueous layer was acidified
with 2N HCl solution and stirred for 30 min. The precipitated solid
was filtered, washed with water and dried in desiccator over
P.sub.2O.sub.5. The title compound was obtained as a white solid
(0.38 g, 95%). .sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta. 3.65 (3H,
s); 6.40-6.78 (4H, m); 7.16 (1H, m); 7.45-8.09 (5H, m); 10.32 (1H,
br s).
Example 38
3-[3-(3-Methoxy-phenylsulfamoyl)-phenyl]-acryloyl chloride (6i)
[1067] To a suspension of
3-[3-(3-methoxyphenyl-sulfamoyl)-phenyl]-acrylic acid (5i) (0.38 g,
1.14 mmol) in dichloromethane (4 ml) oxalyl chloride (0.3 ml, 3.43
mmol) and one drop of dimethylformamide were added. The reaction
mixture was stirred at 40.degree. C. for one hour and concentrated
under reduced pressure to give crude title compound (0.40 g,
100%).
Example 39
N-Hydroxy-3-[3-(3-methoxy-phenylsulfamoyl)-phenyl]-acrylamide (7i)
(PX117712)
[1068] 226
[1069] To a suspension of hydroxylamine hydrochloride (0.39 g, 5.7
mmol) in tetrahydrofuran (6 ml) a saturated NaHCO.sub.3 solution
(4.5 ml) was added and the resultant mixture was stirred at ambient
temperature for 10 min. To the reaction mixture a solution of crude
3-[3-(3-methoxy-phenylsu- lfamoyl)-phenyl]-acryloyl chloride (6i)
(0.40 g) in tetrahydrofuran (4 ml)-was added and the mixture was
stirred at ambient temperature for one hour. The reaction mixture
was partitioned between ethyl acetate and 2N HCl. The organic layer
was washed successively with water and saturated NaCl, then the
solvent was removed. The residue was crystallised from ethyl
acetate-acetonitrile affording the title compound (0.15 g. 39%) as
a lightly pink crystals. M.p. 137.degree. C. .sup.1H NMR
(DMSO-d.sub.6, HMDSO) .delta.: 3.65 (3H, s); 6.38-6.78 (4H, m);
6.98-7.27 (1H, m); 7.34-8.03 (5H, m); 9.14 (1H, br s); 10.30 (1H,
s); 10.83 (1H, br s). HPLC analysis on Symmetry C.sub.8 column:
impurities 5% (column size 3.9.times.150 mm; mobile phase
acetonitrile--0.1M phosphate buffer (pH 2.5), 40:60; sample
concentration 0.5 mg/ml; flow rate 1.2 ml/min; detector UV 254 nm).
Anal. Calcd for C.sub.16H.sub.16n.sub.2O.sub.5S containing 1% of
inorganic impurities, %: C, 54.67; H, 4.50; N, 8.09. Found, %: C,
54.61; H, 4.58; N, 7.96.
Example 40
3-[3-(Biphenyl-2-ylsulfamoyl)-phenyl)-acrylic Acid Methyl Ester
(4j)
[1070] Using an analogous method, the title compound was obtained
from 3-(3-chlorosulfonylphenyl)acrylic acid methyl ester (3) and
2-aminobiphenyl, as a white solid, yield 48%, .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 3.65 (3H, s); 6.56 (1H, d, J=16.0
Hz); 6.93-8.02 (14H, m); 9.54 (1H, brs).
Example 41
3-[3-(Biphenyl-2-ylsulfamoyl)-phenyl]-acrylic acid (5j)
[1071] Using an analogous method, the title compound was obtained
from 3-[3-(biphenyl-2-ylsulfamoyl)-phenyl]-acrylic acid methyl
ester (4j) and sodium hydroxide, yield 89%. .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 6.47 (1H, d, J=16.0 Hz); 6.98-8.03
(14H, m); 9.54 (1H, brs).
Example 42
3-[3-(Biphenyl-2-ylsulfamoyl)-phenyl]-acryloyl chloride (6j)
[1072] Using an analogous method, the title compound was obtained
from 3-[3-(biphenyl-2-ylsufamoyl)-phenyl]-acrylic acid (5j) and
oxalyl chloride in a form of a crude product, yield ca. 97%.
Example 43
3-[3-(Biphenyl-2-ylsulfamoyl)-phenyl]-N-hydroxy-acrylamide (7j)
(PX117713)
[1073] 227
[1074] Using an analogous method, the title compound was obtained
from 3-[3-(biphenyl-2-ylsulfamoyl)-phenyl]-acryloyl chloride (6j)
and hydroxylamine hydrochloride, yield 47%, foam. .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 6.43 (1H, d, J=16.0 Hz); 6.94-7.85
(14H, m); 9.07 (1H, br s); 9.58 (1H, br s); 10.78 (1H, br s). HPLC
analysis on Symmetry C.sub.8 column: impurities 6.4% (column size
3.9.times.150 mm; mobile phase acetonitrile-0.1M phosphate buffer,
pH 2.5, 50:50; sample concentration 0.5 mg/ml; flow rate 1.0
ml/min; detector UV 254 nm). Anal. Calcd for
C.sub.21H.sub.18N.sub.2O.sub.4S* 0.5H.sub.2O, %: 62.52, H, 4.75, N,
6.94. Found, %: C, 62.58; H, 4.66; N, 6.65.
Example 44
3-[3-(Biphenyl-4-ylsulfamoyl)-phenyl]-acrylic Acid Methyl Ester
(4k)
[1075] Using an analogous method, the title compound was obtained
from 3-(3-chlorosulfonylphenyl)-acrylic acid methyl ester (3) and
4-aminobiphenyl as a white solid, yield 88%, .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 3.71 (3H, s); 6.67 (1H, d, J=16.0
Hz); 7.07-8.09 (14H, m); 10.36 ppm (1H, br s).
Example 45
3-[3-(Biphenyl-4-ylsulfamoyl)-phenyl]-acrylic Acid (5k)
[1076] Using an analogous method, the title compound was obtained
from 3-[3-(biphenyl-4-ylsulfamoyl)-phenyl]-acrylic acid methyl
ester (4k) and sodium hydroxide, yield 88%. .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 6.56 (1H, d, J=16.0 Hz); 7.09-8.12
(14H, m); 10.38 ppm (1H, br s).
Example 46
3-[3-(Biphenyl-4-ylsulfamoyl)-phenyl]-acryloyl Chloride (6k)
[1077] Using an analogous method, the title compound was obtained
from 3-(3-(biphenyl-4-ylsulfamoyl)-phenyl]-acrylic acid (5k) and
oxalyl chloride in a form of a crude product, yield ca. 98%.
Example 47
3-[3-(Biphenyl-4-ylsulfamoyl)-phenyl]-N-hydroxy-acrylamide (7k)
(PX117715)
[1078] 228
[1079] Using an analogous method, the title compound was obtained
from 3-[3-(biphenyl-4-ylsulfamoyl)-phenyl]-acryloyl chloride (6k)
and hydroxylamine hydrochloride, yield 78%. M.p. 188.degree. C.
.sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 6.49 (1H, d, J=16.0
Hz); 7.07-8.07 (14H, m); 9.09 (1H, br s); 10.35 (1H, br s); 10.80
(1H, br s). HPLC analysis on Symmetry C.sub.8 column: impurities
2.2% (column size 3.9.times.150 mm; mobile phase acetonitrile-0.1M
phosphate buffer, pH 2.5, 40:60; sample concentration 0.5 mg/ml;
flow rate 1.5 ml/min; detector UV 254 nm). Anal. Calcd for
C.sub.21H.sub.18N.sub.2O.sub.4S*0.2H.sub.2O, %: C, 63.37; H, 4.66;
N, 7.04. Found, %: C, 63.42, 4.57, N, 6.95.
Example 48
3-[3-(3-Bromo-phenylsulfamoyl)-phenyl]-acrylic Acid Methyl Ester
(41)
[1080] Using an analogous method, the title compound was obtained
from 3-(3-chlorosulfonylphenyl)-acrylic acid methyl ester (3) and
3-bromoaniline as a white solid, yield 79%, .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 3.73 (3H, s); 6.65 (1H, d, J=16.0
Hz); 6.98-7.34 (4H, m); 7.49-8.07 (5H, m); 10.52 ppm (1H, br
s).
Example 49
3-[3-(3-Bromo-phenylsulfamoyl)-phenyl]-acrylic Acid (51)
[1081] Using an analogous method, the title compound was obtained
from 3-[3-(3-bromo-phenylsulfamoyl)phenyl]-acrylic acid methyl
ester (41) and sodium hydroxide, yield 85%.
Example 50
3-[3-(3-Bromo-phenylsulfamoyl)-phenyl]-acryloyl Chloride (61)
[1082] Using an analogous method, the title compound was obtained
from 3-[3-(3-bromo-phenylsulfamoyl)-phenyl]-acrylic acid (51) and
oxalyl chloride in a form of a crude product, yield ca. 98%.
Example 51
3-[3-(3-Bromo-phenylsulfamoyl)-phenyl]-N-hydroxy-acrylamide (71)
(PX117734)
[1083] 229
[1084] Using an analogous method, the title compound was obtained
from 3-[3-(3-bromo-phenylsulfamoyl)-phenyl]-acryloyl chloride (6l)
and hydroxylamine hydrochloride, yield 24%. M.p.
135.5-136.5.degree. C. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.:
6.53 (1H, d, J=15.6 Hz); 7.07-7.28 (4H, m); 7.48 (1H, d, J=15.6
Hz); 7.60 (1H, t, J=7.6 Hz); 7.72 (1H, d, J=7.6 Hz); 7.81 (1H, d,
J=7.6 Hz); 7.94 (1H, s); 9.15 (1H, br s); 10.60 (1H, br s); 10.84
(1H, br s). HPLC analysis on Symmetry C.sub.8 column: impurities
2.5% (column size 3.9.times.150 mm; mobile phase acetonitrile-0.1M
phosphate buffer, pH 2.5, 50:50; sample concentration 0.5 mg/ml;
flow rate 0.8 ml/min; detector UV 220 nm). Anal. Calcd for
C.sub.15H.sub.13BrN.sub.2O.sub.4S, %: C, 45.35; H, 3.30; N, 7.05.
Found, C, 45.38, H, 3.03, N, 6.96.
Example 52
3-[3-(Indan-2-ylsulfamoyl)-phenyl]-acrylic Acid Methyl Ester
(4m)
[1085] Using an analogous method, the title compound was obtained
from 3-(3-chlorosulfonylphenyl)-acrylic acid methyl ester (3) and
2-aminoindane hydrochloride as a white solid, yield 80%, .sup.1H
NMR (DMSO-d.sub.6, HMDSO), .delta.: 2.65-2.93 (4H, m); 3.71 (3H,
s); 3.93 (1H, m); 6.71 (1H, d, J=116.0 Hz); 7.09 (4H, s); 7.49-8.27
ppm (6H, m).
Example 53
3-[3-(Indan-2-ylsulfamoyl)-phenyl]-acrylic Acid (5m)
[1086] Using an analogous method, the title compound was obtained
from 3-[3-(indan-2-ylsulfamoyl)-phenyl]-acrylic acid methyl ester
(4m) and sodium hydroxide, yield 86%.
Example 54
3-[3-(Indan-2-ylsulfamoyl)-phenyl]-acryloyl chloride (6m)
[1087] Using an analogous method, the title compound was obtained
from 3-[3-(indan-2-ylsulfamoyl)-phenyl]-acrylic acid (5m) and
oxalyl chloride in a form of a crude product, yield ca. 98%.
Example 55
N-Hydroxy-3-[3-(indan-2-ylsulfamoyl)-phenyl]-acrylamide (7m)
(PX117735)
[1088] 230
[1089] Using an analogous method, the title compound was obtained
from 3-[3-(indan-2-ylsulfamoyl)-phenyl]-acryloyl chloride (6m) and
hydroxylamine hydrochloride, yield 63%. M.p. 164.degree. C. (from
acetonitrile). .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 2.72
(2H, dd, J=15.8 and 7.0 Hz); 2.94 (2H, dd, J=15.8 and 7.4 Hz);
3.83-4.03 (1H, m); 6.59 (1H, d, J=15.9 Hz); 7.04-7.19 (4H, m); 7.55
(1H, d, J=15.9 Hz); 7.66 (1H, t, J=Hz); 7.84 (1H, d, J=7.2 Hz);
7.84 (1H, d, J=8.2 Hz); 8.02 (1H, s); 8.11 (1H, br d, J=6.6 Hz);
9.15 (1H, br s); 10.84 (1H, br s). HPLC analysis on Symmetry
C.sub.8 column: impurities 1% (column size 3.9.times.150 mm; mobile
phase acetonitrile-0.1M phosphate buffer, pH 2.5, 45:55; sample
concentration 0.5 mg/ml; flow rate 1.0 ml/min; detector UV 254 nm).
Anal. Calcd for C.sub.11H.sub.18N.sub.2O.sub.4S*0.25- H.sub.2O, %:
C, 59.57, H, 5.14, N, 7.72. Found C, 59.51; H, 5.01; N, 7.54.
Example 56
3-[3-(Benzhydryl-sulfamoyl)-phenyl]-acrylic Acid Methyl Ester
(4n)
[1090] Using an analogous method, the title compound was obtained
from 3-(3-chlorosulfonylphenyl)-acrylic acid methyl ester (3) and
aminodiphenylmethane as a white solid, yield 73%, .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 3.72 (3H, s); 5.60 (1H, d, J=9.0
Hz); 6.52 (1H, d, J=16.0 Hz); 7.00-7.83 (15H, m); 8.76 ppm (1H, d,
J=9.0 Hz).
Example 57
3-[3-(Benzhydryl-sulfamoyl)-phenyl]-acrylic Acid (5n)
[1091] Using an analogous method, the title compound was obtained
from 3-[3-(benzhydryl-sulfamoyl)-phenyl]-acrylic acid methyl ester
(4n) and sodium hydroxide, yield 78%. .sup.1H NMR (DMSO-d.sub.6,
HMDSO), .delta.: 5.60 (1H, d, J=9.0 Hz); 6.43 (1H, d, J=16.0 Hz);
6.94-7.83 (15H, m); 8.80 ppm (1H, d, J=9.0 Hz).
Example 58
3-[3-(Benzhydryl-sulfamoyl)-phenyl]-acryloyl Chloride (6n)
[1092] Using an analogous method, the title compound was obtained
from 3-[3-(benzhydryl-sulfamoyl)-phenyl]-acrylic acid (5n) and
oxalyl chloride in a form of a crude product, yield ca. 98%.
Example 59
3-[3-(Benzhydryl-sulfamoyl)-phenyl]-N-hydroxy-acrylamide (7n)
(PX117773)
[1093] 231
[1094] Using an analogous method, the title compound was obtained
from 3-[3-(benzhydryl-sulfamoyl)-phenyl]-acryloyl chloride (6n) and
hydroxylamine hydrochloride, yield 68%. M.p. 180.degree. C. .sup.1H
NMR (DMSO-d.sub.6, HMDSO), .delta.: 5.60 (1H, d, J=9.0 Hz); 6.43
(1H, d, J=16.0 Hz); 6.98-7.83 (15H, m); 8.85 (1H, d, J=9.0 Hz);
9.14 (1H, br s); 10.80 (1H, br s). HPLC analysis on Symmetry
C.sub.8 column: impurities <1% (column size 3.9.times.150 mm;
mobile phase acetonitrile-0.1M phosphate buffer, pH 2.5, 45:55;
sample concentration 0.5 mg/ml; flow rate 1.4 ml/min; detector UV
220 nm). Anal. Calcd for C.sub.22H.sub.20N.sub.2O.sub.4S, %: C,
64.69; H, 4.94; N, 6.86. Found C, 64.60; H, 4.94; N, 6.77.
Example 60
3-[3-(1,2-Diphenyl-ethylsulfamoyl)-phenyl]-acrylic acid methyl
ester (4o)
[1095] Using an analogous method, the title compound was obtained
from 3-(3-chlorosulfonylphenyl)-acrylic acid methyl ester (3) and
1,2-diphenylamine as a white solid, yield 96%, .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 2.83 (2H, d, J=9.0 Hz); 3.78 (3H,
s); 4.49 (1H, q, J=9.0 Hz); 6.54 (1H, d, J=16.0 Hz); 6.94-7.83
(15H, m); 8.38 ppm (1H, d, J=9.0 Hz).
Example 61
3-[3-(1,2-Diphenyl-ethylsulfamoyl)-phenyl]-acrylic Acid (5o)
[1096] Using an analogous method, the title compound was obtained
from 3-[3-(1,2-diphenyl-ethylsulfamoyl)-phenyl]-acrylic acid methyl
ester (4o) and sodium hydroxide, yield 70%. .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 2.85 (2H, d, J=9.0 Hz); 4.49 (1H,
q, J=9.0 Hz); 6.40 (1H, d, J=16.0 Hz); 6.85-7.78 (15H, m); 8.38 ppm
(1H, d, J=9.0 Hz).
Example 62
3-[3-(1,2-Diphenyl-ethylsulfamoyl)-phenyl]-acryloyl chloride
(6o)
[1097] Using an analogous method, the title compound was obtained
from 3-[3-(1,2-diphenyl-ethylsulfamoyl)-phenyl]-acrylic acid (5o)
and oxalyl chloride in a form of a crude product, yield ca.
98%.
Example 63
3-[3-(1,2-Diphenyl-ethylsulfamoyl)-phenyl]-N-hydroxy-acrylamide
(7o) (PX117774)
[1098] 232
[1099] Using an analogous method, the title compound was obtained
from 3-[3-(1,2-diphenyl-ethylsulfamoyl)-phenyl]-acryloyl chloride
(6o) and hydroxylamine hydrochloride, yield 72%. M.p. 150.degree.
C. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 2.83 (2H, d, J=9.0
Hz); 4.47 (1H, q, J=9.0 Hz); 6.38 (1H, d, J=16.0 Hz); 6.92-7.65
(15H, m); 8.38 (1H, d, J=9.0 Hz); 9.12 (1H, br s); 10.80 (1H, br
s). HPLC analysis on Symmetry C.sub.8 column: impurities 1% (column
size 3.9.times.150 mm; mobile phase acetonitrile-0.1M phosphate
buffer, pH 2.5, 45:55; sample concentration 0.5 mg/ml; flow rate
1.4 ml/min; detector UV 220 nm). Anal. Calcd for
C.sub.23H.sub.22N.sub.2O.sub.4S, %: C, 65.39; H, 5.25; N, 6.63.
Found C, 64.97; H, 5.14; N, 6.57.
Example 64
3-[3-(4-Trifluoromethoxy-phenylsulfamoyl)-phenyl]-acrylic Acid
Methyl Ester (4p)
[1100] Using an analogous method, the title compound was obtained
from 3-(3-chlorosulfonylphenyl)-acrylic acid methyl ester (3) and
4-trifluoromethoxyaniline as a white solid, yield 82%, .sup.1H NMR
(CDCl.sub.3, TMS) .delta.: 3.82 (3H, s); 6.47 (1H, d, J=16.0 Hz);
6.89-7.98 ppm (10H, m).
Example 65
3-[3-(4-Trifluoromethoxy-phenylsulfamoyl)-phenyl]-acrylic Acid
(5p)
[1101] Using an analogous method, the title compound was obtained
from 3-[3-(4-trifluoromethoxy-phenylsulfamoyl)phenyl]-acrylic acid
methyl ester (4p) and sodium hydroxide, yield 94%. .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 6.54 (1H, d, J=16.0 Hz); 7.23 (4H,
s) 7.47-8.14 (6H, m); 10.54 ppm (1H, br s).
Example 66
3-[3-(4-trifluoromethoxy-phenylsulfamoyl)-phenyl]-acryloyl chloride
(6p)
[1102] Using an analogous method, the title compound was obtained
from 3-[3-(4-trifluoromethoxy-phenylsulfamoyl)phenyl]-acrylic acid
(5p) and oxalyl chloride in a form of a crude product, yield ca.
98%.
Example 67
N-Hydroxy-3-[3-(4-trifluoromethoxy-phenylsulfamoyl)-phenyl]-acrylamide
(7p) (PX117775)
[1103] 233
[1104] Using an analogous method, the title compound was obtained
from 3-[3-(4-trifluoromethoxy-phenylsulfamoyl)-phenyl]-acryloyl
chloride (6p) and hydroxylamine hydrochloride, yield 46%. M.p.
131.degree. C. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 6.49
(1H, d, J=16.0 Hz); 7.03-8.05 (9H, m); 8.98 (1H, br s); 10.54 (1-H,
br s); 10.78 (1H, br s). HPLC analysis on Symmetry C.sub.8 column:
impurities 3.5% (column size 3.9.times.150 mm; mobile phase
acetonitrile-0.1M phosphate buffer, pH 2.5, 45:55; sample
concentration 0.5 mg/ml; flow rate 1.4 ml/min; detector UV 220 nm).
Anal. Calcd for C.sub.16H.sub.13F.sub.3N.sub.2O.sub.- 5S, %: C,
47.76; H, 3.26; N, 6.96. Found C, 47.68, H, 3.15, N, 6.91.
Example 68
3-[3-(3,4,5-Trimethoxy-benzylsulfamoyl)phenyl]-acrylic Acid Methyl
Ester (4q)
[1105] Using an analogous method, the title compound was obtained
from 3-(3-chlorosulfonylphenyl)acrylic acid methyl ester (3) and
3,4,5-trimethoxybenzylamine as a white solid, yield 85%, .sup.1H
NMR (CDCl.sub.3, TMS) .delta.: 3.72 (6H, s); 3.78 (3H, s); 3.83
(3H, s); 4.14 (2H, d, J=8.0 Hz); 5.07 (1H, t, J=8.0 Hz); 6.38 (2H,
s); 6.49 (1H, d, J=16.0 Hz); 7.36-8.07 ppm (5H, m).
Example 69
3-[3-(3,4,5-Trimethoxy-benzylsulfamoyl)-phenyl]-acrylic Acid
(5q)
[1106] Using an analogous method, the title compound was obtained
from 3-[3-(3,4,5-trimethoxy-benzylsulfamoyl)-phenyl]-acrylic acid
methyl ester (4q) and sodium hydroxide, yield 90%. .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 3.52 (3H, s); 3.65 (6H, s); 3.98
(2H, d, J=8.0 Hz); 6.43 (2H, s); 6.49 (1H, d; J=16.0 Hz); 7.38-8.27
ppm, (6H, m).
Example 70
3-[3-(3,4,5-Trimethoxy-benzylsulfamoyl)-phenyl]-acryloyl chloride
(6q)
[1107] Using an analogous method, the title compound was obtained
from 3-[3-(3,4,5-trimethoxy-benzylsulfamoyl)-phenyl]-acrylic acid
(5q) and oxalyl chloride in a form of a crude product, yield ca.
100%.
Example 71
N-Hydroxy-3-[3-(3,4,5-trimethoxy-benzylsulfamoyl)-phenyl]-acrylamide
(7q) (PX117778)
[1108] 234
[1109] Using an analogous method, the title compound was obtained
from 3-[3-(3,4,5-trimethoxy-benzylsulfamoyl)-phenyl]-acryloyl
chloride (6q) and hydroxylamine hydrochloride, yield 19%, foam.
.sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 3.54 (3H, s); 3.65 (6H,
s); 3.98 (2H, m); 6.46 (2H, s); 6.56 (1H, d, J=15.0 Hz); 7.32-7.98
(5H, m); 8.18 (1H, br t, J=5.5 Hz); 9.12(1H, br s); 10.78 (1H, br
s). HPLC analysis on Symmetry C.sub.8 column: impurities 7% (column
size 3.9.times.150 mm; mobile phase acetonitrile-0.1M phosphate
buffer, pH 2.5, 30:70; sample concentration 0.5 mg/ml; flow rate
1.4 ml/min; detector UV 220 nm). Anal. Calcd for
C.sub.19H.sub.22N.sub.2O.sub.7S*0.25 EtOAc, containing 1.6% of
inorganic impurities, %: C, 53.18; H, 5.36; N, 6.20. Found C,
53.13; H, 5.31; N, 6.02.
Example 72
3-{3-[2-(3,4-Dimethoxy-phenyl)-ethylsulfamoyl]-phenyl}-acrylic Acid
Methyl Ester (4r)
[1110] Using an analogous method, the title compound was obtained
from 3-(3-chlorosulfonylphenyl)-acrylic acid methyl ester (3) and
2-(3,4-dimethoxyphenyl)ethylamine as a white solid, yield 81%,
.sup.1H NMR (CDCl.sub.3, TMS) .delta.: 2.72 (2H, t, J=7.0 Hz); 3.20
(2H, q, J=7.0 Hz); 3.80 (9H, s); 4.49 (1H, t, J=7.0 Hz); 6.36-6.87
(4H, m); 7.38-8.00 ppm (5H, m).
Example 73
3-{3-[2-(3,4-Dimethoxy-phenyl)-ethylsulfamoyl]-phenyl}-acrylic Acid
(5r)
[1111] Using an analogous method, the title compound was obtained
from 3-{3-[2-(3,4-dimethoxy-phenyl)-ethylsulfamoyl]-phenyl}acrylic
acid methyl ester (4r) and sodium hydroxide, yield 87%. .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 2.58 (2H, t, partially overlapped
with a signal of DMSO); 2.83-3.20 (2H, m, partially overlapped with
a water signal of DMSO); 3.72 (6H, s); 6.43-6.89 (4H, m); 7.49-8.09
ppm (6H, m).
Example 74
3-{3-[2-(3,4-Dimethoxy-phenyl)-ethylsulfamoyl]-phenyl}acryloyl
Chloride (6r)
[1112] Using an analogous method, the title compound was obtained
from 3-{3-[2-(3,4-dimethoxy-phenyl)-ethylsulfamoyl]-phenyl}-acrylic
acid (5r) and oxalyl chloride in a form of a crude product, yield
ca. 100%.
Example 75
3-{3-[2-(3,4-Dimethoxy-phenyl)-ethylsulfamoyl]-phenyl}-N-hydroxy-acrylamid-
e (7r) (PX1 17779)
[1113] 235
[1114] Using an analogous method, the title compound was obtained
from
3-{3-[2-(3,4-dimethoxy-phenyl)-ethylsulfamoyl]-phenyl}-acryloyl
chloride (6r) and hydroxylamine hydrochloride, yield 32%, foam.
.sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 2.58 (2H, t, partially
overlapped with a signal of DMSO, J=7.0 Hz); 2.85-3.16 (2H, m);
3.67 (6H, s); 6.38-6.94 (4H, m); 7.38-8.05 (6H, m); 9.16 (1H, brs);
10.76 (1H, br s). HPLC analysis on Symmetry C.sub.8 column:
impurities 3.6% (column size 3.9.times.150 mm; mobile phase
acetonitrile-0.1M phosphate buffer, pH 2.5, 30:70; sample
concentration 0.5 mg/ml; flow rate 1.5 ml/min; detector UV 254 nm).
Anal. Calcd for C.sub.19H.sub.22N.sub.2O.sub.6S containing 4.3% of
inorganic impurities, %: C, 53.73, H, 5.22, N, 6.60. Found C,
53.75; H, 5.24; N, 6.45.
Example 76
3-[3-(3,4-Dimethoxy-phenylsulfamoyl)-phenyl]-acrylic acid methyl
ester (4s)
[1115] Using an analogous method, the title compound was obtained
from 3-(3-chlorosulfonylphenyl)-acrylic acid methyl ester (3) and
3,4-dimethoxyaniline as a white solid, yield 90%, .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 3.60 (3H, s); 3.65 (3H, s); 3.76
(3H, s); 6.45-6.85 (4H, m); 7.47-8.05 (5H, m); 9.92 ppm (1H, br
s).
Example 77
3-[3-(3,4-Dimethoxy-phenylsulfamoyl)-phenyl]-acrylic Acid (5s)
[1116] Using an analogous method, the title compound was obtained
from 3-[3-(3,4-dimethoxy-phenylsulfamoyl)-phenyl]-acrylic acid
methyl ester (4s) and sodium hydroxide, yield 90%. .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 3.60 (3H, s); 3.65 (3H, S);
6.29-6.89 (4H, m); 7.47-8.09 (5H, m); 9.93 ppm (1H, br s).
Example 78
3-[3-(3,4-Dimethoxy-phenylsulfamoyl)-phenyl]-acryloyl Chloride
(6s)
[1117] Using an analogous method, the title compound was obtained
from 3-[3-(3,4-dimethoxy-phenylsulfamoyl)-phenyl]-acrylic acid (5s)
and oxalyl chloride in a form of a crude product, yield ca.
100%.
Example 79
3-[3-(3,4-Dimethoxy-phenylsulfamoyl)-phenyl]-N-hydroxy-acrylamide
(7s) (PX117782)
[1118] 236
[1119] Using an analogous method, the title compound was obtained
from 3-[3-(3,4-dimethoxy-phenylsulfamoyl)-phenyl]-acryloyl chloride
(VI.sub.12) and hydroxylamine hydrochloride, yield 45%. M.p.
191.degree. C. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 3.60
(3H, s); 3.65 (3H, s); 6.34-6.87 (4H, m); 7.32-8.03 (5H, m); 9.09
(1H, br s); 9.92 (1H, br s); 10.80 (1H, br s). HPLC analysis on
Symmetry C.sub.8 column: impurities 6% (column size 3.9.times.150
mm; mobile phase acetonitrile-0.1M phosphate buffer, pH 2.5, 30:70;
sample concentration 0.5 mg/ml; flow rate 1.3 ml/min; detector UV
220 nm). Anal. Calcd for C.sub.17H.sub.18N.sub.2O.sub.6S, %: C,
53.96; H, 4.79; N, 7.40. Found C, 53.84; H, 4.78; N, 7.25.
Example 80
3-[3-(4-Difluoromethoxy-phenylsulfamoyl)-phenyl]-acrylic Acid
Methyl Ester (4t)
[1120] Using an analogous method, the title compound was obtained
from 3-(3-chlorosulfonylphenyl)-acrylic acid methyl ester (3) and
4-difluoromethoxyphenylamine as a white solid, yield 79%.
Example 81
3-[3-(4-Difluoromethoxy-phenylsulfamoyl)-phenyl]-acrylic Acid
(5t)
[1121] Using an analogous method, the title compound was obtained
from 3-[3-(4-difluoromethoxy-phenylsulfamoyl)-phenyl]-acrylic acid
methyl ester (4t) and sodium hydroxide, yield 71%. .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 6.56 (1H, d, J=16.0 Hz); 7.11 (4H,
s); 7.47-8.04 (6H, m).
Example 82
3-[3-(4-Difluoromethoxy-phenylsulfamoyl)-phenyl]-acryloyl Chloride
(6t)
[1122] Using an analogous method, the title compound was obtained
from 3-[3-(4-difluoromethoxy-phenylsulfamoyl)-phenyl]-acrylic acid
(5t) and oxalyl chloride, ca. yield of the crude product 98%
(yellow oil).
Example 83
3-[3-(4-Difluoromethoxy-phenylsulfamoyl)-phenyl]-N-hydroxy-acrylamide
(7t) (PX117789)
[1123] 237
[1124] Using an analogous method, the title compound was obtained
from 3-[3-(4-difluoromethoxy-phenylsulfamoyl)-phenyl]-acryloyl
chloride (6t) and hydroxylamine hydrochloride, yield 65%. M.p.
91-93.degree. C. .sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.: 6.47
(1H, d, J=16.0 Hz); 6.96 (4H, s); 7.31-7.93 (6H, m). HPLC analysis
on Symmetry C.sub.8 column: impurities 3.5% (column size
3.9.times.150 mm; mobile phase acetonitrile--0.1M phosphate buffer
(pH 2.5), 40:60; detector UV 220 nm; flow rate 1.4 ml/min; sample
concentration 0.5 mg/ml). Anal. Calcd for
C.sub.16H.sub.14N.sub.2O.sub.5F.sub.2S*0.2H.sub.2O*0.5 EtOH, %: C,
49.68; H, 4.27; N, 6.82, S, 7.80. Found, %: C, 49.46; H, 3.95; N,
6.65, S, 7.39.
Example 84
3-[3-(9-Ethyl-9H-carbazol-3-ylsulfamoyl)-phenyl]-acrylic Acid
Methyl Ester (4u)
[1125] Using an analogous method, the title compound was obtained
from 3-(3-chlorosulfonylphenyl)-acrylic acid methyl ester (3) and
9-ethyl-9H-carbazol-3-ylamine in a form of yellow solid, yield 86%.
.sup.1H NMR (CDCl.sub.3, HMDSO), .delta.: 1.38 (3H, t, J=7.0 Hz);
3.78 (3H, s); 4.33 (2H, q, J=7.0 Hz); 6.33 (1H, d, J=16.0 Hz); 6.58
(1H, s); 7.02-8.04 (12H, m).
Example 85
3-[3-(9-Ethyl-9H-carbazol-3-ylsulfamoyl)-phenyl]-acrylic Acid
(5u)
[1126] Using an analogous method, the title compound was obtained
from 3-[3-(9-ethyl-9H-carbazol-3-ylsulfamoyl)-phenyl]-acrylic acid
methyl ester (4u) and sodium hydroxide, yield 65%.
Example 86
3-[3-(9-Ethyl-9H-carbazol-3-ylsulfamoyl)-phenyl]-acryloyl Chloride
(6u)
[1127] Using an analogous method, the title compound was obtained
from 3-[3-(9-ethyl-9H-carbazol-3-ylsulfamoyl)phenyl]-acrylic acid
(5u) and oxalyl chloride, ca. yield of the crude product 98%
(yellow oil).
Example 87
3-[3-(9-Ethyl-9H-carbazol-3-ylsulfamoyl)-phenyl]-N-hydroxy-acrylamide
(7u) (PX117798)
[1128] 238
[1129] Using an analogous method, the title compound was obtained
from 3-[3-(9-ethyl-9H-carbazol-3-ylsulfamoyl)-phenyl]-acryloyl
chloride (6u) and hydroxylamine hydrochloride, yield 42%. M.p.
130-133.degree. C. .sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.: 1.20
(3H, t, J=6.6 Hz); 4.34 (2H, q, J=6.6 Hz); 6.42 (1H, d, J=16 Hz);
6.93-8.07 (13H, m); 9.07 (1H, br. s); 10.3 (1H, br. s). HPLC
analysis on Symmetry C.sub.8 column: impurities 10% (column size
3.9.times.150 mm; mobile phase acetonitrile --0.1M phosphate buffer
(pH 2.5), 40:60; detector UV 254 nm; flow rate 1.0 ml/min; sample
concentration 1 mg/ml). Anal. Calcd for
C.sub.23H.sub.21N.sub.3O.sub.4S*1H.sub.2O, %: C, 60.91; H, 5.11; N,
9.27, S, 7.07. Found, %: C, 61.01; H, 5.15; N, 8.75, S, 6.65.
Example 88
3-[3-(2,6-Difluoro-phenylsulfamoyl)-phenyl]-acrylic Acid Methyl
Ester (4v)
[1130] Using an analogous method, the title compound was obtained
from 3-(3-chlorosulfonylphenyl)acrylic acid methyl ester (3) and
2,4-difluorophenylamine in a form of yellow crystals, yield 70%.
.sup.1H NMR (CDCl.sub.3, HMDSO), .delta.: 3.82 (3H, s); 6.49 (1H,
d, J=16.0 Hz); 7.00 (1H, t, J=8 Hz); 5.89-6.69 (7H, m).
Example 89
3-[3-(2,4-Difluoro-phenylsulfamoyl)-phenyl]-acrylic acid (5v)
[1131] Using an analogous method, the title compound was obtained
from 3-[3-(2,4-difluoro-phenylsulfamoyl)-phenyl]-acrylic acid
methyl ester (4v) and sodium hydroxide in a form of white solid,
yield 66%. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 6.56 (1H, d,
J=16.0 Hz); 6.96-8.09 (9H, m); 10.13 (1H, br. s).
Example 90
3-[3-(2,4-Difluoro-phenylsulfamoyl)-phenyl]-acryloyl Chloride
(6v)
[1132] Using an analogous method, the title compound was obtained
from 3-[3-(2,4-difluoro-phenylsulfamoyl)-phenyl]-acrylic acid (5v)
and oxalyl chloride, ca. yield of the crude product 98% (yellow
oil).
Example 91
3-[3-(2,4-Difluoro-phenylsulfamoyl)-phenyl]-N-hydroxy-acrylamide
(7v) (PX117790)
[1133] 239
[1134] Using an analogous method, the title compound was obtained
from 3-[3-(2,4-difluoro-phenylsulfamoyl)-phenyl]-acryloyl chloride
(6v) and hydroxylamine hydrochloride, yield 26%. M.p. 79-82.degree.
C. .sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.: 6.47 (1H, d, J=16.0
Hz); 6.89-7.89 (8H, m); 9.07 (1H, br. s); 10.02 (1H, br. s); 10.73
(1H, br s). HPLC analysis on Symmetry C.sub.8 column: impurities
7.5% (column size 3.9.times.150 mm; mobile phase acetonitrile-0.1M
phosphate buffer (pH 2.5), 35:65; detector UV 220 nm; flow rate 1.4
ml/min; sample concentration 0.5 mg/ml). Anal. Calcd for
C.sub.15H.sub.12N.sub.2O.sub.4F.sub.2S.1 EtOH, %: C, 51.00; H,
4.53; N, 7.00, S, 8.01. Found, %: C, 50.84; H, 4.60; N, 6.78, S,
7.76.
Example 92
3-[3-(2-Fluoro-phenylsulfamoyl)-phenyl]-acrylic Acid Methyl Ester
(4w)
[1135] Using an analogous method, the title compound was obtained
from 3-(3-chlorosulfonyl-phenyl)acrylic acid methyl ester (3) and
2-fluorophenylamine in a form of white crystals, yield 65%. .sup.1H
NMR (CDCl.sub.3, HMDSO), .delta.: 3.80 (3H, s); 6.44 (1H, d, J=16.0
Hz); 6.71-7.22 (4H, m); 7.44-7.93 (6H, m).
Example 93
3-[3-(2-Fluoro-phenylsulfamoyl)-phenyl]-acrylic Acid (5w)
[1136] Using an analogous method, the title compound was obtained
from 3-[3-(2-fluoro-phenylsulfamoyl)-phenyl]-acrylic acid methyl
ester (4w) and sodium hydroxide, yield 50%. .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 6.58 (1H, d, J=16.0 Hz); 7.04-7.36
(4H, m); 7.51-8.09 (5H, m).
Example 94
3-[3-(2-Fluoro-phenylsulfamoyl)-phenyl]-acryloyl chloride (6w)
[1137] Using an analogous method, the title compound was obtained
from 3-[3-(2-fluoro-phenylsulfamoyl)-phenyl]-acrylic acid (5w) and
oxalyl chloride, ca. yield of the crude product 98% (yellow
oil).
Example 95
3-[3-(2-Fluoro-phenylsulfamoyl)-phenyl]-N-hydroxy-acrylamide (7w)
(PX117787)
[1138] 240
[1139] Using an analogous method, the title compound was obtained
from 3-[3-(2-fluoro-phenylsulfamoyl)-phenyl]-acryloyl chloride (6w)
and hydroxylamine hydrochloride, yield 30%. M.p. 102-103.degree. C.
.sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 6.44 (1H, d, J=16.0
Hz); 6.96-7.24 (4H, m); 7.43 (1H, d, J=16.0 Hz); 7.49-7.91 (4H, m);
9.04 (1H, br s); 10.13 (1H, br s); 10.73 (1H, br s). HPLC analysis
on Symmetry C.sub.8 column: impurities 4.5% (column size
3.9.times.150 mm; mobile phase acetonitrile-0.1M phosphate buffer
(pH 2.5), 35:65; detector UV 220 nm; flow rate 1.4 ml/min; sample
concentration 0.5 mg/ml). Anal. Calcd for
C.sub.15H.sub.13N.sub.2O.sub.4FS*0.9 EtOH, %: C, 53.41, H, 4.91, N,
7.41. Found, %: C, 53.79; H, 4.62; N, 7.13.
Example 96
3-[3-(3-Fluoro-phenylsulfamoyl)phenyl]-acrylic Acid Methyl Ester
(4.times.)
[1140] Using an analogous method, the title compound was obtained
from 3-(3-chlorosulfonyl-phenyl)acrylic acid methyl ester (3) and
3-fluorophenylamine in a form of white crystals, yield 80%. .sup.1H
NMR (CDCl.sub.3, HMDSO), .delta.: 3.78 (3H, s); 6.42 (1H, d, J=16.0
Hz); 6.64-8.02 (10H m).
Example 97
3-[3-(3-Fluoro-phenylsulfamoyl)-phenyl]-acrylic acid (5x)
[1141] Using an analogous method, the title compound was obtained
from 3-[3-(3-fluoro-phenylsulfamoyl)-phenyl]-acrylic acid methyl
ester (4x) and sodium hydroxide, yield 60%. .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 6.56 (1H, d, J=16.0 Hz); 6.80-7.36
(4H, m); 7.49-8.09 (6H, m).
Example 98
3-[3-(3-Fluoro-phenylsulfamoyl)-phenyl]-acryloyl Chloride (6x)
[1142] Using an analogous method, the title compound was obtained
from 3-[3-(3-fluoro-phenylsulfamoyl)-phenyl]-acrylic acid (5x) and
oxalyl dichloride, ca. yield of the crude product 99% (yellow
oil).
Example 99
3-[3-(3-Fluoro-phenylsulfamoyl)-phenyl]-N-hydroxy-acrylamide (7x)
(PX117788)
[1143] 241
[1144] Using an analogous method, the title compound was obtained
from 3-[3-(3-fluoro-phenylsulfamoyl-phenyl]-acryloyl chloride (6x)
and hydroxylamine hydrochloride, yield 65%. M.p. 130-133.degree. C.
.sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.: 6.52 (1H, d, J=15.8 Hz);
6.75-6.97 (4H, m); 7.17-7.32 (1H, m); 7.47 (1H, d, J=15.8 Hz); 7.58
(1H, t, J=7.8 Hz); 7.67-7.85 (2H, m); 7.94 (1H, s); 9.19 (1H, br
s); 10.89 (1H, br s analysis on Symmetry C.sub.8 column: impurities
5.5% (column size 3.9.times.150 mm; mobile phase acetonitrile--0.1M
phosphate buffer (pH 2.5), 40:60; detector UV 254 nm; flow rate 1.5
ml/min; sample concentration 0.5 mg/ml). Anal. Calcd for
C.sub.15H.sub.13N.sub.2O.sub.4F- S*0.65 EtOH, %: C, 53.45; H, 4.65;
N, 7.65, S, 8.75. Found, %: C, 53.54, H, 4.32, N, 7.37, S,
8.50.
Example 100
3-[3-(2-Methoxy-5-trifluoromethyl-phenylsulfamoyl)-phenyl]-acrylic
Acid Methyl Ester (4y)
[1145] Using an analogous method, the title compound was obtained
from 3-(3-chlorosulfonylphenyl)-acrylic acid methyl ester (3) and
2-methoxy-5-(trifluoromethyl)aniline as a white solid, yield 55%.
.sup.1H NMR (CDCl.sub.3, HMDSO), .delta.: 3.68 (3H, s), 3.80 (3H,
s); 6.39 (1H, d, J=16.0 Hz); 6.77 (1H, d, J=8.4 Hz); 7.11 (1H, s);
7.20-7.95 ppm (7H, m).
Example 101
3-[3-(2-Methoxy-5-trifluoromethyl-phenylsulfamoyl)-phenyl]-acrylic
Acid (5y)
[1146] Using an analogous method, the title compound was obtained
from
3-[3-(2-methoxy-5-trifluoromethyl-phenylsulfamoyl)-phenyl]-acrylic
acid methyl ester (4y) and sodium hydroxide, yield 80%. .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 3.60 (3H, s); 6.54 (1H, d, J=16.0
Hz); 7.07 (1H, d, J=8.4 Hz); 7.45-7.97 (8H, m); 9.70 ppm (1H,
brs).
Example 102
3-[3-(2-Methoxy-5-trifluoromethyl-phenylsulfamoyl)-phenyl]-acryloyl
Chloride (6y)
[1147] Using an analogous method, the title compound was obtained
from
3-[3-(2-methoxy-5-trifluoromethyl-phenylsulfamoyl)-phenyl]-acrylic
acid (5y) and oxalyl chloride, ca. yield of the crude product 98%
(yellow oil).
Example 103
N-Hydroxy-3-[3-(2-methoxy-5-trifluoromethyl-phenylsulfamoyl)-phenyl]-acryl-
amide (7y) (PX117791)
[1148] 242
[1149] Using an analogous method, the title compound was obtained
from
3-[3-(2-methoxy-5-trifluoromethyl-phenylsulfamoyl)-phenyl]-acryloyl
chloride (6y) and hydroxylamine hydrochloride, yield 64%. M.p.
207.degree. C. (dec.). .sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.:
3.57 (3H, s); 6.52 (1H, d, J=15.8 Hz); 7.12 (1H, d, J=8.4 Hz);
7.36-8.09 (7H, m); 9.11 (1H, br s); 9.98 (1H, s); 10.82 (1H, s).
HPLC analysis on Symmetry C.sub.8 column: impurities 1.8% (column
size 3.9.times.150 mm; mobile phase acetonitrile--0.1M phosphate
buffer (pH 2.5), 50:50; detector UV 254 nm; flow rate 0.9 ml/min;
sample concentration 0.5 mg/ml). Anal. Calcd for
C.sub.17H.sub.15F.sub.3N.sub.2O.sub.5S, %: C, 49.04; H, 3.63; N,
6.78. Found, %: C, 49.39; H, 3.41; N, 6.66.
Example 104
3-{3-[(Furan-2-ylmethyl)-sulfamoyl]-phenyl}-acrylic Acid Methyl
Ester (4z)
[1150] Using an analogous method, the title compound was obtained
from 3-(3-chlorosulfonylphenyl)-acrylic acid methyl ester (3) and
furfurilamine as a white solid, yield 87%. .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 3.73 (3H, s); 4.05 (2H, d, J=6.4
Hz); 6.20 (2H, m); 6.71 (1H, d, J=16.0 Hz); 7.38-8.38 (7H, m).
Example 105
3-(3-[(Furan-2-ylmethyl)-sulfamoyl]-phenyl)acrylic Acid (5z)
[1151] Using an analogous method, the title compound was obtained
from 3-{3-[(furan-2-ylmethyl)-sulfamoyl]-phenyl}-acrylic acid
methyl ester (4z) and sodium hydroxide, yield 89%.
Example 106
3-{3-[(Furan-2-ylmethyl)-sulfamoyl]-phenyl}-N-hydroxyacrylamide
(7z) (PX1177100)
[1152] 243
[1153] To a solution of
3-{3-[(furan-2-ylmethyl)-sulfamoyl]-phenyl}-acryli- c acid (5z)
(0.17 g, 0.55 mmol) in tetrahydrofuran (2.0 ml) at 0.degree. C.
temperature ethylchloroformate (0.072 g, 0.66 mmol) and
triethylamine (0.1 ml, 0.72 mmol) were added and the resulting
mixture was stirred for 15 min. To a stirred solution of KOH (0.058
g, 1.04 mmol) in methanol (0.25 ml) a solution of hydroxylamine
hydrohloride (0.072 g, 1.04 mmol) in methanol (0.7 ml) was added at
0.degree. C. The mixture was stirred for 15 min., the precipitated
KCl was removed and the filtrate was added to the first solution.
The reaction mixture was stirred at room temperature for 2 hours.
Then the mixture was partitioned between 1N KH.sub.2PO.sub.4
solution and ethyl acetate. The organic layer was washed with
water, saturated NaCl, and dried (Na.sub.2SO.sub.4). The solvent
was evaporated and the residue was washed successively with
dichloromathane and ethyl acetate affording the title compound
(0.057 g, 32%). M.p. 165.degree. C. .sup.1H NMR (DMSO-d.sub.6,
HMDSO) .delta.: 4.03 (2H, d, J=6.4 Hz); 6.23 (2H, m); 6.54 (1H, d,
J=16.0 Hz); 7.38-8.05 (6H, m); 8.20 (1H, t, J=6.4 Hz); 9.09 (1H, br
s); 10.83 (1H, br s). HPLC analysis on Zorbax SB-C.sub.18 column:
impurities 8% (column size 4.6.times.150 mm; mobile phase
methanol-0.1% H.sub.3PO.sub.4, gradient from 30 to 90%; detector UV
270 nm; flow rate 1.5 ml/min; sample concentration 1.0 mg/ml).
Anal. Calcd for C.sub.14H.sub.14N.sub.2O.sub.5S, %: C, 52.17; H,
4.38; N, 8.69. Found, %: C, 51.87, H, 4.39, N, 8.41.
Example 107
3-(4-(((Phenylmethyl)sulfonyl)amino)phenyl)acrylic acid ethyl ester
(9)
[1154] 244
[1155] .alpha.-Toluenesulfonyl chloride (1.0 g, 5.2 mmol) was added
to a mixture of 4-aminocinnamic acid ethyl ester (1.0 g, 5.2 mmol),
pyridine (0.42 ml, 5.2 mmol) and dichloromethane (10 ml) and the
resultant solution was stirred at ambient temperature for twelve
hours. The solution was then heated at reflux for a further eight
hours.
[1156] The mixture was allowed to cool to ambient temperature and
was diluted with dichloromethane (100 ml) and was washed with 10%
aqueous citric acid (20 ml), saturated aqueous sodium hydrogen
carbonate (20 ml), and water (2.times.20 ml). The organic extract
was dried (MgSO.sub.4), filtered and the solvent was removed under
reduced pressure.
[1157] The crude product was purified by column chromatography on
silica gel using a gradient of ethyl acetate B hexane (1:10) to
ethyl acetate as the eluent to afford the title compound as a
yellow solid (0.80 g, 45%), t.sub.R 5.18 (254 nm, 3.0 mlmin.sup.-1,
5% ACN/95% H.sub.2O+0.2% TFA to 95% ACN/5% H.sub.2O+0.2% TFA over
3.5 min then 2.5 min at 95% ACN/5% H.sub.2O+0.2% TFA), m/z [ES] 368
[M--Na].sup.+.
Example 108
3-(4-(((Phenylmethyl)sulfonyl)amino)phenyl)acrylic Acid (10)
[1158] 245
[1159] A 1 M aqueous solution of lithium hydroxide (2.9 ml, 2.9
mmol) was added to a solution of
3-(4-(((phenylmethyl)sulfonyl)amino)phenyl)acrylic acid ethyl ester
(9) (500 mg, 1.45 mmol) in dioxane (4 ml). The resultant solution
was stirred at ambient temperature for two hours. Additional 1 M
aqueous lithium hydroxide (2.9 ml, 2.9 mmol) was added and the
reaction mixture was stirred at ambient temperature for one hour.
The solution was stored at +4.degree. C. for sixteen hours.
[1160] The solvent was removed under reduced pressure and ethyl
acetate (15 ml) was added to the residue. The resultant mixture was
washed with water (2.times.10 ml).
[1161] The aqueous extracts were combined and acidified to
.about.pH 4 with a 1 M aqueous solution of hydrochloric acid. The
acidified solution was extracted with ethyl acetate (4.times.10
ml). The combined organic extracts were washed with water (10 ml),
dried (MgSO.sub.4) and the solvent was removed under reduced
pressure.
[1162] The crude product was purified by column chromatography on
silica gel using of ethyl acetate as the eluent to afford to afford
the title compound as a yellow solid (320 mg, 70%), t.sub.R 4.56
(254 nm, 3.0 mlmin.sup.-1, 5% ACN/95% H.sub.2O+0.2% TFA to 95%
ACN/5% H.sub.2O+0.2% TFA over 3.5 min then 2.5 min at 95% ACN/5%
H.sub.2O+0.2% TFA), m/z [ES] 316 [M+TFA].sup.- and 430
[M+TFA].sup.-.
Example 109
3-(4-(((Phenylmethyl)sulfonyl)amino)phenyl)acrylic Acid
Hydroxyamide (11) (PX089343)
[1163] 246
[1164] N-Fmoc-hydroxylamine 2-chlorotrityl resin (0.80 g, 0.57
mmol) (Calbiochem-Novabiochem Corp., Nottingham, UK) was swollen
with a solution of piperidine in dichloromethane (20/80, v/v) (5
ml) and then agitated at ambient temperature for two hours. The
resin was filtered and was washed with 1-methylpyrrolidinone (5
ml), alternately with methanol (4.times.5 ml) and dichloromethane
(4.times.5 ml) and finally with diethyl ether (5 ml).
[1165] The resin was placed in a reaction vessel and was swollen
with dichloromethane (2 ml). The swollen resin was treated with
3-(4-(((Phenylmethyl)sulfonyl) amino)phenyl)acrylic acid (10) (90
mg, 0.28 mmol), 1-hydroxy-7-azabenzotriazole (HOAt) (Aldrich,
Dorset, UK) (77 mg, 0.57 mmol),
O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (HATU) (216 mg, 0.57 mmol) (Aldrich, Dorset,
UK), N,N-diisopropylethylamine (198 pH, 1.14 mmol) and a mixture of
dichloromethane and N,N-dimethylformamide (4:1, v/v) (5 ml). The
resultant mixture was agitated at ambient temperature for sixteen
hours.
[1166] The resin was filtered and was washed with
1-methylpyrrolidinone (5 ml), alternately with methanol (4.times.5
ml) and dichloromethane (4.times.5 ml) and finally with diethyl
ether (5 ml). The resin was placed in a reaction vessel and was
swollen with dichloromethane (2 ml). The swollen resin was treated
with a solution of trifluoroacetic acid in dichloromethane (5/95,
v/v) (3 ml) and the resultant mixture was agitated at ambient
temperature for ninety minutes. The mixture was filtered and the
resin was washed with methanol (2.times.5 ml). The solvent was
removed from the combined filtrates under reduced pressure.
[1167] The crude product obtained was purified by preparative hplc
using a 150.times.21.2 mm 5 .mu.m Hypersil7 Elite C.sub.18 column
eluting with a gradient of 5% ACN/95% H.sub.2O+0.2% TFA to 95%
ACN/5% H.sub.2O+0.2% TFA over 10 minutes. The flow rate was 25
mlmin.sup.-1 and the detector was set at 254 nm. The fractions that
contained the desired product were concentrated under reduced
pressure and the resultant residue was lyophilised from a mixture
of dioxane and water. The title compound was obtained as a white
solid (1.2 mg, 14%), t.sub.R 4.11 (254 nm, 3.0 mlmin.sup.-1, 5%
ACN/95% H.sub.2O+0.2% TFA to 95% ACN/5% H.sub.2O+0.2% TFA over 3.5
min then 2.5 min at 95% ACN/5% H.sub.2O+0.2% TFA), m/z [ES] 317
[M-H].sup.- and 311 [M+H].sup.-.
Example 110
3-{3-[(Naphthalen-1-ylmethyl)-sulfamoyl]-phenyl}-acrylic Acid
Methyl Ester (14a)
[1168] 247
[1169] A solution of 3-(3-chlorosulfonylphenyl)acrylic acid methyl
ester (3) (0.4 g, 1.53 mmol) in dioxane (5 ml) was added to a
mixture of 1-naphthalenemethylamine (0.24 g, 1.53 mmol) in dioxane
(1 ml) and NaHCO.sub.3 (0.25 g, 3.06 mmol) In water (3 ml), and the
resultant solution was stirred at room temperature until the
completion of the reaction (control by TLC). The reaction mixture
was evaporated and the residue was partitioned between ethyl
acetate and 2N HCl. The organic layer was washed successively with
water, saturated NaCl, and dried (Na.sub.2SO.sub.4). The solvent
was removed and the residue was chromatographed on silica gel with
petroleum ether-ethyl acetate (2:1, v/v) as eluent. The obtained
product was washed with diethyl ether to give the title compound
(0.44 g, 76%) as a white solid. .sup.1H NMR (DMSO-d.sub.6, HMDSO),
.delta.: 3.74 (3H, s); 4.47 (2H, d, J=6.0 Hz); 6.69 (1H, d, J=16.0
Hz); 7.32-8.32 (13H, m).
Example 111
3-{3-[(Naphthalen-1-ylmethyl)-sulfamoyl]-phenyl}-acrylic Acid
(15a)
[1170] 248
[1171] To a suspension of
3-{3-[(naphthalen-1-ylmethyl)-sulfamoyl]-phenyl}- -acrylic acid
methyl ester (14a) (0.44 g, 1.15 mmol) in methanol (5 ml) 1N NaOH
solution (3.45 ml, 3.45 mmol) was added and the resultant mixture
was stirred at ambient temperature overnight. The reaction mixture
was partitioned between ethyl acetate and water. The aqueous layer
was acidified with 2N HCl solution and stirred for 30 min. The
precipitated solid was filtered, washed with water and dried in
desiccator over P.sub.2O.sub.5. The title compound was obtained as
a white solid (0.32 g, 76%).
Example 112
3-{3-[(Naphthalen-1-ylmethyl)-sulfamoyl]-phenyl}-acryloyl Chloride
(16a)
[1172] 249
[1173] To a suspension of
3-{3-[(naphthalen-1-ylmethyl)-sulfamoyl]-phenyl}- -acrylic acid
(15a) (0.32 g, 0.87 mmol) in dichloromethane (4 ml) oxalyl chloride
(0.22 ml, 2.61 mmol) and one drop of dimethylformamide were added.
The reaction mixture was stirred at 40.degree. C. for one hour and
concentrated under reduced pressure to give the title compound
(0.33 g, 98%).
Example 113
N-Hydroxy-3-{3-[(naphthalen-1-ylmethyl)-sulfamoyl]-phenyl}-acrylamide
(17a) (PX117225)
[1174] 250
[1175] To a suspension of hydroxylamine hydrochloride (0.30 g, 4.35
mmol) in tetrahydrofuran (6 ml) a saturated NaHCO.sub.3 solution (4
ml) was added and the resultant mixture was stirred at ambient
temperature for 10 min. To the reaction mixture a solution of crude
3-{3-[(naphthalen-1-ylme- thyl)-sulfamoyl]-phenyl}-acryloyl
chloride (16a) (0.33 g) in tetrahydrofuran (4 ml) was added and the
mixture was stirred at ambient temperature for one hour. The
reaction mixture was partitoned between ethyl acetate and 2N HCl.
The organic layer was washed successively with water and saturated
NaCl, then the solvent was removed. The residue was crystallised
from ethyl acetate-acetonitrile affording the title compound (0.13
g, 40%) as a lightly pink crystals. M.p. 177.degree. C. .sup.1H NMR
(DMSO-d.sub.6, HMDSO) .delta.: 4.45 (2H, d, J=6.0 Hz); 6.58 (1H, d,
J=16.0 Hz); 7.29-8.38 (13H, m); 9.12 (1H, br s); 10.83 (1H, br s).
HPLC analysis on Symmetry C.sub.8 column: impurities 1.5% (column
size 3.9.times.150 mm; mobile phase acetonitrile--0.1M phosphate
buffer (pH 2.5), 40:60; sample concentration 0.25 mg/ml; flow rate
1.2 ml/min; detector UV 220 nm). Anal. Calcd for
C.sub.20H.sub.18N.sub.2O.sub.4S, %: C, 62.54; H, 4.70; N, 7.21.
Found, %: C, 62.81; H, 4.74; N, 7.32.
Example 114
3-{3-[(Pyridin-3-ylmethyl)-sulfamoyl]-phenyl}-acrylic Acid Methyl
Ester (14b)
[1176] 251
[1177] A solution of 3-(3-chlorosulfonylphenyl)acrylic acid methyl
ester (3) (0.40 g, 1.53 mmol) in dioxane (5 ml) was added to a
mixture of 3-(aminomethyl)pyridine (0.16 g, 1.48 mmol) in dioxane
(1 ml) and NaHCO.sub.3 (0.37 g, 4.49 mmol) in water (3 ml), and the
resultant solution was stirred at room temperature until the
completion of the reaction (control by TLC). The reaction mixture
was evaporated and the residue was partitioned between ethyl
acetate and water. The organic layer was washed successively with
water, saturated NaCl, and dried (Na.sub.2SO.sub.4). The solvent
was removed and the residue was chromatographed on silica gel with
dichloromethane-methanol (20:1, v/v) as eluent. The obtained
product was washed with diethyl ether to give the title compound
(0.35 g, 71%) as a white solid. .sup.1H NMR (DMSO-d.sub.6, HMDSO),
.delta.: 3.76 (3H, s); 4.09 (2H, d, J=6.0 Hz); 6.72 (1H, d, J=16.2
Hz); 7.29 (1H, dd, J=8.0 and 5.0 Hz); 7.51-8.12 (6H, m); 8.27 (1H,
br t, J=6.0 Hz); 8.31-8.50 (2H, m).
Example 115
3-{3-[(Pyridin-3-ylmethyl)-sulfamoyl]-phenyl}-acrylic Acid
(15b)
[1178] 252
[1179] To a suspension of
3-{3-[(pyridin-3-ylmethyl)-sulfamoyl]-phenyl}-ac- rylic acid methyl
ester (14b) (0.35 g, 1.05 mmol) in methanol (4.3 ml) 1N NaOH
solution (3.15 ml, 3.15 mmol) was added and the resultant mixture
was stirred at ambient temperature overnight. The reaction mixture
was partitioned between ethyl acetate and water. The aqueous layer
was acidified with 2N HCl solution to pH.about.5 of the reaction
medium and stirred for 30 min. The precipitated solid was filtered,
washed with water and dried in desiccator over P.sub.2O.sub.5. The
title compound was obtained as a white solid (0.28 g, 84%).
Example 116
3-{3-[(Pyridin-3-ylmethyl)-sulfamoyl]-phenyl)acryloyl Chloride
(16b)
[1180] 253
[1181] To a suspension of
3-{3-[(pyridin-3-ylmethyl)-sulfamoyl]-phenyl}-ac- rylic acid (15b)
(0.28 g, 0.88 mmol) in dichloromethane (3.5 ml) oxalyl chloride
(0.23 ml, 2.64 mmol) and one drop of dimethylformamide were added.
The reaction mixture was stirred at 40.degree. C. for one hour and
concentrated under reduced pressure to give crude title compound
(0.29 g, 98%).
Example 117
N-Hydroxy-3-{3-[(pyridin-3-ylmethyl)-sulfamoyl]-phenyl}acrylamide
(17b) (PX117250)
[1182] 254
[1183] To a suspension of hydroxylamine hydrochloride (0.31 g, 4.40
mmol) in tetrahydrofuran (5 ml) a saturated NaHCO.sub.3 solution
(6.8 ml) was added and the resultant mixture was stirred at ambient
temperature for 10 min. To the reaction mixture a solution of crude
3-{3-[(pyridin-3-ylmethy- l)-sulfamoyl]-phenyl}-acryloyl chloride
(16b) (0.29 g, 0.86 mmol) in tetrahydrofuran (5 ml) was added and
the mixture was stirred at ambient temperature for one hour. The
reaction mixture was poured into water, the obtained solution was
acidified with 2N HCl to pH.about.5 of the reaction medium and
extracted with ethyl acetate. The organic layer was washed
successively with water and saturated NaCl, then the solvent was
removed. The residue was washed with hot ethyl acetate and methanol
affording the title compound (0.12 g, 37%). M.p. 191.degree. C.
.sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.: 4.05 (2H, d, J=6.4 Hz);
6.56 (1H, d, J=16.0 Hz); 7.16-8.05 (7H, m); 8.16-8.49 (3H, m); 9.12
(1H, br s); 10.80 (1H, br s). HPLC analysis on Symmetry C.sub.18
column: impurities 8% (column size 3.9.times.150 mm; mobile phase
acetonitrile--0.1M phosphate buffer (pH 2.5), 10:90; sample
concentration 0.4 mg/ml; flow rate 1.3 ml/min; detector UV 270 nm).
Anal. Calcd for C.sub.15H.sub.15N.sub.3O.sub- .4S containing 0.5%
of inorganic impurities, %: C, 53.77; H, 4.51; N, 12.54. Found, %:
C, 53.72, H, 4.33, N, 12.41.
Example 118
3-[3-(2-Methoxy-phenylsulfamoyl)-phenyl]-acrylic Acid Methyl Ester
(14c)
[1184] 255
[1185] A solution of 3-(3-chlorosulfonylphenyl)acrylic acid methyl
ester (3) (0.40 g, 1.53 mmol) in dioxane (5 ml) was added to a
mixture of o-anisidine (0.19 g, 1.54 mmol) in dioxane (1 ml) and
NaHCO.sub.3 (0.26 g, 3.06 mmol) in water (3 ml), and the resultant
solution was stirred at room temperature until the completion of
the reaction (control by TLC). The reaction mixture was evaporated
and the residue was partitioned between ethyl acetate and water.
The organic layer was washed successively with water, saturated
NaCl, and dried (Na.sub.2SO.sub.4). The solvent was removed and the
residue was chromatographed on silica gel with petroleum
ether-ethyl acetate (2:1, v/v) as eluent. The obtained product was
washed with diethyl ether to give the title compound (0.42 g, 79%)
as a white solid. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 3.43
(3H, s); 3.72 (3H, s); 6.60 (1H, d, J=16.0 Hz); 6.72-7.27 (4H, m);
7.45-8.12 (5H, m); 9.47 (1H, s).
Example 119
3-[3-(2-Methoxy-phenylsulfamoyl)-phenyl]-acrylic Acid (15c)
[1186] 256
[1187] To a suspension of
3-[3-(2-methoxy-phenylsulfamoyl)-phenyl]-acrylic acid methyl ester
(14c) (0.42 g, 1.20 mmol) in methanol (5.5 ml) 1N NaOH solution
(3.6 ml, 3.60 mmol) was added and the resultant mixture was stirred
at ambient temperature overnight. The reaction mixture was
partitioned between ethyl acetate and water. The aqueous layer was
acidified with 2N HCl solution and extracted with ethyl acetate.
The extract was washed with saturated NaCl and dried
(Na.sub.2SO.sub.4). The solvent was removed and the residue was
dried in desiccator over P.sub.2O.sub.5 to give the title compound
as a white solid (0.37 g, 92%).
Example 120
3-[3-(2-Methoxy-phenylsulfamoyl)-phenyl]-acryloyl Chloride
(16c)
[1188] 257
[1189] To a suspension of
3-[3-(2-methoxy-phenylsulfamoyl)-phenyl]-acrylic Acid (15c) (0.36
g, 1.04 mmol) in dichloromethane (4 ml) oxalyl chloride (0.27 ml,
3.12 mmol) and one drop of dimethylformamide were added. The
reaction mixture was stirred at 40.degree. C. for one hour and
concentrated under reduced pressure to give crude title compound
(0.37 g, 97%).
Example 121
N-Hydroxy-3-[3-(2-methoxy-phenylsulfamoyl)-phenyl]-acrylamide (17c)
(PX117227)
[1190] 258
[1191] To a suspension of hydroxylamine hydrochloride (0.36 g, 5.20
mmol) in tetrahydrofuran (6 ml) a saturated NaHCO.sub.3 solution
(4.5 ml) was added and the resultant mixture was stirred at ambient
temperature for 10 min. To the reaction mixture a solution of crude
3-[3-(2-methoxy-phenylsu- lfamoyl)-phenyl]-acryloyl chloride (16c)
(0.37 g, 1.05 mmol) in tetrahydrofuran (5 ml) was added and the
mixture was stirred at ambient temperature for one hour. The
reaction mixture was poured into water, the obtained solution was
acidified with 2N HCl and extracted with ethyl acetate. The organic
layer was washed successively with water and saturated NaCl, then
the solvent was removed. The residue was crystallised from ethyl
acetate and washed with diethyl ether affording the title compound
(0.23 g, 64%). M.p. 181.degree. C. .sup.1H NMR (DMSO-d.sub.6,
HMDSO) .delta.: 3.45 (3H, s); 6.49 (1H, d, J=16.0 Hz); 6.76-7.96
(9H, m); 9.09 (1H, br s); 9.54 (1H, s); 10.78 (1H, br s). HPLC
analysis on Symmetry C.sub.8 column: impurities 1.3% (column size
3.9.times.150 mm; mobile phase acetonitrile--0.1M phosphate buffer
(pH 2.5), 35:65; sample concentration 0.15 mg/ml; flow rate 1.2
ml/min; detector UV 230 nm). Anal. Calcd for
C.sub.16H.sub.16n.sub.2O.sub.5S, %: C, 55.16; H, 4.63; N, 8.04.
Found, %: C, 55.14, H, 4.52, N, 7.99.
Example 122
3-[3-(Naphthalen-1-ylsulfamoyl)-phenyl]-acrylic Acid Methyl Ester
(14d)
[1192] 259
[1193] A solution of 3-(3-chlorosulfonylphenyl)acrylic acid methyl
ester (3) (0.4 g, 1.53 mmol) in dioxane (5 ml) was added to a
mixture of 1-aminonaphthalene (0.22 g, 1.53 mmol) in dioxane (1 ml)
and NaHCO.sub.3 (0.26 g, 3.09 mmol) in water (3 ml), and the
resultant solution was stirred at room temperature until the
completion of the reaction (control by TLC). The reaction mixture
was evaporated and the residue was partitioned between ethyl
acetate and 2N HCl. The organic layer was washed successively with
water, saturated NaCl, and dried (Na.sub.2SO.sub.4). The solvent
was removed and the residue was chromatographed on silica gel with
petroleum ether-ethyl acetate (gradient from 2:1 to 1:1, v/v) as
eluent. The obtained product was washed with diethyl ether to give
the title compound (0.29 g, 51%) as a white solid. .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 3.69 (3H, s); 6.56 (1H, d, J=16.0
Hz); 7.16 (1H, dd, J=7.0 and 1.4 Hz); 7.27-8.14 (11H, m); 10.25
(1H, s).
Example 123
3-[3-(Naphthalen-1-ylsulfamoyl)-phenyl]-acrylic Acid (15d)
[1194] 260
[1195] To a suspension of
3-[3-(naphthalen-1-ylsulfamoyl)-phenyl]-acrylic acid methyl ester
(14d) (0.29 g, 0.79 mmol) in methanol (3 ml) 1N NaOH solution (2.4
ml, 2.4 mmol) was added and the resultant mixture was stirred at
ambient temperature overnight. The reaction mixture was partitioned
between ethyl acetate and water. The aqueous layer was acidified
with 2N HCl solution and stirred for 30 min. The precipitated solid
was filtered, washed with water and dried in desiccator over
P.sub.2O.sub.5. The title compound was obtained as a white solid
(0.22 g, 79%).
Example 124
3-[3-(Naphthalen-1-ylsulfamoyl)-phenyl]-acryloyl Chloride (16d)
[1196] 261
[1197] To a suspension of
3-[3-(naphthalen-1-ylsulfamoyl)-phenyl]-acrylic acid (15d) (0.22 g,
0.62 mmol) in dichloromethane (2.5 ml) oxalyl chloride (0.16 ml,
1.86 mmol) and one drop of dimethylformamide were added. The
reaction mixture was stirred at 40.degree. C. for one hour and
concentrated under reduced pressure to give crude title compound
(0.23 g, 99%).
Example 125
N-Hydroxy-3-[3-(naphthalen-1-ylsulfamoyl)-phenyl]-acrylamide (17d)
(PX117228)
[1198] 262
[1199] To a suspension of hydroxylamine hydrochloride (0.215 g, 3.1
mmol) in tetrahydrofuran (3.5 ml) a saturated NaHCO.sub.3 solution
(2.7 ml) was added and the resultant mixture was stirred at ambient
temperature for 10 min. To the reaction mixture a solution of crude
3-[3-(naphthalen-1-ylsul- famoyl)-phenyl]-acryloyl chloride (16d)
(0.23 g) in tetrahydrofuran (2.5 ml) was added and the mixture was
stirred at ambient temperature for one hour. The reaction mixture
was partitioned between ethyl acetate and 2N HCl. The organic layer
was washed successively with water and saturated NaCl, then the
solvent was removed. The residue was crystallised from ethyl
acetate affording the title compound (0.054 g, 24%). M.p.
180.degree. C. .sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.: 6.45 (1H,
d, J=16.0 Hz); 7.14 (1H, dd, J=7.0 and 1.4 Hz); 7.31-8.14 (11H, m);
9.09 (1H, br s); 10.27 (1H, s); 10.76 (1H, br s). HPLC analysis on
Symmetry C.sub.18 column: impurities 4% (column size 3.9.times.150
mm; mobile phase acetonitrile --0.1M phosphate buffer (pH 2.5),
40:60; sample concentration 0.3 mg/ml; flow rate 1.2 ml/min;
detector UV 220 nm). Anal. Calcd for
C.sub.19H.sub.16n.sub.2O.sub.4S, %: C, 61.94; H, 4.38; N, 7.60.
Found, %: C, 61.18, H, 4.32, N, 7.54.
Example 126
3-[3-(Naphthalen-2-ylsulfamoyl)-phenyl]-acrylic Acid Methyl Ester
(14e)
[1200] 263
[1201] A solution of 3-(3-chlorosulfonylphenyl)acrylic acid methyl
ester (3) (1.0 g, 3.83 mmol) in dioxane (10 ml) was added to a
mixture of 2-aminonaphthalene (0.55 g, 3.83 mmol) and NaHCO.sub.3
(0.48 g, 5.71 mmol) in water (6 ml), and the resultant solution was
stirred at room temperature until the completion of the reaction
(control by TLC). The reaction mixture was evaporated and the
residue was partitioned between ethyl acetate and 2N HCl. The
organic layer was washed successively with water, saturated NaCl,
and dried (Na.sub.2SO.sub.4). The solvent was removed and the
residue was chromatographed on silica gel with petroleum
ether-ethyl acetate (3:2, v/v) as eluent. The obtained product was
crystallised from petroleum ether-ethyl acetate to give the title
compound (0.52 g, 34%) as a white solid. .sup.1H NMR (DMSO-d.sub.6
HMDSO), .delta.: 3.73 (3H, s); 6.67 (1H, d, J=16.0 Hz); 7.21-8.07
(11H, m); 8.16 (1H, s); 10.55 (1H, s).
Example 127
3-[3-(Naphthalen-2-ylsulfamoyl)-phenyl]-acrylic Acid (15e)
[1202] 264
[1203] To a suspension of
3-[3-(naphthalen-2-ylsulfamoyl)-phenyl]-acrylic acid methyl ester
(14e) (0.25 g, 0.68 mmol) in methanol (3.5 ml) 2N NaOH solution
(1.0 ml, 2.0 mmol) was added and the resultant mixture was stirred
at ambient temperature overnight. The reaction mixture was
partitioned between ethyl acetate and water. The aqueous layer was
acidified with 2N HCl solution and stirred for 30 min. The
precipitated solid was filtered, washed with water and dried in
desiccator over P.sub.2O.sub.5. The title compound was obtained as
a white solid (0.21 g, 87%). .sup.1H NMR (DMSO-d.sub.6, HMDSO),
.delta.: 6.56 (1H, d, J=16.0 Hz); 7.21-8.01 (11H, m); 8.12 (1H, s);
10.56 (1H, br s); 12.54 (1H, br s).
Example 128
3-[3-(Naphthalen-2-ylsulfamoyl)phenyl]-acryloyl Chloride (16e)
[1204] 265
[1205] To a suspension of
3-[3-(naphthalen-2-ylsulfamoyl)-phenyl]-acrylic acid (15e) (0.21 g,
0.57 mmol) in dichloromethane (2.5 ml) oxalyl chloride (0.15 ml,
1.71 mmol) and one drop of dimethylformamide were added. The
reaction mixture was stirred at 40.degree. C. for one hour and
concentrated under reduced pressure to give crude title compound
(0.21 g, 95%).
Example 129
N-Hydroxy-3-[3-(naphthalen-2-ylsulfamoyl)-phenyl]-acrylamide (17e)
(PX117445)
[1206] 266
[1207] To a suspension of hydroxylamine hydrochloride (0.2 g, 2.85
mmol) in tetrahydrofuran (3.5 ml) a saturated NaHCO.sub.3 solution
(2.3 ml) was added and the resultant mixture was stirred at ambient
temperature for 10 min. To the reaction mixture a solution of crude
3-[3-(naphthalen-2-ylsul- famoyl)-phenyl]-acryloyl chloride (16e)
(0.21 g) in tetrahydrofuran (2.5 ml) was added and the mixture was
stirred at ambient temperature for one hour. The reaction mixture
was partitioned between ethyl acetate and 2N HCl. The organic layer
was washed successively with water and saturated NaCl, then the
solvent was removed. The residue was washed with diethyl ether and
potroleum ether-ethyl acetate (3:1) affording the title compound
(0.14 g, 68%). M.p. 164.degree. C. .sup.1H NMR (DMSO-d.sub.6,
HMDSO) .delta.: 6.49 (1H, d, J=116.0 Hz); 7.16-7.89 (12H, m); 7.98
(1H, br s); 10.52 (1H, s); 10.76 (1H, br s). HPLC analysis on
Symmetry C.sub.18 column: impurities 5% (column size 3.9.times.150
mm; mobile phase acetonitrile --0.1M phosphate buffer (pH 2.5),
50:50; sample concentration 0.5 mg/ml; flow rate 0.8 ml/min;
detector UV 220 nm). Anal. Calcd for
C.sub.19H.sub.16n.sub.2O.sub.4S, %: C, 61.94; H, 4.38; N, 7.60.
Found, %: C, 61.44, H, 4.39, N, 7.48.
Example 130
3-(3-Nitro-phenyl)-acrylic Acid Methyl Ester (22)
[1208] 267
[1209] Acetyl chloride (6.5 ml, 0.09 mol) was added dropwise to
methanol (130 ml) at -15.degree. C. temperature. The reaction
mixture was stirred for 30 min. simultaneously allowing to warm up
to 0.degree. C. 3-(3-Nitrophenyl)-acrylic acid (21) (25 g, 0.13
mol) was added by small portions to the mixture at 0.degree. C. and
the resulting reaction mixture was stirred overnight at ambient
temperature. The forming precipitate was filtered, washed with
methanol and dried affording the title compound in a form of white
crystals (26.58 g, 98%).
Example 131
3-(3-Amino-phenyl)-acrylic Acid Methyl Ester (23)
[1210] 268
[1211] A mixture of 3-(3-nitro-phenyl)-acrylic acid methyl ester
(22) (10.0 g, 48 mmol) and SnCl.sub.2.2H.sub.2O (54 g, 240 mmol) in
anhydrous ethanol (200 ml) was heated at 80.degree. C. for 1 hour.
The reaction mixture was allowed to cool to room temperature, then
the solvent was partially evaporated by vacuum rotary evaporator
(up to ca. % volume). The residue was poured in ice water,
neutralised (pH.about.7) with saturated Na.sub.2CO.sub.3 and the
resulting mixture was extracted with ethyl acetate. The organic
extract was washed with saturated NaCl and dried
(Na.sub.2SO.sub.4). The extract was filtrated through a small
amount of silicagel and evaporated to give pure title compound in a
form of white crystals (8.5 g, 99%). .sup.1H NMR (CDCl.sub.3,
HMDSO), .delta.: 3.69 (2H, br s); 3.79 (3H, s); 6.39 (1H, d, J=16.0
Hz); 6.61-7.03 (3H, m); 7.18 (1H, t, J=7.6 Hz); 7.62 (1H, d, J=16.0
Hz).
Example 132
3-3-[(E)-2-Phenylethenesulfonylamino]phenyl}acrylic Acid Methyl
Ester (25a)
[1212] 269
[1213] A solution of (E)-2-phenylethenesulfonyl chloride (24a)
(0.59 g, 2.82 mmol) in dioxane (3 ml) was added to a mixture of
3-(3-aminophenyl)-acrylic acid methyl ester (23) (0.50 g, 2.82
mmol) in dioxane (12 ml) and NaHCO.sub.3 (0.36 g, 4.28 mmol) in
water (8 ml), and the resultant solution was stirred at room
temperature until the completion of the reaction (control by TLC).
The reaction mixture was evaporated and the residue was partitioned
between ethyl acetate and 2N HCl. The organic layer was washed
successively with water, saturated NaCl, and dried
(Na.sub.2SO.sub.4). The solvent was removed and the residue was
chromatographed on silica gel with chloroform-ethyl acetate (100:2,
v/v) as eluent to give the title compound (0.68 g, 70%) as a white
solid. .sup.1H NMR (CDCl.sub.3, HMDSO), .delta.: 3.78 (3H, s); 6.39
(1H, d, J=16.0 Hz); 6.77 (1H, d, J=15.8 Hz); 6.78 (1H, s);
7.17-7.48 (9H, m); 7.49 (1H, d, J=15.8 Hz); 7.58 (1H, d, J=16.0
Hz).
Example 133
3-{3-[(E)-2-Phenylethenesulfonylamino]phenyl}acrylic Acid (26a)
[1214] 270
[1215] To a suspension of
3-{3-[(E)-2-phenylethenesulfonylamino]phenyl}acr- ylic acid methyl
ester (25a) (0.30 g, 0.87 mmol) in methanol (4 ml) 1N NaOH solution
(2.62 ml, 2.62 mmol) was added and the resultant mixture was
stirred at ambient temperature overnight. The reaction mixture was
partitioned between ethyl acetate and water. The aqueous layer was
acidified with 2N HCl solution and extracted with ethyl acetate.
The extract was washed with saturated NaCl and dried
(Na.sub.2SO.sub.4). The solvent was evaporated and the residue was
dried in desiccator over P.sub.2O.sub.5. The tite compound was
obtained as a white solid (0.26 g, 90%). .sup.1H NMR (DMSO-d.sub.6,
HMDSO) 6:6.41 (1H, d, J=16.0 Hz); 7.12-7.51 (9H, m); 7.55-7.81 (3H,
m); 10.16 (1H, br s), 12.32 (1H, br s).
Example 134
3-{3-[(E)-2-Phenylethenesulfonylamino]phenyl}acryloyl Chloride
(27a)
[1216] 271
[1217] To a suspension of
3-{3-[(E)-2-phenylethenesulfonylamino]phenyl}acr- ylic acid (26a)
(0.26 g, 0.79 mmol) in dichloromethane (3.5 ml) oxalyl chloride
(0.21 ml, 2.37 mmol) and one drop of dimethylformamide were added.
The reaction mixture was stirred at 40.degree. C. for one hour and
concentrated under reduced pressure to give crude title compound
(0.27 g, 98%).
Example 135
N-Hydroxy-3-{3-[(E)-2-phenylethenesulfonylamino]phenyl}acrylamide
(28a) (PX117446)
[1218] 272
[1219] To a suspension of hydroxylamine hydrochloride (0.27 g, 3.88
mmol) in tetrahydrofuran (5 ml) a saturated NaHCO.sub.3 solution (3
ml) was added and the resultant mixture was stirred at ambient
temperature for 10 min. To the reaction mixture a solution of crude
3-{3-[(E)-2-phenylethene- sulfonylamino]phenyl}acryloyl chloride
(27a) (0.27 g, 0.77 mmol) in tetrahydrofuran (3.5 ml) was added and
the mixture was stirred at ambient temperature for one hour. The
reaction mixture was partitioned between ethyl acetate and 2N HCl.
The organic layer was washed successively with water and saturated
NaCl, then the solvent was removed. The residue was crystallised
from ethyl acetate and washed with diethyl ether affording the
title compound (0.115 g, 42%) as white crystals. M.p. 171.degree.
C. .sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.: 6.38 (d, J=16.0 Hz,
1H); 7.07-7.80 (m, 12H); 9.03 (br s, 1H); 10.16 (s, 1H); 10.76
(brs, 1H). HPLC analysis on Symmetry C.sub.18 column: impurities 1%
(column size 3.9.times.150 mm; mobile phase acetonitrile--0.1M
phosphate buffer (pH 2.5), 35:65; sample concentration 0.4 mg/ml;
flow rate 1.2 ml/min; detector UV 254 nm). Anal. Calcd for
C.sub.17H.sub.16n.sub.2O.sub.4S, %: C, 59.29; H, 4.68; N, 8.13.
Found, %: C, 59.13, H, 4.70, N, 7.92.
Example 136
3-[3-(3,4-Dimethoxy-benzenesulfonylamino)-phenyl]-acrylic Acid
Methyl Ester (25b)
[1220] 273
[1221] Using an analogous method, the title compound was obtained
from 3,4-dimethoxybenzenesulphonyl chloride (24b) and
3-(3-aminophenyl)acrylic acid methyl ester (23) as a white solid,
yield 77%. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 3.69(3H, s);
3.72 (3H, s); 3.78 (3H, s); 6.45 (1H, d, J=16.0 Hz); 6.94-7.67 m);
10.23 ppm (1H, br s).
Example 137
3-[3-(3,4-Dimethoxy-benzenesulfonylamino)-phenyl]-acrylic Acid
(26b)
[1222] 274
[1223] Using an analogous method, the title compound was obtained
from 3-[3-(3,4-dimethoxy-benzenesulfonylamino)-phenyl]-acrylic acid
methyl ester (25b) and sodium hydroxide, ca. yield of the crude
product 95%.
Example 138
3-[3-(3,4-Dimethoxy-benzenesulfonylamino)-phenyl]-acryloyl Chloride
(27b)
[1224] 275
[1225] Using an analogous method, the title compound was obtained
from 3-[3-(3,4-dimethoxy-benzenesulfonylamino)-phenyl]-acrylic acid
(26b) and oxalyl chloride, ca. yield of the crude product 98%
(yellow oil).
Example 139
3-[3-(3,4-Dimethoxy-benzenesulfonylamino)-phenyl]-N-hydroxy-acrylamide
(28b) (PX117780)
[1226] 276
[1227] Using an analogous method, the title compound was obtained
from 3-[3-(3,4-dimethoxy-benzenesulfonylamino)-phenyl]-acryloyl
chloride (27b) and hydroxylamine hydrochloride, yield 32%. M.p.
158.degree. C. .sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.: 3.72 (3H,
s); 3.80 (3H, s); 6.36 (1H, d, J=16.0 Hz); 6.89-7.52 (8H, 9.03 (1H,
br s); 10.16 (1H, br s); 10.78 (1H, br s). HPLC analysis on
Symmetry C.sub.8 column: impurities 2.5% (column size 3.9.times.150
mm; mobile phase acetonitrile --0.1M phosphate buffer (pH 2.5),
30:70; detector UV 254 nm; flow rate 1.3 ml/min; sample
concentration 0.5 mg/ml). Anal. Calcd for
C.sub.17H.sub.18N.sub.2O.sub.6S- , %: C, 53.96, H, 4.79, N, 7.40.
Found, %: C, 53.74; H, 4.71; N, 7.35.
Example 140
3-[3-(Biphenyl-4-sulfonylamino)-phenyl]-acrylic Acid Methyl Ester
(25c)
[1228] 277
[1229] Using an analogous method, the title compound was obtained
from biphenyl-4-sulfonyl chloride (24c) and
3-(3-aminophenyl)acrylic acid methyl ester (23) as a white solid,
yield 78%. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 3.71 (3H,
s); 6.43 (1H, d, J=16.0 Hz); 7.12-8.11 (14H, m); 10.49 ppm (1H, br
s).
Example 141
3-[3-(Biphenyl-4-sulfonylamino)-phenyl]-acrylic Acid (26c)
[1230] 278
[1231] Using an analogous method, the title compound was obtained
from 3-[3-(biphenyl-4-sulfonylamino)-phenyl]-acrylic acid methyl
ester (25c) and sodium hydroxide, ca. yield of the crude product
87%.
Example 142
3-[3-(Biphenyl-4-sulfonylamino)-phenyl]-acryloyl Chloride (27c)
[1232] 279
[1233] Using an analogous method, the title compound was obtained
from 3-[3-(biphenyl-4-sulfonylamino)-phenyl]-acrylic acid (26c) and
oxalyl chloride, ca. yield of the crude product 98% (yellow
oil).
Example 143
3-[3-(Biphenyl-4-sulfonylamino)-phenyl]-N-hydroxy-acrylamide (28c)
(PX117781)
[1234] 280
[1235] Using an analogous method, the title compound was obtained
from 3-[3-(biphenyl-4-sulfonylamino)-phenyl]-acryloyl chloride
(27c) and hydroxylamine hydrochloride, yield 20%. M.p. 115.degree.
C. .sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.: 6.38 (1H, d, J=16.0
Hz); 6.98-7.65 (10H, m); 7.87 (4H, s); 9.03 (1H, br s); 10.45 (1H,
br s); 10.78 (1H, br s). HPLC analysis on Symmetry C.sub.8 column:
impurities 2.5% (column size 3.9.times.150 mm; mobile phase
acetonitrile-0.1M phosphate buffer (pH 2.5), 50:50; detector UV 254
nm; flow rate 1.0 ml/min; sample concentration 0.5 mg/ml). Anal.
Calcd for C.sub.21H.sub.18N.sub.2O.sub.4S containing 1.3% of
inorganic impurities, %: C, 63.11, H, 4.54, N, 7.01. Found, %: C,
63.16; H, 4.53; N, 6.93.
Example 144
3-[3-(Toluene-4-sulfonylamino)-phenyl]-acrylic Acid Methyl Ester
(25d)
[1236] 281
[1237] Using an analogous method, the title compound was obtained
from tolylsulfonyl chloride (24d) and 3-(3-aminophenyl)acrylic acid
methyl ester (23) as a white solid, yield 78%. .sup.1H NMR
(CDCl.sub.3, TMS), .delta.: 2.38 (3H, s); 3.78 (3H, s); 6.34 (1H,
d, J=16.0 Hz); 6.80 (1H, br, s); 7.00-7.76 (9H, m).
Example 145
3-[3-(Toluene-4-sulfonylamino)-phenyl]-acrylic acid (26d)
[1238] 282
[1239] Using an analogous method, the title compound was obtained
from 3-[3-(toluene-4-sulfonylamino)-phenyl]-acrylic acid methyl
ester (25d) and sodium hydroxide, ca. yield of the crude product
91%.
Example 146
3-[3-(Toluene-4-sulfonylamino)-phenyl]-acryloyl Chloride (27d)
[1240] 283
[1241] Using an analogous method, the title compound was obtained
from 3-[3-(toluene-4-sulfonylamino)-phenyl]-acrylic acid (26d) and
oxalyl chloride, ca. yield of the crude product 98% (yellow
oil).
Example 147
N-Hydroxy-3-[3-(toluene-4-sulfonylamino)-phenyl]-acrylamide (28d)
(PX089342)
[1242] 284
[1243] Using an analogous method, the t compound was obtained from
3-[3-(toluene-4-sulfonylamino)phenyl]-acryloyl chloride (27d) and
hydroxylamine hydrochloride, yield 82%. M.p. 147.degree. C. .sup.1H
NMR (DMSO-d.sub.6, HMDSO) .delta.: 2.32 (s, 3H); 6.36 (d, J=16.0
Hz, 1H); 6.94-7.76 (m, 9H); 9.03 (br s, 1H); 10.32 (s, 1H); 10.78
ppm (br s, 1H). HPLC analysis on Symmetry C.sub.18 column:
impurities <1% (column size 3.9.times.150 mm; mobile phase
acetonitrile--0.1M phosphate buffer (pH 2.5), 35:65; detector UV
220 nm; flow rate 1.0 ml/min; sample concentration 1.0 mg/ml).
Anal. Calcd for C.sub.16H.sub.16n.sub.2O.sub.4S- , %: C, 57.82; H,
4.85; N, 8.43. Found, %: C, 57.73, H, 4.86, N, 8.36.
Example 148
3-[3-(Benzene-4-sulfonylamino)-phenyl]-acrylic Acid Methyl Ester
(25e)
[1244] 285
[1245] Using an analogous method, the title compound was obtained
from benzenesulfonyl chloride (24e) and 3-(3-aminophenyl)acrylic
acid methyl ester (23) as a white solid, yield 85%. .sup.1H NMR
(CDCl.sub.3, TMS), .delta.: 3.78 (3H, s); 6.34 (1H, d, J=16.0 Hz);
6.74 (1H, br, s); 6.98-7.83 (10H, m).
Example 149
3-[3-(Benzene-4-sulfonylamino)-phenyl]-acrylic Acid (26e)
[1246] 286
[1247] Using an analogous method, the title compound was obtained
from 3-[3-(benzene-4-sulfonylamino)-phenyl]-acrylic acid methyl
ester (25e) and sodium hydroxide, ca. yield of the crude product
88%.
Example 150
3-[3-(Benzene-4-sulfonylamino)-phenyl]-acryloyl Chloride (27e)
[1248] 287
[1249] Using an analogous method, the title compound was obtained
from 3-[3-(benzene-4-sulfonylamino)-phenyl]-acrylic acid (26e) and
oxalyl chloride, ca. yield of the crude product 98% (yellow
oil).
Example 151
3-(3-Benzenesulfonylamino-phenyl)-N-hydroxy-acrylamide
(PX089344)
[1250] 288
[1251] Using an analogous method, the title compound was obtained
from 3-[3-(benzene-4-sulfonylamino)-phenyl]-acryloyl chloride (27e)
and hydroxylamine hydrochloride, yield 86%.,M.p. 172.degree. C.
.sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.: 6.35 (d, J=16.0 Hz, 1H);
6.96-7.92 (m, 10H); 9.03 (brs, 1H); 10.38 (s, 1H); 10.78 ppm (br s,
1H). HPLC analysis on Symmetry C.sub.18 column: impurities <3%
(column size 3.9.times.150 mm; mobile phase acetonitrile-0.1M
phosphate buffer (pH 2.5), 35:65; detector UV 220 nm; flow rate 0.8
ml/min; sample concentration 1.0 mg/ml). Anal. Calcd for
C.sub.15H.sub.14N.sub.2O.sub.4S, %: C, 56.59; H, 4.43; N, 8.80.
Found, %: C, 56.48, H, 4.57, N, 8.45.
Example 152
Sodium 2-(2-methoxycarbonyl-vinyl)benzenesulfonate (32)
[1252] 289
[1253] A mixture of sodium 2-formylbenzenesulfonate hydrate (31)
(tech., purity 75%; 1.33 g, 4.79 mmol), potassium carbonate (1.32
g, 9.56 mmol), and trimethyl phosphonoacetate (1.05 g, 5.77 mmol)
in water (2.5 ml) was vigorously stirred at ambient temperature for
1 hour. The precipitate was filtered and carefully washed with
methanol. The methanol extract was evaporated to give the title
compound (0.66 g, 52%) as a white solid. .sup.1H NMR (DMSO-d.sub.6,
HMDSO), .delta.: 3.72 (3H, s); 6.43 (1H, d, J=16.0 Hz); 7.18-7.96
(4H, m); 8.83 (1H, d, J=16.0 Hz).
Example 153
3-(2-Chlorosulfonylphenyl)acrylic Acid Methyl Ester (33)
[1254] 290
[1255] To a solution of 2-(2-methoxycarbonyl-vinyl)benzenesulfonate
(32) (0.63 g, 2.38 mmol) in benzene (2 ml) thionyl chloride (1.43
g, 12.00 mmol) and three drops of dimethylformamide were added, and
the resultant suspension was stirred at reflux temperature for 1.5
hours. The reaction mixture was evaporated and the residue was
dissolved in benzene (5 ml). The benzene solution was filtered and
the filtrate was evaporated to give the title compound (0.47 g,
71%) as an oil.
Example 154
3-(2-Phenylsulfamoyl-phenyl)-acrylic acid methyl ester (34a)
[1256] 291
[1257] To a mixture of aniline (0.33 g, 3.53 mmol) and pyridine (1
ml) a solution of 3-(2-chlorosulfonylphenyl)acrylic acid methyl
ester (33) (0.45 g, 1.72 mmol) in dichloromethane (3 ml) was added
and the resultant solution was stirred at 50.degree. C. for 1 hour.
The reaction mixture was evaporated and the residue was partitioned
between ethyl acetate and 10% HCl. The organic layer was washed
successively with water, saturated NaCl and dried
(Na.sub.2SO.sub.4). The solvent was removed and the residue was
chromatographed on silica gel with ethyl acetate-chloroform (1:7,
v/v) as eluent. The obtained product was washed with diethyl ether
to give the title compound (0.33 g, 60%). .sup.1H NMR (CDCl.sub.3,
HMDSO), .delta.: 3.86 (3H, s); 6.27 (1H, d, J=16.0 Hz); 6.69 (1H,
br s); 6.87-7.67 (8H, m); 7.94-8.13 (1H, m); 8.49 (1H, d, J=16.0
Hz).
Example 155
3-(2-Phenylsulfamoyl-phenyl)-acrylic Acid (35a)
[1258] 292
[1259] 3-(2-phenylsulfamoyl-phenyl)-acrylic acid methyl ester (34a)
(0.30 g, 0.94 mmol) was dissolved in methanol (4 ml), 1N NaOH
solution (2.82 ml, 2.82 mmol) was added and the resultant solution
was stirred at ambient temperature overnight. The reaction mixture
was partitioned between ethyl acetate and water. The aqueous layer
was acidified with 10% HCl solution and stirred at ambient
temperature for 1 hour. The precipitated solid was filtered, washed
with water and dried in desiccator over P.sub.2O.sub.5. The title
compound (0.2 g, 70%) was obtained as a white solid. .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 6.40 (1H, d, J=16.0 Hz); 6.93-7.32
(5H, m); 7.45-8.00 (5H, m); 8.47 (1H, d, J=16.0 Hz); 10.59 (1H, br
s).
Example 156
3-(2-Phenylsulfamoyl-phenyl)-acryloyl Chloride (36a)
[1260] 293
[1261] To a suspension of 3-(2-phenylsulfamoyl-phenyl)-acrylic acid
(35a) (0.18 g, 0.59 mmol) in dichloromethane (3.0 ml) oxalyl
chloride (0.18 ml, 2.06 mmol) and one drop of dimethylformamide
were added. The reaction mixture was stirred at 40.degree. C. for
one hour and concentrated under reduced pressure to give crude
title compound (0.19 g, 99%).
Example 157
N-Hydroxy-3-(2-phenylsulfamoylphenyl)acrylamide (37a)
(PX116242)
[1262] 294
[1263] To a suspension of hydroxylamine hydrochloride (0.21 g, 3.01
mmol) in tetrahydrofuran (4.0 ml) a saturated NaHCO.sub.3 solution
(2.6 ml) was added and the resultant mixture was stirred at ambient
temperature for 25 min. To the reaction mixture a
3-(2-phenylsulfamoyl-phenylyacryloyl chloride (36a) (0.19 g, 0.59
mmol) solution in tetrahydrofuran (2.5 ml) was added and the
mixture was stirred at ambient temperature for 2 hours. The
reaction mixture was partitioned between ethyl acetate and 2N HCl.
The organic layer was washed successively with water and saturated
NaCl, and the solvent was removed. The residue was washed with
diethyl ether and crystallised from acetonitrile to give the title
compound (0.056 g, 30%) as white crystals, m.p. 205-206.5.degree.
C. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 6.37 (1H, d, J=16.0
Hz); 6.99-8.04 (10H, m); 8.23 (1H, d, J=16.0 Hz); 10.55 (1H, s);
10.83 (1H, br s). HPLC analysis on Symmetry C.sub.18 column:
impurities 6.4% (column size 3.9.times.150 mm; mobile phase
acetonitrile--0.1M phosphate buffer, pH 2.5, 30:70; sample
concentration 0.2 mg/ml; flow rate 1.2 ml/min; detector UV 220 nm).
Anal. Calcd for C.sub.15H.sub.14N.sub.2O.sub.4S*0.1H- .sub.2O, %:
C, 56.28; H, 8.75; N, 4.47. Found, %: C, 55.63; H, 9.07; N,
4.36.
Example 158
3-[2-(Naphthalen-1-ylsulfamoyl)-phenyl]-acrylic Acid Methyl Ester
(34b)
[1264] 295
[1265] Using an analogous method, the title compound was obtained
from 3-(2-chlorosulfonylphenyl)acrylic acid methyl ester (33) and
1-aminonaphthalene, yield 59%. .sup.1H NMR (CDCl.sub.3, HMDSO),
.delta.: 3.76 (3H, s); 6.22 (1H, d, J=16.0 Hz); 6.88-7.85 (11H, m);
7.94-8.12 (1H, m); 8.51 (1H, d, J=16.0 Hz).
Example 159
3-[2-(Naphthalen-1-ylsulfamoyl)-phenyl]-acrylic Acid (35b)
[1266] 296
[1267] Using an analogous method, the title compound was obtained
from 3-[2-(naphthalen-1-ylsulfamoyl)-phenyl]-acrylic acid methyl
ester (34b) and sodium hydroxide, yield 41%. .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 6.16 (1H, d, J=16.0 Hz); 7.18-7.95
(12H, m); 8.29 (1H, d, J=16.0 Hz); 10.54 (1H, br s).
Example 160
3-[2-(Naphthalen-1-ylsulfamoyl)-phenyl]-acryloyl Chloride (36b)
[1268] 297
[1269] Using an analogous method, the title compound was obtained
from 3-[2-(naphthalen-1-ylsulfamoyl)-phenyl]-acrylic acid (35b) and
oxalyl chloride in a form of a crude product, yield ca. 98%.
Example 161
N-Hydroxy-3-[2-(naphthalen-1-ylsulfamoyl)-phenyl]-acrylamide (37b)
(PX117447)
[1270] 298
[1271] Using an analogous method, the title compound was obtained
from 3-[2-(naphthalen-1-ylsulfamoyl)-phenyl]-acryloyl chloride
(36b) and hydroxylamine hydrochloride, yield 38%, m.p.
186-187.degree. C. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 6.29
(1H, d, J=15.0 Hz); 7.17-8.16 (11H, m); 8.36 (1H, d, J=15.0 Hz);
9.14 (1H, 10.57 (1H, s); 10.83 (1H, s). HPLC analysis on Symmetry
C.sub.8 column: impurities 6.4% (column size 3.9.times.150 mm;
mobile phase acetonitrile-0.1M phosphate buffer, pH 2.5, 35:65;
sample concentration 0.5 mg/ml; flow rate 1.6 ml/min; detector UV
220 nm). Anal. Calcd for C.sub.19H.sub.16n.sub.2O.sub.4S*0.4H-
.sub.2O, %: C, 60.76; H, 4.51; N, 7.46. Found, %: C, 60.46; H,
4.35; N, 7.69.
Example 162
3-[2-(Methyl-phenyl-sulfamoyl)phenyl]-acrylic Acid Methyl Ester
(34c)
[1272] 299
[1273] Using an analogous method, the title compound was obtained
from 3-(2-chlorosulfonylphenyl)acrylic acid methyl ester (33) and
N-methylaniline, yield 54%. .sup.1H NMR (DMSO-d.sub.6, HMDSO),
.delta.: 3.13 (3H, s); 3.67 (3H, s); 6.29 (1H, d, J=16.0 Hz);
7.01-7.45 (5H, m); 7.52-8.09 (5H, m).
Example 163
3-[2-(Methyl-phenyl-sulfamoyl)-phenyl]-acrylic Acid (35c)
[1274] 300
[1275] Using an analogous method, the title compound was obtained
from 3-[2-(methyl-phenyl-sulfamoyl)-phenyl]-acrylic acid methyl
ester (34c) and sodium hydroxide, yield 48%. .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 3.17 (3H, s); 6.28 (1H, d, J=16.0
Hz); 7.06-7.42 (5H, m); 7.53-8.20 (6H, m).
Example 164
3-[2-(Methyl-phenyl-sulfamoyl)-phenyl]-acryloyl Chloride (36c)
[1276] 301
[1277] Using an analogous method, the title compound was obtained
from 3-[2-(methyl-phenyl-sulfamoyl)-phenyl]-acrylic acid (35c) and
oxalyl chloride in a form of the crude product, yield ca. 99%.
Example 165
N-Hydroxy-3-[2-(methyl-phenyl-sulfamoyl)-phenyl]-acrylamide (37c)
(PX117448)
[1278] 302
[1279] Using an analogous method, the title compound was obtained
from 3-[2-(methyl-phenyl-sulfamoyl)-phenyl]-acryloyl chloride (36c)
and hydroxylamine hydrochloride, yield 40%, m.p.
144.5-145.5.degree. C. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.:
3.16 (3H, s); 6.32 (1H, d, J=16.0 Hz); 7.00-7.86 (9H, m); 8.09 (1H,
d, J=16.0 Hz); 9.12 (1H, br s); 10.80 (1H, s). HPLC analysis on
Zorbax SB C.sub.18 column: impurities 1.0% (column size
4.6.times.150 mm; mobile phase methanol-0.1% H.sub.3PO.sub.4,
gradient from 50:50 to 90:10; sample concentration 0.5 mg/ml; flow
rate 1.5 ml/min; detector UV 230 nm). Anal. Calcd for
C.sub.16H.sub.16n.sub.2O.sub.4S*0.7H.sub.2O, %: C, 55.70; H, 5.08;
N, 8.12. Found, %: C, 55.17; H, 4.65; N, 8.05.
Example 166
3-(4-Chlorosulfonyl-phenyl)-acrylic Acid (42)
[1280] 303
[1281] To neat chlorosulfonic acid (5.3 ml, 80 mmol) at 0-5.degree.
C. temperature slowly cinnamic acid (41) (1.47 g, 10 mmol) was
added. As the reaction proceeded hydrogen chloride gas evolved. The
reaction mixture was stirred successively at 0.degree. C. for 1
hour, at ambient temperature for 2 hours and at 40-42.degree. C.
for 2 hours. The dark, viscous syrup was poured onto ice, the
precipitated solid was filtered and washed with water. The title
compound (0.5 g, 20%) as a white solid was obtained. .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 6.55 (1H, d, J=16 Hz); 7.58 (1H, d,
J=16.0 Hz); 7.65 (4H, s); 8.15 (1H, br s).
Example 167
3-(4-Phenylsulfamoyl-phenyl)-acrylic Acid (43a)
[1282] 304
[1283] To a mixture of aniline (0.35 g, 3.75 mmol) and pyridine (1
ml) a solution of 3-(4-chlorosulfonyl-phenyl)-acrylic acid (42)
(0.45 g, 1.82 mmol) in dichloromethane (3 ml) was added and the
resultant solution was stirred at 40.degree. C. for 1 hour. The
reaction mixture was evaporated and the residue was partitioned
between ethyl acetate and 6n HCl. The organic layer was washed
successively with water, saturated NaCl and dried
(Na.sub.2SO.sub.4). The solvent was evaporated under reduced
pressure to give the title compound (0.30 g, 54%). .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 6.60 (1H, d, J=16.0 Hz); 6.93-7.43
(5H, m); 7.60 (1H, d, J=16.0 Hz); 7.79 (2H, d, J=8.0 Hz); 7.87 (2H,
d, J=8.0 Hz); 10.35 (1H, s).
Example 168
3-(4-Phenylsulfamoyl-phenyl)-acryloyl Chloride (44a).degree.
[1284] 305
[1285] To a suspension of 3-(4-phenylsulfamoyl-phenyl)-acrylic acid
(43a) (0.25 g, 0.82 mmol) in dichloromethane (4.7 ml) oxalyl
chloride (0.32 ml, 3.68 mmol) and one drop of dimethylformamide
were added. The reaction mixture was stirred at 40.degree. C. for
one hour and concentrated under reduced pressure to give crude
title compound (0.24 g, 92%).
Example 169
N-Hydroxy-3-(4-phenylsulfamoylphenyl)-acrylamide (45a)
(PX117450)
[1286] 306
[1287] To a suspension of hydroxylamine hydrochloride (0.21 g, 3.01
mmol) in tetrahydrofuran (4.0 ml) a saturated NaHCO.sub.3 solution
(2.6 ml) was added and the resultant mixture was stirred at ambient
temperature for 25 min. To the reaction mixture a
3-(4-phenylsulfamoyl-phenyl)-acryloyl chloride (44a) (0.19 g, 0.59
mmol) solution in tetrahydrofuran (2.5 ml) was added and the
mixture was stirred at ambient temperature for 2 hours. The
reaction mixture was partitioned between ethyl acetate and 2N HCl.
The organic layer was washed successively with water and saturated
NaCl, and the solvent was removed. The residue was washed with
diethyl ether to give the title compound (0.074 g, 39%) as white
crystals, m.p. 176-177.5.degree. C. .sup.1H NMR (DMSO-d.sub.6,
HMDSO), .delta.: 6.54 (1H, d, J=16.0 Hz); 6.96-7.32 (5H, m); 7.47
(1H, d, J=16.0 Hz); 7.76 (4H, s); 9.14 (1H, br s); 10.29 (1H, br
s); 10.86 (1H, s). Anal. Calcd for C.sub.15H.sub.14N.sub.2O.sub.4S,
%: C, 56.59; H, 4.43; N, 8.80. Found, %: 55.82, H, 4.38, N,
9.01.
Example 170
3-[4-(Naphthalen-2-ylsulfamoyl)-phenyl]-acrylic acid (43b)
[1288] 307
[1289] Using an analogous method, the title compound was obtained
from 3-(4-chlorosulfonyl-phenyl)-acrylic acid (42) and
2-aminonaphthalene, yield 49%. .sup.1H NMR (DMSO-d.sub.6, HMDSO),
.delta.: 6.62 (1H, d, J=16.0 Hz); 7.19 (1H, dd, J=8.0 and 2.0 Hz);
7.34-8.14 (11H, m); 10.32 (1H, br s).
Example 171
3-[4-(Naphthalen-2-ylsulfamoyl)-phenyl]-acryloyl chloride (44b)
[1290] 308
[1291] Using an analogous method, the title compound was obtained
from 3-[4-(naphthalen-2-ylsulfamoyl)-phenyl]-acrylic acid (43b) and
oxalyl chloride, ca. yield of the crude product 98% (yellow
oil).
Example 172
N-Hydroxy-3-[4-(naphthalen-2-ylsulfamoyl)-phenyl]-acrylamide (45b)
(PX117736)
[1292] 309
[1293] Using an analogous method, the title compound was obtained
from 3-[4-(naphthalen-2-ylsulfamoyl)-phenyl]-acryloyl chloride
(44b) and hydroxylamine hydrochloride, yield 25%. M.p.
198.5-199.5.degree. C. .sup.1H NMR (DMSO-d.sub.6, HMDSO), 6: 6.54
(1H, d, J=16.0 Hz); 7.16 (1H, dd, J=8.0 and 2.0 Hz); 7.29-8.12
(11H, m); 9.11 (1H, br s); 10.07 (1H, s); 10.87 (1H, s). HPLC
analysis on Symmetry CB column: impurities 1.8% (column size
3.9.times.150 mm; mobile phase acetonitrile--0.1M phosphate buffer
(pH 2.5), 35:65; detector UV 254 nm; flow rate 1.5 ml/min; sample
concentration 0.5 mg/ml). Anal. Calcd for
C.sub.19H.sub.16n.sub.2O.sub.4S- *0.2H.sub.2O, %: C, 61.34, H,
4.44, N, 7.53. Found, %: C, 60.96; H, 4.28; N, 7.56.
Example 173
3-[4-(Biphenyl-4-ylsulfamoyl)-phenyl]-acrylic Acid (43c)
[1294] 310
[1295] Using an analogous method, the title compound was obtained
from 3-(4-chlorosulfonyl-phenyl)-acrylic acid (42) and
4-aminobiphenyl, yield 67%. .sup.1H NMR (DMSO-d.sub.6, HMDSO),
.delta.: 6.62 (1H, d, J=16.0 Hz); 7.19 (2H, d, J=8.0 Hz); 7.25-7.75
(9H, m); 7.77-7.95 (4H, m); 10.46 (1H, br s).
Example 174
3-[4-(Biphenyl-4-ylsulfamoyl)-phenyl]-acryloyl Chloride (44c)
[1296] 311
[1297] Using an analogous method, the title compound was obtained
from 3-[4-(biphenyl-4-ylsulfamoyl)-phenyl]-acrylic acid (43c) and
oxalyl chloride, ca. yield of the crude product 79% (yellow
oil).
Example 175
N-Hydroxy-3-[4-(biphenyl-4-ylsulfamoyl)-phenyl]-acrylamide (45c)
(PX117792)
[1298] 312
[1299] Using an analogous method, the title compound was obtained
from 3-[4-(biphenyl-4-ylsulfamoyl)-phenyl]-acryloyl chloride (44c)
and hydroxylamine hydrochloride, yield 32%. M.p. 211-211.5.degree.
C. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 6.53 (1H, d, J=16.0
Hz); 7.19 (2H, d, J=8.0 Hz); 7.32-7.69 (8H, m); 7.72-7.92 (4H, m);
9.09 (1H, br s); 10.45 (1H, s); 10.85 (1H, br s). HPLC analysis on
Zorbax SBC18 column: impurities 3% (column size 4.6.times.150 mm;
mobile phase acetonitrile-0.1% H.sub.3PO.sub.4, gradient from 50 to
100% (10 min); detector UV 254 nm; flow rate 1.0 ml/min; sample
concentration 0.65 mg/ml). Anal. Calcd for
C.sub.21H.sub.18N.sub.2O.sub.4S, %: C, 63.94, H, 4.60, N, 7.10.
Found, %: C, 63.51; H, 4.37; N, 7.11.
Example 176
3-[4-(4-Bromo-phenylsulfamoyl)-phenyl]-acrylic Acid (43d)
[1300] 313
[1301] Using an analogous method, the title compound was obtained
from 3-(4-chlorosulfonyl-phenyl)-acrylic acid (42) and
4-bromoaniline, yield 66%. .sup.1H NMR (DMSO-d.sub.6, HMDSO),
.delta.: 6.60 (1H, d, J=16.0 Hz); 7.09 (2H, d, J=8.0 Hz); 7.44 (2H,
d, J=8.0 Hz); 7.60 (1H, d, J=16.0 Hz); 7.73-7.85 (4H, m); 10.49
(1H, br s).
Example 177
3-[4-(4-Bromo-phenylsulfamoyl)phenyl]-acryloyl Chloride (44d)
[1302] 314
[1303] Using an analogous method, the title compound was obtained
from 3-[4-(4-bromo-phenylsulfamoyl)-phenyl]-acrylic acid (43d) and
oxalyl chloride, ca. yield of the crude product 91% (yellow
oil).
Example 178
N-Hydroxy-3-[4-(4-bromo-phenylsulfamoyl)-phenyl]-acrylamide (45d)
(PX117795)
[1304] 315
[1305] Using an analogous method, the title compound was obtained
from 3-[4-(4-bromo-phenylsulfamoyl)-phenyl]-acryloyl chloride (44d)
and hydroxylamine hydrochloride, yield 59%. M.p. 219-220.5.degree.
C. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 6.54 (1H, d, J=16.0
Hz); 7.05 (2H, d, J=8.0 Hz); 7.43 (2H, d, J=8.0 Hz); 7.49 (1H, d,
J=16.0 Hz); 7.63-7.87 (4H, m); 9.11 (1H, br s); 10.45 (1H, s);
10.83 (1H, br HPLC analysis on Zorbax SB-C18 column: impurities 3%
(column size 4.6.times.150 mm; mobile phase acetonitrile--0.1%
H.sub.3PO.sub.4, gradient from 30 to 100% (15 min); detector UV 254
nm; flow rate 1.0 ml/min; sample concentration 0.65 mg/ml).
[1306] Anal. Calcd for C.sub.15H.sub.13BrN.sub.2O.sub.4S, %: C,
45.35; H, 3.30; N, 7.05. Found, %: C, 45.44, H, 3.28, N, 7.05.
Example 179
3-[4-(4-Chloro-phenylsulfamoyl)-phenyl]-acrylic Acid (43e)
[1307] 316
[1308] Using an analogous method, the title compound was obtained
from 3-(4-chlorosulfonyl-phenyl)-acrylic acid (42) and
4-chloroaniline, yield 83%. .sup.1H NMR (DMSO-d.sub.6, HMDSO),
.delta.: 6.63 (1H, d, J=16.0 Hz); 7.09 (2H, d, J=8.0 Hz); 7.34 (2H,
d, J=8.0 Hz); 7.58 (2H, d, J=8.0 Hz); 7.72 (2H, d, J=8.0 Hz); 7.84
(2H, d, J=8.0 Hz); 10.47 (1H, br s).
Example 180
3-[4-(4-Chloro-phenylsulfamoyl)-phenyl]-acryloyl Chloride (44e)
[1309] 317
[1310] Using an analogous method, the title compound was obtained
from 3-[4-(4-chloro-phenylsulfamoyl)-phenyl]-acrylic acid (43e) and
oxalyl chloride, ca. yield of the crude product 71% (yellow
oil).
Example 181
N-Hydroxy-3-[4-(4-chloro-phenylsulfamoyl)-phenyl]-acrylamide (45e)
(PX117796)
[1311] 318
[1312] Using an analogous method, the title compound was obtained
from 3-[4-(4-chloro-phenylsulfamoyl)-phenyl]-acryloyl chloride
(44e) and hydroxylamine hydrochloride, yield 33%. M.p.
201-202.degree. C. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 6.52
(1H, d, J=16.0 Hz); 7.08 (2H, d, J=8.0 Hz); 7.29 (2H, d, J=8.0 Hz);
7.45 (1H, d, J=16.0 Hz); 7.6-7.89 (5H, m); 10.43 (1H, br s); 10.83
(1H, br s). HPLC analysis on Zorbax SB-C18 column: impurities 6%
(column size 4.6.times.150 mm; mobile phase acetonitrile --0.1%
H.sub.3PO.sub.4, gradient from 30 to 100% (15 min); detector UV 254
nm; flow rate 1.0 ml/min; sample concentration 0.5 mg/ml). Anal.
Calcd for C.sub.15H.sub.13ClN.sub.2O.sub.4S, %: C, 51.07; H, 3.71;
N, 7.94. Found, %: C, 51.14; H, 3.70; N, 7.86.
Example 182
3-Bromo-N-phenyl-benzenesulfonamide (52a)
[1313] 319
[1314] 3-Bromobenzenesulfonyl chloride (51a) (1.0 g, 3.9 mmol) was
added to a mixture of aniline (0.47 g, 5.1 mmol) in acetonitrile
(10 ml) and sodium carbonate (1.3 g, 12.3 mmol) in water (10 ml).
The mixture was stirred at ambient temperature for 1 hour and the
reaction product was extracted with ethyl acetate (30 ml). The
extract was dried (Na.sub.2SO.sub.4) and solvents were removed
under reduced pressure to give the title compound (1.15 g, 94%) as
an oil witch solidified upon standing. M.p. 98-100.degree. C.
.sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.: 6.94-7.48 (5H, m,
C.sub.6H.sub.5); 7.50-7.96 (4H, m, C.sub.6H.sub.4); 10.36 (1H, s,
NH).
Example 183
3-(3-Hydroxyprop-1-ynyl)-N-phenylbenzenesulfonamide (53a)
[1315] 320
[1316] A mixture of 3-bromo-N-phenyl-benzenesulfonamide (52a) (1.0
g, 3.2 mmol), benzene (2.4 ml),
tetrakis(triphenylphosphine)palladium(0) (0.4 g, 0.34 mmol), copper
iodide (0.032 g, 0.16 mmol), triethylamine (2.4 ml, 17.2 mmol), and
propargyl alcohol (1.0 ml, 17.2 mmol)) was refluxed under argon for
30 min. The reaction mixture was diluted with 5% HCl (50 ml) and
product was extracted with ethyl acetate (50 ml). The extract was
washed successively with 5% NaHCO.sub.3, water and dried
(Na.sub.2SO.sub.4). The solvents were removed under reduced
pressure and the product was purified on silica gel with ethyl
acetate-hexane (1:1, v/v) as eluent. The title compound (0.59 g,
64%) was obtained as an oil. .sup.1H NMR (DMSO-d.sub.6, HMDSO)
5:4.29 (2H, d, J=6.0 Hz, CH.sub.2); 5.36 (1H, t, J=6.0 Hz, OH);
6.94-7.32 (5H, m, C.sub.6H.sub.5); 7.35-7.91 (4H, m,
C.sub.6H.sub.4); 10.32 (1H, s, NH).
Example 184
3-(3-Oxoprop-1-ynyl)-N-phenylbenzenesulfonamide (54a)
[1317] 321
[1318] 3-(3-Hydroxyprop-1-ynyl)-N-phenylbenzenesulfonamide (53a)
(0.55 g, 1.9 mmol) was dissolved in a solution of Dess-Martin
reagent in methylene chloride (0.157 g/ml) (8.2 ml) and the
resultant mixture was stirred at ambient temperature for 30 min.
The mixture was partitioned between water (50 ml) and ether (50
ml), and ether solution was washed successively with 5%
Na.sub.2CO.sub.3, water, and dried (Na.sub.2SO.sub.4). The solvents
were removed under reduced pressure to give the title compound
(0.47 g, 72%) as an oil. The crude product 54a was used in the
further step without an additional purification. .sup.1H NMR
(DMSO-d.sub.6, HMDSO) .delta.: 6.96-7.41 (5H, m, C.sub.6H.sub.5);
7.54-8.07 (4H, m, C.sub.6H.sub.4); 9.45 (1H, s, CH); 10.41 (1H, s,
NH).
Example 185
(E)-5-(3-Phenylsulfamoylphenyl)pent-2-en-4-ynoic Acid Methyl Ester
(55a)
[1319] 322
[1320] To a solution of trimethyl phosphonoacetate (0.81 g, 4.5
mmol) in dry tetrahydrofuran (20 ml) under an argon atmosphere at
1520.degree. C. sodium hydride (0.12 g, 5.0 mmol) was added. The
mixture was stirred at ambient temperature for 1 hour, and a
solution of 3-(3-oxoprop-1-ynyl)-N-- phenylbenzenesulfonamide (54a)
(0.44 g, 1.5 mmol) in dry tetrahydrofuran (20 ml) was added
dropwise at 15-20.degree. C. The reaction mixture was stirred at
ambient temperature for 1 hour and quenched by 3% HCl (20 ml). The
product was extracted with ethyl acetate (50 ml), the extract was
washed with 5% NaHCO.sub.3, water and dried (Na.sub.2SO.sub.4). The
solvents were removed under reduced pressure and the residue was
chromatographed on silica gel with ethyl acetate-hexane (1:2, v/v)
as eluent to give the title compound (0.39 g, 74%) as a white
solid. M.p. 134-136.degree. C. .sup.1H NMR (DMSO-d.sub.6, HMDSO)
.delta.: 3.73 (3H, s, CH.sub.3); 6.49 (1H, d, J=15.5 Hz, CH); 7.03
(1H, d, J=15.5 Hz, CH); 7.01-7.38 (5H, m, C.sub.6H.sub.5);
7.41-7.89 (4H, m, C.sub.6H.sub.4); 10.34 (1H, s, NH).
Example 186
(E)-5-(3-Phenylsulfamoylphenyl)pent-2-en-4-ynoic Acid (56a)
[1321] 323
[1322] To a solution of
E-5-(3-phenylsulfamoylphenyl)pent-2-en-4-ynoic acid methyl ester
(55a) (0.34 g, 1 mmol) in methanol (3 ml) 1N solution of sodium
hydroxide (3 ml) was added and the mixture was stirred at ambient
temperature for 3 hours. Methanol was removed under reduced
pressure, to the residue water (5 ml) was added and the mixture was
acidified with 3% HCl. The precipitate was filtered, washed with
water, and dried to give the title compound (0.31 g, 95%) as white
crystals. M.p. 188-190.degree. C. .sup.1H NMR (DMSO-d.sub.6, HMDSO)
8:6.36 (1H, d, J=15.8 Hz, CH); 6.92 (1H, d, J=15.8 Hz, CH);
7.01-7.36 (5H, m, C.sub.6H.sub.5); 7.38-7.89 (4H, m,
C.sub.6H.sub.4); 10.32 (1H, s, NH).
Example 187
(E)-5-(3-Phenylsulfamoylphenyl)pent-2-en-4-ynoic Acid Hydroxyamide
(58a) (PX116238)
[1323] 324
[1324] To a solution of
(E)-5-(3-phenylsulfamoylphenyl)pent-2-en-4-ynoic acid (56a) (0.25 g
0.77 mmol) in methylene chloride (5 ml) oxalyl chloride (0.42 g 3.1
mmol) was added. The resultant mixture was stirred for 1 hour at
ambient temperature and the solvents were removed under reduced
pressure. The crude product (57a) was dissolved in acetonitrile (5
ml) and the obtained solution to a mixture of hydroxylamine
hydrochloride (0.3 g, 4.3 mmol) and NaHCO.sub.3 (0.3 g, 3.6 mmol)
in water (8 ml) was added. The reaction mixture was stirred for 10
min. and the product was extracted with ethyl acetate (30 ml). The
extract was washed with 10% Na.sub.2CO.sub.3, and the aqueous phase
was acidified with 3% HCl. The precipitate was filtered and dried
to give the title compound (0.12 g, (46%). M.p 88-90.degree. C.
.sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.: 6.41 (1H, d, J=15.8 Hz,
CH); 6.82 (1H, d, J=15.8 Hz, CH); 6.92-7.41 (5H, m,
C.sub.6H.sub.5); 7.47-8.01 (4H, m, C.sub.6H.sub.4); 8.94-11.21 (3H,
br s, NH, NH, OH). Anal. Calcd for
C.sub.17H.sub.14N.sub.2O.sub.4S*0.4H.sub.2O: C, 58.58; H, 4.27; N,
8.01. Found: C, 58.12; H, 4.03; N, 7.80.
Example 188
4-Iodo-N-phenyl-benzenesulfonamide (52b)
[1325] 325
[1326] Using an analogous method, the title compound was obtained
from 4-iodobenzenesulfonyl chloride (51b) and aniline, yield 86%,
m.p. 135-137.degree. C. .sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.:
6.85-7.36 (5H, m, C.sub.6H.sub.5); 7.52 (2H, d, J=8.5 Hz,
C.sub.6H.sub.2); 7.89 (2H, d, J=8.5 Hz, C.sub.6H.sub.2); 10.32 (1H,
s, NH).
Example 189
4-(3-Hydroxyprop-1-ynyl)-N-phenylbenzenesulfonamide (53b)
[1327] 326
[1328] Using an analogous method, the title compound was obtained
from 4-iodo-N-phenyl-benzenesulfonamide (52b) and propargyl
alcohol, yield 86%, m.p. 161-163.degree. C. .sup.1H NMR
(DMSO-d.sub.6, HMDSO) .delta.: 4.29 (2H, d, J=6.0 Hz, CH.sub.2);
5.38 (1H, t, J=6.0 Hz, OH); 6.92-7.38 (5H, m, C.sub.6H.sub.5); 7.54
(2H, d, J=9.0 Hz, C.sub.6H.sub.2); 7.73 (2H, d, J=9.0 Hz,
C.sub.6H.sub.2); 10.29 (1H, s, NH).
Example 190
4-(3-Oxoprop-1-ynyl)-N-phenylbenzenesulfonamide (54b)
[1329] 327
[1330] Using an analogous method, the title compound was obtained
from 4-(3-hydroxyprop-1-ynyl)-N-phenylbenzenesulfonamide (53b) and
Dess-Martin reagent, yield 70%, m.p. 161-163.degree. C. .sup.1H NMR
(DMSO-d.sub.6, HMDSO) .delta.: 6.92-7.41 (5H, m, C.sub.6H.sub.5);
7.83 (4H, s, C.sub.6H.sub.4); 9.43 (1H, s, CH); 10.42 (1H, s,
NH).
Example 191
E-5-(4-Phenylsulfamoylphenyl)pent-2-en-4-ynoic Acid Methyl Ester
(55b)
[1331] 328
[1332] Using an analogous method, the title compound was obtained
from 4-(3-oxoprop-1-ynyl)-N-phenylbenzenesulfonamide (54b) and
trimethyl phosphonoacetate, yield 49%, m.p. 153-155.degree. C.
.sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.: 3.72 (3H, s, CH.sub.3);
6.49 (1H, d, J=16.0 Hz, CH); 6.98 (1H, d, J=16.0 Hz, CH); 6.92-7.38
(5H, m, C.sub.6H.sub.5); 7.64 (2H, d, J=9.0 Hz, C.sub.6H.sub.2);
7.76 (2H, d, J=9.0 Hz, C.sub.6H.sub.2); 10.32 (1H, s, NH).
Example 192
5-(4-Phenylsulfamoylphenyl)pent-2-en-4-ynoic Acid (56b)
[1333] 329
[1334] Using an analogous method, the title compound was obtained
from E-5-(4-phenylsulfamoylphenyl)pent-2-en-4-ynoic acid methyl
ester (55b), yield 81%, m.p. 234-236.degree. C. .sup.1H NMR
(DMSO-d.sub.6, HMDSO) .delta.: 6.39 (1H, d, J=16.0 Hz, CH); 6.95
(1H, d, J=16.0 Hz, CH); 6.94-7.39 (5H, m, C.sub.6H.sub.5); 7.69
(2H, d, J=9.0 C.sub.6H.sub.2); 7.83 (2H, d, J=9.0 Hz,
C.sub.6H.sub.2); 10.36 (1H, s, NH), 12.77 (1H, br s, OH).
Example 193
E-5-(4-Phenylsulfamoylphenyl)pent-2-en-4-ynoic Acid Hydroxyamide
(58b) (PX117453)
[1335] 330
[1336] Using an analogous method, the title compound was obtained
from 5-(4-phenylsulfamoylphenyl)pent-2-en-4-ynoic acid (56b) via
(E)-5-[4-phenylsulfamoylphenyl]-2-penten-4-ynoyl chloride (57b),
yield 59%, m.p. 161-163.degree. C. .sup.1H NMR (DMSO-d.sub.6,
HMDSO) 6:6.38 (1H, d, J=16.0 Hz, CH); 6.78 (1H, d, J=16.0 Hz, CH);
6.89-7.43 (5H, m, C.sub.6H.sub.5); 7.67 (2H, d, J=9.0 Hz,
C.sub.6H.sub.2); 7.78 (2H, d, J=9.0 Hz, C.sub.6H.sub.2); 10.05 (3H,
br s, NH, NH, OH). Anal. Calcd for C.sub.17H.sub.14N.sub.2O.sub.4S*
0.25H.sub.2O: C, 58.86; H, 4.21; N, 8.08. Found: C, 58.36; H, 3.93;
N, 7.82.
Example 194
Sodium 6-ethoxy-6-oxo-1-hexanesulfonate (62b)
[1337] 331
[1338] To a solution of ethyl 6-bromohexanoate (61 b) (2.48 g, 11.0
mmol) in ethanol (6 ml) a solution of sodium sulfite (2.16 g, 20.6
mmol) in water (9 ml) was added and the resulting mixture was
refluxed for 1 hour. The reaction mixture was evaporated under
reduced pressure and the obtained solid was extracted with boiling
ethanol in Soxhlet extraction apparatus for 15-20 hours. The
extract was evaporated and the residue was crystallised from
ethanol-diethyl ether (1:10) giving the title compound (2.71 g,
99%) in a form of a white solid material. .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 1.05-1.78 (6H, m); 1.17 (3H, t,
J=7.2 Hz); 2.26 (4H, t, J=7.5 Hz); 4.05 (2H, q, J=7.2 Hz).
Example 195
Ethyl 6-(chlorosulfonyl)hexanoate (63b)
[1339] 332
[1340] Sodium 6-ethoxy-6-oxo-1-hexanesulfonate (62b) (1.68 g, 6.8
mmol) was mixed with phosphorus pentachloride and the mixture was
carefully pestled in a mortar. After the reaction came to the end
(the foaming of the reaction mixture ceased) the mixture was
extracted with dry benzene (50 ml). The extract was evaporated
under reduced pressure and the residue was dried in vacuum to give
crude title compound (1.03 g, 61%) as a hygroscopic oil. The
chloride (63b) was used in further reactions without additional
purification.
Example 196
Ethyl 6-(amilinosulfonyl)hexanoate (64b)
[1341] 333
[1342] To a solution of ethyl 6-(chlorosulfonyl)hexanoate (63b)
(0.5 g, 2.0 mmol) in benzene (5 ml) aniline (0.8 g, 8.5 mmol) was
added and the resulting solution was stirred at ambient temperature
for 24 hours. The reaction mixture was partitioned between ethyl
acetate and 1N HCl. The organic layer was washed successively with
water, saturated NaCl, and dried (Na.sub.2SO.sub.4). The solvent
was evaporated and the residue was chromatographed on silica gel
with petroleum ether-tert-butylmethyl ether (3:2, v/v) as eluent to
give the title compound (0.45 g, 75%) as an oil. .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 1.03-1.81 (6H, m); 1.15 (3H, t,
J=7.1 Hz); 2.23 (2H, t, J=6.8 Hz); 3.07 (2H, t, J=7.6 Hz); 4.04
(2H, q, J=7.1 Hz); 7.00-7.47 (5H, m); 9.76 (1H, s).
Example 197
6-(Anilinosulfonyl)-N-hydroxyhexanamide (67b) (PX117234)
[1343] 334
[1344] To a mixture of ethyl 6-(anilinosulfonyl)hexanoate (64b) and
hydroxylamine hydrochloride (0.43 g, 6.2 mmol) in methanol (5 ml)
the 3.43 N solution of sodium methylate (2.62 ml, 9.0 mmol) in
methanol was added and the reaction was stirred at ambient
temperature for 40 min. The reaction mixture was poured into
saturated NaH.sub.2PO.sub.4 (15 ml) and extracted with ethyl
acetate. The extract was washed successively with water, saturated
NaCl, and dried (Na.sub.2SO.sub.4). The solvent was evaporated, the
residue was washed with diethyl ether and crystallised from ethyl
acetate. The title compound (0.3 g, 69%) was obtained as white
crystals, m.p. 97-98.degree. C. .sup.1H NMR (DMSO-d.sub.6, HMDSO),
.delta.: 1.02-1.78 (m, 6H, CH.sub.2); 1.90 (br t, 2H, J=6.4 Hz,
CH.sub.2); 3.06 (t, 2H, J=7.0 Hz, CH.sub.2); 6.94-7.60 (m, 5H,
arom.); 8.66 (br s, 1H, NH); 9.76 (br s, 1H, NH); 10.36 (br s, 1H,
OH). HPLC analysis on Symmetry C.sub.8 column: impurities 3.5%
(column size 3.9.times.150 mm; mobile phase acetonitrile--0.1M
phosphate buffer (pH 2.5), 30:70; detector UV 220 nm; flow rate 1.1
ml/min; sample concentration 0.4 mg/ml). Anal. Calcd for
C.sub.12H.sub.18N.sub.2O.sub.4S- , %: C, 50.33; H, 6.34; N, 9.78,
S, 11.20. Found, %: C, 50.10; H, 6.22; N, 9.83, S, 11.10.
Example 198
Sodium 5-ethoxy-5-oxo-1-pentanesulfonate (62a)
[1345] 335
[1346] Using an analogous method, the title compound was obtained
from ethyl 5-bromopentanoate (61a) and sodium sulfite in a form of
white crystals, yield 98%.
[1347] .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 1.17 (3H, t,
J=7.0 Hz); 1.37-1.73 (4H, m); 2.12-2.56 (4H, m, partially
overlapped with a signal of DMSO); 4.04 (2H, q, J=7.0 Hz).
Example 199
Ethyl 6-(chlorosulfonyl)pentanoate (63a)
[1348] 336
[1349] Using an analogous method, the title compound was obtained
from sodium 5-ethoxy-5-oxo-1-pentanesulfonate (62a) and phosphorus
pentachloride, ca. yield of the crude product 90% (hygroscopic
oil).
Example 200
Ethyl 6-(anilinosulfonyl)pentanoate (64a)
[1350] 337
[1351] Using an analogous method, the title compound was obtained
from ethyl 6-(chlorosulfonyl)pentanoate (63a) and aniline as an
oil, yield 38%. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 1.15
(3H, t, J=7.0 Hz); 1.48-1.81 (4H, m); 2.27 (2H, t, J=6.2 Hz); 3.09
(2H, t, J=6.7 Hz); 4.04 (2H, q, J=7.0 Hz); 6.98-7.48 (5H, m); 9.78
(1H, s).
Example 201
5-(Anilinosulfonyl)-N-hydroxypentanamide (67a) (PX117233)
[1352] 338
[1353] Using an analogous method, the title compound was obtained
from ethyl 6-(anilinosulfonyl)pentanoate (64a) and hydroxylamine
hydrochloride, yield 49%, m.p. 128-129.degree. C. (from ethyl
acetate). .sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.: 1.37-1.78 (m,
4H, CH.sub.2); 1.92 (t, 2H, J=5.9 Hz, CH.sub.2); 3.07 (t, 2H, J=7.0
Hz, CH.sub.2); 6.97-7.47 (m, 5H, C.sub.6H.sub.5); 8.69 (s, 1H, NH);
9.78 (s, 1H, NH); 10.33 (s, 1H, OH). HPLC analysis on Symmetry
C.sub.8 column: impurities 1.2% (column size 3.9.times.150 mm;
mobile phase acetonitrile--0.1M phosphate buffer (pH 2.5), 25:75;
detector UV 220 nm; flow rate 1.2 ml/min; sample concentration 0.5
mg/ml). Anal. Calcd for C.sub.11H.sub.16n.sub.2O.sub.4S, %: C,
48.52; H, 5.92; N, 10.29; S, 11.77. Found, %: C, 48.57; H, 5.92; N,
10.21; S, 11.65.
Example 202
Ethyl 5-[(2-naphthylamino)sulfonyl]pentanoate (64e)
[1354] 339
[1355] Using an analogous method, the title compound was obtained
from ethyl 6-(chlorosulfonyl)pentanoate (63a) and 2-naphthylamine
as brown crystals, yield 20%. .sup.1H NMR (DMSO-d.sub.6, HMDSO),
.delta.: 1.11 (3H, t, J=7.1 Hz); 1.35-1.88 (4H, m); 2.25 (2H, t,
J=6.2 Hz); 3.18 (2H, t, J=6.7 Hz); 3.99 (2H, q, J=7.1 Hz); 7.27
(7H, m); 10.03 (1H, s).
Example 203
N-Hydroxy-5-[(2-naphthylamino)sulfonyl]pentanamide (67e)
(PX117235)
[1356] 340
[1357] Using an analogous method, the title compound was obtained
from ethyl 5-[(2-naphthylamino)sulfonyl]pentanoate (64e) and
hydroxylamine hydrochloride, yield 55%, m.p. 163-164.degree. C.
(from ethyl acetate). .sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.:
1.39-1.78 (m, 4H, CH.sub.2); 1.93 (t, 2H, J=6.4 Hz, CH.sub.2); 3.16
(m, 2H, overlapped with a H.sub.2O signal from DMSO-d.sub.6,
CH.sub.2); 7.30-7.61 (m, 3H, arom.); 7.67 (1H, d, J=2.0 Hz, arom.);
7.76-7.99 (m, 3H, arom.); 8.67 (br s, 1H, NH); 10.00 (br s, 1H,
NH); 10.31 (br s, 1H, OH). HPLC analysis on Symmetry C.sub.18
column: impurities 1% (column size 3.9.times.150 mm; mobile phase
acetonitrile--0.1M phosphate buffer (pH 2.5), 35:65; detector UV
230 nm; flow rate 1.1 ml/min; sample concentration 0.5 mg/ml).
Anal. Calcd for C.sub.15H.sub.18N.sub.2O.sub.4S, %: C, 55.89; H,
5.63; N, 8.69, S, 9.95. Found, %: C, 55.83; H, 5.52; N, 8.68, S,
9.95.
Example 204
Sodium 7-methoxy-7-oxo-1-heptanesulfonate (62c)
[1358] 341
[1359] Using an analogous method, the title compound was obtained
from methyl 7-bromoheptanoate (61c) and sodium sulfite as white
crystals, yield 98%. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.:
1.05-1.76 (8H, m); 2.27 (4H, t, partially overlapped with a signal
of DMSO, J=6.6 Hz); 3.58 (3H, s).
Example 205
Methyl 7-(chlorosulfonyl)heptanoate (63c)
[1360] 342
[1361] Using an analogous method, the title compound was obtained
from sodium 7-methoxy-7-oxo-1-heptanesulfonate (62c) and phosphorus
pentachloride, ca. yield of the crude product 73% (hygroscopic
oil).
Example 206
Methyl 7-(anilinosulfonyl)heptanoate (64c)
[1362] 343
[1363] Using an analogous method, the title compound was obtained
from methyl 7-(chlorosulfonyl)heptanoate (63c) and aniline as an
oil, yield 53%. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.:
1.05-1.83 (8H, m); 2.24 (2H, t, J=6.8 Hz); 3.06 (2H, t, J=7.4 Hz);
3.57 (3H, s); 6.97-7.45 (5H, m); 9.76 (1H, s).
Example 207
5-(Anilinosulfonyl)-N-hydroxyheptanamide (67c) (PX117236)
[1364] 344
[1365] Using an analogous method, the title compound was obtained
from methyl 7-(anilinosulfonyl)heptanoate (64c) and hydroxylamine
hydrochloride, yield 74%, m.p. 94-95.degree. C. (from ethyl
acetate). .sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.: 1.07-1.51 (m,
6H, CH.sub.2); 1.53-1.73 (m, 2H, CH.sub.2); 1.89 (t, 2H, J=7.2 Hz,
CH.sub.2); 3.04 (t, 2H, J=7.6 Hz, CH.sub.2); 7.03-7.40 (m, 5H,
C.sub.6H.sub.5); 8.67 (s, 1H, NH); 9.78 (s, 1H, NH); 10.33 (s, 1H,
OH). HPLC analysis on Symmetry Co column: impurities 3.5% (column
size 3.9.times.150 mm; mobile phase acetonitrile --0.1M phosphate
buffer (pH 2.5), 35:65; detector UV 220 nm; flow rate 0.9 ml/min;
sample concentration 0.3 mg/ml). Anal. Calcd for
C.sub.13H.sub.20N.sub.2O.sub.4S, %: C, 51.98; H, 6.71; N, 9.33; S,
10.67. Found, %: C, 51.83; H, 6.64; N, 9.23; S, 10.65.
Example 208
Sodium 8-methoxy-8-oxo-1-octanesulfonate (62d)
[1366] 345
[1367] Using an analogous method, the title compound was obtained
from methyl 8-bromooctanoate (61d) and sodium sulfite as white
crystals, yield 98%. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.:
1.00-1.75 (10H, m); 2.28 (4H, t, partially overlapped with a signal
of DMSO, J=7.8 Hz); 3.58 (3H, s).
Example 209
Methyl 8-(chlorosulfonyl)octanoate (63d)
[1368] 346
[1369] Using an analogous method, the title compound was obtained
from sodium 8-methoxy-8-oxo-1-octanesulfonate (62d) and phosphorus
pentachloride, ca. yield of the crude product 73% (hygroscopic
oil).
Example 210
Methyl 8-(anilinosulfonyl)octanoate (64d)
[1370] 347
[1371] Using an analogous method, the title compound was obtained
from methyl 8-(chlorosulfonyl)octanoate (63d) and aniline as an
oil, yield 54%. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.:
1.01-1.80 (10H, m); 2.25 (2H, t, J=6.9 Hz); 3.06 (2H, t, J=7.5 Hz);
3.57 (3H, s); 6.99-7.46 (5H, m); 9.75 (1H, s).
Example 211
5-(Anilinosulfonyl)-N-hydroxyoctanamide (67d) (PX117245)
[1372] 348
[1373] Using an analogous method, the title compound was obtained
from methyl 8-(anilinosulfonyl)octanoate (64d) and hydroxylamine
hydrochloride, yield 76%, m.p. 87-88.degree. C. (from ethyl
acetate). .sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.: 1.08-1.51 (m,
8H, CH.sub.2); 1.52-1.73 (m, 2H, CH.sub.2); 1.90 (t, 2H, J=7.2 Hz,
CH.sub.2); 3.05 (t, 2H, J=7.6 Hz, CH.sub.2); 7.02-7.39 (m, 5H,
C.sub.6H.sub.5); 8.66 (s, 1H, NH); 9.74 (s, 1H, NH); 10.32 (s, 1H,
OH). HPLC analysis on Symmetry C.sub.8 column: impurities 3%
(column size 3.9.times.150 mm; mobile phase acetonitrile--0.1M
phosphate buffer (pH 2.5), 35:65; detector UV 220 nm; flow rate 1.1
ml/min; sample concentration 0.4 mg/ml). Anal. Calcd for
C.sub.14H.sub.22N.sub.2O.sub.4S, %: C, 53.48; H, 7.05; N, 8.91, S,
10.20. Found, %: C, 53.23; H, 7.05; N, 8.82, S, 10.25.
Example 212
Methyl 7-[(methylanilino)sulfonyl]heptanoate (65c)
[1374] 349
[1375] Using an analogous method, the title compound was obtained
from methyl 7-(chlorosulfonyl)heptanoate (63c) and N-methylaniline
as white crystals, yield 70%. .sup.1H NMR (DMSO-d.sub.6, HMDSO),
.delta.: 1.10-1.77 (8H, m); 2.26 (2H, t, J=6.8 Hz); 3.11 (2H, t,
J=7.4 Hz); 3.25 (3H, s); 3.57 (3H, s); 7.24-7.51 (5H, m).
Example 213
N-Hydroxy-7-[methylanilino)sulfonyl]heptanamide (68c)
(PX117260)
[1376] 350
[1377] Using an analogous method, the title compound was obtained
from methyl 7-(methylanilinosulfonyl)heptanoate (65c) and
hydroxylamine hydrochloride, yield 59%, m.p. 69-70.degree. C. (from
ethyl acetate). .sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.:
1.11-1.70 (m, 8H, CH.sub.2); 1.91 (t, 2H, J=7.2 Hz, CH.sub.2); 3.09
(t, 2H, J=7.7 Hz, CH.sub.2); 3.25 (s, 3H, CH.sub.3); 7.21-7.45 (m,
5H, C.sub.6H.sub.5); 8.65 (br s, 1H, NH); 10.32 (s, 1H, OH). HPLC
analysis on Symmetry C.sub.18 column: impurities <1% (column
size 3.9.times.150 mm; mobile phase acetonitrile --0.1M phosphate
buffer (pH 2.5), 30:70; detector UV 220 nm; flow rate 1.1 ml/min;
sample concentration 0.5 mg/ml). Anal. Calcd for
C.sub.14H.sub.22N.sub.2O.sub.4S, %: C, 53.48; H, 7.05; N, 8.91, S,
10.20. Found, %: C, 53.44, H, 7.05, N, 8.86, S, 10.13.
Example 214
Ethyl 6-[(methylanilino)sulfonyl]hexanoate (65b)
[1378] 351
[1379] Using an analogous method, the title compound was obtained
from ethyl 6-(chlorosulfonyl)hexanoate (63b) and N-methylaniline as
an oil, yield 43%. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.:
1.10-1.77 (8H, m); 2.26 (2H, t, J=6.8 Hz); 3.11 (2H, t, J=7.4 Hz);
3.25 (3H, s); 3.57 (3H, s); 7.24-7.51 (5H, m).
Example 215
N-Hydroxy-6-[(methylanilino)sulfonyl]hexanamide (68b)
(PX117410)
[1380] 352
[1381] Using an analogous method, the title compound was obtained
from ethyl 6-(methylanilinosulfonyl)hexanoate (65b) and
hydroxylamine hydrochloride, yield 40%, m.p. 121-122.degree. C.
(from ethyl acetate). .sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.:
1.13-1.72 (m, 6H, CH.sub.2); 1.91 (t, 2H, J=7.0 Hz, CH.sub.2); 3.09
(t, 2H, J=7.6 Hz, CH.sub.2); 3.25 (s, 3H, CH.sub.3); 7.22-7.46 (m,
5H, C.sub.6H.sub.5); 8.68 (s, 1H, NH); 10.35 (s, 1H, OH). HPLC
analysis on Zorbax SB-C.sub.18 column: impurities --6% (column size
4.6.times.150 mm; mobile phase methanol--0.1% H.sub.3PO.sub.4,
gradient from 50:50 to 90:10; detector UV 230 nm; flow rate 1.5
ml/min; sample concentration 0.5 mg/ml). Anal. Calcd for
C.sub.13H.sub.20N.sub.2O.sub.4S, %: C, 51.98; H, 6.71; N, 9.33; S,
10.67. Found, %: C, 51.76; H, 6.63, N 9.29; S, 10.63.
Example 216
Methyl 8-[(methylanilino)sulfonyl]octanoate (65d)
[1382] 353
[1383] Using an analogous method, the title compound was obtained
from methyl 8-(chlorosulfonyl)octanoate (63d) and N-methylaniline
as an oil, yield 68%. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.:
1.05-1.76 (10H, m); 2.27 (2H, t, J=7.0 Hz); 3.11 (2H, t, J=7.3 Hz);
3.25 (3H, s); 3.57 (3H, s); 7.23-7.51 (5H, m).
Example 217
N-Hydroxy-8-[(methylanilino)sulfonyl]octanamide (68d)
(PX117411)
[1384] 354
[1385] Using an analogous method, the title compound was obtained
from methyl 8-(methylanilinosulfonyl)octanoate (65d) and
hydroxylamine hydrochloride, yield 66%, m.p. 65.5-66.5.degree. C.
(from ethyl acetate). .sup.1H NMR (DMSO-d.sub.6r HMDSO) .delta.:
1.06-1.72 (m, 10H, CH.sub.2); 1.91 (t, 2H, J=7.2 Hz, CH.sub.2);
3.09 (t, 2H, J=7.6 Hz, CH.sub.2); 3.25 (s, 3H, CH.sub.3); 7.21-7.50
(m, 5H, C.sub.6H.sub.5); 8.64 (s, 1H, NH); 10.31 (s, 1H, OH
analysis on Zorbax SB-C.sub.18 column: impurities --6% (column size
4.6.times.150 mm; mobile phase methanol --0.1% H.sub.3PO.sub.4,
gradient from 50:50 to 90:10; detector UV 230 nm; flow rate 1.5
ml/min; sample concentration 0.7 mg/ml). Anal. Calcd for
C.sub.15H.sub.24N.sub.2O.sub.4S, %: C, 54.86; H, 7.37; N, 8.53, S,
9.76. Found, %: C, 54.68, H, 7.30, N, 8.55, S, 9.70.
Example 218
Ethyl 6-[(benzylanilino)sulfonyl]hexanoate (66b)
[1386] 355
[1387] To a cold solution (ice bath) of ethyl
6-(anilinosulfonyl)hexanoate (64b) (0.86 g, 2.88 mmol) in
1,2-dimethoxyethane (5 ml) a 60% suspension of sodium hydride in
mineral oil (0.12 g, 3.0 mmol) and a solution of benzylbromide
(0.49 g, 2.88 mmol) in 1,2-dimethoxyethane (3 ml) were added, and
the resulting solution was stirred at ambient temperature for 24
hours. The reaction mixture was poured into water and the resulting
mixture was extracted with ethyl acetate. The organic layer was
washed successively with water, saturated NaCl, and dried
(Na.sub.2SO.sub.4). The solvent was evaporated and the residue was
chromatographed on silica gel with petroleum ether-tert-butylmethyl
ether (3:2, v/v) as eluent to give the title compound (0.56 g, 50%)
as an oil. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 1.16 (3H, t,
J=7.0 Hz); 1.21-1.87 (6H, m); 2.27 (2H, t, J=6.6 Hz); 3.21 (2H, t,
partially overlapped with a signal of H.sub.2O, J=7.6 Hz); 4.05
(2H, q, J=7.0 Hz); 4.89 (2H, s); 7.14-7.58 (10H, m).
Example 219
6-[(Benzylanilino)sulfonyl]-N-hydroxyhexanamide (69b)
(PX117414)
[1388] 356
[1389] Using an analogous method, the title compound was obtained
from ethyl 6-[(benzylanilino)sulfonyl]hexanoate (66b) and
hydroxylamine hydrochloride, yield 93%, m.p. 129-129.5.degree. C.
(from ethyl acetate). .sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.:
1.11-1.56 (m, 4H, CH.sub.2); 1.61-1.79 (m, 2H, CH.sub.2); 1.93 (t,
2H, J=7.2 Hz, CH.sub.2); 3.19 (t, 2H, J=7.5 Hz, CH.sub.2); 4.89 (s,
2H, CH.sub.2Ph); 7.16-7.41 (m, 10H, 2C.sub.6H.sub.5); 8.67 (s, 1H,
NH); 10.36 (s, 1H, OH). HPLC analysis on Symmetry C.sub.18 column:
impurities 3% (column size 3.9.times.150 mm; acetonitrile-0.1M
phosphate buffer (pH 2.5), 40:60; detector UV 220 nm; flow rate 1.2
ml/min; sample concentration 0.5 mg/ml). Anal. Calcd for
C.sub.19H.sub.24N.sub.2O.sub.4S, %: C, 60.62; H, 6.43; N, 7.44, S,
8.52. Found, %: C, 60.37; H, 6.35; N, 7.45, S, 8.46.
Example 220
Methyl 8-[(benzylanilino)sulfonyl]octanoate (66d)
[1390] 357
[1391] Using an analogous method, the title compound was obtained
from methyl 8-(anilinosulfonyl)octanoate (64d), 60% suspension of
sodium hydride in mineral oil, and benzylamine as white crystals,
yield 23%. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 1.06-1.87
(10H, m); 2.28 (2H, t, J=6.8 Hz); 3.21 (2H, t, J=7.8 Hz); 3.58 (3H,
s); 4.89 (2H, s); 7.14-7.45 (10H, m).
Example 221
8-[(Benzylanilino)sulfonyl]-N-hydroxyoctanamide (69d)
(PX117412)
[1392] 358
[1393] Using an analogous method, the title compound was obtained
from methyl 8-[(benzylanilino)sulfonyl]octanoate (66d) and
hydroxylamine hydrochloride, yield 83%, m.p. 119-119.5.degree. C.
(from ethyl acetate). .sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.:
1.11-1.57 (m, 8H, CH.sub.2); 1.60-1.81 (m, 2H, CH.sub.2); 1.93 (t,
2H, J=7.2 Hz, CH.sub.2); 3.20 (t, 2H, J=7.5 Hz, CH.sub.2); 4.89 (s,
2H, CH.sub.2Ph); 7.17-7.41 (m, 10H, 2C.sub.6H.sub.5); 8.67 (s, 1H,
NH); 10.34 (s, 1H, OH). HPLC analysis on Symmetry Ca column:
impurities 5.6% (column size 3.9.times.150 mm; acetonitrile--0.1M
phosphate buffer (pH 2.5), 50:50; detector UV 220 nm; flow rate 1.3
ml/min; sample concentration 0.5 mg/ml). Anal. Calcd for
C.sub.21H.sub.28N.sub.2O.sub.4S*0.25H.sub.2O, %: C, 61.67; H, 7.02;
N, 6.85, S, 7.84. Found, %: C, 61.50; H, 6.87; N, 6.85, S,
7.89.
Example 222
3-(4-Nitro-phenyl)-acrylic acid methyl ester (72)
[1394] 359
[1395] Thionyl chloride (28.8 ml, 0.4 mol) was added dropwise to
methanol (450 ml) at -10.degree. C. temperature. To the obtained
solution was added 3-(4-nitrophenyl)-acrylic acid (71) (38.63 g,
0.2 mol) and the reaction mixture was stirred at 0.degree. C. for 3
hours, at ambient temperature for 24 hours and at 40.degree. C. for
1 hour. The resulting precipitate was filtered, washed with
methanol (2.times.10 ml) and dried affording the title compound in
a form of yellow crystals (39.55 g, 96%). .sup.1H NMR
(DMSO-d.sub.6, HMDSO), .delta.: 3.69 (2H, br s); 3.77 (3H, s); 6.87
(1H, d, J=116.0 Hz); 7.67-8.39 (5H, m).
Example 223
3-(4-Amino-phenyl)-acrylic Acid Methyl Ester (73)
[1396] 360
[1397] A mixture of 3-(4-nitro-phenyl)-acrylic acid methyl ester
(72) (39.54 g, 0.191 mol) and SnCl.sub.2.2H.sub.2O (220 g, 0.98
mol) in anhydrous ethanol (300 ml) was heated at 50.degree. C. for
1 hour and at 75.degree. C. for 1 hour. The reaction mixture was
allowed to cool to 10.degree. C., treated with 20% NaOH solution to
pH 8-9, and extracted with ethyl acetate (3.times.200 ml). The
organic extract was washed with saturated NaCl (3.times.150 ml),
dried (MgSO.sub.4), and evaporated under reduced pressure.
Recrystallization from isopropanol (180 ml) afforded pure title
compound in a form of yellowish crystals (17.938 g, 53%). .sup.1H
NMR (DMSO-d.sub.6, HMDSO), .delta.: 3.64 (3H, s); 5.73 (2H, s);
6.22 (1H, d, J=16.0 Hz); 6.57 (2H, d, J=8.0 Hz); 7.38 (2H, d, J=8.0
Hz); 7.50 (1H, d, J=16.0 Hz).
Example 224
3-(4-Benzenesulfonylamino-phenyl)-acrylic Acid Methyl Ester
(74)
[1398] 361
[1399] To a suspension of 3-(4-amino-phenyl)-acrylic acid methyl
ester (73) (1.740 g, 6.18 mmol) in methylene chloride (10 ml)
benzenesulfonyl chloride (1.094 g, 6.20 mmol) and pyridine (0.563
g, 7.00 mmol) were added. The resulting suspension was stirred at
15.degree. C. for 24 hours and filtrated. The precipitate was
washed with methylene chloride (10 ml), NaHCO.sub.3 solution (10
ml), and water (2.times.20 ml). The obtained solid was dried to
give the title compound (1.962 g, 75%). .sup.1H NMR (DMSO-d.sub.6,
HMDSO), .delta.: 3.71 (3H, s); 6.51 (1H, d, J=16.0 Hz); 7.57-8.11
(10H, m); 10.59 (1H, s).
Example 225
3-(4-Benzenesulfonylaminophenyl)-N-hydroxyacrylamide (75)
(PX106499)
[1400] 362
[1401] To a mixture, consisting of dioxane (25 ml), methanol (3
ml), and water (1 ml), hydroxylamine hydrochloride (0.834 g, 12
mmol) and NaOH (0.960 g, 24 mmol) followed by
3-(4-benzenesulfonylamino-phenyl)-acrylic acid methyl ester (74)
(1.735 g, 4.1 mmol)) were added. The resulting mixture was
vigorously stirred at ambient temperature for 24 hours and
evaporated under reduced pressure. The residue was mixed with warm
(50.degree. C.) water and filtered. The aqueous solution was
acidified with hydrochloric acid to pH 4 and filtered. The
precipitate was washed with water (2.times.10 ml), ethyl acetate
(10 ml), and crystallised from acetonitrile (15 ml) to give title
compound as a yellow solid (0.405 g, 31%). M.p. 189-191.degree. C.
.sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.: 6.30 (d, 1H, J=15.8 Hz);
7.12 (d, 2H, J=8.6 Hz); 7.32 (d, 1H, J=15.8 Hz); 7.45 (d, 2H, J=8.4
Hz); 7.48-7.86 (6H, m); 9.01 (s, 1H); 10.56 (s, 1H); 10.72 (s, 1H).
HPLC analysis on Zorbax SB-C18 column: impurities 1.8% (column size
4.6.times.150 mm; mobile phase acetonitrile --0.1% H.sub.3PO.sub.4,
gradient from 30:70 to 100:0; sample concentration 1.0 mg/ml;
detector UV 220 nm). Anal. Calcd for C.sub.15H.sub.14N.sub.2O.sub.-
4S, %: C, 56.59; H, 4.43; N, 8.80, S. 10.07. Found, %: C, 56.03, H,
4.24; N, 8.66; S, 10.02.
Example 226
3-[4-(Biphenyl-4-sulfonylamino)-phenyl]-acrylic Acid (82a)
[1402] 363
[1403] To a solution of 3-(4-aminophenyl)-acrylic acid
hydrochloride (81) (0.3 g, 1.5 mmol) in dioxane (10 ml) and 0.63 M
NaHCO.sub.3 (9.56 ml, 6.0 mmol) biphenyl-4-sulfochloride (0.5 g,
1.78 mmol) was added and the resulting mixture was stirred at room
temperature for 60 min. The reaction mixture was partitioned
between ethyl acetate and 2N HCl. The organic layer was washed
successively with water, saturated NaCl, and dried
(Na.sub.2SO.sub.4). The solvent was evaporated and the residue was
crystallised from acetonitrile to give the title compound (0.27 g,
47%). .sup.1H NMR (DMSO-d.sub.6, HMDSO), &, 6.37 (1H, d, J=16.0
Hz); 7.19 (2H, d, J=8.0 Hz); 7.36-7.80 (8H, m); 7.86 (5H, m); 10.66
(1H, br s).
Example 227
3-[4-(Biphenyl-4-sulfonylamino)-phenyl]-acryloyl Chloride (83a)
[1404] 364
[1405] To a suspension of
3-[4-(biphenyl-4-sulfonylamino)-phenyl]-acrylic acid (82a) (0.27 g,
0.71 mmol) in dichloromethane (3 ml) oxalyl chloride (0.3 ml, 3.39
mmol) and one drop of dimethylformamide were added. The reaction
mixture was stirred at 40.degree. C. for one hour and concentrated
under reduced pressure to give crude title compound (0.277 g,
98%).
Example 228
(E)-N-Hydroxy-3-[4-(4-biphenylsulfonylamino)-phenyl]-2-propenamide
(84a) (PX117793)
[1406] 365
[1407] To a suspension of hydroxylamine hydrochloride (0.27 g, 3.88
mmol) in tetrahydrofuran (5 ml) saturated NaHCO.sub.3 solution (3
ml) was added and the resultant mixture was stirred at ambient
temperature for 10 min. To the reaction mixture a solution. of
crude 3-[3-(3-methoxy-phenylsulfam- oyl)-phenyl]-acryloyl chloride
(83a) (0.27 g, 0.68 mmol) in tetrahydrofuran (3.5 ml) was added and
the mixture was stirred at ambient temperature for one hour. The
reaction mixture was partitioned between ethyl acetate and 2N HCl.
The organic layer was washed successively with water and saturated
NaCl, then the solvent was removed. The residue was crystallised
from acetonitrile and washed with diethyl ether affording the title
compound as a white solid (0.1 g, 37%). M.p. 190-191.5.degree. C.
.sup.1H NMR (DMSO-d.sub.6, HMDSO) .delta.: 6.29 (1H, d, J=16.0 Hz);
7.16 (2H, d, J=8.0 Hz); 7.24-7.78 (8H, m); 7.86 (4H, m); 8.94 (1H,
br s); 10.57 (1H, s); 10.66 (1H, br s). HPLC analysis on Zorbax
SB-C18 column: impurities 4% (column size 4.6.times.150 mm; mobile
phase acetonitrile--0.1% H.sub.3PO.sub.4, gradient from 30 to 100%;
sample concentration 0.2 mg/ml; flow rate 1.0 ml/min; detector UV
254 nm). Anal. Calcd for C.sub.21H.sub.18N.sub.2O.sub.4S, %: C,
63.94; H, 4.60; N, 7.10. Found, %: C C, 63.64; H, 4.45; N,
7.00.
Example 229
3-[4-(3,4-Dimethoxy-benzenesulfonylamino)-phenyl]-acrylic Acid
(82b)
[1408] 366
[1409] Using an analogous method, the title compound was obtained
from 3-(4-aminophenyl)-acrylic acid hydrochloride (81) and
3,4-dimethoxybenzenesulfonyl chloride as a white solid, yield 56%.
.sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 3.74 (3H, s); 3.77 (3H,
s); 6.34 (1H, d, J=16.0 Hz); 6.94-7.69 (8H, m); 10.36 (1H, br
s).
Example 230
3-[4-(3,4-Dimethoxy-benzenesulfonylamino)-phenyl]-acryloyl Chloride
(83b)
[1410] 367
[1411] Using an analogous method, the title compound was obtained
from 3-[4-(3,4-dimethoxy-benzenesulfonylamino)-phenyl]-acrylic acid
(82b) and oxalyl chloride, yield of the crude product ca. 76%.
Example 231
(E)-N-Hydroxy-3-[4-(3,4-dimethoxyphenylsulfonylamino)-phenyl]-2-propenamid-
e (84b) (PX117794)
[1412] 368
[1413] Using an analogous method, the title compound was obtained
from 3-[4-(3,4-dimethoxy-benzenesulfonylamino)-phenyl]-acryloyl
chloride (83b) and hydroxylamine hydrochloride, yield 35%. M.p.
178.5-179.degree. C. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.:
3.72 (3H, s); 3.78 (3H, s); 6.32 (1H, d, J=16.0 Hz); 7.00-7.65 (8H,
m); 8.98 (1H, br s); 10.32 (1H, br s); 10.69 (1H, s). HPLC analysis
on Zorbax SB-C18 column: impurities 3.5% (column size 4.6.times.150
mm; mobile phase acetonitrile--0,1 M phosphate buffer (pH 2.5),
25:75; sample concentration 0.5 mg/ml; flow rate 1.0 ml/min;
detector UV 254 nm). Anal. Calcd for
C.sub.17H.sub.18N.sub.2O.sub.6S, %: C, 53.96; H, 4.79; N, 7.40.
Found, %: C, 53.58; H, 4.56; N, 7.62.
Example 232
6-Benzenesulfonylaminohexanoic Acid Methyl Ester (93a)
[1414] 369
[1415] Benzenesulfonyl chloride (92a) (0.88 g, 5.0 mmol) was added
to the mixture of methyl 6-aminohexanoate hydrochloride (91) (1.82
g, 10 mmol) in acetonitrile (10 ml) and sodium carbonate (2.6 g,
24.6 mmol) in water (10 ml). The mixture was stirred for 6 hours at
ambient temperature, and the product was extracted with ethyl
acetate (30 ml). The extract was dried (Na.sub.2SO.sub.4) and
solvents were removed under reduced pressure. The product was
chromatographed on silica gel with ethyl acetate-hexane (1:2) as
eluent. The title compound was obtained as oil (1.28 g, 90%).
.sup.1H NMR SH (90 MHz, DMSO-d.sub.6) .delta.: 0.90-1.63 (6H, m,
CH.sub.2); 2.21 (2H, t, J=7.0 Hz, CH.sub.2); 2.71 (2H, q, J=6.0 Hz,
CH.sub.2N); 3.58 (3H, s, CH.sub.3); 7.40-7.72 (3H, m,
C.sub.6H.sub.3); 7.72-7.89 (2H, m, C.sub.6H.sub.2).
Example 233
6-Benzenesulfonylaminohexanoic Acid Hydroxyamide (94a)
(PX106522)
[1416] 370
[1417] By an analogous method, the title compound was obtained from
6-benzenesulfonylaminohexanoic acid methyl ester (93a). Yield 47%,
m.p. 80-82.degree. C. .sup.1H NMR SH (90 MHz, DMSO-d.sub.6)
.delta.: 0.98-1.58 (6H, m, CH.sub.2); 1.87 (2H, t, J=7.5 Hz,
CH.sub.2); 2.69 (2H, q, J=6.0 Hz, CH.sub.2N); 7.38-7.69 (4H, m,
C.sub.6H.sub.3, NH); 7.69-7.87 (2H, m, C.sub.6H.sub.2); 8.58 (1H,
s, NH), 10.27 (1H, s, OH). HPLC analysis on Symmetry c.sub.18
column: impurities <1% (column size 3.9.times.150 mm; mobile
phase acetonitrile--0.1M phosphate buffer (pH 2.5), 25:75; detector
UV 220 nm; sample concentration 1.0 mg/ml). Anal. Calcd for
C.sub.12H.sub.18N.sub.2O.sub.4S: C, 50.33; H, 6.34; N, 9.78. Found:
C, 50.48; H, 6.25; N, 9.69.
Example 234
6-(E-2-Phenylethenesulfonylamino)hexanoic Acid Methyl Ester
(93b)
[1418] 371
[1419] By an analogous method, the title compound was obtained from
2-phenylethenesulfonyl chloride (92b) and and methyl
6-aminohexanoate hydrochloride (91) by the method of example 2,
yield 56%, m.p. 47-49.degree. C. .sup.1H NMR .delta.H (90 MHz,
DMSO-d.sub.6) .delta.: 0.98-1.66 (6H, m, CH.sub.2); 1.91 (2H, t,
J=6.5 Hz, CH.sub.2); 2.83 (2H, t, J=6.0 Hz, CH.sub.2); 3.59 (3H, s,
CH.sub.3); 7.14 (1H, d, J=16.0 Hz, CH); 7.33 (1H, d, J=16.0 Hz,
CH); 7.33-7.89 (5H, m, C.sub.6H.sub.5).
Example 235
6-(2-Phenylethenesulfonylamino)hexanoic Acid Hydroxyamide (94b)
(PX117429)
[1420] 372
[1421] By an analogous method, the title compound was obtained from
6-(E-2-phenylethenesulfonylamino)hexanoic acid methyl ester (93b).
Yield 62%, m.p. 107-109.degree. C. .sup.1H NMR SH. (90 MHz,
DMSO-d.sub.6) 8:1.03-1.670 (6H, m, CH.sub.2); 2.25 (2H, t, J=6.6
Hz, CH.sub.2); 2.86 (2H, t, J=6.5 Hz, CH.sub.2); 7.13 (1H, d,
J=16.0 Hz, CH); 7.36 (1H, d, J=16.0 Hz, CH); 7.36-7.87 (5H, m,
C.sub.6H.sub.5); 8.38-9.43 (3H, br s, NH, NH, OH). HPLC analysis on
Symmetry C.sub.18 column: impurities <1% (column size
3.9.times.150 mm; mobile phase acetonitrile--0.1M phosphate buffer
(pH 2.5), 30:70; detector UV 230 nm; sample concentration 0.11
mg/ml). Anal. Calcd for C.sub.14H.sub.20N.sub.2O.sub.4S: C, 53.83;
H, 6.45; N, 8.97. Found: C, 53.30; H, 6.32; N, 8.53.
Example 236
6-(Pyridine-3-sulfonylamino)hexanoic Acid Methyl Ester (93c)
[1422] 373
[1423] Pyridine-3-sulfonyl chloride hydrochloride (92c) (1.8 g, 5.0
mmol) was added to a solution of methyl 6-aminohexanoate
hydrochloride (91) (1.82 g, 10 mmol) and triethylamine (3.03 g, 30
mmol) in acetonitrile (30 ml). The mixture was stirred for 1 hour
at ambient temperature, filtered and solvents were removed under
reduced pressure. The oily product was dissolved in water (15 ml)
and extracted with ethyl ether (50 ml). The extract was dried
(Na.sub.2SO.sub.4) and the solvents were removed under reduced
pressure. The title compound (1.09 g, 76%) was obtained as oil and
was used for the next step without an additional purification.
.sup.1H NMR .delta.H (90 MHz, DMSO-d.sub.6) .delta.: 0.80-1.51 (6H,
m, CH.sub.2); 1.83 (2H, t, J=6.5 Hz, CH.sub.2); 2.76 (2H, t, J=6.5
Hz, CH.sub.2N); 3.58 (3H, s, CH.sub.3); 7.54 (1H, dd, J=5.0 Hz,
J=8.2 Hz, C.sub.5HN); 8.12 (1H, dt, J=2.0 Hz, J=8.2 Hz, C.sub.5HN);
8.61 (1H, dd, J=2.0 Hz, J=5.0 Hz, C.sub.5HN); 8.81 (1H, d, J=2.0
Hz, C.sub.5HN).
Example 237
6-(Pyridine-3-sulfonylamino)hexanoic Acid Hydroxyamide Oxalate
(94c) (PX117432)
[1424] 374
[1425] A solution of sodium methylate (12 mmol) in methanol (10 ml)
was added to a solution of hydroxylamine hydrochloride (0.56 g, 8
mmol) in methanol (16 ml). The mixture was stirred for 10 min, and
NaCl was filtered off. 6-(Pyridine-3-sulfonylamino)hexanoic acid
methyl ester (93c) (0.58 g, 2 mmol) was added to the filtrate and
the mixture was left to stand overnight at ambient temperature. The
precipitate was filtered off, dissolved in water (20 ml) and oxalic
acid (0.36 g, 4 mmol) was added to the solution. Water was removed
under reduced pressure and the product was crystallised from
methanol. The title compound (0.33 g, 44%) was obtained as white
solid. M.p. 132-134.degree. C. .sup.1H NMR .delta.H (90 MHz,
DMSO-d.sub.6) .delta.: 0.78-1.49 (6H, m, CH.sub.2); 1.83 (2H, t,
J=6.5 Hz, CH.sub.2); 2.76 (2H, CH.sub.2N); 7.54 (1H, dd, J=5.0 Hz,
J=8.2 Hz, C.sub.5HN); 8.12 (1H, dt, J=2.0 Hz, J=8.2 Hz, C.sub.5HN);
8.61 (1H, dd, J=2.0 Hz, J=5.0 Hz, C.sub.5HN); 8.81 (1H, d, J=2.0
Hz, C.sub.5HN). HPLC analysis on Symmetry C.sub.18 column:
impurities <1% (column size 3.9.times.150 mm; mobile phase
acetonitrile --0.1M phosphate buffer (pH 2.5), 5:95; detector UV
254 nm; sample concentration 1.0 mg/ml). Anal. Calcd for
C.sub.11H.sub.17N.sub.3O.sub.4S*(COOH).sub.2: C, 41.38; H, 5.07; N,
11.13. Found: C, 41.53, H, 5.10, N, 19.83.
Example 238
3-{3-[(Benzo[1,3]dioxol-5-ylmethyl)-sulfamoyl]-phenyl}acrylic Acid
Methyl Ester
[1426] 375
[1427] A solution of 3-(3-chlorosulfonylphenyl)acrylic acid methyl
ester (0.4 g, 1.53 mmol) in dioxane (5 ml) was added to a mixture
of piperonylamine (0.23 g, 1.52 mmol) in dioxane (1 ml) and
NaHCO.sub.3 (0.25 g, 3.06 mmol) in water (3 ml), and the resultant
solution was stirred at room temperature until the completion of
the reaction (control by TLC). The reaction mixture was evaporated
and the residue was partitioned between ethyl acetate and 2N HCl.
The organic layer was washed successively with water, saturated
NaCl, and dried (Na.sub.2SO.sub.4). The solvent was removed and the
residue was chromatographed on silica gel with petroleum
ether-ethyl acetate (2:1, v/v) as eluent. The obtained product was
washed with diethyl ether to give the title compound (0.47 g, 81%)
as a white solid. .sup.1H NMR (DMSO-d.sub.6, HMDSO), .delta.: 3.72
(3H, s); 3.96 (2H, d, J=6.4 Hz); 5.94 (2H, s); 6.66-6.85 (3H, m);
6.71 (1H, d, J=16.4 Hz); 7.49-8.07 (5H, m); 8.14 (1H, br t, J=6.4
Hz).
Example 239
3-{3-[(Benzo[1,3]dioxol-5-ylmethyl)-sulfamoyl]-phenyl}-acrylic
Acid
[1428] 376
[1429] To a suspension of
3-3-[(benzo[1,3]dioxol-5-ylmethyl)-sulfamoyl]-ph- enyl)-acrylic
acid methyl ester (0.47 g, 1.25 mmol) in methanol (6 ml) 1N NaOH
solution (3.75 ml, 3.75 mmol) was added and the resultant mixture
was stirred at ambient temperature overnight. The reaction mixture
was partitioned between ethyl acetate and water. The aqueous layer
was acidified with 2N HCl solution and stirred for 30 min. The
precipitated solid was filtered, washed with water and dried in
desiccator over P.sub.2O.sub.5. The title compound was obtained as
a white solid (0.39 g, 87%).
Example 240
3-{3-[(Benzo[1,3]dioxol-5-ylmethyl)-sulfamoyl]-phenyl}-acryloyl
Chloride
[1430] 377
[1431] To a suspension of
3-3-[(benzo[1,3]dioxol-5-ylmethyl)-sulfamoyl]-ph- enyl)acrylic acid
(0.39 g, 1.08 mmol) in dichloromethane (4 ml) oxalyl chloride (0.28
ml, 3.24 mmol) and one drop of dimethylformamide were added. The
reaction mixture was stirred at 40.degree. C. for one hour and
concentrated under reduced pressure to give crude title compound
(0.41 g, quant.).
Example 241
3-{3-[(Benzo[1,3]dioxol-5-ylmethyl)-sulfamoyl]-phenyl}-N-hydroxy-acrylamid-
e (PX117226)
[1432] 378
[1433] To a suspension of hydroxylamine hydrochloride (0.37 g, 5.40
mmol) in tetrahydrofuran (6 ml) a saturated NaHCO.sub.3 solution
(4.5 ml) was added and the resultant mixture was stirred at ambient
temperature for 10 min. To the reaction mixture a solution of crude
3-{3-[(benzo[1,3]dioxol-- 5-ylmethyl)-sulfamoyl]-phenyl}-acryloyl
chloride (0.41 g) in tetrahydrofuran (4 ml) was added and the
mixture was stirred at ambient temperature for one hour. The
reaction mixture was partitioned between ethyl acetate and 2N HCl.
The organic layer was washed successively with water and saturated
NaCl, then the solvent was removed. The residue was crystallised
from ethyl acetate and washed with diethyl ether affording the
title compound (0.14 g, 35%). M.p. 163.degree. C. .sup.1H NMR
(DMSO-d.sub.6, HMDSO) .delta.: 3.92 (2H, d, J=6.4 Hz); 5.92 (2H,
s); 6.49 (1H, d, J=16.0 Hz); 6.67 (3H, s); 7.34-7.89 (5H, m); 8.12
(1H, t, J=6.4 Hz); 9.07 (1H, br s); 10.78 (1H, br s). HPLC analysis
on Symmetry C.sub.8 column: impurities 3.5% (column size
3.9.times.150 mm; mobile phase acetonitrile--0.1M phosphate buffer
(pH 2.5), 30:70; sample concentration 0.25 mg/ml; flow rate 1.2
ml/min; detector UV 254 nm). Anal. Calcd for
C.sub.17H.sub.16n.sub.2O.sub.6S, %: C, 54.25; H, 4.28; N, 7.44.
Found, %: C, 54.19; H, 4.20; N, 7.33.
[1434] Biological Activity
[1435] Candidate compounds were assessed for their ability to
inhibit deacetylase activity (biochemical assays) and to inhibit
cell proliferation (cell-based antiproliferation assays), as
described below.
[1436] Primary Assay: Deacetylase Activity
[1437] Briefly, this assay relies on the release of radioactive
acetate from a radioactively labelled histone fragment by the
action of HDAC enzyme. Test compounds, which inhibit HDAC, reduce
the yield of radioactive acetate. Signal (e.g., scintillation
counts) measured in the presence and absence of a test compound
provide an indication of that compound's ability to inhibit HDAC
activity. Decreased activity indicates increased inhibition by the
test compound.
[1438] The histone fragment was an N-terminal sequence from histone
H4, and it was labelled with radioactively labelled acetyl groups
using tritiated acetylcoenzyme A (coA) in conjunction with an
enzyme which is the histone acetyltransferase domain of the
transcriptional coactivator p300. 0.33 mg of peptide H4 (the
N-terminal 20 amino acids of histone H4, synthesised using
conventional methods) were incubated with His6-tagged p300 histone
acetyltransferase domain (amino acids 1195-1673, expressed in E.
coli strain BLR(DE3)pLysS (Novagen, Cat. No. 69451-3) and 3H-acetyl
coA (10 .mu.L of 3.95 Ci/mmol; from Amersham) in a total volume of
300 .mu.L of HAT buffer (50 mM TrisCl pH 8, 5% glycerol, 50 mM KCl,
0.1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM dithiothreitol
(DTT) and 1 mM 4-(2-aminoethyl)-benzenesulfonylfluoride (AEBSF)).
The mixture was incubated at 30.degree. C. for 45 min after which
the His-p300 was removed using nickel-trinitriloacetic acid agarose
(Qiagen, Cat No. 30210). The acetylated peptide was then separated
from free acetyl coA by size exclusion chromatography on Sephadex
G-15 (Sigma G-15-120), using distilled H.sub.2O as the mobile
phase.
[1439] After purification of the radiolabelled histone fragment, it
was incubated with a source of HDAC (e.g., an extract of HeLa cells
(a rich source of HDAC), recombinantly produced HDAC1 or HDAC2) and
any released acetate was extracted into an organic phase and
quantitatively determined using scintillation counting. By
including a test compound with the source of HDAC, that compound's
ability to inhibit the HDAC was determined.
[1440] HeLa Cell Extract
[1441] The HeLa cell extract was made from HeLa cells (ATCC Ref.
No. CCL-2) by freeze-thawing three times in 60 mM Tris Cl pH 8.0,
450 mM NaCl, 30% glycerol. Two cell volumes of extraction buffer
were used, and particulate material was centrifuged out (20800 g,
4.degree. C., 10 min). The supernatant extract having deacetylase
activity was aliquotted and frozen for storage.
[1442] Recombinantly Produced HDAC1 and HDAC2
[1443] Recombinant plasmids were prepared as follows.
[1444] Full length human HDAC1 was cloned by PCR using a
.lambda.gt11 Jurkat cDNA library (Clontech-HL5012b). The amplified
fragment was inserted into the EcoRI-SalI sites of pFlag-CTC vector
(Sigma-E5394), in frame with the Flag tag. A second PCR was carried
out in order to amplify a fragment containing the HDAC1 sequence
fused to the Flag tag. The resulting fragment was subcloned into
the EcoRI-Sac1 sites of the baculovirus transfer vector pAcHTL-C
(Pharmingen-21466P).
[1445] Full length human HDAC2 was subcloned into pAcHLT-A
baculovirus transfer vector (Pharmingen-21464P) by PCR
amplification of the EcoRI-Sac1 fragment from a HDAC2-pFlag-CTC
construct.
[1446] Recombinant protein expression and purification was
performed as follows. HDAC1 and HDAC2 recombinant baculoviruses
were constructed using BaculoGold Transfection Kit
(Pharmingen-554740). Transfer vectors were co-transfected into SF9
insect cells (Pharmingen-21300C). Amplification of recombinant
viruses was performed according to the Pharmingen Instruction
Manual. SF9 cells were maintained in serum-free SF900 medium (Gibco
10902-096).
[1447] For protein production, 2.times.10.sup.7 cells were infected
with the appropriate recombinant virus for 3 days. Cells were then
harvested and spun at 3,000 rpm for 5 minutes. They were then
washed twice in PBS and resuspended in 2 pellet volumes of lysis
buffer (25 mM HEPES pH 7.9, 0.1 mM EDTA, 400 mM KCl, 10% glycerol,
0.1% NP-40, 1 mM AEBSF). Resuspended cells were frozen on dry ice
and thawed at 37.degree. C. 3 times and centrifuged for 10 minutes
at 14,000 rpm. The supernatant was collected and incubated with 300
.mu.l of 50% Ni-NTA agarose bead slurry (Qiagen-30210). Incubation
was carried out at 4.degree. C. for 1 hour on a rotating wheel. The
slurry was then centrifuged at 500 g for 5 minutes. Beads were
washed twice in 1 ml of wash buffer (25 mM HEPES pH7.9, 0.1 mM
EDTA, 150 mM KCl, 10% glycerol, 0.1% NP-40, 1 mM AEBSF). Protein
was eluted 3 times in 300 .mu.l elution buffer (25 mM HEPES pH 7.9,
0.1 mM EDTA, 250 mM KCl, 10% glycerol, 0.1% NP-40, 1 mM AEBSF)
containing increasing concentrations of imidazole: 0.2 M, 0.5 M and
1 M. Each elution was performed for 5 minutes at room temperature.
Eluted protein was kept in 50% glycerol at -70.degree. C.
[1448] Assay Method
[1449] A source of HDAC (e.g., 2 .mu.L of crude HeLa extract, 5
.mu.L of HDAC1 or HDAC2; in elution buffer, as above) was incubated
with 3 .mu.L of radioactively labelled peptide along with
appropriate dilutions of candidate compounds (1.5 .mu.L) in a total
volume of 150 .mu.L of buffer (20 mM Tris pH 7.4, 10% glycerol).
The reaction was carried out at 37.degree. C. for one hour, after
which the reaction was stopped by adding 20 .mu.L of 1 M HCl/0.4 M
sodium acetate. Then, 750 .mu.L of ethyl acetate was added, the
samples vortexed and, after centrifugation (14000 rpm, 5 min), 600
.mu.L from the upper phase were transferred to a vial containing 3
mL of scintillation liquid (UltimaGold, Packard, Cat. No. 6013329).
Radioactivity was measured using a Tri-Carb 2100TR Liquid
Scintillation Analyzer (Packard).
[1450] Percent activity (% activity) for each test compound was
calculated as:
% activity={(S.sup.c-B)/(S.degree.-B)}.times.100
[1451] wherein S.sup.c denotes signal measured in the presence of
enzyme and the compound being tested, S.degree. denotes signal
measured in the presence of enzyme but in the absence of the
compound being tested, and B denotes the background signal measured
in the absence of both enzyme and compound being tested. The IC50
corresponds to the concentration which achieves 50% activity. IC50
data for several compounds of the present invention, as determined
using this assay, are also shown in Table 1, below.
[1452] Measurement of cell viability in the presence of increasing
concentration of test compound at different time points is used to
assess both cytotoxicity and the effect of the compound on cell
proliferation.
[1453] Secondary Assay: Cell Proliferation
[1454] Compounds with HDAC inhibition activity, as determined using
the primary assay, were subsequently evaluated using secondary
cell-based assays. The following cell lines were used:
[1455] HeLa-Human cervical adenocarcinoma cell line (ATCC ref. No.
CCL-2).
[1456] K11--HPV E7 transformed human keratinocyte line provided by
Pidder Jansen-Duerr, Institut fur Biomedizinische Alternsforschung,
Innsbruck, Austria.
[1457] NHEK-Ad--Primary human adult keratinocyte line (Cambrex
Corp., East Rutherford, N.J., USA).
[1458] JURKAT--Human T-cell line (ATCC no. TIB-152).
[1459] Assay Method
[1460] Cells were cultured, exposed to candidate compounds, and
incubated for a time, and the number of viable cells was then
assessed using the Cell Proliferation Reagent WST-1 from Boehringer
Mannheim (Cat. No. 1 644 807), described below.
[1461] Cells were plated in 96-well plates at 3-10.times.10.sup.3
cells/well in 100 .mu.L of culture medium. The following day,
different concentrations of candidate compounds were added and the
cells incubated at 37.degree. C. for 48 h. Subsequently, 10
.mu.L/well of WST-1 reagent was added and the cells reincubated for
1 hour. After the incubation time, absorbance was measured.
[1462] WST-1 is a tetrazolium salt which is cleaved to formazan dye
by cellular enzymes. An expansion in the number of viable cells
results in an increase in the overall activity of mitochondrial
dehydrogenases in the sample. This augmentation in the enzyme
activity leads to an increase in the amount of formazan dye formed,
which directly correlates to the number of metabolically active
cells in the culture. The formazan dye produced is quantified by a
scanning multiwell spectrophotometer by measuring the absorbance of
the dye solution at 450 nm wavelength (reference wavelength 690
nm).
[1463] Percent activity (% activity) in reducing the number of
viable cells was calculated for each test compound as:
% activity={(S.sup.c-B)/(S.degree.-B)}.times.100
[1464] wherein S.sup.C denotes signal measured in the presence of
the compound being tested, S.degree. denotes signal measured in the
absence of the compound being tested, and B denotes the background
signal measured in blank wells containing medium only. The IC50
corresponds to the concentration which achieves 50% activity. IC50
values were calculated using the software package Prism 3.0
(GraphPad Software Inc., San Diego, Calif.), setting top value at
100 and bottom value at 0.
[1465] IC50 data for several compounds of the present invention, as
determined using this assay, are also shown in Table 2, below.
[1466] Measurement of cell viability in the presence of increasing
concentration of test compound at different time points is used to
assess both cytotoxicity and the effect of the compound on cell
proliferation.
[1467] Biological Data
[1468] IC50 (or percent activity) data for several compounds of the
present invention, as determined using the assays described above
are summarised in Table 1 and Table 2, below.
3TABLE 1 Biochemical Assay Data HDAC Inhibition Compound (IC50
unless otherwise specified) No. Ref. HeLa HDAC1 HDAC2 TSA 5 15 17
Oxamflatin 38 -- -- 1 PX089342 125 50 -- 2 PX089344 89 -- 172 3
PX106499 35 -- -- 4 PX106522 1580 -- -- 5 PX117432 24%@ 500 -- -- 6
PX117780 125 -- -- 7 PX117781 58 -- -- 8 PX117793 50 -- -- 9
PX117794 24 -- -- 10 PX089343 24%@ 1 .mu.M -- -- 11 PX105684 19.5
-- 124 12 PX105685 238 -- 600 13 PX105844 15 29 -- 14 PX106508 31
90 -- 15 PX106509 6 -- -- 16 PX106510 12 -- -- 17 PX106511 35 -- --
18 PX106512 22 458 -- 19 PX116238 14 -- -- 20 PX116242 9%@ 500 --
-- 21 PX117225 640 -- -- 22 PX117226 26.3 -- -- 23 PX117227 50 --
-- 24 PX117228 7 -- -- 25 PX117233 21%@ 500 -- -- 26 PX117234 59%@
500 -- -- 27 PX117235 40%@ 500 -- -- 28 PX117236 54%@ 500 -- -- 29
PX117245 16 -- -- 30 PX117250 192 -- -- 31 PX117260 35%@ 500 -- --
32 PX117410 40%@ 500 -- -- 33 PX117411 39%@ 500 -- -- 34 PX117412
54%@ 500 -- -- 35 PX117414 46%@ 500 -- -- 36 PX117429 73%@ 500 --
-- 37 PX117445 2 -- -- 38 PX117446 18 -- -- 39 PX117447 3%@ 500 --
-- 40 PX117448 3%@ 500 -- -- 41 PX117450 20 -- -- 42 PX117453 45 --
-- 43 PX117710 125 -- -- 44 PX117712 14 -- -- 45 PX117713 138 -- --
46 PX117715 10 -- -- 47 PX117734 8 -- -- 48 PX117735 6 -- -- 49
PX117736 6 -- -- 50 PX117773 67 -- -- 51 PX117774 396 -- -- 52
PX117775 16 -- -- 53 PX117778 >400 -- -- 54 PX117779 250 -- --
55 PX117782 38 -- -- 56 PX117787 67 -- -- 57 PX117788 36 -- -- 58
PX117789 30 -- -- 59 PX117790 175 -- -- 60 PX117791 250 -- -- 61
PX117792 48 -- -- 62 PX117795 13 -- -- 63 PX117796 19 -- -- 64
PX117798 50 -- --
[1469]
4TABLE 2 Cell-Based Antiproliferation Assay Data Cell Proliferation
Inhibition WST-1 Compound (IC50 unless otherwise specified) No.
Ref. HeLa K11 NHEK-AD Jurkat TSA 0.350 0.38 0.2 0.042 Oxamflatin
1.1 4.56 3.53 0.260 MS-275 -- 9.16 3.1 0.365 SAHA -- 6.82 5.37
0.750 1 PX089342 4.1 -- -- -- 2 PX089344 8.9 -- -- -- 3 PX106499
3.8 -- -- -- 4 PX106522 16.7 -- -- -- 5 PX117432 -- -- -- -- 6
PX117780 16.8 10.5 -- 4.0 7 PX117781 3.4 2.2 -- 0.8 8 PX117793 2.0
2.7 -- 0.5 9 PX117794 3.3 2.3 -- 0.6 10 PX089343 -- -- -- -- 11
PX105684 2.2 2.4 1.5 0.2 12 PX105685 7.3 -- -- -- 13 PX105844 0.4
-- -- -- 14 PX106508 1.6 3.5 -- 0.30 15 PX106509 2.0 2.0 -- 0.33 16
PX106510 2.3 4.2 -- 0.25 17 PX106511 0.38 2.5 -- 0.235 18 PX106512
1.9 2.4 -- 0.21 19 PX116238 0.8 -- -- -- 20 PX116242 -- -- -- -- 21
PX117225 11.9 26% @20 .mu.M -- 3.3 22 PX117226 0.5 2.8 -- 0.10 23
PX117227 1.2 4.7 -- 0.36 24 PX117228 0.8 1.4 1.2 0.15 25 PX117233
-- -- -- -- 26 PX117234 -- -- -- -- 27 PX117235 -- -- -- -- 28
PX117236 -- -- -- -- 29 PX117245 0.31 -- 0.52 1.1 30 PX117250 7.8
-- 1.0 31 PX117260 -- -- -- -- 32 PX117410 -- -- -- -- 33 PX117411
-- -- -- -- 34 PX117412 -- -- -- -- 35 PX117414 -- -- -- -- 36
PX117429 -- -- -- -- 37 PX117445 1.1 1.2 0.75 0.13 38 PX117446 6.0
3.7 -- 0.43 39 PX117447 77.8 -- -- -- 40 PX117448 88.9 -- -- -- 41
PX117450 1.6 -- -- -- 42 PX117453 5.7 4.2 -- 1.1 43 PX117710 5.0
4.0 -- 0.42 44 PX117712 1.1 0.65 -- 0.13 45 PX117713 5.1 9.2 --
0.62 46 PX117715 1.5 0.93 -- 0.29 47 PX117734 2.1 0.88 -- 0.079 48
PX117735 -- 3.1 -- 0.074 49 PX117736 -- 0.80 -- 0.12 50 PX117773
3.4 6.2 -- 1.2 51 PX117774 6.4 7.0 -- 1.0 52 PX117775 2.1 5.3 --
0.53 53 PX117778 -- >30 -- >10 54 PX117779 9.6 1.4 -- 1.1 55
PX117782 2.9 15.6 -- 0.35 56 PX117787 2.6 1.2 -- 0.50 57 PX117788
2.0 1.7 -- 0.29 58 PX117789 1.1 0.8 -- 0.3 59 PX117790 12.5 8.0 --
2.1 60 PX117791 3.6 6.7 -- 1.3 61 PX117792 1.4 0.4 -- 0.43 62
PX117795 3.4 1.5 -- 0.51 63 PX117796 2.6 1.2 -- 0.56 64 PX117798
0.9 0.35 -- 3.6
[1470] Activity
[1471] (1)(A) As mentioned above, in one embodiment, the compounds
employ, as J, a "reverse" sulfonamide linkage (i.e.,
--NHSO.sub.2--). Such compounds enjoy the surprising and unexpected
property of superior activity as compared to their "forward"
sulfonamide (i.e., --SO.sub.2NH--) analogs.
[1472] (2)(B1) As mentioned above, in one embodiment, the compounds
employ, as Q.sup.2, a phenylene-meta-C.sub.1-7alkylene linkage.
Such compounds enjoy the surprising and unexpected property of
superior activity as compared to their ortho and para analogs.
[1473] (3)(B2) As mentioned above, in one embodiment, the compounds
employ, as Q.sup.2, a phenylene-meta-ethylene linkage. Such
compounds enjoy the surprising and unexpected property of superior
activity as compared to their ortho and para analogs.
[1474] (4)(C1) As mentioned above, in one embodiment, the compounds
employ, as Q.sup.1, either: a covalent bond, or: an aryl leader
having a backbone of at least two carbon atoms. Such compounds
enjoy the surprising and unexpected property of superior activity
as compared to analogs which comprise, as Q.sup.1, an aryl leader
having a backbone of one carbon atom.
[1475] (5)(C2) As mentioned above, in one embodiment, the compounds
employ, as Q.sup.1, a covalent bond. Such compounds enjoy the
surprising and unexpected property of superior activity as compared
to analogs which comprise, as Q.sup.1, an aryl leader having a
backbone of one carbon atom.
[1476] (6)(C3) As mentioned above, in one embodiment, the compounds
employ, as Q.sup.1, an aryl leader having a backbone of at least
two carbon atoms. Such compounds enjoy the surprising and
unexpected property of superior activity as compared to analogs
which comprise, as Q.sup.1, an aryl leader having a backbone of one
carbon atom, and often as compared to analogs which comprise, as
Q.sup.1, a covalent bond.
[1477] (7)(A+B1) As mentioned above, in one embodiment, the
compounds employ, as J, a "reverse" sulfonamide linkage (i.e.,
--NHSO.sub.2--); and as Q.sup.2, a phenylene-meta-C.sub.1-7alkylene
linkage. Such compounds enjoy the surprising and unexpected
property of superior activity as compared to analogs which do not
employ these groups.
[1478] (8)(A+B2) As mentioned above, in one embodiment, the
compounds employ, as J, a "reverse" sulfonamide linkage (i.e.,
--NHSO.sub.2--); and as Q.sup.2, a phenylene-meta-ethylene linkage.
Such compounds enjoy the surprising and unexpected property of
superior activity as compared to analogs which do not employ these
groups.
[1479] (9)(A+C1) As mentioned above, in one embodiment, the
compounds employ, as J, a "reverse" sulfonamide linkage (i.e.,
--NHSO.sub.2--); and as Q.sup.1, either: a covalent bond, or an
aryl leader having a backbone of at least two carbon atoms. Such
compounds enjoy the surprising and unexpected property of superior
activity as compared to analogs which do not employ these
groups.
[1480] (10)(A+C2) As mentioned above, in one embodiment, the
compounds employ, as J, a "reverse" sulfonamide linkage (i.e.,
--NHSO.sub.2); and as Q.sup.1, a covalent bond.
[1481] Such compounds enjoy the surprising and unexpected property
of superior activity as compared to analogs which do not employ
these groups.
[1482] (11)(A+C3) As mentioned above, in one embodiment, the
compounds employ, as J, a "reverse" sulfonamide linkage (i.e.,
--NHSO.sub.2--); and as Q.sup.1, an aryl leader having a backbone
of at least two carbon atoms. Such compounds enjoy the surprising
and unexpected property of superior activity as compared to analogs
which do not employ these groups.
[1483] (12)(B1+C1) As mentioned above, in one embodiment, the
compounds employ, as Q.sup.2, a phenylene-meta-C.sub.1-7alkylene
linkage; and, as Q.sup.1, either: a covalent bond, or: an aryl
leader having a backbone of at least two carbon atoms. Such
compounds enjoy the surprising and unexpected property of superior
activity as compared to analogs which do not employ these
groups.
[1484] (13)(B1+C2) As mentioned above, in one embodiment, the
compounds employ, as Q.sup.2, a phenylene-meta-C.sub.1-7alkylene
linkage; and, as Q.sup.1, a covalent bond. Such compounds enjoy the
surprising and unexpected property of superior activity as compared
to analogs which do not employ these groups.
[1485] (14) (B1+C3) As mentioned above, in one embodiment, the
compounds employ, as Q.sup.2, a phenylene-meta-C.sub.1-7alkylene
linkage; and, as Q.sup.1, an aryl leader having a backbone of at
least two carbon atoms. Such compounds enjoy the surprising and
unexpected property of superior activity as compared to analogs
which do not employ these groups.
[1486] (15) (B2+C1) As mentioned above, in one embodiment, the
compounds employ, as Q.sup.2, a phenylene-meta-ethylene linkage;
and, as Q.sup.1, either: a covalent bond, or: an aryl leader having
a backbone of at least two carbon atoms. Such compounds enjoy the
surprising and unexpected property of superior activity as compared
to analogs which do not employ these groups.
[1487] (16) (B2+C2) As mentioned above, in one embodiment, the
compounds employ, as Q.sup.2, a phenylene-meta-ethylene linkage;
and, as Q.sup.1, a covalent bond. Such compounds enjoy the
surprising and unexpected property of superior activity as compared
to analogs which do not employ these groups.
[1488] (17) (B2+C3) As mentioned above, in one embodiment, the
compounds employ, as Q.sup.2, a phenylene-meta-ethylene linkage;
and, as Q.sup.1, an aryl leader having a backbone of at least two
carbon atoms. Such compounds enjoy the surprising and unexpected
property of superior activity as compared to analogs which do not
employ these groups.
[1489] (18) (A+B1+C1) As mentioned above, in one embodiment, the
compounds employ, as J, a "reverse" sulfonamide linkage (i.e.,
--NHSO.sub.2--); as Q.sup.2, a phenylene-meta-C.sub.1-7alkylene
linkage; and, as Q.sup.1, either: a covalent bond, or: an aryl
leader having a backbone of at least two carbon atoms. Such
compounds enjoy the surprising and unexpected property of superior
activity as compared to analogs which do not employ these
groups.
[1490] (19) (A+B1+C2) As mentioned above, in one embodiment, the
compounds employ, as J, a "reverse" sulfonamide linkage (i.e.,
--NHSO.sub.2--); as Q.sup.2, a phenylene-meta-C.sub.1-7alkylene
linkage; and, as Q.sup.1, a covalent bond. Such compounds enjoy the
surprising and unexpected property of superior activity as compared
to analogs which do not employ these groups.
[1491] (20) (A+B1+C3) As mentioned above, in one embodiment, the
compounds employ, as J, a "reverse" sulfonamide linkage (i.e.,
--NHSO.sub.2--); as Q.sup.2, a phenylene-meta-C.sub.1-7alkylene
linkage; and, as Q.sup.1, an aryl leader having a backbone of at
least two carbon atoms. Such compounds enjoy the surprising and
unexpected property of superior activity as compared to analogs
which do not employ these groups.
[1492] (21) (A+B2+C1) As mentioned above, in one embodiment, the
compounds employ, as J, a "reverse" sulfonamide linkage (i.e.,
--NHSO.sub.2--); as Q.sup.2, a phenylene-meta-ethylene linkage;
and, as Q.sup.1, either: a covalent bond, or: an aryl leader having
a backbone of at least two carbon atoms. Such compounds enjoy the
surprising and unexpected property of superior activity as compared
to analogs which do not employ these groups.
[1493] (22) (A+B2+C2) As mentioned above, in one embodiment, the
compounds employ, as J, a "reverse" sulfonamide linkage (i.e.,
--NHSO.sub.2--); as Q.sup.2, a phenylene-meta-ethylene linkage;
and, as Q.sup.1, a covalent bond. Such compounds enjoy the
surprising and unexpected property of superior activity as compared
to analogs which do not employ these groups.
[1494] (23) (A+B2+C3) As mentioned above, in one embodiment, the
compounds employ, as J, a "reverse" sulfonamide linkage (i.e.,
--NHSO.sub.2--); as Q.sup.2, a phenylene-meta-ethylene linkage;
and, as Q.sup.1, an aryl leader having a backbone of at least two
carbon atoms. Such compounds enjoy the surprising and unexpected
property of superior activity as compared to analogs which do not
employ these groups.
[1495] Comparative Data for Sulfonamide Direction
[1496] Comparative data for sets of compounds, where the only
difference in chemical structure is the sulfonamide direction, are
shown below.
[1497] Compounds which employ, as J, a "reverse" sulfonamide
linkage (i.e., --NHSOZ) surprisingly and unexpectedly have superior
activity as compared to their "forward" sulfonamide (i.e.,
--SO.sub.2NH--) analogs.
5 379 Compound Q.sup.1 J o/m/p HeLa IC50 PX117234 -- --NHSO.sub.2--
-- 59% @ 500 nM PX106522 -- --SO.sub.2NH-- -- 1.6 .mu.M 380
Compound Q.sup.1 J o/m/p HeLa IC50 PX105684 -- --NHSO.sub.2-- m 20
nM PX089344 -- --SO.sub.2NH-- m 89 nM 381 Compound Q.sup.1 J o/m/p
HeLa IC50 PX106511 --CH.sub.2-- --NHSO.sub.2-- m 35 nM PX089343
--CH.sub.2-- --SO.sub.2NH-- m 24% @ 1 .mu.M 382 Compound Q.sup.1 J
o/m/p HeLa IC50 PX117450 -- --NHSO.sub.2-- p 20 nM PX106499 --
--SO.sub.2NH-- p 35 nM 383 Compound Q.sup.1 J o/m/p HeLa IC50
PX106508 -- --NHSO.sub.2-- m 31 nM PX089342 -- --SO.sub.2NH-- m 125
nM 384 Compound Q.sup.1 J o/m/p HeLa IC50 PX116238 --
--NHSO.sub.2-- m 14 nM Oxamflatin -- --SO.sub.2NH-- m 38 nM
[1498] Comparative Data for Phenylene-Alkylene Acid Leader
Orientation
[1499] Comparative data for sets of compounds, where the only
difference in chemical structure is the ortho/meta/para orientation
of the phenylene-alkylene acid leader, are shown below.
[1500] In some embodiments, compounds which employ, as Q.sup.2, a
phenylene-meta-C.sub.1-7alkylene linkage surprisingly and
unexpectedly have superior activity as compared to their ortho and
para analogs. For compounds with a "forward" sulfonamide linkage,
para analogs are more active than meta analogs. Surprisingly and
unexpectedly, for compounds with a "reverse" sulfonamide linkage,
meta analogs are as active, or more active, than para analogs.
Thus, compounds which employ both, as J, a "reverse" sulfonamide
linkage (i.e., --NHSO.sub.2--) and, as Q.sup.2, a
phenylene-meta-C.sub.1-7alkylene linkage, surprisingly and
unexpectedly have superior activity as compared to their "forward"
analogs.
6 385 Compound Q.sup.1 J o/m/p HeLa IC50 PX117447 -- --NHSO.sub.2--
o 3% @ 500 nM PX117228 -- --NHSO.sub.2-- m 7 nM 386 Compound
Q.sup.1 J o/m/p HeLa IC50 PX117448 -- NMeSO.sub.2-- o 3% @ 500 nM
PX105685 -- NMeSO.sub.2-- m 238 nM 387 Compound Q.sup.1 J o/m/p
HeLa IC50 PX116242 -- --NHSO.sub.2-- o 9% @ 500 nM PX105684 --
--NHSO.sub.2-- m 20 nM PX117450 -- --NHSO.sub.2-- p 20 nM 388
Compound Q.sup.1 J o/m/p HeLa IC50 PX089344 -- SO.sub.2NH-- m 89 nM
PX106499 -- SO.sub.2NH-- p 35 nM 389 Compound Q.sup.1 J o/m/p HeLa
IC50 PX116238 -- NHSO.sub.2-- m 14 nM PX117453 -- NHSO.sub.2-- p 45
nM
[1501] Comparative Data for Aryl Leader, Q.sup.1
[1502] Comparative data for sets of compounds, where the only
difference in chemical structure is the aryl leader, are shown
below.
[1503] Compounds which employ, as Q.sup.1, either: a covalent bond,
or: an aryl leader having a backbone of at least two carbon atoms
surprisingly and unexpectedly have superior activity as compared to
their analogs which comprise, as Q.sup.1, an aryl leader having a
backbone of one carbon atom. The observation that, as Q.sup.1, a
one atom backbone gives substantially reduced activity as compared
to a covalent bond, but that a two atom backbone give substantially
improved activity as compared to a one atom backbone, is surprising
and unexpected.
7 390 Compound Q.sup.1 J o/m/p HeLa IC50 PX105684 -- --NHSO.sub.2--
m 19.5 nM PX106511 --CH.sub.2-- --NHSO.sub.2-- m 35 nM PX106512
--CH.sub.2CH.sub.2-- --NHSO.sub.2-- m 22 nM 391 Compound Q.sup.1 J
o/m/p HeLa IC50 PX089344 -- --SO.sub.2NH-- m 89 nM PX089343
--CH.sub.2-- --SO.sub.2NH-- m 24% @ 1 M PX117446 --CH.dbd.CH--
--SO.sub.2NH-- m 18 nM 392 Compound Q.sup.1 J o/m/p HeLa IC50
PX117228 -- --NHSO.sub.2-- m 7 nM PX117225 --CH.sub.2--
--NHSO.sub.2-- m 640 nM
REFERENCES
[1504] A number of patents and publications are cited herein in
order to more fully describe and disclose the invention and the
state of the art to which the invention pertains. Full citations
for these references are provided herein. Each of these references
is incorporated herein by reference in its entirety into the
present disclosure.
[1505] Andrews et al., 2000, Int. J. Parasitol., Vol. 30, No. 6,
pp. 761-768.
[1506] Bernhard, D. et al., 1999, "Apoptosis induced by the histone
deacetylase inhibitor sodium butyrate in human leukemic
lymphoblasts," FASEB J., Vol.13, No. 14, pp. 1991-2001.
[1507] Bernstein et al., 2000, Proc. Natl. Acad. Sci. USA, Vol. 97,
No. 25, pp. 13708-13713.
[1508] Brehm, A., et al., 1998, "Retinoblastoma protein recruits
histone deacetylase to repress transcription," Nature, 1998, Vol.
391, pp. 597-601.
[1509] Breslow et al., 1994, "Potent inducers of terminal
differentiation and methods of use thereof," U.S. Pat. No.
5,369,108 issued 29 Nov. 1994.
[1510] Breslow et al., 1995, "Novel potent inducers of terminal
differentiation and methods of use thereof," published
international (PCT) patent application number WO 95/31977 published
30 Nov. 1995.
[1511] Breslow et al., 1997, "Potent inducers of terminal
differentiation and methods of use thereof," U.S. Pat. No.
5,700,811 issued 23 Dec. 1997.
[1512] Chang et al., 2000, Nucleic Acids Res., Vol. 28, No. 20, pp.
3918-3925.
[1513] Corneil et al., 1998, published Japanese patent application,
publication number JP 10114681 A2.
[1514] Dangond et al., 1998, Biochem. Biophys. Res. Commun., Vol.
242, No. 3, pp. 648-652.
[1515] David, G., et al., 1998, Oncogene, Vol.16(19), pp.
2549-2556.
[1516] Davie, J. R., 1998, "Covalent modifications of histones:
expression from chromatic templates," Curr. Opin. Genet. Dev., Vol.
8, pp.173-178.
[1517] Delorme et al., 2001, "Inhibitors of Histone Deacetylase,"
published international (PCT) patent application number WO 01/38322
published 31 May 2001.
[1518] Desai et al., 1999, Proc. AACR, Vol. 40, abstract #2396.
[1519] Emiliani, S., et al., 1998, "Characterization of a human
RPD3 ortholog, HDAC3," Proc. Natl. Acad. Sci. USA, Vol. 95, p.
2795-2800.
[1520] Finnin et al., 1999, Nature, Vol. 401, pp. 188-193.
[1521] Furukawa et al., 1998, U.S. Pat. No. 5,834,249, "Process for
production of protein," 10 Nov. 1998.
[1522] Geerts et al., 1998, European patent publication no. EP 0
827 742 A1, published 11 Mar. 1998.
[1523] Glick, R. D., et al., 1999, "Hybrid polar histone
deacetylase inhibitor induces apoptosis and CD95/CD95 ligand
expression in human neuroblastoma," Cancer Research, Vol. 59, No.
17, pp. 4392-4399.
[1524] Grozinger et al., 1999, Proc. Natl. Acad. Sci. USA, Vol. 96,
pp.4868-4873.
[1525] Hashimoto, N., et al., 1989, "Cell proliferation
inhibitors," European Patent Publication No. EP 0 301 861 A1.
[1526] Hoshikawa, Y., et al., 1994, Exp. Cell. Res., Vol. 214(1),
pp. 189-197.
[1527] Howe, L., et al., 1999, Crit. Rev. Eukarvot. Gene Expr.,
Vol. 9(3-4), pp. 231-243.
[1528] Iavarone et al., 1999, Mol. Cell Biol., Vol. 19, No. 1, pp.
916-922.
[1529] Jung et al., 1997, Bioorganic & Medicinal Chemistry
Letters, Vol. 7, No. 13, pp. 1655-1658.
[1530] Jung et al., 1999, J. Med. Chem., Vol. 42, pp.
4669-4679.
[1531] Kao et al., 2000, Genes & Dev., Vol. 14, p. 55-66.
[1532] Kato et al., 1998, U.S. Pat. No. 5,804,601, "Aromatic
hydroxamic acid compounds, their production and use," 8 Sep.
1998.
[1533] Kijima et al., 1993, J. Biol. Chem., Vol. 268, pp.
22429-22435.
[1534] Kim et al., 1999, Oncogene, Vol. 18(15), pp. 2461-2470.
[1535] Kim et al., 2001, Nature Medicine, Vol. 7, No. 4, pp.
437443.
[1536] Kim, M. S., et al., 2001' Histone deacetylases induce
angiogenesis by negative regulation of tumour suppressor genes,"
Nature Medicine, Vol 7. No. 4 pp. 437-443.
[1537] Kimura et al., 1994, Biol. Pharm. Bull., Vol. 17, No. 3, pp.
399-402.
[1538] Kitamura, K., et al., 2000, Br. J. Haematol., Vol.108(4),
pp. 696-702.
[1539] Kouzaddes, T., 1999, "Histone acetylases and deacetylases in
cell proliferation," Curr. Opin. Genet. Dev., Vol.9, No. 1,
pp.40-48.
[1540] Kuusisto et al., 2001, Biochem. Biophys. Res. Commun., Vol.
280, No. 1, pp. 223-228.
[1541] Kwon et al., 1998, Proc. Natl. Acad. Sci. USA, Vol. 95, pp.
3356-3361.
[1542] Laherty, C. D., et al., 1997, Cell, Vol. 89(3), pp.
349-356.
[1543] Lea and Tulsyan, 1995, Anticancer Res., Vol. 15, pp.
879-883.
[1544] Lea et al., 1999, Int. J. Oncol., Vol. 2, pp. 347-352.
[1545] Lin, R. J., et al., 1998, Nature, Vol. 391(6669), pp.
811-814.
[1546] Massa et al., 26 May 2001, Journal of Medicinal Chemistry,
Vol.44, No. 13, pp. 2069-2072.
[1547] McCaffrey et al., 1997, Blood, Vol. 90, No. 5, pp.
2075-2083.
[1548] Mielnicki, L. M., et al., 1999, Exp. Cell. Res., Vol.
249(1), pp. 161-176.
[1549] Ng, H. H. and Bird, A., 2000, Trends Biochem. Sci., Vol.
25(3), pp. 121-126.
[1550] Niki et al., 1999, Hepatology, Vol. 29, No. 3, pp.
858-867.
[1551] Nokajima et al., 1998, Exp. Cell Res., Vol. 241, pp.
126-133.
[1552] Ohtani et al., 1993, "Hydroxamic acid derivatives based on
aromatic sulfonamide," published international (PCT) patent
application number WO 93/12075 published 24 Jun. 1993.
[1553] Ohtani et al., 1996,
"(2E)-5-[3-[(Phenylsulfonyl)amino]phenyl]-pent-
-2-en-4-yno-hydroxamic acid and its derivatives as novel and potent
inhibitors of ras transformation," J. Medicinal Chemistry, Vol. 39,
No. 15, pp. 2871-2873.
[1554] Onishi et al., 1996, Science, Vol. 274, pp. 939-940.
[1555] Parsons et al., 1998, "Hydroxamic acid compounds having
anticancer and anti-parasitic properties," published international
(PCT) patent application number WO 98/55449 published 10 Dec.
1998.
[1556] Pazin, M. J., et al., 1997, "What's up and down with histone
deacetylation and transcription," Cell, Vol. 89, No. 3, pp.
325-328.
[1557] Richon et al, 1996, Proc. Natl. Acad. Sci. USA, Vol. 93, pp.
5705-5708.
[1558] Richon et al., 1998, "A class of hybrid poler inducers of
transformed cell differentiation inhibits histone deacetylases,"
Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 3003-3007.
[1559] Richon et al., 2001, "Novel class of cytodifferentiating
agents and histone deacetylase inhibitors, and methods of use
thereof," published international (PCT) patent application number
WO 01/18171 published 15 Mar. 2001.
[1560] Saito et al., 1999, Proc. Natl. Acad. Sci. USA, Vol. 96, pp.
4592-4597.
[1561] Saunders, N. et al, 1999 "Histone deacetylase inhibitors as
potential anti-skin cancer agents," Cancer Res., Vol. 59, No. 2 pp.
399-404.
[1562] Sonoda, H. et al., 1996, Oncogene, Vol. 13, pp. 143-149.
[1563] Spencer, V. A. and Davie, J. R., 1999, Gene, Vol. 240(1),
pp. 1-12.
[1564] Suzuki et al., 1998, Japanese patent publication number
10-182583 published 7 Jul. 1998.
[1565] Suzuki et al., 1999, "Synthesis and histone deactylase
inhibitory activity of new benzamide derivatives," J. Med. Chem.,
Vol. 42, pp. 3001-3003.
[1566] Takahashi et al., 1996, J. Antibiot. (Tokyo), Vol. 49, No.
5, pp. 453-457.
[1567] Takahashi, I., et al, 1996, "Selective inhibition of IL-2
gene expression by trichostatin A, a potent inhibitor of mammalian
histone deacetylase," J. Antibiot. (Tokyo), Vol. 49, No. 5, pp.
453-457.
[1568] Tauton, J., et al., 1996, "A mammalian histone deacetylase
related to the yeast transcriptional regulator Rpd3p," Science,
Vol. 272, pp. 408-411.
[1569] Tsuji et al., 1976, J. Antibiot. (Tokyo), Vol. 29, No. 1,
pp. 1-6.
[1570] Ueda, H., et al., 1994, J. Antibiot. (Tokyo), Vol. 47(3),
pp. 315-323.
[1571] Van den Wyngaert et al., 2000, FEBS, Vol. 478, pp.
77-83.
[1572] Vigushin et al., 2001, Clin. Cancer Res., Vol. 7, No. 4, pp.
971-976.
[1573] Warrell et al., 1998, J. Natl. Cancer Inst., Vol.90, pp.
1621-1625.
[1574] Wong, J., et al., 1998, EMBO J., Vol. 17(2), pp.
520-534.
[1575] Yang, W. M., et al., 1996, "Transcriptional repression of
YY1 is mediated by interaction with a mammalian homolog of the
yeast global regulator RPD3," Proc. Natl. Acad. Sci. USA, Vol. 93,
pp. 12845-12850.
[1576] Yang, W. M., et al., 1997, "Isolation and characterization
of cDNAs corresponding to an additional member of the human histone
deacetylase gene family," J. Biol. Chem., Vol 272, pp.
28001-28007.
[1577] Yoshida et al., 1995, Bioessays, Vol. 17, pp. 423430.
[1578] Yoshida, M. and Horinouchi, S., 1999, Ann. N.Y. Acad. Sci.,
Vol. 886, pp. 23-36.
[1579] Yoshida, M., Beppu, T., 1988, "Reversible arrest of
proliferation of rat 3Y1 fibroblasts in both G1 and G2 phases by
trichostatin A," Exp. Cell. Res., Vol. 177, pp. 122-131.
[1580] Yoshida, M., et al., 1990a, J. Biol. Chem., Vol. 265(28),
pp. 17174-17179.
[1581] Yoshida, M., et al., 1990b, J. Antibiot. (Tokyo), Vol.
43(9), pp. 1101-1106.
* * * * *